Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
33200.0 | 2018-10-03 00:00:00 UTC | Abbott's CE Mark for FreeStyle Libre 2 Boosts Diabetes Arm | ABT | https://www.nasdaq.com/articles/abbotts-ce-mark-for-freestyle-libre-2-boosts-diabetes-arm-2018-10-03 | nan | nan | Abbott LaboratoriesABT recently announced the receipt of CE Mark for its next-generation FreeStyle Libre 2 - a continuous glucose monitoring system. This system comes with optional glucose alarms which can promptly alert patients of hypoglycemia or hyperglycemia, at no extra cost.
Abbott plans to soon launch the FreeStyle Libre 2 system on a rolling basis throughout Europe. With additional features, we expect this launch to help the company expand its customer base and boost top-line contributions from the Diabetes unit.
Market Potential
Per a report by Mordor Intelligence, theglobal marketfor diabetes care devices is expected to reach a value of $30.25 billion by 2021, at a CAGR of 5.93%. Considering the huge potential of the market, we believe the latest development will help Abbott gain traction in this space.
Progress Within Diabetes Business
There have been a slew of developments within the Diabetics business of Abbott. We are upbeat about the recent reimbursement approval of FreeStyle Libre Flash Glucose Monitoring System in the United States and the United Kingdom.
Plus, the company announced the receipt of Health Canada License and Japanese national reimbursement for the same. In May 2017, the company received full or partial reimbursement from the French Health Ministry for the product. With these positives in place, Abbott's FreeStyle Libre system stands partially or fully covered in 21 countries.
Notably, these developments are expected to fortify the company's hold in the Diabetes Care segment, which saw significant sales growth in the last reported quarter on continued consumer acceptance of FreeStyle Libre internationally.
According to the company, Freestyle Libre currently has over 650,000 patients across the globe. Abbott encouragingly noted that, it is adding over 50,000 patients each month and has gained about 150,000 in the first quarter.
Also, Abbott authenticated the use of its FreeStyle Libre glucose sensing technology for innovation and marketing of insulin delivery systems after it entered into a collaboration agreement with Bigfoot Biomedical.
Share Price Performance
Abbott has been gaining investor confidence on consistently positive results. Over the past six months, the stock has outperformed its industry . It has gained 24.1%, in comparison with the industry's 20.8% rise.
Zacks Rank & Key Picks
Abbott carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Intuitive Surgical ISRG , Amedisys, Inc. AMED and Masimo Corporation MASI .
Intuitive Surgical's long-term expected earnings growth rate is 14.7%. The stock currently carries a Zacks Rank of 2 (Buy).
Amedisys' long-term expected earnings growth rate is 19.4%. The stock holds a Zacks Rank #2 at the moment. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Masimo's long-term expected earnings growth rate is 14.8%. The stock has a Zacks Rank #2 at present.
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT recently announced the receipt of CE Mark for its next-generation FreeStyle Libre 2 - a continuous glucose monitoring system. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, these developments are expected to fortify the company's hold in the Diabetes Care segment, which saw significant sales growth in the last reported quarter on continued consumer acceptance of FreeStyle Libre internationally. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT recently announced the receipt of CE Mark for its next-generation FreeStyle Libre 2 - a continuous glucose monitoring system. Some better-ranked stocks in the broader medical space are Intuitive Surgical ISRG , Amedisys, Inc. AMED and Masimo Corporation MASI . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT recently announced the receipt of CE Mark for its next-generation FreeStyle Libre 2 - a continuous glucose monitoring system. Notably, these developments are expected to fortify the company's hold in the Diabetes Care segment, which saw significant sales growth in the last reported quarter on continued consumer acceptance of FreeStyle Libre internationally. | Abbott LaboratoriesABT recently announced the receipt of CE Mark for its next-generation FreeStyle Libre 2 - a continuous glucose monitoring system. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. With these positives in place, Abbott's FreeStyle Libre system stands partially or fully covered in 21 countries. |
33201.0 | 2018-10-02 00:00:00 UTC | 3 Medical-Device Stocks at All-Time Highs -- Are They Buys? | ABT | https://www.nasdaq.com/articles/3-medical-device-stocks-all-time-highs-are-they-buys-2018-10-02 | nan | nan | It's a great time to be in the medical-device industry. Sales are booming. Innovation is flourishing. And many stocks are skyrocketing.
Three big medical-device stocks are now at all-time highs: Abbott Laboratories (NYSE: ABT) , Abiomed (NASDAQ: ABMD) , and Edwards Lifesciences (NYSE: EW) . Here's why these stocks are performing so well and a look at whether any of them are still smart picks to buy.
1. Abbott Labs
Abbott Labs' share price is up nearly 30% so far in 2018. The stock has more than doubled over the last five years. And with dividends reinvested, Abbott has generated a total return during the period of nearly 150%.
Of course, Abbott is more than just a medical-device company. It also markets diagnostics and nutrition products and sells branded generic drugs outside of the U.S. Abbott's international pharmaceuticals business has been the company's fastest-growing unit.
However, Abbott's biggest moneymaker continues to be its medical-devices segment. This segment has posted strong growth thanks largely to two areas: electrophysiology and diabetes care. Abbott's cardiac mapping and ablation products and its launch earlier this year of the first smartphone-enabled insertable cardiac monitor (ICM) have boosted electrophysiology product sales.
But the strongest growth for the company's medical-devices unit has come from Abbott's Freestyle Libre sensor-based continuous glucose monitoring (CGM) system. This CGM, which doesn't require finger sticks, has put Abbott on the map as one of the top diabetes stocks .
2. Abiomed
Abiomed stock has soared close to 140% year to date. Over the last five years, Abiomed has delivered a staggering return of roughly 2,260%.
It wasn't always such sunshine and roses for Abiomed. The company's AbioCor artificial heart, which won FDA approval in 2006, didn't succeed commercially. However, the acquisition of Impella Cardiosystems in 2004 ended up radically changing Abiomed's fortunes.
The Impella minimally invasive heart pumps now generate nearly all of Abiomed's revenue. And that revenue is growing nicely, up 36% year over year in the second quarter . What's especially impressive is Abiomed's momentum in international markets.
Abiomed's heart pumps are much more expensive than the intra-aortic balloon pumps (IBPs) that have been used for years. However, the company's data showing reduced hospital stays and lower readmission rates have helped convince healthcare providers and payers that Impella heart pumps are worth the higher price.
3. Edwards Lifesciences
Shares of Edwards Lifesciences are up more than 50% this year. Edwards stock has nearly quintupled in value over the last five years.
Like Abiomed, Edwards Lifesciences' medical devices focus on the heart. But instead of heart pumps, Edwards makes products for structural heart disease -- especially transcatheter heart valve therapies (THVTs) -- and critical-care monitoring systems.
The company's most important product is its Sapien transcatheter heart valve. Edwards' THVTs generated 62% of total revenue in the second quarter of 2018. Total sales grew by 12% year over year in Q2, with an even stronger bottom-line performance.
Edwards Lifesciences plans to launch two new THVTs soon -- the Sapien 3 Ultra and Centera valves. The company expects the global market for these valves will increase in the mid-teens to more than $5 billion by 2021.
Are they buys?
In my view, all three of these high-flying medical-device stocks should be able to keep their momentum going. Abbott Labs is likely to continue to see success from its Freestyle Libre CGM system and its introductions of other new products. Edwards Lifesciences should also get a boost from its new product launches.
I'm most optimistic about Abiomed. The stock claims a nosebleed valuation. However, Abiomed still has a lot of room for growth with its current lineup of Impella heart pumps. The company is also developing new devices that could greatly expand its total addressable market. Abiomed is at an all-time high, but records are meant to be broken.
10 stocks we like better than Abiomed
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abiomed wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Abiomed. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Three big medical-device stocks are now at all-time highs: Abbott Laboratories (NYSE: ABT) , Abiomed (NASDAQ: ABMD) , and Edwards Lifesciences (NYSE: EW) . It also markets diagnostics and nutrition products and sells branded generic drugs outside of the U.S. Abbott's international pharmaceuticals business has been the company's fastest-growing unit. But the strongest growth for the company's medical-devices unit has come from Abbott's Freestyle Libre sensor-based continuous glucose monitoring (CGM) system. | Three big medical-device stocks are now at all-time highs: Abbott Laboratories (NYSE: ABT) , Abiomed (NASDAQ: ABMD) , and Edwards Lifesciences (NYSE: EW) . But the strongest growth for the company's medical-devices unit has come from Abbott's Freestyle Libre sensor-based continuous glucose monitoring (CGM) system. But instead of heart pumps, Edwards makes products for structural heart disease -- especially transcatheter heart valve therapies (THVTs) -- and critical-care monitoring systems. | Three big medical-device stocks are now at all-time highs: Abbott Laboratories (NYSE: ABT) , Abiomed (NASDAQ: ABMD) , and Edwards Lifesciences (NYSE: EW) . Abiomed Abiomed stock has soared close to 140% year to date. But instead of heart pumps, Edwards makes products for structural heart disease -- especially transcatheter heart valve therapies (THVTs) -- and critical-care monitoring systems. | Three big medical-device stocks are now at all-time highs: Abbott Laboratories (NYSE: ABT) , Abiomed (NASDAQ: ABMD) , and Edwards Lifesciences (NYSE: EW) . Of course, Abbott is more than just a medical-device company. Abiomed Abiomed stock has soared close to 140% year to date. |
33202.0 | 2018-09-27 00:00:00 UTC | Abbott's Troponin-I Wins CE Mark, Vascular Arm Gets a Revamp | ABT | https://www.nasdaq.com/articles/abbotts-troponin-i-wins-ce-mark-vascular-arm-gets-a-revamp-2018-09-27 | nan | nan | As a major breakthrough for its vascular business, Abbott LaboratoriesABT recently received a CE Mark for its High Sensitive Troponin-I diagnostic test. This Troponin blood test, the first to win this recognition, is claimed to accurately predict the chances of heart attack, months or years in advance among apparently looking healthy people.
At present, cardiovascular diseases are the leading causes for death globally. Per a WHO report, in 2016 alone, 17.9 million people died from cardiovascular diseases, representing 31% of all universal deaths. Of these, 85% was due to heart attack and stroke. Based on this data, we consider Troponin-I's entry into the European market to be highly strategic and timely.
Troponin-I at a Glance
Notably, Troponin I is a cardiac and skeletal muscle protein. It is examined for laboratory diagnosis of heart attack. Thisdiagnostic test is applied for the quantitative measurement of cardiac troponin I in whole blood or plasma. According to Abbott,this life-changing technology uses a biomarker, specific to the heart. As a result, it has potential to help doctors detect prospective heart patients or identify those at risk for developing heart disease.
it is important to note that the European guidelines traditionally recommend indirect heart health factors to determine risk for developing heart disease. These factors include cholesterol levels, blood pressure as well as if the person is diabetic or a smoker. However, a substantial body of research has shown that measuring a person's troponin levels using Abbott's High Sensitive Troponin-I test provides better predictive information to indicate a person's chances of developing future heart disease.
Sluggish Vascular Arm Gets a Revamp
Over the last few quarters, Abbott has been witnessing a declining revenue trend in its core Vascular product line. This underperformance organically was partly the due to the divestment of Abbott's medical optics and St. Jude's vascular closure businesses. However, several recent developments including the latest European approval of Troponin-I are expected to be accretive to the company's vascular business growth.
Share Price Performance
Over the past year, shares of Abbott have outperformed its industry . The stock has rallied 18.8% compared with the industry's 10.9% rise.
Zacks Rank & Key Picks
Abbott currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Intuitive Surgical ISRG , Amedisys, Inc. AMED and Masimo Corporation MASI .
Intuitive Surgical's expected long-term earnings growth rate is 14.7%. The stock currently carries a Zacks Rank #2 (Buy).
Amedisys' expected long-term earnings growth rate is 19.4%. The stock sports a Zacks Rank #1 (Strong Buy) at the moment. You can see the complete list of today's Zacks #1 Rank stocks here.
Masimo's expected long-term earnings growth rate is 14.8%. The stock has a Zacks Rank of 2 at present.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As a major breakthrough for its vascular business, Abbott LaboratoriesABT recently received a CE Mark for its High Sensitive Troponin-I diagnostic test. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. This Troponin blood test, the first to win this recognition, is claimed to accurately predict the chances of heart attack, months or years in advance among apparently looking healthy people. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. As a major breakthrough for its vascular business, Abbott LaboratoriesABT recently received a CE Mark for its High Sensitive Troponin-I diagnostic test. However, a substantial body of research has shown that measuring a person's troponin levels using Abbott's High Sensitive Troponin-I test provides better predictive information to indicate a person's chances of developing future heart disease. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. As a major breakthrough for its vascular business, Abbott LaboratoriesABT recently received a CE Mark for its High Sensitive Troponin-I diagnostic test. it is important to note that the European guidelines traditionally recommend indirect heart health factors to determine risk for developing heart disease. | As a major breakthrough for its vascular business, Abbott LaboratoriesABT recently received a CE Mark for its High Sensitive Troponin-I diagnostic test. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. However, a substantial body of research has shown that measuring a person's troponin levels using Abbott's High Sensitive Troponin-I test provides better predictive information to indicate a person's chances of developing future heart disease. |
33203.0 | 2018-09-25 00:00:00 UTC | iShares Edge MSCI USA Momentum Factor ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/ishares-edge-msci-usa-momentum-factor-etf-experiences-big-inflow-2018-09-25 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $65.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 86,950,000 to 87,500,000). Among the largest underlying components of MTUM, in trading today JPMorgan Chase & Co (Symbol: JPM) is up about 1%, Intel Corp (Symbol: INTC) is down about 1.8%, and Abbott Laboratories (Symbol: ABT) is up by about 0.4%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average:
Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $119.0671 as the 52 week high point - that compares with a last trade of $118.80. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of MTUM, in trading today JPMorgan Chase & Co (Symbol: JPM) is up about 1%, Intel Corp (Symbol: INTC) is down about 1.8%, and Abbott Laboratories (Symbol: ABT) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $65.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 86,950,000 to 87,500,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of MTUM, in trading today JPMorgan Chase & Co (Symbol: JPM) is up about 1%, Intel Corp (Symbol: INTC) is down about 1.8%, and Abbott Laboratories (Symbol: ABT) is up by about 0.4%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $119.0671 as the 52 week high point - that compares with a last trade of $118.80. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of MTUM, in trading today JPMorgan Chase & Co (Symbol: JPM) is up about 1%, Intel Corp (Symbol: INTC) is down about 1.8%, and Abbott Laboratories (Symbol: ABT) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $65.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 86,950,000 to 87,500,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $119.0671 as the 52 week high point - that compares with a last trade of $118.80. | Among the largest underlying components of MTUM, in trading today JPMorgan Chase & Co (Symbol: JPM) is up about 1%, Intel Corp (Symbol: INTC) is down about 1.8%, and Abbott Laboratories (Symbol: ABT) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $65.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 86,950,000 to 87,500,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $119.0671 as the 52 week high point - that compares with a last trade of $118.80. |
33204.0 | 2018-09-24 00:00:00 UTC | Why Abbott (ABT) is Poised to Beat Earnings Estimates Again | ABT | https://www.nasdaq.com/articles/why-abbott-abt-is-poised-to-beat-earnings-estimates-again-2018-09-24 | nan | nan | Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry.
When looking at the last two reports, this maker of infant formula, medical devices and drugs has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 2.27%, on average, in the last two quarters.
For the most recent quarter, Abbott was expected to post earnings of $0.71 per share, but it reported $0.73 per share instead, representing a surprise of 2.82%. For the previous quarter, the consensus estimate was $0.58 per share, while it actually produced $0.59 per share, a surprise of 1.72%.
Price and EPS Surprise
Thanks in part to this history, there has been a favorable change in earnings estimates for Abbott lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time . In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Abbott currently has an Earnings ESP of +0.27%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on October 17, 2018.
With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. When looking at the last two reports, this maker of infant formula, medical devices and drugs has recorded a strong streak of surpassing earnings estimates. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank. |
33205.0 | 2018-09-20 00:00:00 UTC | Abbott Banks on New Approvals and Buyouts, Competition Rife | ABT | https://www.nasdaq.com/articles/abbott-banks-on-new-approvals-and-buyouts-competition-rife-2018-09-20 | nan | nan | On Sep 19, we issued an updated research report on Abbott LaboratoriesABT . Notably, branded generics and international diabetes businesses of Abbott should drive growth in the coming quarters. Nevertheless, a competitive environment persists to raise concerns for Abbott. The stock carries a Zacks Rank #3 (Hold).
Over the past year, shares of Abbott have outperformed its industry . The stock has surged 31.9% compared with the industry's 21.5% rally.
Notably, in second-quarter 2018, Abbott once again steered past the Zacks Consensus Estimate for both earnings as well as revenues. We are also optimistic about the strong and consistent performance delivered by the company's EPD and Medical Devices segments. Also, solid contributions from Diagnostics and Nutrition businesses encourage us.
Abbott Laboratories Price
Abbott Laboratories Price | Abbott Laboratories Quote
We believe, the company's receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement nod in Japan for the same device will help it revive the dull Vascular business. Within Structural Heart, the strong worldwide uptake of MitraClip therapy further improves following the recent approval of its next-generation version by the regulatory body.
We are also impressed by Abbott's progress with Alere integration. Synergies from this consolidation in the form of revenues drawn from Rapid Diagnostics have been driving the company's growth. Meanwhile, the company's emerging market performance has been extremely promising owing to several strategic developments.
On the flip side, Abbott's sluggish pediatric business in China continues to mar growth. Management is concerned about the prevalent economic problems in Venezuela that are expected to remain unresolved for some time. Also, foreign exchange is a major headwind for Abbott as a considerable portion of its revenues comes from outside the United States.
Key Stocks
A few better-ranked stocks in the broader medical space are athenahealth ATHN , Intuitive Surgical ISRG and Veeva Systems VEEV .
athenahealth has an expected long-term earnings growth rate of 17.6%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Intuitive Surgical's expected long-term earnings growth rate is pegged at 14.7%. The stock flaunts a Zacks Rank of #1.
Veeva Systems' long-term earnings growth rate is projected at 19.3%. The stock is a Zacks #1 Ranked player.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Veeva Systems Inc. (VEEV): Free Stock Analysis Report
athenahealth, Inc. (ATHN): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Sep 19, we issued an updated research report on Abbott LaboratoriesABT . Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, branded generics and international diabetes businesses of Abbott should drive growth in the coming quarters. | Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. On Sep 19, we issued an updated research report on Abbott LaboratoriesABT . Abbott Laboratories Price Abbott Laboratories Price | Abbott Laboratories Quote We believe, the company's receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement nod in Japan for the same device will help it revive the dull Vascular business. | Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. On Sep 19, we issued an updated research report on Abbott LaboratoriesABT . Abbott Laboratories Price Abbott Laboratories Price | Abbott Laboratories Quote We believe, the company's receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement nod in Japan for the same device will help it revive the dull Vascular business. | On Sep 19, we issued an updated research report on Abbott LaboratoriesABT . Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Over the past year, shares of Abbott have outperformed its industry . |
33206.0 | 2018-09-18 00:00:00 UTC | ABT or PETQ: Which Is the Better Value Stock Right Now? | ABT | https://www.nasdaq.com/articles/abt-or-petq%3A-which-is-the-better-value-stock-right-now-2018-09-18 | nan | nan | Investors looking for stocks in the Medical - Products sector might want to consider either Abbott (ABT) or PetIQ (PETQ). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Abbott has a Zacks Rank of #2 (Buy), while PetIQ has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that ABT likely has seen a stronger improvement to its earnings outlook than PETQ has recently. But this is just one factor that value investors are interested in.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
ABT currently has a forward P/E ratio of 23.46, while PETQ has a forward P/E of 51.78. We also note that ABT has a PEG ratio of 1.89. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. PETQ currently has a PEG ratio of 2.07.
Another notable valuation metric for ABT is its P/B ratio of 3.86. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, PETQ has a P/B of 5.17.
Based on these metrics and many more, ABT holds a Value grade of B, while PETQ has a Value grade of C.
ABT is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that ABT is likely the superior value option right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
PetIQ, Inc. (PETQ): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors looking for stocks in the Medical - Products sector might want to consider either Abbott (ABT) or PetIQ (PETQ). Investors should feel comfortable knowing that ABT likely has seen a stronger improvement to its earnings outlook than PETQ has recently. ABT currently has a forward P/E ratio of 23.46, while PETQ has a forward P/E of 51.78. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report PetIQ, Inc. (PETQ): Free Stock Analysis Report To read this article on Zacks.com click here. Investors looking for stocks in the Medical - Products sector might want to consider either Abbott (ABT) or PetIQ (PETQ). Investors should feel comfortable knowing that ABT likely has seen a stronger improvement to its earnings outlook than PETQ has recently. | Based on these metrics and many more, ABT holds a Value grade of B, while PETQ has a Value grade of C. ABT is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report PetIQ, Inc. (PETQ): Free Stock Analysis Report To read this article on Zacks.com click here. Investors looking for stocks in the Medical - Products sector might want to consider either Abbott (ABT) or PetIQ (PETQ). | Investors looking for stocks in the Medical - Products sector might want to consider either Abbott (ABT) or PetIQ (PETQ). Investors should feel comfortable knowing that ABT likely has seen a stronger improvement to its earnings outlook than PETQ has recently. ABT currently has a forward P/E ratio of 23.46, while PETQ has a forward P/E of 51.78. |
33207.0 | 2018-09-18 00:00:00 UTC | Here's Why You Should Add Abbott (ABT) to Your Portfolio Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-add-abbott-abt-to-your-portfolio-now-2018-09-18 | nan | nan | Abbott ABT has been gaining investors' confidence on consistently positive results. Over the past year, the company's stock has outperformed its industry . The stock has gained 29.9%, compared with the industry's 19.8% and the S&P 500's 16.6%.
This leading developer, manufacturer and seller of a diversified line of health care products has a market cap of $120.03 billion. The company's projected earnings growth rate for the current year is favorable at 12.4% compared with the industry's 11.7%.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
The company's earnings estimate revision trend for the current year has been positive. In the past 60 days, two analysts revised the estimates upward, with no movement in the opposite direction. Resultantly, earnings estimates rose 0.7% to $2.88 per share.
Per our Zacks Style Score system, Abbott has a Growth Score of B which reflects the company's solid prospects. Our research shows that stocks with a Growth Style Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or 2 offer the best upside potential.
Let's find out whether the recent positive trend is a sustainable one.
Raised Guidance Buoys Optimism
Abbott has raised its 2018 adjusted earnings per share guidance. Adjusting for certain net specified items for the full year, adjusted earnings from continuing operations are now expected in the band of $2.85-$2.91 as compared to the earlier range of $2.80-$2.90.
Growing Medical Device Business
Abbott's Medical Devices business has been going strong of late on solid sub-segmental performance. The segment comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business.
Management expects high single-digit growth in Medical Devices' third-quarter 2018 sales along with continued double-digit growth at certain sub-segments.
In the last quarter, sales improvement at the segment was driven by strong double-digit growth in Electrophysiology, Structural Heart and Diabetes Care. Moreover, the company received approvals for a few products alongside achieving clinical trial milestones.
Progress with Diabetes BusinessImpressive
There have been a slew of developments within the Diabetics business. We are upbeat about Abbott's FreeStyle Libre Flash Glucose Monitoring System's recent reimbursement approval in the United States and the United Kingdom.
Plus, the company announced receipt of Health Canada License and Japanese national reimbursement for the same. In May 2017, the company received full or partial reimbursement from the French Health Ministry for the product. With these positives in place, Abbott's FreeStyle Libre system stands partially or fully covered in 21 countries.
Other Key Picks
A few other top-ranked stocks in the broader medical space are Intuitive Surgical ISRG , Amedisys, Inc. AMED and Masimo Corporation MASI .
Intuitive Surgical's long-term expected earnings growth rate is 14.7%. The stock currently carries a Zacks Rank of 1. You can see the complete list of today's Zacks #1 Rank stocks here.
Amedisys' long-term expected earnings growth rate is 18.6%. The stock holds a Zacks Rank #1 at the moment.
Masimo's long-term expected earnings growth rate is 14.8%. The stock holds a Zacks Rank #2 at present.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT has been gaining investors' confidence on consistently positive results. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Our research shows that stocks with a Growth Style Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or 2 offer the best upside potential. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has been gaining investors' confidence on consistently positive results. Per our Zacks Style Score system, Abbott has a Growth Score of B which reflects the company's solid prospects. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has been gaining investors' confidence on consistently positive results. Per our Zacks Style Score system, Abbott has a Growth Score of B which reflects the company's solid prospects. | Abbott ABT has been gaining investors' confidence on consistently positive results. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment. |
33208.0 | 2018-09-18 00:00:00 UTC | Medical - Products Stock Outlook: Short-Term Pain Inevitable | ABT | https://www.nasdaq.com/articles/medical-products-stock-outlook%3A-short-term-pain-inevitable-2018-09-18 | nan | nan | The medical products sector has been gaining prominence on the back of encouraging demographics, changing market dynamics toward Artificial Intelligence (AI), big-data applications and increased business investments.
However, the space witnesses hindrance from short-term hurdles associated with the U.S.-China trade war.
Yesterday, the Trump administration announced a new round of tariffs (almost 10%) on about $200 billion on Chinese imports, effective from Sep 24. By Jan 1, 2019, the tariffs are likely to rise to 25%. Not to forget, a significant amount of these imports are medical products, devices and medical imaging components.
According to a recent survey conducted by the Medical Imaging & Technology Alliance (MITA), the tariffs will cost the medical products companies nearly $140 million per year. Thus, the companies will be compelled to reduce U.S. workforces and their investments in R&D to fund this 'new and unnecessary expense'. Peter Roff, Fox News, criticized the latest decision and stated, " The American people, some businesses and the nation's health care will all be harmed to a considerable degree by the imposition of tariffs President Trump announced Monday ".
Despite these short-term geo-political uncertainties, the long-term prospects of the Medical - Products industry are bright at the moment.
In the past decade, the industry has witnessed major improvements in precision surgeries, gene therapies, hybrid closed-loop insulin delivery systems, continuous glucose-monitoring platforms, centralized monitoring of hospital patients and electronic health records (EHR). Additionally, a bipartisan two-year suspension of a 2.3% excise tax on Medical Product and Medical Device manufacturers at the beginning of 2018 has encouraged massive investments in the sector.
Industry Performance vs. S&P 500
The Zacks Medical - Products Industry, within the broader Zacks Medical Sector, has outperformed the Zacks S&P 500 Composite and its own sector in the past year. While stocks in the industry have collectively gained 21.2%, the Zacks S&P 500 Composite improved 16.5% and the Zacks Medical Sector rose 9.8%.
One-Year Price Performance
Looking at shareholders' returns over the past year, it is quite apparent that investors are quite optimistic about the industry's prospects.
The industry is catching up with the digital-data age. The latest trend of adopting EHR, Electronic Medical Records and Predictive Analytical services has been gaining popularity in the U.S. MedTech space.
However, headwinds such as increased operating expenses on account of higher R&D investments cannot be ignored. This may strain margins in the short run.
Zacks Medical - Products Stocks Trading Cheap
In spite of outperforming the broader market in the past year, the Medical - Products industry has been trading quite cheap right now.
Valuation is a tricky business for the medical product companies. Not to forget, these companies invest significantly on unplanned R&D and hence it is difficult to account for such high expenses. However, one might gain a fair idea of the industry's relative valuation from its Price/Book ratio.
The industry currently has a Price/Book TTM ratio of 3.35, which is significantly above the median level of 2.84.
The space also looks inexpensive compared with the Medical market at large, as the current Price/Book TTM ratio for the Medical sector is 4.50 and the median Price/Book TTM ratio is 3.17.
Price-to-Book Trailing Twelve Months (TTM)
The space looks inexpensive compared with the Zacks S&P 500 composite. The current ratio for the S&P 500 is 4.08 and the median level is 3.84. So, the figures are above the medical products industry's respective ratios.
Price-to-Book Trailing Twelve Months (TTM)
Dim Earnings Outlook Keeps Us Cautious
Despite the strong price movements and inexpensive nature of the medical products stocks, there are a few factors that have been denting the industry's growth in the short term. Of the major issues, trade-war definitely tops the list.
Further, there has been regulatory hurdles in the space. For instance, the Unique Device Identification (UDI) system by the FDA has been quite costly and difficult to implement for the medical product manufacturers.
Adding to the woes, the medical-device tax repeal amendment is a temporary relief for manufacturers. It will be back again in 2020.
One reliable metric that can give investors an idea of the industry's future price performance is its earnings outlook. Empirical research shows that earnings outlook for the industry, projecting the earnings revision trend for the constituent companies, has a direct bearing on its stock market performance.
The Price & Consensus chart for the industry indicates the market's evolving bottom-up earnings expectations for and the industry's aggregate stock market performance. The red line in the chart represents the Zacks measure of consensus earnings expectations for 2019, while the light blue line shows the same for 2018.
Price and Consensus: Medical - Products industry
Please note that the $2.52 EPS estimate for the industry for 2018 is not the actual bottom-up EPS estimate for every company in the Zacks Medical - Products industry, but rather an illustrative aggregate number created by our proprietary analytics model. The key factor to keep in mind is not the EPS of the industry for 2018 but how this estimate has been moving recently.
This becomes clear by focusing on the aggregate EPS revisions trend. The chart below shows the evolution of aggregate consensus expectations for 2018.
Current Fiscal Year EPS Estimate Revisions
As you can see, the $2.52 EPS estimate for the Zacks Medical - Products industry implies a deterioration of 7.7% on a year-over-year basis.
Looking at the earnings estimate revisions, it appears that analysts are losing confidence in this group's earnings potential. This could possibly be due to the challenges associated with the continuous technological advancements within the Medical - Products industry and trade-war fears.
Zacks Industry Rank Indicates Bleak Near-Term Prospects
The group's Zacks Industry Rank , which is basically the average of the Zacks Rank of all the member stocks, indicates underperformance in the near term.
The Zacks categorized Medical - Products industry currently carries a Zacks Industry Rank #180, which places it in the bottom 30% of more than 250 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Our proprietary Heat Map shows that the industry's rank was in the bottom 40% for the past three weeks.
Medical - Products Industry Promises Long-Term Growth
Interistingly, the long-term prospects for the industry indicate steady growth. When compared with the broader Zacks S&P 500 composite, the long-term (3-5 years) EPS growth estimate for the Zacks Medical - Products industry of 10.4% appears promising. The corresponding figure for the Zacks S&P 500 composite is 9.8%.
The group's mean estimate of long-term EPS growth rate has been declining from the high of 10.7% achieved in December 2017, and the current estimates are near the median level in a year's time.
Mean Estimate of Long-Term EPS Growth Rate
In fact, the basis of this long-term EPS growth could be a steady increase in the top line that the Medical - Products industry has seen since the end of 2014.
Bottom Line
The U.S.-China trade war is gradually becoming more intense with no signs of relaxation anytime soon.
If China takes further retaliatory action on yesterday's decision, Trump has promised to impose higher tariffs (phase three) that will be on $267 billion of additional Chinese imports. Needless to say, this has triggered a short-term decline in the sector. Thus, the Medical - Products industry might not be able to tide over the broader challenges in the near term.
However, keeping the long-term expectations in mind, investors can take advantage of the cheap valuation and bet on a few medical product stocks that have a strong earnings outlook.
Here we pick stocks from the Medical - Products industry with a Zacks Rank #1 (Strong Buy) or 2 (Buy), which have seen positive earnings estimate revision. You can see the complete list of today's Zacks #1 Rank stocks here .
Surmodics, Inc. (SRDX): Headquartered in Eden Prairie, MN, Surmodics is a leading provider of medical devices and In Vitro Diagnostics (IVD) technologies to the healthcare industry. The stock flaunts a Zacks Rank #1.
The Zacks Consensus Estimate for current-year earnings is pegged at 43 cents, up from a loss of 2 cents estimated 60 days ago. Surmodics' shares have returned 156% in a year's time.
Price and Consensus: SRDX
Quidel Corporation
The Zacks Consensus Estimate for current-year earnings increased 7.7% in the past 60 days. The stock has returned 64.3% in a year's time.
Price and Consensus: QDEL
ICU Medical, Inc. (ICUI): Headquartered in San Clemente, California, ICU Medical develops, manufactures and sells medical devices used in vascular therapy, critical care as well as oncology applications worldwide. The stock sports a Zacks Rank #1.
The Zacks Consensus Estimate for current-year earnings increased 13.7% in the past 60 days. The stock has returned 49.7% in a year's time.
Price and Consensus: ICUI
Abbott Laboratories (ABT): Abbott Park, IL-based Abbott discovers, develops, manufactures and sells a diversified line of health care products. The stock has a Zacks Rank #2.
The Zacks Consensus Estimate for current-year earnings increased 15.2% on a year-over-year basis. Abbott's shares have returned 29.9% in a year's time.
Price and Consensus: ABT
New Report: An Investor's Guide to Cybersecurity
Cyberattacks have become more frequent and destructive than ever. In fact, they're expected to cause $6 trillion per year in damage by 2020.
The cybersecurity industry is expanding quickly in response to these threats. In fact, a projected $170 billion per year will be spent to protect consumer and corporate assets. Zacks has just released Cybersecurity: An Investor's Guide to Locking Down Profits which reveals 4 promising investment candidates.
Download the new report now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
Quidel Corporation (QDEL): Free Stock Analysis Report
ICU Medical, Inc. (ICUI): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Price and Consensus: ICUI Abbott Laboratories (ABT): Abbott Park, IL-based Abbott discovers, develops, manufactures and sells a diversified line of health care products. Price and Consensus: ABT New Report: An Investor's Guide to Cybersecurity Cyberattacks have become more frequent and destructive than ever. Click to get this free report Surmodics, Inc. (SRDX): Free Stock Analysis Report Quidel Corporation (QDEL): Free Stock Analysis Report ICU Medical, Inc. (ICUI): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Surmodics, Inc. (SRDX): Free Stock Analysis Report Quidel Corporation (QDEL): Free Stock Analysis Report ICU Medical, Inc. (ICUI): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Price and Consensus: ICUI Abbott Laboratories (ABT): Abbott Park, IL-based Abbott discovers, develops, manufactures and sells a diversified line of health care products. Price and Consensus: ABT New Report: An Investor's Guide to Cybersecurity Cyberattacks have become more frequent and destructive than ever. | Price and Consensus: ICUI Abbott Laboratories (ABT): Abbott Park, IL-based Abbott discovers, develops, manufactures and sells a diversified line of health care products. Price and Consensus: ABT New Report: An Investor's Guide to Cybersecurity Cyberattacks have become more frequent and destructive than ever. Click to get this free report Surmodics, Inc. (SRDX): Free Stock Analysis Report Quidel Corporation (QDEL): Free Stock Analysis Report ICU Medical, Inc. (ICUI): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. | Price and Consensus: ICUI Abbott Laboratories (ABT): Abbott Park, IL-based Abbott discovers, develops, manufactures and sells a diversified line of health care products. Price and Consensus: ABT New Report: An Investor's Guide to Cybersecurity Cyberattacks have become more frequent and destructive than ever. Click to get this free report Surmodics, Inc. (SRDX): Free Stock Analysis Report Quidel Corporation (QDEL): Free Stock Analysis Report ICU Medical, Inc. (ICUI): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. |
33209.0 | 2018-09-17 00:00:00 UTC | Cyber Attack Fears Grip MedTech: 3 Safe Stocks | ABT | https://www.nasdaq.com/articles/cyber-attack-fears-grip-medtech-3-safe-stocks-2018-09-17 | nan | nan | Technological advancements can at times be a bane. Medical devices linked to the cloud and the Internet of Things (IoT) are now quite a double-edged sword. While they effectively enhance the treatment procedure, these devices are exposed to cyber risks.
Any wearable and implantable patient monitoring or therapy device with features like wireless connectivity to alter device functionality and extract patient information can now be hacked.
For instance, in April, the FDA had to issue a Safety Communication to inform the patients about the availability of an additional firmware update to combat with the confirmed cybersecurity risks discovered in Abbott Laboratories' ABT implantable cardiac devices along with managing rapid battery depletion.
This is not the only mention of the need to ensure cyber security. A recent survey report by KPMG revealed that around 81% of health care organizations experienced data breach over a two-year period beginning 2015-end (per an article published on 24x7). Going by the same article, medical device threats are ranked as a top information security issue by around one-third of industry executives.
Furthermore, according to the 2018 Cost of a Data Breach Study released by the Ponemon Institute, the average cost of a successful cyberattack across all industries is $3.8 million (per an article from Health Care on Bloomberg Law).
This has developed apprehension in investors who had once considered investing in the MedTech space as relatively safe.
FDA's Stance on Cyber Risk
A series of incidences like the 2017 WannaCry and Petya ransomware attacks which wreaked havoc on several health care systems worldwide have been continuously drawing attention of regulators. Furthermore, a report published by McAfee, a cyber security company, puts spotlight on the possibility to alter real-time patient heart monitor data by hacking into a hospital network and gaining control of medical devices.
However, the FDA has been working on combating cyber risks since 2013 with the creation of 'cybersecurity working group' and has been continuously evolving its device program alongside changes in medical technology and advancements in the systems.
Encouragingly, in April, the FDA announced its Medical Device Safety Action Plan involving changes to the pre- and post-market requirements. As part of the changes, manufacturers will be required to develop 'Software Bills of Materials' to be submitted to the FDA during premarket reviews and also handed over to customers and end-users to allow for improved management of networked devices and technologies.
At the same time, the FDA has proposed the formation of the CyberMed Safety (Expert) Analysis Board (CYMSAB). In this regard, we encouragingly note that the proposed federal budget for 2019 by the Trump Administration includes funding to create the CYMSAB (per an article published on Emergo by UL).
Combating Cyber Risk: A Tough Challenge for MedTech Players
There is a growing need for medical device manufacturers to prevent hacking in case of network-connected medical devices.
Most of the analysts are of the opinion that a major hurdle faced by medical device makers is that by the time a product hits the market post approval, which takes five to six years, the technology on which it is based becomes outdated.
Further, per an article published on The Wall Street Journal, several product engineers and architects lack the training necessary for designing safe and secure medical devices.
Going by the same article, manufacturers are believed to have comparatively weaker incident response processes which make it difficult to screen, respond or contain breaches at the time of occurrence. Furthermore, inadequate staff for addressing device security needs is a challenge.
3 Stocks to Escape the Cyber Risks
In the wake of rising threats to cybersecurity of medical devices, investors must be in continuous search for stocks who for the time being safe havens. In this regard, we have zeroed down on some medical information system stocks.
The medical information systems industry comprises a number of companies which develop and market healthcare information systems. These firms offer software and hardware solutions that provide healthcare providers with secure access to clinical, administrative and financial data in a time efficient manner.
The latest trend of electronic health records, electronic medical records, predictive analytics, real-time alerting and revenue cycle management services in the U.S. MedTech space has been gaining prominence.
Here we pick three stocks from the Medical Info Systems industry which make perfect investment choices for your portfolio.
athenahealth, Inc.ATHN : The stock of this Zacks Rank #1 (Strong Buy) and Watertown, MA-based cloud-based network provider of services that manage the administrative duties of medical providers has gained 13.5% over the past year. The company's Bridges suite of solutions support cyber and compliance requirements for healthcare organizations. The Zacks Consensus Estimate for its current-year EPS has been revised 3.2% upward over the last 30 days. You can see the complete list of today's Zacks #1 Rank stocks here.
HMS Holdings CorpHMSY : Headquartered in Irving, TX, HMS Holdings provides cost-containment solutions in the U.S. healthcare space. The stock has a Zacks Rank #2 (Buy).
Last year, HMS Holdings announced the acquisition of patient engagement specialist Eliza Corporation for $170 million in cash. Eliza offers SaaS services to employers, providers, health plans, hospitals, pharmacies and clinics for medication adherence. In the second quarter of 2018, Eliza completed a special project, which generated revenues of approximately $1.5 million. Management expects Eliza growth to be relatively flat in the third quarter. However, revenues are expected to grow significantly in the fourth quarter.
HMS Holdings has rallied 77.3% in a year's time.
Fulgent Genetics, Inc.FLGT
This Zacks Rank #2 company has however, declined by 29.2% in a year's time.
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
HMS Holdings Corp (HMSY): Free Stock Analysis Report
athenahealth, Inc. (ATHN): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
FULGENT GENETIC (FLGT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For instance, in April, the FDA had to issue a Safety Communication to inform the patients about the availability of an additional firmware update to combat with the confirmed cybersecurity risks discovered in Abbott Laboratories' ABT implantable cardiac devices along with managing rapid battery depletion. Click to get this free report HMS Holdings Corp (HMSY): Free Stock Analysis Report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report FULGENT GENETIC (FLGT): Free Stock Analysis Report To read this article on Zacks.com click here. FDA's Stance on Cyber Risk A series of incidences like the 2017 WannaCry and Petya ransomware attacks which wreaked havoc on several health care systems worldwide have been continuously drawing attention of regulators. | Click to get this free report HMS Holdings Corp (HMSY): Free Stock Analysis Report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report FULGENT GENETIC (FLGT): Free Stock Analysis Report To read this article on Zacks.com click here. For instance, in April, the FDA had to issue a Safety Communication to inform the patients about the availability of an additional firmware update to combat with the confirmed cybersecurity risks discovered in Abbott Laboratories' ABT implantable cardiac devices along with managing rapid battery depletion. Furthermore, a report published by McAfee, a cyber security company, puts spotlight on the possibility to alter real-time patient heart monitor data by hacking into a hospital network and gaining control of medical devices. | Click to get this free report HMS Holdings Corp (HMSY): Free Stock Analysis Report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report FULGENT GENETIC (FLGT): Free Stock Analysis Report To read this article on Zacks.com click here. For instance, in April, the FDA had to issue a Safety Communication to inform the patients about the availability of an additional firmware update to combat with the confirmed cybersecurity risks discovered in Abbott Laboratories' ABT implantable cardiac devices along with managing rapid battery depletion. Combating Cyber Risk: A Tough Challenge for MedTech Players There is a growing need for medical device manufacturers to prevent hacking in case of network-connected medical devices. | For instance, in April, the FDA had to issue a Safety Communication to inform the patients about the availability of an additional firmware update to combat with the confirmed cybersecurity risks discovered in Abbott Laboratories' ABT implantable cardiac devices along with managing rapid battery depletion. Click to get this free report HMS Holdings Corp (HMSY): Free Stock Analysis Report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report FULGENT GENETIC (FLGT): Free Stock Analysis Report To read this article on Zacks.com click here. Combating Cyber Risk: A Tough Challenge for MedTech Players There is a growing need for medical device manufacturers to prevent hacking in case of network-connected medical devices. |
33210.0 | 2018-09-13 00:00:00 UTC | Daily Dividend Report: ABT, BMY, ZBH, CW, NFG | ABT | https://www.nasdaq.com/articles/daily-dividend-report-abt-bmy-zbh-cw-nfg-2018-09-13 | nan | nan | Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. The cash dividend is payable Nov. 15, 2018, to shareholders of record at the close of business on Oct. 15, 2018.
Bristol-Myers Squibb Company ( BMY ) declared a quarterly dividend of forty cents ($0.40) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on November 1, 2018, to stockholders of record at the close of business on October 5, 2018.
Zimmer Biomet Holdings ( ZBH ) has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2018. The cash dividend of $0.24 per share is payable on October 31, 2018 to stockholders of record as of the close of business on September 28, 2018.
Curtiss-Wright Corporation ( CW ) announced that the Board of Directors declared a dividend of fifteen cents ($0.15) per share on Curtiss-Wright Common Stock, payable October 18, 2018 to stockholders of record October 4, 2018.
National Fuel Gas Company ( NFG ) approved a regular quarterly dividend of 42.5 cents per share on the Company's common stock. The dividend is payable Oct. 15, 2018, to shareholders of record at the close of business on Sept. 28, 2018.
VIDEO: Daily Dividend Report: ABT, BMY, ZBH, CW, NFG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. VIDEO: Daily Dividend Report: ABT, BMY, ZBH, CW, NFG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bristol-Myers Squibb Company ( BMY ) declared a quarterly dividend of forty cents ($0.40) per share on the $.10 par value Common Stock of the corporation. | VIDEO: Daily Dividend Report: ABT, BMY, ZBH, CW, NFG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. Curtiss-Wright Corporation ( CW ) announced that the Board of Directors declared a dividend of fifteen cents ($0.15) per share on Curtiss-Wright Common Stock, payable October 18, 2018 to stockholders of record October 4, 2018. | VIDEO: Daily Dividend Report: ABT, BMY, ZBH, CW, NFG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. The next quarterly dividend will be payable on November 1, 2018, to stockholders of record at the close of business on October 5, 2018. Zimmer Biomet Holdings ( ZBH ) has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2018. | Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. VIDEO: Daily Dividend Report: ABT, BMY, ZBH, CW, NFG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The next quarterly dividend will be payable on November 1, 2018, to stockholders of record at the close of business on October 5, 2018. Zimmer Biomet Holdings ( ZBH ) has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2018. |
33211.0 | 2018-09-10 00:00:00 UTC | The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbott-gilead-fedex-archer-daniels-and-cbre-2018-09-10 | nan | nan | For Immediate Release
Chicago, IL -September 10, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbottABT , GileadGILD , FedExFDX , Archer DanielsADM and CBRE GroupCBRE .
Here are highlights from Friday's Analyst Blog:
Top Research Reports for Abbott, Gilead and FedEx
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Abbott, Gilead and FedEx. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Abbott 's shares have gained +26.5% over the past year, outperforming the Zacks Medical Products industry, which has gained +18.7% over the same period. The Zacks analyst likes the strong and consistent performance across all segments by Abbott in the last reported quarter.
Within Structural Heart, worldwide strong uptake of MitraClip therapy improves further following the recent FDA approval of its next-generation version. This apart, synergies from Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth.
Meanwhile, emerging market performance has been extremely promising. The company has been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre. On the flip side, sluggish Vascular business continues to dent growth. However, the FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan should help Abbott to revive the dull Vascular business.
Shares of Strong Buy-ranked Gilead have outperformed the Zacks Biotech industry year to date, gaining +1.7% vs. a decline of -4.9%. The Zacks analyst thinks Gilead's HIV franchise maintains momentum driven by the rapid adoption of Descovy-based regimens.
The FDA approval of Biktarvy has further widened the portfolio. Biktarvy has also been approved in Europe which should boost sales further. The launch of Yescarta is progressing well in the United States and the approval in Europe will further boost sales.
Meanwhile, Gilead is intending to foray into the nonalcoholic steatohepatitis (NASH) and inflammation market with late-stage candidates, selonsertib and filgotinib, respectively. A tentative approval will diversify Gilead's portfolio. However, Gilead's HCV franchise is under pressure due to competitive and pricing pressure. The departure of the CEO at this crucial time further clouds the growth prospects of the company.
FedEx 's shares have outperformed the Zacks Air Freight and Cargo industry (+16.9% vs. +10.2%) and rival United Parcel Service (+7.6%) in the past year. The Zacks analyst thinks a buoyant U.S. economy and e-commerce growth has been aiding the company.
Additionally, higher shipping rates and volume growth are huge positives for FedEx. Meanwhile, lower tax rates are boosting the company's bottom-line performance. FedEx's decision to reward its shareholders through dividend payments and share buybacks is impressive. However, high costs are hurting the bottom line.
Significant investments at the company's key divisions are pushing up costs as well. Capital expenses are estimated at $5.6 billion for fiscal 2019. Trade-war related fears are also weighing on FedEx.
Other noteworthy reports we are featuring today include Archer Daniels and CBRE Group.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
FedEx Corporation (FDX): Free Stock Analysis Report
Archer Daniels Midland Company (ADM): Free Stock Analysis Report
CBRE Group, Inc. (CBRE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: AbbottABT , GileadGILD , FedExFDX , Archer DanielsADM and CBRE GroupCBRE . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report Archer Daniels Midland Company (ADM): Free Stock Analysis Report CBRE Group, Inc. (CBRE): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks analyst thinks Gilead's HIV franchise maintains momentum driven by the rapid adoption of Descovy-based regimens. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report Archer Daniels Midland Company (ADM): Free Stock Analysis Report CBRE Group, Inc. (CBRE): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: AbbottABT , GileadGILD , FedExFDX , Archer DanielsADM and CBRE GroupCBRE . Here are highlights from Friday's Analyst Blog: Top Research Reports for Abbott, Gilead and FedEx The Zacks Research Daily presents the best research output of our analyst team. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report Archer Daniels Midland Company (ADM): Free Stock Analysis Report CBRE Group, Inc. (CBRE): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: AbbottABT , GileadGILD , FedExFDX , Archer DanielsADM and CBRE GroupCBRE . Here are highlights from Friday's Analyst Blog: Top Research Reports for Abbott, Gilead and FedEx The Zacks Research Daily presents the best research output of our analyst team. | Stocks recently featured in the blog include: AbbottABT , GileadGILD , FedExFDX , Archer DanielsADM and CBRE GroupCBRE . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report Archer Daniels Midland Company (ADM): Free Stock Analysis Report CBRE Group, Inc. (CBRE): Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including Abbott, Gilead and FedEx. |
33212.0 | 2018-09-07 00:00:00 UTC | Noteworthy ETF Inflows: XLV, MDT, ABT, BMY | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-xlv-mdt-abt-bmy-2018-09-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $115.4 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 196,315,324 to 197,565,324). Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is relatively unchanged. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $93.11 as the 52 week high point - that compares with a last trade of $92.43. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $115.4 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 196,315,324 to 197,565,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is relatively unchanged. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $93.11 as the 52 week high point - that compares with a last trade of $92.43. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $115.4 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 196,315,324 to 197,565,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $93.11 as the 52 week high point - that compares with a last trade of $92.43. | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $115.4 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 196,315,324 to 197,565,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $93.11 as the 52 week high point - that compares with a last trade of $92.43. |
33213.0 | 2018-09-06 00:00:00 UTC | 7 Lucrative Biotech Stocks With Up to 300% Upside | ABT | https://www.nasdaq.com/articles/7-lucrative-biotech-stocks-300-upside-2018-09-06 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Forget market dynamics. These biotechs are playing to their own tune. According to the Street's top analysts this can be a very lucrative path. Biotech stocks can spike massively on positive news - be it key trial results or regulatory approvals. Of course, the opposite is also true and the biotech sector can crash just as quickly on unexpected disappointments.
But the key point remains: Biotechs provide an outlet away from the rest of the market to potentially make serious money. That's especially welcome in the month of September - a notoriously tricky time for the markets. Indeed, September has been the worst performing month of the year for the Dow Jones Industrial Average and the S&P 500 since 1950.
Your Chance to Cash In With Legal Sports Betting
With that in mind, let's now turn to these seven strong buy biotechs now. I used TipRanks to ensure two crucial points: 1) big support from the Street, especially from top-performing analysts and 2) eye-watering upside potential ahead. Now let's see how these stocks tick these two boxes:
Biotech Stocks to Buy: ObsEva (OBSV)
ObsEva (NASDAQ: OBSV ) is developing best-in-class drug candidates to improve women's reproductive health. The lead is Linzagolix (OBE2109), a potentially best-in-class orally-dosed GnRH antagonist to treat symptoms of endometriosis (Ph2b) and uterine fibroids (Ph3).
Top HC Wainwright analyst Ram Selvaraju ( Profile & Recommendations ) is very bullish on the stock's potential. He has just reiterated his "buy" rating with a $44 price target. From current levels that indicates massive upside potential of 237%!
He notes that just-released data from AbbVie Inc (NYSE: ABBV ) reduces the risk for OBSV's Linzagolix. "In our view, the long-term efficacy for elagolix should bode well for future development of linzagolix in uterine fibroids, since both drugs are GnRH receptor antagonists and have shown comparable potency in clinical studies."
However, one of the key advantages for Linzagolix is the potential to be administered in certain patients without needing add-back therapy (ABT). This is the addition of a small amount of the hormones estrogen and/or progesterone to reduce undesirable effects of GnRH.
Overall, six analysts have published back-to-back buy ratings on OBSV stock. This is with a $32 price target (147% upside potential). See what other Top Analysts are saying about OBSV .
Biotech Stocks to Buy: Tocagen Inc (TOCA)
This cutting-edge biotech stock is at the forefront of cancer therapy. Tocagen Inc (NASDAQ: TOCA ) is developing an RRV platform that can selectively deliver therapeutic genes into the DNA of cancer cells.
Right now, all eyes are on Toca 511 and Toca FC. These drugs are in pivotal Phase 3 trials for recurrent high-grade gliomas (HGGs), with data due in 1H19. These are extremely difficult to treat cancers.
"Given the robustness of overall datasets so far, we model $877.6 mm in 40% risk-adjusted 2030E sales for Toca 511 & Toca FC in HGGs, which drives our $30 PT and buy rating for TOCA" explains Chardan's Gbola Amusa ( Profile & Recommendations ). This translates into 208% upside potential from the current share price of just $9.75.
This five-star analyst sees important differentiators between TOCA's offerings and previously failed therapies. For example, Toca 511 & Toca FC succeeded in gaining both Breakthrough Therapy Designation (BTD) and PRIME designation. "We believe regulators were motivated by the greater robustness of Tocagen's data, which has undergone academic scrutiny" writes Amusa.
20 Consumer Discretionary Stocks to Bolster Your Portfolio
In total, four analysts have published buy ratings on TOCA stock in the last three months. Their average analyst price target of $19.88 suggests prices can more than double. See what other Top Analysts are saying about TOCA .
Biotech Stocks to Buy: Nightstar Therapeutics (NITE)
Nightstar Therapeutics (NASDAQ: NITE ) is revolutionizing the treatment of blinding eye diseases. It's dealing with rare inherited retinal diseases that would otherwise progress to blindness. Encouragingly, Nightstar is easily ahead of competitors MeiraGTx (NASDAQ: MGTX ) and Applied Genetic Tech Corp (NASDAQ: AGTC ).
And a crucial date is fast approaching. Nightstar is due to report preliminary data from its X-Linked Retinitis Pigmentosa (XLRP) program on Sept. 22 at the European Society of Retina Specialists (EURETINA) meeting in Austria.
"We believe the data will be an important catalyst for shares" says five-star Mizuho Securities analyst Difei Yang ( Profile & Recommendations ). She has just reiterated her "buy" rating on the stock with a $24 price target.
Yang continues: "In our view, positive results would further validate the Nightstar platform and would be a significant de-risking event for the XLRP program which we believe is given minimal credit for now. We would be buyers ahead of this binary event."
The average analyst price target is currently at $33 (52% upside potential). This is from three analysts who have all published recent buy ratings on the stock. See what other Top Analysts are saying about NITE .
Biotech Stocks to Buy: Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) is developing novel RNAi-based therapies to treat a wide range of debilitating diseases with high unmet medical need. The involves a cellular mechanism that use the gene's own DNA sequence of gene to turn it off, known as silencing.
On Aug. 10, ALNY announced FDA approval for lead product candidate ONPATTRO for hATTR Polyneuropathy - a disease caused by the buildup of protein. Onpattro is the first approved drug using an RNAi to treat a disease.
The drug has also now received European approval - way earlier than expected. "We consider this a positive event for ALNY shares, as it initiates the commercial launch of Onpattro in Europe, an important market for hATTR disease" cheers B.Riley FBR's Madhu Kumar ( Profile & Recommendations ).
This five-star analyst has a $230 price target on the stock (87% upside potential). And he has a word of advice for investors: "We believe ALNY shares could face volatility during the early phase of the Onpattro launch. As such, we would view any initial weakness as an especially attractive entry point."
5 Penny Stocks You'd Have to Be Crazy to Buy
Overall, this strong buy stock has received 10 buy ratings versus just one hold rating and one sell rating. This is in the last three months. These analysts have an average price target of $149. See what other Top Analysts are saying about ALNY .
Biotech Stocks to Buy: Sorrento Therapeutics (SRNE)
Sorrento Therapeutics, Inc (NASDAQ: SRNE ) is a clinical-stage biopharma developing new therapies to turn malignant cancers into manageable and possibly curable diseases. This includes everything from antibodies to pain management.
For top HC Wainwright analyst Ram Selvaraju ( Profile & Recommendations ) this stock could climb all the way to $40. Considering that the current share price is just $5.55, we are looking at mind-blowing upside potential of 620%. This values SRNE at $6.4 billion based on a sum-of-the-parts approach, and assuming 159 million shares outstanding as of end 2Q 2019.
So what's driving this extremely bullish sentiment? A key element is the company's plethora of immuno-oncology technology platforms. According to Selvaraju "any one of these could be the basis of a transformative or validating strategic transaction."
He notes a very lucrative recent transaction between Affimed NV and Genentech, Inc. as setting a strong precedent. Currently, however, the market does not appear to be valuing Sorrento's various platforms in this regard, says this top analyst.
In total, three analysts have published buy ratings on the stock in the last three months. This is with a slightly more conservative average price target of $22 - although 290% upside doesn't sound too bad! See what other Top Analysts are saying about SRNE .
Biotech Stocks to Buy: Galmed Pharmaceuticals (GLMD)
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) has exploded by 80% in just the last three months. The catalyst: the release of much-anticipated one-year biopsy results for NASH (non-alcoholic steatohepatitis, a type of fatty liver disease) for its lead drug Aramchol. Bear in mind, NASH represents a huge untapped pharma market, which affects up to 18 million Americans today.
"We believe Aramchol's result for NASH resolution without worsening of fibrosis to be unequivocally positive" gushes top HC Wainwright analyst Ed Arce ( Profile & Recommendations ). This came with "excellent" safety and tolerability results. He sees shares climbing by a further 166% to hit $36.
Plus the drug now has a strong foundation for the critical Phase 3 trials. Following a call with management, Arce notes that the Phase 3 trial should start end of 1Q19 or early 2Q19 at a cost of around $75 million.
7 Mid-Cap Stocks to Sell Now
No less than seven analysts have published recent buy ratings on the stock. These analysts have an average price target on Galmed of $36.60 (169% upside). See what other Top Analysts are saying about GLMD .
Biotech Stocks to Buy: Spring Bank Pharmaceuticals (SBPH)
Last but not least we have budding biotech Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ). The company, founded in 2002, is developing treatments using its small molecule nucleic acid hybrid (SMNH) technology.
Alongside collaborator Gilead Sciences, Inc. (NASDAQ: GILD ), SBPH is working on the lead asset, inarigivir, for chronic hepatitis B (HBV). Following on the success of curative hepatitis C (HCV) therapies, HBV cures would present an excitingglobal marketopportunity.
"With 270 mm chronic HBV patients worldwide and 17 mm in the US and Europe, chronic HBV represents a substantial unmet medical need" comments top Chardan Capital analyst Gbola Amusa ( Profile & Recommendations ). Indeed, his $45 price target indicates an incredible 228% upside potential from current levels.
Luckily the drug continues to demonstrate impressive efficacy. Based on impressive data, SBPH has now fast-tracked inarigivir into phase 2b/3 trials. "To us, this acceleration of the clinical program and the increased involvement of Gilead in the development of inarigivir is a strong positive for this approach focusing on immunomodulation" says Amusa.
In total, the stock has received five recent buy ratings. This is with a $31 price target (126% upside potential). See what other Top Analysts are saying about SBPH .
TipRanks.com offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more. See what the experts are saying about your stocks now at TipRanks.com . As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities.
Compare Brokers
The post 7 Lucrative Biotech Stocks With Up to 300% Upside appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, one of the key advantages for Linzagolix is the potential to be administered in certain patients without needing add-back therapy (ABT). "In our view, the long-term efficacy for elagolix should bode well for future development of linzagolix in uterine fibroids, since both drugs are GnRH receptor antagonists and have shown comparable potency in clinical studies." Nightstar is due to report preliminary data from its X-Linked Retinitis Pigmentosa (XLRP) program on Sept. 22 at the European Society of Retina Specialists (EURETINA) meeting in Austria. | However, one of the key advantages for Linzagolix is the potential to be administered in certain patients without needing add-back therapy (ABT). Now let's see how these stocks tick these two boxes: Biotech Stocks to Buy: ObsEva (OBSV) ObsEva (NASDAQ: OBSV ) is developing best-in-class drug candidates to improve women's reproductive health. Biotech Stocks to Buy: Nightstar Therapeutics (NITE) Nightstar Therapeutics (NASDAQ: NITE ) is revolutionizing the treatment of blinding eye diseases. | However, one of the key advantages for Linzagolix is the potential to be administered in certain patients without needing add-back therapy (ABT). Biotech Stocks to Buy: Tocagen Inc (TOCA) This cutting-edge biotech stock is at the forefront of cancer therapy. 20 Consumer Discretionary Stocks to Bolster Your Portfolio In total, four analysts have published buy ratings on TOCA stock in the last three months. | However, one of the key advantages for Linzagolix is the potential to be administered in certain patients without needing add-back therapy (ABT). Biotech Stocks to Buy: Tocagen Inc (TOCA) This cutting-edge biotech stock is at the forefront of cancer therapy. Yang continues: "In our view, positive results would further validate the Nightstar platform and would be a significant de-risking event for the XLRP program which we believe is given minimal credit for now. |
33214.0 | 2018-08-30 00:00:00 UTC | SPYG, HD, BAC, ABT: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/spyg-hd-bac-abt-large-outflows-detected-etf-2018-08-30 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $99.2 million dollar outflow -- that's a 2.7% decrease week over week (from 95,500,108 to 92,900,108). Among the largest underlying components of SPYG, in trading today Home Depot Inc (Symbol: HD) is down about 1%, Bank of America Corp (Symbol: BAC) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.1%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average:
Looking at the chart above, SPYG's low point in its 52 week range is $7.6119 per share, with $38.20 as the 52 week high point - that compares with a last trade of $38.15. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Home Depot Inc (Symbol: HD) is down about 1%, Bank of America Corp (Symbol: BAC) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.1%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.6119 per share, with $38.20 as the 52 week high point - that compares with a last trade of $38.15. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SPYG, in trading today Home Depot Inc (Symbol: HD) is down about 1%, Bank of America Corp (Symbol: BAC) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.1%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.6119 per share, with $38.20 as the 52 week high point - that compares with a last trade of $38.15. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of SPYG, in trading today Home Depot Inc (Symbol: HD) is down about 1%, Bank of America Corp (Symbol: BAC) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $99.2 million dollar outflow -- that's a 2.7% decrease week over week (from 95,500,108 to 92,900,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.6119 per share, with $38.20 as the 52 week high point - that compares with a last trade of $38.15. | Among the largest underlying components of SPYG, in trading today Home Depot Inc (Symbol: HD) is down about 1%, Bank of America Corp (Symbol: BAC) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $99.2 million dollar outflow -- that's a 2.7% decrease week over week (from 95,500,108 to 92,900,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.6119 per share, with $38.20 as the 52 week high point - that compares with a last trade of $38.15. |
33215.0 | 2018-08-22 00:00:00 UTC | IUSG, BAC, ABT, TXN: Large Inflows Detected at ETF | ABT | https://www.nasdaq.com/articles/iusg-bac-abt-txn-large-inflows-detected-etf-2018-08-22 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $54.4 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 82,900,000 to 83,800,000). Among the largest underlying components of IUSG, in trading today Bank of America Corp (Symbol: BAC) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is trading flat, and Texas Instruments Inc. (Symbol: TXN) is lower by about 0.8%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average:
Looking at the chart above, IUSG's low point in its 52 week range is $48.90 per share, with $60.65 as the 52 week high point - that compares with a last trade of $60.36. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSG, in trading today Bank of America Corp (Symbol: BAC) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is trading flat, and Texas Instruments Inc. (Symbol: TXN) is lower by about 0.8%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.90 per share, with $60.65 as the 52 week high point - that compares with a last trade of $60.36. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IUSG, in trading today Bank of America Corp (Symbol: BAC) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is trading flat, and Texas Instruments Inc. (Symbol: TXN) is lower by about 0.8%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.90 per share, with $60.65 as the 52 week high point - that compares with a last trade of $60.36. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSG, in trading today Bank of America Corp (Symbol: BAC) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is trading flat, and Texas Instruments Inc. (Symbol: TXN) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $54.4 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 82,900,000 to 83,800,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.90 per share, with $60.65 as the 52 week high point - that compares with a last trade of $60.36. | Among the largest underlying components of IUSG, in trading today Bank of America Corp (Symbol: BAC) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is trading flat, and Texas Instruments Inc. (Symbol: TXN) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $54.4 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 82,900,000 to 83,800,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.90 per share, with $60.65 as the 52 week high point - that compares with a last trade of $60.36. |
33216.0 | 2018-08-22 00:00:00 UTC | Wednesday Sector Leaders: Energy, Healthcare | ABT | https://www.nasdaq.com/articles/wednesday-sector-leaders-energy-healthcare-2018-08-22 | nan | nan | In afternoon trading on Wednesday, Energy stocks are the best performing sector, up 1.4%. Within that group, Marathon Oil Corp. (Symbol: MRO) and Noble Energy Inc (Symbol: NBL) are two of the day's stand-outs, showing a gain of 3.7% and 3.1%, respectively. Among energy ETFs , one ETF following the sector is the Energy Select Sector SPDR ETF (Symbol: XLE), which is up 1.3% on the day, and up 4.38% year-to-date. Marathon Oil Corp., meanwhile, is up 24.63% year-to-date, and Noble Energy Inc is up 2.76% year-to-date. Combined, MRO and NBL make up approximately 2.3% of the underlying holdings of XLE.
The next best performing sector is the Healthcare sector, higher by 0.4%. Among large Healthcare stocks, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are the most notable, showing a gain of 1.5% and 1.5%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF ( XLV ), which is up 0.3% in midday trading, and up 11.59% on a year-to-date basis. Abbott Laboratories, meanwhile, is up 16.59% year-to-date, and Align Technology Inc is up 62.63% year-to-date. Combined, ABT and ALGN make up approximately 3.9% of the underlying holdings of XLV.
Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:
Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, four sectors are up on the day, while five sectors are down.
25 Dividend Giants Widely Held By ETFs »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Combined, ABT and ALGN make up approximately 3.9% of the underlying holdings of XLV. Among large Healthcare stocks, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are the most notable, showing a gain of 1.5% and 1.5%, respectively. Combined, MRO and NBL make up approximately 2.3% of the underlying holdings of XLE. | Among large Healthcare stocks, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are the most notable, showing a gain of 1.5% and 1.5%, respectively. Combined, ABT and ALGN make up approximately 3.9% of the underlying holdings of XLV. Within that group, Marathon Oil Corp. (Symbol: MRO) and Noble Energy Inc (Symbol: NBL) are two of the day's stand-outs, showing a gain of 3.7% and 3.1%, respectively. | Among large Healthcare stocks, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are the most notable, showing a gain of 1.5% and 1.5%, respectively. Combined, ABT and ALGN make up approximately 3.9% of the underlying holdings of XLV. Among energy ETFs , one ETF following the sector is the Energy Select Sector SPDR ETF (Symbol: XLE), which is up 1.3% on the day, and up 4.38% year-to-date. | Among large Healthcare stocks, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are the most notable, showing a gain of 1.5% and 1.5%, respectively. Combined, ABT and ALGN make up approximately 3.9% of the underlying holdings of XLV. In afternoon trading on Wednesday, Energy stocks are the best performing sector, up 1.4%. |
33217.0 | 2018-08-17 00:00:00 UTC | S&P 500 Analyst Moves: ABT | ABT | https://www.nasdaq.com/articles/sp-500-analyst-moves-abt-2018-08-17 | nan | nan | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #42 analyst pick, moving up by 1 spot.
This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values.
Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 12.6%.
VIDEO: S&P 500 Analyst Moves: ABT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #42 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 12.6%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 12.6%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #42 analyst pick, moving up by 1 spot. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #42 analyst pick, moving up by 1 spot. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 12.6%. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #42 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 12.6%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33218.0 | 2018-08-14 00:00:00 UTC | IYH's Holdings Imply 10% Gain Potential | ABT | https://www.nasdaq.com/articles/iyhs-holdings-imply-10-gain-potential-2018-08-14 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Healthcare ETF (Symbol: IYH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $210.01 per unit.
With IYH trading at a recent price near $191.38 per unit, that means that analysts see 9.73% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYH's underlying holdings with notable upside to their analyst target prices are Intercept Pharmaceuticals Inc (Symbol: ICPT), Abbott Laboratories (Symbol: ABT), and Avanos Medical Inc (Symbol: AVNS). Although ICPT has traded at a recent price of $110.67/share, the average analyst target is 12.43% higher at $124.43/share. Similarly, ABT has 10.26% upside from the recent share price of $63.43 if the average analyst target price of $69.94/share is reached, and analysts on average are expecting AVNS to reach a target price of $68.75/share, which is 9.88% above the recent price of $62.57. Below is a twelve month price history chart comparing the stock performance of ICPT, ABT, and AVNS:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of ICPT, ABT, and AVNS: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Intercept Pharmaceuticals Inc (Symbol: ICPT), Abbott Laboratories (Symbol: ABT), and Avanos Medical Inc (Symbol: AVNS). Similarly, ABT has 10.26% upside from the recent share price of $63.43 if the average analyst target price of $69.94/share is reached, and analysts on average are expecting AVNS to reach a target price of $68.75/share, which is 9.88% above the recent price of $62.57. | Similarly, ABT has 10.26% upside from the recent share price of $63.43 if the average analyst target price of $69.94/share is reached, and analysts on average are expecting AVNS to reach a target price of $68.75/share, which is 9.88% above the recent price of $62.57. Three of IYH's underlying holdings with notable upside to their analyst target prices are Intercept Pharmaceuticals Inc (Symbol: ICPT), Abbott Laboratories (Symbol: ABT), and Avanos Medical Inc (Symbol: AVNS). Below is a twelve month price history chart comparing the stock performance of ICPT, ABT, and AVNS: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, ABT has 10.26% upside from the recent share price of $63.43 if the average analyst target price of $69.94/share is reached, and analysts on average are expecting AVNS to reach a target price of $68.75/share, which is 9.88% above the recent price of $62.57. Below is a twelve month price history chart comparing the stock performance of ICPT, ABT, and AVNS: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Intercept Pharmaceuticals Inc (Symbol: ICPT), Abbott Laboratories (Symbol: ABT), and Avanos Medical Inc (Symbol: AVNS). | Below is a twelve month price history chart comparing the stock performance of ICPT, ABT, and AVNS: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Intercept Pharmaceuticals Inc (Symbol: ICPT), Abbott Laboratories (Symbol: ABT), and Avanos Medical Inc (Symbol: AVNS). Similarly, ABT has 10.26% upside from the recent share price of $63.43 if the average analyst target price of $69.94/share is reached, and analysts on average are expecting AVNS to reach a target price of $68.75/share, which is 9.88% above the recent price of $62.57. |
33219.0 | 2018-08-02 00:00:00 UTC | Why Dexcom Is Soaring Today | ABT | https://www.nasdaq.com/articles/why-dexcom-soaring-today-2018-08-02 | nan | nan | What happened
Shares of Dexcom (NASDAQ: DXCM) , a medical device maker focused on diabetes , surged 23% as of 11 a.m. EDT on Thursday. The huge jump is attributable to the release of second-quarter results that smashed expectations and featured a huge boost to guidance.
So what
Here's a review of the key figures from Dexcom's second quarter:
Revenue jumped 42% to $242.5 million. For perspective, Wall Street was only expecting revenue of $204.9 million, so the company handily beat estimates.
Non- GAAP net loss was $9.2 million, or $0.10 per share. That was also much better than the $0.18 loss that market watchers were expecting.
The better-than-expected results also allowed management to significantly boost its guidance for the year. The company now expects full-year revenue of about $925 million. That's much higher than its prior range of $850 million to $860 million.
Given the significant beat-and-raise, it isn't hard to figure out why shares are flying high today.
Now what
Dexcom's second-quarter results should go a long way to silence the doubters who believed that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre glucose monitoring system was going to put a stop to the company's huge growth. Instead, Dexcom just reported an acceleration in its revenue growth rate, which suggests that the total market is large enough for both companies' products to coexist.
Looking to the future, Dexcom's partnerships with Tandem Diabetes Care and Insulet should keep on serving as catalysts to drive continued adoption. In other words, investors have plenty of reasons to believe that this company's growth engine is still warming up.
10 stocks we like better than DexCom
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Now what Dexcom's second-quarter results should go a long way to silence the doubters who believed that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre glucose monitoring system was going to put a stop to the company's huge growth. What happened Shares of Dexcom (NASDAQ: DXCM) , a medical device maker focused on diabetes , surged 23% as of 11 a.m. EDT on Thursday. Instead, Dexcom just reported an acceleration in its revenue growth rate, which suggests that the total market is large enough for both companies' products to coexist. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Now what Dexcom's second-quarter results should go a long way to silence the doubters who believed that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre glucose monitoring system was going to put a stop to the company's huge growth. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market. | Now what Dexcom's second-quarter results should go a long way to silence the doubters who believed that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre glucose monitoring system was going to put a stop to the company's huge growth. Instead, Dexcom just reported an acceleration in its revenue growth rate, which suggests that the total market is large enough for both companies' products to coexist. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Now what Dexcom's second-quarter results should go a long way to silence the doubters who believed that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre glucose monitoring system was going to put a stop to the company's huge growth. The huge jump is attributable to the release of second-quarter results that smashed expectations and featured a huge boost to guidance. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market. |
33220.0 | 2018-08-02 00:00:00 UTC | Health Care Select Sector SPDR Fund Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-inflow-2018-08-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $142.3 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 189,765,324 to 191,365,324). Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is trading flat, Pfizer Inc (Symbol: PFE) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $77.82 per share, with $91.79 as the 52 week high point - that compares with a last trade of $88.90. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is trading flat, Pfizer Inc (Symbol: PFE) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $142.3 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 189,765,324 to 191,365,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is trading flat, Pfizer Inc (Symbol: PFE) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $77.82 per share, with $91.79 as the 52 week high point - that compares with a last trade of $88.90. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is trading flat, Pfizer Inc (Symbol: PFE) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $142.3 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 189,765,324 to 191,365,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $77.82 per share, with $91.79 as the 52 week high point - that compares with a last trade of $88.90. | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is trading flat, Pfizer Inc (Symbol: PFE) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $142.3 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 189,765,324 to 191,365,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $77.82 per share, with $91.79 as the 52 week high point - that compares with a last trade of $88.90. |
33221.0 | 2018-08-02 00:00:00 UTC | What DexCom Just Said About Its Future | ABT | https://www.nasdaq.com/articles/what-dexcom-just-said-about-its-future-2018-08-02 | nan | nan | DexCom, Inc. 's (NASDAQ: DXCM) continuous glucose monitors (CGM) are increasingly being used by diabetics to track their blood glucose levels, and based on the company's second-quarter results, the company's sales momentum is accelerating following the approval of its newest device, the G6. Is this stock worth adding to your portfolio? Here's what management's saying about its business today and its potential in the future.
What they do
Normally, beta cells in the pancreas produce insulin that turns glucose in the blood into energy; however, people with type 1 diabetes don't produce insulin, and type 2 patients have developed a resistance to insulin. There are an estimated 30 million people with diabetes in the U.S. alone, including about 1.5 million people with type 1 diabetes.
In the past, patients with type 1 disease and many patients with type 2 diabetes have relied upon finger sticks to draw blood, blood glucose monitors to measure blood sugar levels, and insulin injections to bring blood glucose readings down to a normal range.
More recently, patients requiring multiple insulin doses per day have been reducing their need for finger sticks by using CGMs, including those made by DexCom, to track and report blood glucose levels in real time. These devices include the use of wearable sensors that record the data and a receiver, or in the case of DexCom, an app, that communicates with the sensors, tracks the data, and reports it to patients and caregivers.
A big advance in care
Until competitor Abbott Labs (NYSE: ABT) won approval of its Freestyle Libre CGM last year, patients still had to use fingersticks to calibrate their CGMs. The approval of the Freestyle Libre did away with that requirement, significantly reducing patient burden and, in the process, giving Abbott Labs an edge in the CGM market.
However, Abbott's advantage didn't last very long. In March, the FDA approved DexCom's G6, which similarly does away with finger sticks for calibration. Importantly, the G6 packs features the Freestyle Libre doesn't, which could tilt market share back in DexCom's favor. Specifically, the G6 doesn't require a stand-alone receiver, and its sensors automatically communicate data to a user's app or another compatible device. Abbott requires a receiver (there's no app yet), and it has to be held within 1.5 inches of its sensors to transfer data. The G6 also has an alarm to alert patients of dangerous glucose readings that the Freestyle Libre doesn't.
Those advantages appear to be resonating with patients. Although the G6 was only available for part of the quarter, DexCom's sales jumped 42% year over year to $242.5 million in Q2 2018. As a result, after backing out gains associated with DexCom's equity investments, the company's adjusted loss improved to $0.10, which was $0.08 better than industry watchers were expecting.
What's on tap from here
There was plenty to like about the company's second-quarter performance, including a 78% year-over-year increase in international sales, but what's really moving the needle for investors is the company's potential to profit from its inclusion in next-generation, closed-loop, automated-insulin delivery systems that pair its CGMs with insulin pumps.
Last year, Medtronic (NYSE: MDT) won FDA approval for the first closed-loop monitoring and insulin pump solution, the MiniMed 670G. A DexCom competitor, Medtronic built its system using its own Guardian CGM and pump. The system has been a success, with Medtronic reporting 70,000 users at the end of March, up from 20,000 exiting December.
Soon, though, the MiniMed 670G is going to face stiff competition from Tandem Diabetes (NASDAQ: TNDM) t:slim X2 system, which relies on DexCom's G6 and Tandem's own insulin pump. The FDA gave Tandem Diabetes the OK to market its automated solution in June when it approved Basal-IQ, an algorithm that shuts off insulin delivery from Tandem's pump when blood glucose levels are predicted to get too low in the future.
Tandem says it's on track to launch its system with the G6 this month. The availability of Tandem's automated-insulin system could benefit DexCom in two ways: It could increase G6 demand in the coming year, and since DexCom has a $55 million equity stake in Tandem Diabetes, a successful launch could increase the value of its investment. For consideration, DexCom's cost basis in Tandem is only $5 million.
Tandem isn't the only manufacturer using DexCom's G6, though. DexCom's CGMs are also being evaluated as part of automated insulin systems being developed at Insulet (NASDAQ: PODD) and Eli Lilly (NYSE: LLY) .
Is DexCom a stock to buy?
DexCom's profitability has been a question mark, but that's due in part to the company's international expansion plans and research and development efforts. If those investments pay off, then earnings should follow. Because international revenue grew more quickly than U.S. revenue last quarter, overseas sales now represent 22% of revenue, up from 17% of revenue in Q2 2017.
Due to greater global demand for its CGMs, management now thinks its full year 2018 sales will be approximately $925 million, and that's significantly higher than its prior range of between $850 million to $860 million.
Given that reports suggest CGMs have only penetrated about 20% of the addressable market for type 1 patients, and even less in type 2 patients, there's good reason to think DexCom's future is bright enough for it to warrant being included in investors' portfolios.
10 stocks we like better than DexCom
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A big advance in care Until competitor Abbott Labs (NYSE: ABT) won approval of its Freestyle Libre CGM last year, patients still had to use fingersticks to calibrate their CGMs. More recently, patients requiring multiple insulin doses per day have been reducing their need for finger sticks by using CGMs, including those made by DexCom, to track and report blood glucose levels in real time. DexCom's CGMs are also being evaluated as part of automated insulin systems being developed at Insulet (NASDAQ: PODD) and Eli Lilly (NYSE: LLY) . | A big advance in care Until competitor Abbott Labs (NYSE: ABT) won approval of its Freestyle Libre CGM last year, patients still had to use fingersticks to calibrate their CGMs. In the past, patients with type 1 disease and many patients with type 2 diabetes have relied upon finger sticks to draw blood, blood glucose monitors to measure blood sugar levels, and insulin injections to bring blood glucose readings down to a normal range. Last year, Medtronic (NYSE: MDT) won FDA approval for the first closed-loop monitoring and insulin pump solution, the MiniMed 670G. | A big advance in care Until competitor Abbott Labs (NYSE: ABT) won approval of its Freestyle Libre CGM last year, patients still had to use fingersticks to calibrate their CGMs. DexCom, Inc. 's (NASDAQ: DXCM) continuous glucose monitors (CGM) are increasingly being used by diabetics to track their blood glucose levels, and based on the company's second-quarter results, the company's sales momentum is accelerating following the approval of its newest device, the G6. In the past, patients with type 1 disease and many patients with type 2 diabetes have relied upon finger sticks to draw blood, blood glucose monitors to measure blood sugar levels, and insulin injections to bring blood glucose readings down to a normal range. | A big advance in care Until competitor Abbott Labs (NYSE: ABT) won approval of its Freestyle Libre CGM last year, patients still had to use fingersticks to calibrate their CGMs. Although the G6 was only available for part of the quarter, DexCom's sales jumped 42% year over year to $242.5 million in Q2 2018. The availability of Tandem's automated-insulin system could benefit DexCom in two ways: It could increase G6 demand in the coming year, and since DexCom has a $55 million equity stake in Tandem Diabetes, a successful launch could increase the value of its investment. |
33222.0 | 2018-07-27 00:00:00 UTC | Edwards Lifesciences (EW) Q2 Earnings Beat, Revenues Miss | ABT | https://www.nasdaq.com/articles/edwards-lifesciences-ew-q2-earnings-beat-revenues-miss-2018-07-27 | nan | nan | Edwards Lifesciences Corporation'sEW second-quarter 2018 adjusted earnings per share (EPS) came in at $1.24. Reported EPS was $1.32.
Adjusted EPS beat the Zacks Consensus Estimate of $1.13 by 9.7%. Moreover, adjusted earnings improved 14.8% year over year, primarily driven by strong sales growth at the transcatheter heart valves business.
Sales Details
Second-quarter sales improved 12.1% to $943.7 million but fell short of the Zacks Consensus Estimate of $964.7 million by 2.2%. Underlying sales increased 10% (including the impact of Germany stocking sales as customers in the nation chose to purchase additional inventory of the SAPIEN 3 valve in anticipation of a potential supply interruption resulting from recent intellectual property litigation).
Revenues were primarily driven by considerable growth in transcatheter heart valve sales as well as strong performance by the Critical Care product line.
Edwards Lifesciences Corporation Price, Consensus and EPS Surprise
Edwards Lifesciences Corporation Price, Consensus and EPS Surprise | Edwards Lifesciences Corporation Quote
Segmental Details
In the second quarter, the company reported Transcatheter Heart Valve Therapy (THVT) sales of $584.9 million, reflecting 20% growth over the prior-year quarter. In the United States, THVT procedures grew in mid-teens year over year. Growth was driven by excellent clinical performance by SAPIEN 3 as well as continued strong therapy implementation across all regions.
Surgical Heart Valve Therapy sales in the quarter totaled $190.3 million, down 8.1% from the prior-year quarter. This includes a sales return reserve for conversion to a consignment inventory model. However, Edwards Lifesciences continued to see solid uptake of the EDWARDS INTUITY Elite valve system along with strong demand for the latest INSPIRIS RESILIA aortic valve in the United States. Further, the company's latest products drove underlying sales growth at a rate which surpassed the total procedure growth rate.
Critical Care sales totaled $168.5 million in the reported quarter, representing an increase of 14.5% from second-quarter 2017. The upside can be attributed to solid growth across all product categories, largely led by HemoSphere advanced monitoring platform supported by new group purchasing organization contracts in the United States.
Margins
In the second quarter, gross margin contracted 100 basis points (bps) to 73.9% owing to adverse currency movements and continued operational investments. However, this was partially offset by a more profitable product mix led by growing sales of transcatheter valves.
SG&A expenses rose 12.8% year over year to $274.9 million on account of sales and personnel-related expenses as well as strengthening of euro in comparison with the dollar. R&D expenditures increased 14.7% year over year to $154.1 million owing to continued investments in the transcatheter aortic valve and mitral valve program along with expenditures on clinical trials. Accordingly, adjusted operating margin in the quarter contracted 150 bps to 28.5%.
Cash Position
Edwards Lifesciences exited the second quarter with cash and cash equivalents and short-term investments of $1.40 billion compared with $1.50 billion at the end of first quarter of 2018. Long-term debt in the reported quarter totaled $593.9 million versus $456 million at the end of the preceding quarter.
Cash flow from operating activities were $140 million in the second quarter. Excluding capital spending of $53 million, free cash flow was $87 million. During the quarter, average diluted shares outstanding totaled 214 million.
2018 Guidance Raised
Edwards Lifesciences raised its 2018 adjusted EPS expectations to $4.60-$4.75 from the previous $4.50-$4.70. The Zacks Consensus Estimate for full-year adjusted EPS was $4.63, within the company's guided range.
However, the company continues to maintain sales expectations at the high end of the previously projected range of $3.5-$3.9 billion. The Zacks Consensus Estimate for full-year revenues is pinned at $3.83 billion, within the guided range.
For the third quarter of 2018, the company projects sales between $900 million and $950 million. The Zacks Consensus Estimate for revenues is pegged at $932.2 million, within the company's estimated range. The company forecasts adjusted EPS between 93 cents and $1.03. Meanwhile, the Zacks Consensus Estimate for adjusted EPS is at $1.08, which is above the company's projected range.
Our Take
Edwards Lifesciences exited the second quarter on a mixed note. Strong transcatheter valve sales in the domestic market as well as overseas is a major positive. The raised 2018 EPS guidance buoys optimism.
Management expects to gain traction in the ever-expanding TAVR market based on increasing preference for transcatheter aortic valve replacement as well as compelling clinical evidence, leading to strong adoption of THV therapy. Further, management seems to be upbeat about Centers for Medicare and Medicaid Services (CMS) opening a National Coverage Analysis to reconsider the National Coverage Determination released in 2012 for transcatheter aortic valve replacement
However, tough competition in the cardiac devices market and reimbursement issues continue to raise concern.
Zacks Rank & Key Picks
Edwards Lifesciences has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector which reported solid results this season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . While Intuitive Surgical and Align Technology sport a Zacks Rank #1 (Strong Buy), Abbott carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Intuitive Surgical reported second-quarter 2018 adjusted EPS of $2.76, which beat the Zacks Consensus Estimate of $2.48. Revenues totaled $909.3 million, also surpassing the consensus estimate of $870 million.
Align Technology posted second-quarter 2018 adjusted EPS of $1.30, steering past the Zacks Consensus Estimate of $1.09. Revenues came in at $490.3 million, beating the consensus mark of $462.9 million.
Abbott posted second-quarter 2018 adjusted EPS of 73 cents, which beat the Zacks Consensus Estimate of 71 cents. Revenues of $7.77 billion also edged past the consensus estimate of $7.73 billion.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector which reported solid results this season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. The upside can be attributed to solid growth across all product categories, largely led by HemoSphere advanced monitoring platform supported by new group purchasing organization contracts in the United States. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector which reported solid results this season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . Moreover, adjusted earnings improved 14.8% year over year, primarily driven by strong sales growth at the transcatheter heart valves business. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector which reported solid results this season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . Sales Details Second-quarter sales improved 12.1% to $943.7 million but fell short of the Zacks Consensus Estimate of $964.7 million by 2.2%. | A few better-ranked stocks in the broader medical sector which reported solid results this season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, adjusted earnings improved 14.8% year over year, primarily driven by strong sales growth at the transcatheter heart valves business. |
33223.0 | 2018-07-27 00:00:00 UTC | Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q2 | ABT | https://www.nasdaq.com/articles/omnicell-omcl-earnings-revenues-beat-estimates-in-q2-2018-07-27 | nan | nan | Omnicell, Inc.OMCL reported adjusted earnings per share (EPS) of 46 cents in second-quarter 2018, beating the Zacks Consensus Estimate of 40 cents.
Earnings improved from the year-ago 33 cents and surpassed the company's guided range of 36-42 cents.
Revenues in Detail
Adjusted revenues in the second quarter increased 4% year over year to $188.7 million, slightly above the Zacks Consensus Estimate of $188.5 million.
On a segmental basis, Automation and Analytics revenues increased 6.6% year over year in the second quarter to $158.4 million.
However, revenues at the Medication Adherence segment declined 6.8% year over year to $30.3 million.
Operational Update
Omnicell's gross profit during the reported quarter increased 13.7% to $88.8 million. Gross margin expanded 390 basis points (bps) to 47.1%.
Omnicell, Inc. Price, Consensus and EPS Surprise
Omnicell, Inc. Price, Consensus and EPS Surprise | Omnicell, Inc. Quote
SG&A expenses in the second quarter increased 6.5% year over year to $65.9 million. Research and development expenses contracted 8.3% year over year to $15.5 million. Operating expenses were $81.5 million in the second quarter, up 3.4% year over year.
Operating profit in the quarter totaled $7.3 million against a loss of $0.7 million in the year-ago quarter.
Financial Update
Omnicell exited second-quarter 2018 with cash and cash equivalents of $46.2 million, compared with $43.8 million at the end of first-quarter 2018.
2018 Guidance
For the third quarter of 2018, Omnicell expects adjusted revenues in the band of $200-$206 million, which includes the impact of reclassification of selling costs as a reduction of revenues. The company expects third-quarter 2018 adjusted earnings per share in the band of 52-57 cents. The Zacks Consensus Estimate for third-quarter revenues is pegged at $201.2 million and earnings per share at 55 cents. Both the estimates are pegged within the guided range.
For 2018, Omnicell raised the product bookings to the range of $630-$665 million compared with the previously provided range of $625-$660 million. However, the company continues to expect adjusted revenues in the band of $780-$800 million, which includes the impact of reclassification of selling costs as a reduction of revenues. The Zacks Consensus Estimate for full-year revenues stands at $787.5 million, within the company's guided range.
Omnicell raised the low end of the adjusted earnings guidance for 2018. The company now expects adjusted EPS in the range of $1.90-$2.05 compared with the previously provided band of $1.85-$2.05. The Zacks Consensus Estimate for full-year earnings is pegged at $1.97, within the company's guided range.
Our Take
Omnicell's second-quarter 2018 performance was impressive. We are encouraged to note that the company is working on product innovation through R&D. Also, Omnicell is expected to gain from recent launches, strategic partnerships and digital transformation.
However, a tough competitive landscape acts as a dampener.
Zacks Rank & Key Picks
Omnicell has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector which reported solid results this earnings season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . While Intuitive Surgical and Align Technology sport a Zacks Rank #1 (Strong Buy), Abbott carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Intuitive Surgical reported second-quarter 2018 adjusted EPS of $2.76, which beat the Zacks Consensus Estimate of $2.48. Revenues totaled $909.3 million, also surpassing the consensus estimate of $870 million.
Align Technology posted second-quarter 2018 adjusted EPS of $1.30, steering past the Zacks Consensus Estimate of $1.09. Revenues came in at $490.3 million, beating the consensus mark of $462.9 million.
Abbott reported second-quarter 2018 adjusted EPS of 73 cents, which trumped the Zacks Consensus Estimate of 71 cents. Revenues of $7.77 billion edged past the Zacks Consensus Estimate of $7.73 billion.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Omnicell, Inc. (OMCL): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked stocks in the broader medical sector which reported solid results this earnings season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Consensus Estimate for third-quarter revenues is pegged at $201.2 million and earnings per share at 55 cents. | Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector which reported solid results this earnings season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . Omnicell, Inc.OMCL reported adjusted earnings per share (EPS) of 46 cents in second-quarter 2018, beating the Zacks Consensus Estimate of 40 cents. | Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector which reported solid results this earnings season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . Revenues in Detail Adjusted revenues in the second quarter increased 4% year over year to $188.7 million, slightly above the Zacks Consensus Estimate of $188.5 million. | A few better-ranked stocks in the broader medical sector which reported solid results this earnings season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Omnicell, Inc.OMCL reported adjusted earnings per share (EPS) of 46 cents in second-quarter 2018, beating the Zacks Consensus Estimate of 40 cents. |
33224.0 | 2018-07-23 00:00:00 UTC | Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo | ABT | https://www.nasdaq.com/articles/agios-agio-secures-fda-approval-for-leukemia-drug-tibsovo-2018-07-23 | nan | nan | Agios Pharmaceuticals, Inc AGIO announced that the FDA has approved its leukemia drug Tibsovo (ivosidenib) for treating adult patients suffering from relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH-1) mutation.
Tibsovo, an oral, targeted inhibitor of the IDH1 enzyme, is the first and the only FDA-approved therapy for patients with R/R AML and an IDH1 mutation.
Notably, last December, Agios submitted a new drug application (NDA) to the FDA for Tibsovo (ivosidenib). Subsequently, in February this year, the FDA accepted the NDA under priority review for the given indication and assigned an action date of Aug 21, 2018. However, the approval came almost a month earlier than expected.
A regulatory filing for the drug in the EU is expected during the fourth quarter of 2018 for the same indication.
The FDA nod comes on the back of encouraging data from a phase I study for front-line AML patients with an IDH1 or IDH2 mutant-positive. Data from the trial showed that Tibsovo has potential to deliver strong, durable responses as a single agent and can also help patients achieve and maintain transfusion independence.
Tibsovo is the second IDHm inhibitor approved in less than a year for the company. Agios' first IDHm inhibitor and its only marketed drug Idhifa was approved by the FDA last August for the treatment of patients with relapsed or refractory AML and an IDH2 mutation.
The approval comes as a huge boost to the company's growth and for AML affected patients with IDH1 mutation, persistently waiting for new treatment options other than a conventional chemotherapy. The drug was approved simultaneously with Abbott's ABT RealTime IDH1 companion diagnostic test for detecting patients with R/R AML.
We remind investors that Agios is also conducting a phase I/II trial in combination with Celgene's CELG Vidaza for the treatment of newly diagnosed AML patients, not eligible for intensive chemotherapy. Also, ivosidenib is being evaluated in phase I study for the therapy of advanced hematologic malignancies
Shares of Agios have soared 59.3% year to date, outperforming the industry's increase of 10.3%.
Agios currently carries a Zacks Rank #3 (Hold). Another better-ranked stock in the same sector is Eagle Pharmaceuticals, Inc. EGRX , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here
Eagle Pharmaceuticals' earnings estimates have been revised 14.2% upward for 2018 and 25% for 2019 over the past 60 days. The stock has surged 56.1% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report
Eagle Pharmaceuticals, Inc. (EGRX): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The drug was approved simultaneously with Abbott's ABT RealTime IDH1 companion diagnostic test for detecting patients with R/R AML. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Eagle Pharmaceuticals, Inc. (EGRX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Data from the trial showed that Tibsovo has potential to deliver strong, durable responses as a single agent and can also help patients achieve and maintain transfusion independence. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Eagle Pharmaceuticals, Inc. (EGRX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. The drug was approved simultaneously with Abbott's ABT RealTime IDH1 companion diagnostic test for detecting patients with R/R AML. Agios Pharmaceuticals, Inc AGIO announced that the FDA has approved its leukemia drug Tibsovo (ivosidenib) for treating adult patients suffering from relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH-1) mutation. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Eagle Pharmaceuticals, Inc. (EGRX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. The drug was approved simultaneously with Abbott's ABT RealTime IDH1 companion diagnostic test for detecting patients with R/R AML. Agios Pharmaceuticals, Inc AGIO announced that the FDA has approved its leukemia drug Tibsovo (ivosidenib) for treating adult patients suffering from relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH-1) mutation. | The drug was approved simultaneously with Abbott's ABT RealTime IDH1 companion diagnostic test for detecting patients with R/R AML. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Eagle Pharmaceuticals, Inc. (EGRX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. However, the approval came almost a month earlier than expected. |
33225.0 | 2018-07-20 00:00:00 UTC | Here's Why You Should Add Abbott (ABT) to Your Portfolio Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-add-abbott-abt-to-your-portfolio-now-2018-07-20 | nan | nan | Abbott ABT has been gaining investors' confidence on consistently positive results. Over the past six months, the company's share price has outperformed its industry . The stock has gained 7.1%, compared to the industry's 5.3%. The company has also fared better than the 0.3% decline of the S&P 500 market.
This leading developer, manufacturer and seller of a diversified line of health care products has a market cap of $113.52 billion. The company's projected earnings growth rate for the current year is also favorable at 14.4% compared with the industry's 10.1%.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
The company's earnings estimate revision trend for the current year has been positive. In the past 60 days, one analyst revised the estimates upward, with no movement in the opposite direction. Resultantly, earnings estimates remained steady at $2.86 per share.
Per our Zacks Style Score system, Abbott has a Growth Score of A which reflects the company's solid prospects. Our research shows that stocks with a Growth Style Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or 2 offer the best upside potential.
Let's find out whether the recent positive trend is a sustainable one.
Solid EPD Business
Abbott's EPD business operates solely in emerging geographies, with leading positions in many of the largest and fastest growing pharmaceutical markets for branded generics in the world. These markets include India, Russia, China and Latin America.
The company recently noted that, banking on successful execution of its Branded Generic operating model, EPD is well positioned for sustained above-market growth in many of these growing pharmaceutical markets. Particularly, India, China, and Latin America have demonstrated double-digit growth of late.
Impressive Synergies From Alere Buyout
The integration of Alere has added Rapid Diagnostics to the company's existing leadership position in the $50-billion global diagnostics market. Alere's complementary portfolio of diagnostic products, comprising tests for infections such as HIV, tuberculosis, malaria and dengue will be added to Abbott's portfolio.
Over the past few months, Abbott has made good progress integrating this business and continues to see several factors for growth acceleration, including opportunities for geographic, platform and test menu expansion.
Rapid Diagnostics registered sales of nearly $484 million in the second quarter on strong infectious disease and cardiometabolic testing. Abbott continues to expect sales from this segment to exceed $2 billion by the end of 2018.
Strengthening Diabetes Business
There have been a slew of developments within the Diabetics business. We are upbeat about Abbott's FreeStyle Libre Flash Glucose Monitoring System's recent reimbursement approval in the United States and the United Kingdom. Plus, the company announced receipt of Health Canada License and Japanese national reimbursement for the same. With these positives in place, Abbott's FreeStyle Libre system stands partially or fully covered in 21 countries.
Notably, all these developments are expected to drive the company's traction in the Diabetes Care segment, which saw significant sales growth in the last reported quarter on continued consumer acceptance of FreeStyle Libre internationally.
Other Key Picks
Other top-ranked stocks in the broader medical space are Genomic Health GHDX , Align Technology, Inc. ALGN and Baxter International Inc. BAX .
Genomic Health has an expected earnings growth rate of 187.5% for the current quarter. The stock sports a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here.
Align Technology has a projected long-term earnings growth rate of 28.4% and a Zacks Rank of 1.
Baxter has a projected long-term earnings growth rate of 13.4%. The stock carries a Zacks Rank of 2.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Baxter International Inc. (BAX): Free Stock Analysis Report
Genomic Health, Inc. (GHDX): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT has been gaining investors' confidence on consistently positive results. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently noted that, banking on successful execution of its Branded Generic operating model, EPD is well positioned for sustained above-market growth in many of these growing pharmaceutical markets. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has been gaining investors' confidence on consistently positive results. Per our Zacks Style Score system, Abbott has a Growth Score of A which reflects the company's solid prospects. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has been gaining investors' confidence on consistently positive results. Per our Zacks Style Score system, Abbott has a Growth Score of A which reflects the company's solid prospects. | Abbott ABT has been gaining investors' confidence on consistently positive results. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment. |
33226.0 | 2018-07-20 00:00:00 UTC | The Zacks Analyst Blog Highlights: Wells Fargo, IBM, Abbott, Texas Instruments and Praxair | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-wells-fargo-ibm-abbott-texas-instruments-and-praxair | nan | nan | For Immediate Release
Chicago, IL -July 20, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Wells FargoWFC , IBMIBM , AbbottABT , Texas InstrumentsTXN and PraxairPX .
Here are highlights from Thursday's Analyst Blog:
Top Stock Reports for Wells Fargo, IBM and Abbott Labs
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), IBM (IBM) and Abbott (ABT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-ranked Wells Fargo 's shares have outperformed the Zacks Major Banks industry over the last three months (+7.6% vs. +1.1%). However, the company possesses a disappointing earnings surprise history, having beaten expectations in only one of the trailing four quarters.
The company's second-quarter 2018 results were impacted by lower mortgage banking revenues and high expenses. Lower provisions and higher net interest income aided results. Following the sales scandal and other issues, Wells Fargo has been slapped with new sanctions, including a cap on the assets position by the Federal Reserve.
Though lower tax rate, easing of regulations and expansions will likely support the bank's growth profile, the Zacks analyst thinks the crisis related to the revelation of illegally opening millions of accounts in 2016, auto-lending issues and impact of other malpractices will take some time to alleviate. Nevertheless, the recent 2018 capital plan approval boosts investors' confidence.
Shares of IBM have underperformed the broader market on a year-to-date basis, losing -5.8% vs. the S&P 500's +5.6% gain. IBM's second-quarter 2018 top-line benefited from strong demand for z14 Mainframe and Power products. Moreover, improving pre-tax margin and lower share count drove earnings growth. However, the Zacks analyst thinks IBM will find it difficult to sustain the Mainframe momentum in the long haul.
Nevertheless, the company's improving position in the cloud, security and analytics bodes well. Moreover, accretive acquisitions have expanded IBM's product portfolio into higher-growth segments, such as cloud computing, AI and Big Data.
The strategic imperatives will take some more time to report meaningful growth and offset weakness in the traditional business. IBM's ongoing heavily time-consuming business model transition to cloud continues to hurt the stock.
Buy-ranked Abbott 's shares have gained +27.3% over the last year, outperforming the Zacks Medical Products industry, which has gained +12.3% over the same period. In the second quarter 2018, Abbott has once again posted better-than-expected earnings and revenues numbers.
The Zacks analyst likes the strong and consistent performance across all segments by Abbott. Within Structural Heart, worldwide strong uptake of MitraClip therapy improves further following the recent FDA approval of its next-generation version. This apart, synergies from Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth.
Meanwhile, emerging market performance has been extremely promising. The company has been taking the limelight within Diabetic Care on progress with its FreeStyle Libre. On the flip side, sluggish Vascular business continues to dent growth. However, the FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan should help Abbott to revive the dull Vascular business.
Other noteworthy reports we are featuring today include Texas Instruments (TXN) and Praxair (PX).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
International Business Machines Corporation (IBM): Free Stock Analysis Report
Wells Fargo & Company (WFC): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Praxair, Inc. (PX): Free Stock Analysis Report
Texas Instruments Incorporated (TXN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Wells FargoWFC , IBMIBM , AbbottABT , Texas InstrumentsTXN and PraxairPX . Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), IBM (IBM) and Abbott (ABT). Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report Wells Fargo & Company (WFC): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Praxair, Inc. (PX): Free Stock Analysis Report Texas Instruments Incorporated (TXN): Free Stock Analysis Report To read this article on Zacks.com click here. | Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), IBM (IBM) and Abbott (ABT). Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report Wells Fargo & Company (WFC): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Praxair, Inc. (PX): Free Stock Analysis Report Texas Instruments Incorporated (TXN): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Wells FargoWFC , IBMIBM , AbbottABT , Texas InstrumentsTXN and PraxairPX . | Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), IBM (IBM) and Abbott (ABT). Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report Wells Fargo & Company (WFC): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Praxair, Inc. (PX): Free Stock Analysis Report Texas Instruments Incorporated (TXN): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Wells FargoWFC , IBMIBM , AbbottABT , Texas InstrumentsTXN and PraxairPX . | Stocks recently featured in the blog include Wells FargoWFC , IBMIBM , AbbottABT , Texas InstrumentsTXN and PraxairPX . Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), IBM (IBM) and Abbott (ABT). Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report Wells Fargo & Company (WFC): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Praxair, Inc. (PX): Free Stock Analysis Report Texas Instruments Incorporated (TXN): Free Stock Analysis Report To read this article on Zacks.com click here. |
33227.0 | 2018-07-19 00:00:00 UTC | Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings? | ABT | https://www.nasdaq.com/articles/can-solid-global-prospects-drive-aligns-algn-q2-earnings-2018-07-19 | nan | nan | Align Technology, Inc. 's ALGN solid Invisalign Technology prospects and growth in North America and internationally, particularly in the Asia-Pacific and EMEA regions, raise optimism. The continued strong uptake of iTero scanners across all geographies is impressive.
We expect this geographical strength to get reflected in second-quarter 2018 results, which are scheduled for release on Jul 25, after market close.
Click here to know how the company's overall Q2 performance is expected to be.
Solid Global Prospects
Align Technology's strategy of international expansion got a solid impetus with the achievement of a landmark in Invisalign adoption. The company recently announced the completion of one million shipments in the EMEA region.
Of late, the company's international Invisalign volumes have been strong with 43.4% growth registered in the first quarter of 2018 on continued adoption in EMEA and APAC regions.
Align Technology, Inc. Price and EPS Surprise
Align Technology, Inc. Price and EPS Surprise | Align Technology, Inc. Quote
In EMEA, first-quarter volumes were up 36.6% on solid Invisalign adoption in the markets of Iberia and France as well as rapid growth in smaller markets like Eastern Europe and Central Europe along with Benelux. In the Asia-Pacific region, the company witnessed a 56.1% surge in first-quarter volumes, led by China, Japan and Australia.
While China stood close as the second largest market after the United States for Align Technology, Iberia was a close third.
The international teen case grew 60% year over year in the last reported quarter. Notably, it was the sixth consecutive quarter when Invisalign teenage patient base grew faster than the adult patient's customer base.
We expect to see a similar trend in the yet-to-be-reported quarter result as well.
The company had introduced a clear Aligner solution for teen Class II correction - the InvisAlign Technology Teen with mandibular advancement - in certain markets of Canada, EMEA and APAC in 2017.
These developments are indicative of the growing popularity of Align Technology's dental products in the international market.
Zacks Rank & Other Stocks to Consider
Align Technology carries a Zacks Rank #1 (Strong Buy).
Other top-ranked stocks in the broader medical space are Genomic Health GHDX , Abbott ABT and Baxter International Inc. BAX .
Genomic Health has an expected earnings growth rate of 187.5% for the current quarter. The stock sports a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here.
Abbott has a projected long-term earnings growth rate of 12% and a Zacks Rank of 2 (Buy).
Baxter has a projected long-term earnings growth rate of 13.4%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Baxter International Inc. (BAX): Free Stock Analysis Report
Genomic Health, Inc. (GHDX): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other top-ranked stocks in the broader medical space are Genomic Health GHDX , Abbott ABT and Baxter International Inc. BAX . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Of late, the company's international Invisalign volumes have been strong with 43.4% growth registered in the first quarter of 2018 on continued adoption in EMEA and APAC regions. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Other top-ranked stocks in the broader medical space are Genomic Health GHDX , Abbott ABT and Baxter International Inc. BAX . Align Technology, Inc. Price and EPS Surprise Align Technology, Inc. Price and EPS Surprise | Align Technology, Inc. Quote In EMEA, first-quarter volumes were up 36.6% on solid Invisalign adoption in the markets of Iberia and France as well as rapid growth in smaller markets like Eastern Europe and Central Europe along with Benelux. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Other top-ranked stocks in the broader medical space are Genomic Health GHDX , Abbott ABT and Baxter International Inc. BAX . Align Technology, Inc. Price and EPS Surprise Align Technology, Inc. Price and EPS Surprise | Align Technology, Inc. Quote In EMEA, first-quarter volumes were up 36.6% on solid Invisalign adoption in the markets of Iberia and France as well as rapid growth in smaller markets like Eastern Europe and Central Europe along with Benelux. | Other top-ranked stocks in the broader medical space are Genomic Health GHDX , Abbott ABT and Baxter International Inc. BAX . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Align Technology, Inc. 's ALGN solid Invisalign Technology prospects and growth in North America and internationally, particularly in the Asia-Pacific and EMEA regions, raise optimism. |
33228.0 | 2018-07-18 00:00:00 UTC | Abbott Laboratories (ABT) Q2 2018 Earnings Conference Call Transcript | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-q2-2018-earnings-conference-call-transcript-2018-07-18 | nan | nan | Abbott Laboratories (NYSE: ABT)
Q2 2018 Earnings Conference Call
July 17, 2018, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to Abbott's Second Quarter 2018 Earnings Conference Call. All participants will be able to listen only until the question and answer portion of this call. During the question and answer session, you will be able to ask your question by pressing *1 on your touchtone phone. Should you become disconnected throughout this conference call, please redial the number provided to you and reference the Abbott earnings call.
This call is being recorded by Abbott. With the exception of any participants' questions asked during the question and answer session, the entire call, including the question and answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's express written permission. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations.
Scott Leinenweber -- Vice President, Investor Relations
Good morning and thank you for joining us. With me today are Miles White, Chairman of the Board and Chief Executive Officer, and Brian Yoor, Executive Vice President, Finance and Chief Financial Officer. Miles will provide opening remarks and Brian will discuss our performance and outlook in more detail. Following their comments, Miles, Brian, and I will take your questions.
Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2018. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Securities and Exchange Commission Form 10-K for the year ended December 31st, 2017. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments except as required by law. Please note the second-quarter financial results and guidance provided on the call today for sales, EPS, and line items of the P&L will be for continuing operations only.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at Abbott.com. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which adjusts the 2017 basis of comparison to exclude the impact of exchange and historical results for Abbott's medical optics and St. Jude's vascular closure businesses, which were divested during the first quarter of 2017, as well as the current and prior-year sales for Alere, which was acquired on October 3rd, 2017. With that, I will now turn the call over to Miles.
Miles D. White -- Chairman and Chief Executive Officer
Okay, thanks, Scott, and good morning. Today, we reported ongoing earnings per share of $0.73, above our previous guidance range. We also raised our full-year adjusted earnings per share guidance and narrowed the range to $2.85 to $2.91, which now reflects 15% growth at the midpoint. All four of our businesses exceeded expectations in the quarter and contributed to 8% organic sales growth overall, above our previous guidance range.
Over the past several years, we've executed a very deliberate strategy of shaping our portfolio, both adding and pruning. At the same time, we've also invested organically in growth areas that have resulted in game-changing technologies such as FreeStyle Libre and Alinity. These steps have created leadership positions in attractive areas of healthcare, where innovation makes a big difference for the customers we serve, and consequently for our performance.
The strong results we're achieving are a direct result of this strategy. Over the past four quarters, we've averaged more than 7% organic sales growth, a true differentiator for a company our size, and with synergies from recent acquisitions and our focus on margin expansion, we're able to fully fund our growth opportunities while at the same time growing earnings significantly faster than sales.
We continue to forecast strong performance for the remainder of the year, as evidenced by the fact that we're raising our full-year earnings guidance despite the recent strengthening of the U.S. dollar. Clearly, we'd be raising guidance a bit higher if based solely on the underlying performance of our business.
I'll now summarize our second-quarter results before turning the call over to Brian. I'll start with Diagnostics, where we achieved sales growth of 6.5% in the quarter, including 8% international growth in our core laboratory business. The pace of our Alinity launch in Europe continues to accelerate, driven by strong competitive win rates and even stronger retention rates. This business, which is already a global leader and growing faster than its market, is well positioned for sustainable growth for years to come as we capture share and roll out the full suite of Alinity systems across additional geographies, including the U.S.
In rapid diagnostics, second-quarter sales were driven by infectious disease and cardiometabolic testing. The management team has done an excellent job integrating and stabilizing the business, identifying and realizing synergies, and implementing strategies to drive long-term growth.
In Established Pharmaceuticals or EPD, where we've built leading positions in the fastest-growing pharmaceutical markets in the world, sales grew more than 12% in the second quarter. EPD continues to execute its unique strategy and is growing faster than the market in several of its priority countries, including India and China. Our focus on enhancing the depth and breadth of our product portfolios and local capabilities continues to strengthen our position and long-term growth opportunities across these markets.
In Nutrition, sales increased 6.5% in the quarter, led by strong performance across our international business. We've now achieved several consecutive quarters of improving performance for this business. In adult nutrition, growth was led by our market-leading Ensure and Glucerna brands, most notably internationally, where we saw double-digit growth. In pediatric nutrition, strong performance was led by balanced growth across several countries in Asia including greater China and Latin America.
And lastly, I'll cover Medical Devices, where sales grew more than 8%, led by strong double-digit growth in electrophysiology, structural heart, and diabetes care. In electrophysiology, growth of 22% was led by our advanced cardiac mapping and ablation portfolio as well as Confirm, the world's first and only smartphone-compatible insertable cardiac monitor. During the quarter, we further strengthened our product portfolio in the U.S. with the launch of our Advisor HD catheter, which includes a first-of-its-kind configuration to create highly detailed maps of the heart.
In structural heart, strong growth across several areas of our portfolio was led by MitraClip, our market-leading device for the minimally invasive repair of the mitral heart valve. Earlier this month, we received U.S. FDA approval for our next-generation version of MitraClip, which includes design enhancements and an additional clip size to enable more patients to be treated.
In vascular, during the quarter, we received FDA approval for XIENCE Sierra, the newest generation of our leading coronary stent system, which will enhance our competitiveness in the U.S. market, and we also received national reimbursement for XIENCE Sierra in Japan during the quarter.
Lastly, in diabetes care, sales grew over 30% for the third consecutive quarter, driven by FreeStyle Libre, our highly differentiated sensor-based glucose monitoring system. Libre offers a true mass-market opportunity with its unique combination of affordability, accessibility, and ease of use, and it's achieving a level of patient adoption that's unprecedented in the industry with more than 800,000 current users globally.
So, in summary, this was another very good quarter as we execute on our strategic priorities. All four of our businesses exceeded expectations for the quarter and contributed to strong growth overall, and lastly, we started the year with strong double-digit EPS guidance, and despite recent currency shifts, today we're raising our outlook even higher based on the strength of our underlying performance. I'll now turn the call over to Brian to discuss our results and outlook for the year in more detail. Brian?
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
Thanks, Miles. As Scott mentioned earlier, please note that all references to sales growth rates -- unless otherwise noted -- are on an organic basis, which is consistent with our previous guidance. Turning to our results, sales for the second quarter increased 8% on an organic basis, above our previous guidance range. Sales in rapid diagnostics, which was acquired late last year and is therefore not included in our organic sales growth results, achieved sales of $484 million.
Exchange had a favorable year-over-year impact of 1.7% on second-quarter sales. During the quarter, we saw the U.S. dollar strengthen versus several currencies, resulting in a less favorable impact on our sales this quarter compared to expectations had exchange rates held steady since the time of our earnings call in April. Regarding other aspects of the P&L, the adjusted gross margin ratio was 59.2% of sales, adjusted R&D investment was 7.1% of sales, and adjusted SG&A expense was 30.7% sales.
Turning to our outlook for the full year 2018, based on our strong performance and momentum, we're increasing our organic sales growth forecast to 6.5% to 7.5%. At current exchange rates, we would expect exchange to have a favorable impact of around 50 basis points on full-year reported sales, which would be around 170 basis points lower than expectations based on exchange rates in April. In addition, we continue to expect rapid diagnostics to contribute sales of a little more than $2 billion.
We continue to forecast an adjusted gross margin ratio of somewhat above 59% of sales, which includes underlying gross margin improvement across our businesses. We forecast adjusted R&D investment of around 7.5% of sales and adjusted SG&A expense of somewhat below 30.5% of sales.
Turning to our outlook for the third quarter of 2018, we forecast an adjusted EPS of $0.73 to $0.75. We forecast organic sales growth of mid to high single digits, and at current rates, would expect exchange to have a negative impact of approximately 2% on reported sales. In addition, we expect rapid diagnostics to contribute sales of approximately $500 million in the third quarter. We forecast an adjusted gross margin ratio of around 59% of sales, adjusted R&D investment of around 7.5% of sales, and adjusted SG&A expense of around 29.5% of sales.
Before we open the call for questions, I'll now provide an overview of our third-quarter organic sales growth outlook by business. For Established Pharmaceuticals, we forecast mid- to high single-digit sales growth, which takes into consideration our strong third-quarter results last year when quarterly sales patterns in India were impacted by the implementation of a new tax system in that country. In Nutrition, we forecast mid-single-digit growth for the third quarter and are increasing our full-year forecast for 2018 to mid-single digits as well.
In Diagnostics, we forecast mid- to high single-digit sales growth, and in Medical Devices, we forecast high single-digit sales growth for the third quarter and are increasing our full-year forecast for 2018 to high single digits as well, which reflects continued double-digit growth in several areas of the business. With that, we will now open the call for questions.
Questions and Answers:
Operator
Thank you. Ladies and gentlemen, if you have a question at this time, please press *1 on your touchtone telephone. If your question has been answered or you wish to remove yourself from the queue, please press #. We kindly ask that if you are using a speakerphone to please pick up the handset before asking a question. And again, ladies and gentlemen, that's *1 to ask a question. And, our first question comes from David Lewis from Morgan Stanley. Your line is open.
David Lewis -- Morgan Stanley -- Managing Director
Good morning and congrats on the quarter. Miles, two dynamics that really stand out to us in this quarter in addition to, obviously, the stronger organic number are just international nutrition recovery and, obviously, the Libre progression. So, can you just give us some details on the drivers of nutrition acceleration and sustainability in the back half of the year? And then, Libre, where it is relative to your plan and your comfort with a $100 million number in the U.S. this year. And, I had a quick follow-up.
Miles D. White -- Chairman and Chief Executive Officer
Okay. In the Nutrition business, I'd say first of all, we're pleased with the successive performance. It's across the board. It's not in any one place. We've been through pretty detailed reviews and plans by geographic area and so forth. A lot of times, we're talking about Nutrition in terms of either the U.S. or China. In this case, it's actually not concentrated that way. It's really across the board in all the countries we're in, so I'm pretty pleased to see a uniform increase in performance and our plans taking hold and working in a lot of countries internationally, and like a lot of things, it's small things and a lot of them, and coordination -- blocking and tackling -- and just doing a better job with our marketing, our positioning of products, and so forth.
So, as far as sustainability goes, I feel like this business ought to be able to perform in a low to mid-single-digit range on a fairly sustainable basis, and if we can stay in the range we're in, that's pretty good. I feel pretty good about that. It's up and down depending on promotions and given geographic areas. From time to time, we'll see a competitor put on a heavy promotion in something like adult nutrition in the U.S., and it goes away -- share doesn't change much in that case. But, long-term sustainable growth here, we continue to maintain our position as the market leader and even advance it in a number of cases. So, I feel like it's pretty solid and look forward to it sustaining at...call it a mid-single-digit level.
With regard to Libre, we can't be anything but pleased. It's going extremely well. We're on track with where we want to be in terms of patient acquisition and growth, et cetera. We have nothing to compare us to, no real market dynamics to compare ourselves to other than the acquisition of patients, and we expect to go out of the year with over $1 million patients, which is unprecedented and unseen. We think this is a mass-market sort of a product as opposed to a very niche-y medical device type product because there are so many people that are either insulin dependent or trying not to be insulin dependent.
So, I think the opportunity here remains enormous. I think the growth is quite sustainable. There's quite a lot more to do to keep enhancing not only the product, the offering, the market, and so forth. We like the mix of patients we're getting, we like the geographic mix, we like the geographic advancement, the reimbursement has been very good, just about everything about this has gone better than planned.
So, I think this is one of the key big sustainable growth drivers of the company along with the system family Alinity in the Diagnostic area. We've got a number of growth drivers here, either big, innovative products like this or a collection of smaller innovative niches like we've got -- and, "niche" is probably too small to describe it, but a lot of places where innovation makes a big difference in medical devices. And then, you've got market growth, and in spite of the volatility of currencies that affect our pharmaceutical or nutrition business, the underlying markets still have very strong growth, so I think all of our growth drivers look very reliable for the long term.
David Lewis -- Morgan Stanley -- Managing Director
All right, thanks, Miles. Very clear. The other quick focus for me was the neuromod focus for the quarter. You're kind of anniversarying some fairly explosive growth in that business, but can you just discuss the relative change in neuromod growth this quarter, the drivers of it, what you're doing to address it, and do you believe this portfolio can get back to market growth? Thanks so much.
Miles D. White -- Chairman and Chief Executive Officer
Good question. I think you've got a couple things going on here, one of which you observed. Explosive growth last year, which is actually interestingly enough part of the problem. I think this was a bit of a self-inflicted wound. This is a business where -- the business is very dependent on the involvement of the sales representative, et cetera, not only with the physician but also with the patients.
We did not expand our sales force in concert with the rate of explosive growth we experienced, and when we finally did expand our sales force recently, it turned out to be pretty disruptive to do that the way we did it, and I'd say the issue we created for ourselves was disruption in our own sales here with additions of new salespeople and new servicepeople in the field, and so forth. You recut territories, you have a lot of training, and so forth. So, I think we've added to our comp issue here.
So, do I think it gets back to market growth? Yeah, absolutely. I think this is a temporary condition created by us, it will be fixed by us, and we'll figure out how to successively expand our sales force in concert with our growth, and let's just call it a much smoother fashion in the future. I think we did this to ourselves.
David Lewis -- Morgan Stanley -- Managing Director
Okay. Thanks so much, Miles.
Operator
Thank you. And, our next question comes from Larry Biegelsen from Wells Fargo. Your line is open.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
Good morning. Thanks for taking the question and congrats again on the good quarter. So, it looks like based on the guidance you're forecasting, similar growth in the second half adjusting for the Indian GST benefit that we saw in EPD in the first half. So, I guess my question is, Miles, why do you feel confident you can sustain similar underlying growth in the second half given that the comps get significantly tougher in the second half? And, I had a follow-up.
Miles D. White -- Chairman and Chief Executive Officer
Well, first of all, the underlying dynamics of our markets -- underlying -- are pretty strong. Our single biggest "forget" for castable or not for castable concern is currency, and I think you're going to hear that from a lot of companies. I think we're all seeing stronger dollar, and in our case -- I'll speak for us -- we have a significant portion of our business in high-growth markets, most of which are unhedgeable currencies and are volatile currencies -- emerging markets, et cetera -- and we like the growth and we like the underlying trends and dynamics of those markets, and I think those have proven to be pretty robust and beneficial, but they also come with the unpredictable volatility of currency from time to time.
So, as I said in my opening remarks, we'd probably be raising guidance even further here but for currency headwinds that we see for the remainder of the year, and having been through this cycle a number of times, you're always cautious about the second half of the year until you get to about now and see what currency is doing because the first half of the year, you think you know what it's going to do, but you really can't predict it that far out and it's clearly made a big change since the first quarter. So, we've absorbed a fair bit of that negative currency headwind already, and we'll probably end up absorbing more here in the second half, but we think we've got a pretty good handle on what we face.
But, the underlying dynamics of the real business are all pretty good. Now, that said, things never go exactly like you expect them to go, and you take a business like our pharmaceutical business -- it's lumpy. If you've got a year with GST or other factors that create oddball comparables from year-later quarters and so forth, you're automatically going to be lumpy the following year again. So, in a business that has a mix of emerging markets, it's almost always up, down, up, down, up, down. The good news is even when it's down, the growth rate is still pretty high, so we go from a good growth rate to a great growth rate to a good growth rate, back and forth, because it's a bit volatile. Last quarter, it was some dynamics in Russia, this quarter, it's comparables to GST, we'll probably have the same thing because, you recall, that created a sequential-quarter comparable issue in the EPD business last year.
So, we're going to see ups and downs that way in some of these businesses, and like you guys, our first question is is there something fundamental about the performance of the business, the performance of the market, or have we just got timing dynamics or volatility dynamics and so forth? The underlying growth rates in EPD remain very strong across our collection of emerging markets, so I think we tend to look at it that way. We address everything we see. I think we're going to see ups and downs here in a lot of these businesses. Look, we see neuromod at a slower growth rate this quarter, as David just pointed out. Do I think the underlying dynamics to that market are somehow unattractive? Absolutely not. That market remains very attractive. Do I think we'll do well in it? Yeah, we'll do really well in it, but next year, we'll be referring back to this quarter from a comparable standpoint and so forth.
So, I am quite confident that what I see in the underlying trends of each of these businesses is pretty good. I'm very pleased with Nutrition, very pleased with the acceleration in Alinity, in Diagnostics, I'm pleased with the steady ramp which only gets better and better with Libre, and those are big, big growth drivers across the board. So, while they may go up and down a couple of percentage points here and there, the underlying overall growth rate is pretty strong, and like I said earlier, we'd probably raise guidance further but for the concern about exchange.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
That's helpful. And then, for my follow-up, to follow up on David's question, within Med Tech, there were some pockets of strength, like diabetes and electrophysiology, but there were a couple soft spots, like CRM, you've already addressed neuromodulation, and heart failure. So, any more color on CRM and heart failure and how we should be thinking about those segments in the second half of the year? Thanks for taking the questions.
Miles D. White -- Chairman and Chief Executive Officer
Yeah, there's a couple dynamics going on with CRM. That one gets a fair amount of my attention, I would tell you. First of all, we've got a little bit of a tough comparison to last year because we launched the low-voltage MRI-compatible products then and obviously had stocking dynamics in the second quarter and so forth. But, beyond that, there's also an underlying battery replacement timing thing going on here because when St. Jude -- prior to us, in '15-'16 -- had its battery issues, it pulled forward a lot of replacements to replace those batteries. And so, you see fewer replacements now because they were pulled forward, whereas in the de novo segment where we've got new patients, we're doing extremely well.
So, when you take it apart, you look at it and say, "Well, if we're right about our diagnosis and analysis here, we should see this pick up in the future with a bit of a tailwind once we get past this replacement phenomenon relative to 2016." So, we've looked at that. For the rest of this year, I think we're probably flat in CRM, but that's not a satisfactory position for us, so my expectation is we keep improving the growth rate here. We're not happy with what the growth rate looks like, but we think we understand why. With regard to electrophysiology and others, these are doing great, as you point out. Heart failure -- we need to just finish in therapy claim, and I think we're going to be in great shape. I think it's that simple.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
Thanks for taking the questions.
Operator
Thank you. And, our next question comes from Bob Hopkins from Bank of America. Your line is open.
Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director
Thanks for taking the questions. I just have two -- one big-picture and one on a divisional level. From a big-picture perspective, you guys have been very clear on the topic of durable revenue growth. I have a question on durable earnings growth. The reason I ask the question is that your earnings growth has obviously been running well above your targets. As we go forward, if you're successful in driving the kind of revenue growth you think you can drive in this business, what does a durable earnings growth outlook look like for the company? Is it closer to 15% than 10%? Any thoughts on that topic will be appreciated.
Miles D. White -- Chairman and Chief Executive Officer
Many times in these calls, somebody tries to get me to forecast future earnings growth, and I think... We start every year with a goal -- in fact, even a long-term of double-digit earnings growth. You might say that backs you into 10%, or 9.999%, or whatever. And, we don't necessarily hit it every single year, but pretty darn close. In some years, a lot more than that. So, I would tell you that our overall strategy is we want to grow at a double-digit rate. Otherwise, it's difficult to call yourself a growth company.
We've got a lot of pieces in this company. We've tried to position it in growth markets, growth segments, growth products, innovative areas, and so forth, and we also have some extremely profitable cash-generating legacy businesses that grow slower, but there's still growth. And, those businesses, we do look for incremental growth and the kind of delivery of profit that's above the sales growth rate, and overall, that makes half the delivery of that double-digit target for us, which is why we've shaped the company as we have over the last six years to add growth and prune away some things that may not fit us over the long term. We've tried to put ourselves in the right geographic markets, the right innovative spaces, the right growing healthcare areas, and so forth that we've talked about. And, we always look for leverage on the bottom line by improvements in margin, gross margin, even our spending efficiency, and so forth.
So, I don't know that I can predict whether it's 10%, 11%, 12%, 13%, 14%, 15%, but we start every year with the presumption that that's our identity, that's our hallmark, that's the mix of our businesses, that's the mix of our products, and we build our product strategies and business strategies to deliver that. There's a lot of things that change, as you know, over the course of a year. The year never goes quite like you expect it to go, and I'm eliminating exchange for a minute here. It's even just the dynamics of market spread, whatever it may be, new product approvals or delays, et cetera.
So, we've got a lot of moving parts, and I think that as a mix of businesses, we've got a really robust, strong, powerful mix of innovative, profitable businesses. We're in a really great new product cycle of launches. Every piece of this has a nice, sustainable, long term ahead of it here, and the business -- you can see the evidence of it growing. So, beyond that, I'm not sure I can predict more accurately for you what it's going to be, other than we put a lot of growth drivers here.
We're not organically getting a lot of growth out of the Alere business this year, as you know, because we're settling that in, but I'm really pleased with its performance. It's above our expectations, and we haven't even begun to see how that's going to deliver for us in the coming year. So, I just look at the way we're managing the delivery of the various pieces of our business -- we always got a lot of shots on goal here and a lot of products to expand, so I'd say our goal is always double digits, and I'm not ready to tell you how many double digits for next year.
Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director
Fair enough. I appreciate the detailed answer. One other thing I wanted to touch on really quickly was if there's one business that seems like it's really done better than you thought at the beginning of the year, it's maybe Nutritionals. So, I was wondering if you could just talk about what's driven the improvement and how sustainable that is. Thank you.
Miles D. White -- Chairman and Chief Executive Officer
Well, I go back to -- there's no one thing. Our markets are all a little different. You'd think that infant formula Ensure wouldn't be that complicated, but it actually is at some level, and the dynamics of each market are a little different. In some ways, we've got the same multinational competitors in most of our geographies, but even they don't have the same strategies or the same products in every market. And then, there's always a lot of local or regional competitors, and in a country like Vietnam, we've got a very strong state competitor there in Vinamilk -- fine company, and they execute very well. They happen to be really strong in rural areas; we happen to be really strong in big cities. That's a dynamic that's unique to Vietnam. The dynamics we face in the Middle East or other markets in Asia are different, so it's no one thing, I'm afraid.
We can try all those consultant four-box matrices to say, "All of these countries are like this," and put them in the upper left-hand corner box and so on, but even doing that -- that's artifice. Each country is a little different. I'd say overall, we needed to improve several things. The focus of our products -- you can have too many, you can have too few, but you've got to have certain ones, you've got to have certain innovations, you've got to have certain ingredients, and you've got to have marketing that appeals to the consumers and/or physicians or hospitals that you're trying to appeal to. It's a little tailored to each market.
We literally went country by country -- call it top 15 countries -- and went through detailed analysis and new strategies and so forth. You say, "Well, was there a lot of management change?" Actually, not. In a few places, yes, but not that many. It's really us and our execution, and we took that bar up, and it shows. It shows. We've got a pretty strong business there. I think we slipped off the rail a little bit for a while, and I'm pleased to see that the top management -- some of which is new -- has established pretty good direction for each of the major geographies now, and beyond that, it gets to be a lot of little details that you've got to execute better.
We've seen a lot of channel change, we've seen a huge impact of online or digital marketing, digital shipment, et cetera. As channels, we've seen specialized channels evolve -- baby stores and so forth. So, I think we were slow to adjust and adapt to that. I think others did it faster than we did, and we got left behind. We now understand what we missed, we understand what we needed to do about it, and we've either done it or we're doing it, and it clearly shows and makes a difference. So, I think we had to be pretty honest with ourselves about mistakes we'd made or things we'd missed, and now we're correcting that with a vengeance and running hard here, so I think the execution is a lot better.
Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director
Thank you.
Operator
Thank you. And, our next question comes from Glenn Novarro from RBC Capital Markets. Your line is open.
Glenn Novarro -- RBC Capital Markets -- Managing Director
Hey, good morning. Hey, Miles, two questions on Libre. First, can you give us a little bit more color on the U.S. rollout and where you are with commercial coverage? And, are you still comfortable with your Libre guidance for the year, which in the U.S. is $90 million to $100 million? And then, I had a follow-up.
Miles D. White -- Chairman and Chief Executive Officer
I have a real quick answer to that. Yeah, we're absolutely comfortable with the guidance for the year. We're on track. Glenn. I'd like to go even faster. As I've said before, we're even investing heavily in capacity expansion and so forth to anticipate even greater growth in the future, and there's really nothing to compare it to. I think the whole space is getting increasing attention, and we have -- as you know -- carved out a very economic position that's extremely profitable for us, but we're in a very economically accessible price point, which has made the uptake and the reception by the patient, or the consumer, or even reimbursing bodies pretty attractive.
I think we found a real value proposition point here with the product, our manufacturing is extremely automated, it gives us a big advantage in terms of cost, and everything is kind of working well here. I'm pretty excited about this product. It's got so much potential because I think a lot of times, whether it's a pharmaceutical, a medical device, et cetera, they can be expensive in the healthcare system for recovery of costs and so forth because the numbers of patients may not be that great, and yet, there's a lot of diabetics in the world, including me. There's millions that are insulin dependent and millions that don't want to be insulin dependent, et cetera. This product hits the sweet spot, and to be a mass-market product, it's got to be accessible, it's got to be affordable, and it's got to be affordable in a way that it's not hard for people to commit to it, use it, and find out what it can do for them, and so forth.
So, I'd say that's all going super. We like the split we're seeing of Type 1s versus Type 2s. We're probably globally about two-thirds Type 1s and one-third Type 2s. I think that's a pretty good mix, and it speaks to the clinical efficacy, and the benefits of the products, and the two different types of users that benefit from it. So, at this point, it's all about how fast can we run? I think the uptake by consumers, the retention, the repeat, all that -- all of our data says this is going well, and as I indicated to you, we'll go out at the end of the year with more than a million patients worldwide, a significant number in the U.S.
I think we'll probably be -- well, we are so far and away the global leader in this space now, it's almost -- there's no way to look at share. We've looked at sensor days -- if you take the sensors, numbers of patients, whatever, and how many days of testing you get out of that, we're already well above 90% globally, and it's -- there's nothing to compare to, and it's a huge market. So, I think that just the opportunity here -- we're comparing to us and how fast we can run, and that's really an exciting product, I'll tell you. It's nice to see a product that has that kind of impact. This one is just fun. It's just fun.
Glenn Novarro -- RBC Capital Markets -- Managing Director
And, let me just have one quick follow-up. Can you discuss what's next in terms of features for Libre and timing? Thanks.
Miles D. White -- Chairman and Chief Executive Officer
I could...but I'm probably not going to set any expectations around that because I don't want to create trigger points, or talking points, or whatever -- catalysts -- I know all the terms you guys like to use. There are a number of things that we have planned, in place, done the work, et cetera, for enhancements to the product -- obvious ones -- some of which are already available overseas. It's a little different challenge working through the FDA here in this country, so I don't want to get into the space or the discussion, but we've got plenty of enhancements and thoughts here for advancing the product still further, Glenn.
Glenn Novarro -- RBC Capital Markets -- Managing Director
Okay. Thanks, Miles.
Operator
Thank you. And, our next question comes from Rick Wise from Stifel. Your line is open.
Rick Wise -- Stifel Financial Corporation -- Analyst
Good morning, Miles.
Miles D. White -- Chairman and Chief Executive Officer
Good morning, Rick.
Rick Wise -- Stifel Financial Corporation -- Analyst
Maybe starting off with a big-picture question, in some of your earlier comments, you lightly touched on this, but when we think about your priorities right now, should we imagine that you're focused -- now that everything's humming along, should we expect you to be largely focused just on continued execution with the portfolio you have, or do you think the portfolio is in good shape as it exists, or are you thinking about not just M&A -- and, of course, I'm always interested in hearing about your interest in opportunistically adding technology or inorganic growth, but with your existing portfolio, are you now more aggressively looking at the pieces you have and thinking you might be more actively thinking about trading out, the net benefit of which would be enhanced growth and/or margins? Both ways, in and out.
Miles D. White -- Chairman and Chief Executive Officer
I get this question in one form or another on every call, every visit to investors, and so forth, and it's always a fun, speculative question. But, the honest answer is we did some very deliberate shaping of the company since the AbbVie split over the last six years, and that's not been accidental or reactive or opportunistic. It's been with intent, a plan, and so forth. At this point, I also think companies can get a little too transactionally oriented -- everything's a transaction as opposed to running it and running it well.
So, philosophically, here's how we operate: Our first baseline is we've got to operate and execute well organically as a company. I know it's a word we've used a lot today, but I want to make a distinction between what we do as part of the ongoing operating of the company versus transactions one way or the other. Our whole goal has been to establish the company with its own internal growth drivers, productive R&D, productive innovation, productive positioning in the right markets, the right segments, the right growth because our investors expect us to make them money, do well with their investment, and grow the company.
So, we've positioned ourselves pretty deliberately and intentionally in those kinds of spaces across the board. I don't know that you're ever done, and I don't know that you ever feel totally comfortable -- you shouldn't -- but I think we're in a pretty good place that way. We've got a lot of what I would say was our intentional repositioning done.
That means for us that we've got to integrate it all -- we've pretty much done that. The integrations of St. Jude and Alere are pretty well done. I mean, it's finished. Other than capturing synergies as we go, and establishing R&D pipelines where they may not have existed, and so forth -- speaking primarily of Alere there and not St. Jude because St. Jude has a robust pipeline -- those kinds of things. It's all about the ongoing delivery of new technologies, new products, new innovations, improvements on the ones you have, and so on.
So, over these last six to eight years, those R&D pipelines and everything have been well established, not just within Abbot, but within St. Jude, too. So, we like the hand we're holding, and you've got to make sure that as a baseline can deliver your company's strategic goals, and in our case, it does. So, that means any transaction for us becomes opportunistic, and does that opportunity fit us strategically? Is it something we're prepared to react or respond to? We'd like to be in a position where it's a choice, not a necessity per se, and I think that's where we are, and right now, we've said for this period of time, because we took on a lot of debt to conclude the St. Jude and Alere acquisitions, we want to pay down that debt.
Well, we're way ahead of schedule paying down our debt, as you know, and shortly here -- we wanted to pay back $8 billion this year. We're just about there, and we'll be there well before year end in terms of debt paydown because we've had really good cash management, really good cash flow, et cetera. We've been able to pay a dividend, we'll raise our dividend at some point, we'll have a steady march with our dividend like we always do. We've been able to fund the capital expenditures internally that drive our growth and our business. We've got some heavy capital investment right now in both Libre and Alinity, and I anticipate that will continue to be the case, but it's not an affordability issue for us.
So, I think our priorities in terms of cash use and investment internally, we're easily making. We're easily making those goals. So, we can afford to be opportunistic if something attractive comes along, but I will tell you that I haven't seen anything that compels me or is sitting on the edge of our radar screen at this point. The single biggest opportunities we've got are all in our own pipelines, and in our businesses now, and in the markets we're in. The biggest opportunities we've got are right in front of you. The question is how big and how fast, and those trends -- what we think we see going forward looks awfully attractive.
And, you'd say, "At some point, how far would you take debt down? How far would you pay down debt? What are you going to do where you hit the point where you think that's enough?" I'd give a couple answers to that. A lot of people seem to get comfortable somewhere between $15 billion and $20 billion. I remember when $15 billion of debt was a hell of a lot of debt, so I think -- and, I also observe, as many of us have -- I think you analysts as well -- share buybacks right now aren't particularly economic. They're not paying off all that well in the market.
So, you try to make your moves at prudent times. I think right now, prudence for us -- we always have our periscope up looking at what's on the radar screen out there. I think there's places in Medical Devices and other things where we might opportunistically think there's something that would be a nice addition to our portfolio, but I don't think anybody should be holding their breath waiting for a great big move here.
I like the portfolio we've got. I'm always questioned about the portfolio because everybody wants to help me tweak it, but it's a pretty strong portfolio. All the businesses are operating well, and for the most part, they're at the early stages of growth cycles driven by new product innovations, and technology innovations, and so forth that are pretty healthy. Because we've got a higher index in emerging markets than a lot of companies, we're going to endure that bumpy road, but the underlying development of those economies and healthcare systems has been a big plus for us, both for Pharma and Nutrition, and honestly, I think it is in Devices and Diagnostics, too. There's some of those markets that don't economically work in those businesses, but some do.
So, I think our platter right now says we can afford to just be opportunistic. I don't have big M&A on the radar screen or big transactions on the radar screen. I'd say from a capital or cash allocation standpoint, I'm going to keep paying down debt because I think that's a prudent path for now. I always like having maximum strategic flexibility for the company. I think our path here is clear. We've been prudent about when it's good to buy back share and when it isn't. I think our capital allocation has been pretty good, and the good news is we've got plenty of cash and capital to have choice, and we can afford to be that discretionary about it. There's a constant stream of friendly investment bankers in and out, always telling us what's on the radar screen, so I don't think we're missing anything, and right now, I like our portfolio a lot better than I like somebody else's.
Rick Wise -- Stifel Financial Corporation -- Analyst
I appreciate that comprehensive answer. Just last for me --
Miles D. White -- Chairman and Chief Executive Officer
That means I talk too much, right, Rick?
Rick Wise -- Stifel Financial Corporation -- Analyst
I would never say that, Miles. No, really, it was very helpful. You had a couple of notable new product approvals this quarter -- the next-gen MitraClip and XIENCE Sierra. XIENCE Sierra is coming in the context of a vascular business that is slightly worse this quarter than the first quarter. Structural heart obviously incredibly strong, accelerated. So, maybe a little color on what we should think from MitraClip. Does the bigger reach open up more procedures? Does it accelerate growth? Does XIENCE Sierra get you back on track in vascular? I'll stop there. Thanks again.
Miles D. White -- Chairman and Chief Executive Officer
Thanks for the question, Rick. I think MitraClip definitely opens up to more patients just because of the size changes and so forth, that we've got more flexibility with that product. Any time you can do incremental improvements of products and enhance them further, you're extending their reach, extending their life, the competitiveness, et cetera, so I think all that's good for our structural heart business, and we've got more things in our pipeline coming.
The XIENCE Sierra -- I'll tell you, early returns in Europe are excellent and performance excellent. Same with Japan. We've just launched in the United States, so all I've got is anecdotal feedback. The U.S., Japan, and Europe -- they're not the same, but they're close. So, I expect Sierra to do well in the United States. You say it gets us back on the track. I think the track in the stent business is low single digits at best. There's always a lot of competition in this business. We've talked about that. There's three or four pretty strong competitors here.
I think the market has said the biggest magnitude of innovation has been had. There's incremental improvements we can all make, but it's a very competitive space, so I think being on track here is low single digits, and that's -- at least right now -- what I expect out of this, and I expect XIENCE Sierra to claim its share of the market, do well, be more than competitive, and we'll see that. We're seeing it in Europe, we're seeing it in Japan, so I expect to see it in the U.S. too. But, I don't think this is a space where there's gigantic quantum leaps and offerings, but it's one of those very strong, very profitable, important legacy cornerstones of the device business that it's important for us to maintain our leadership in and our competitive positioning, and I think XIENCE Sierra puts us back on that track.
Rick Wise -- Stifel Financial Corporation -- Analyst
Thanks again.
Operator
Thank you. And, our next question comes from Joanne Wuensch from BMO Capital Markets. Your line is open.
Joanne Wuensch -- BMO Capital Markets -- Managing Director
Good morning and thank you for taking the question. Can we spend a moment or two looking at the diagnostic business? Alinity has been launched in Europe for over a year. It's rolling out in the United States now. How should we think about that contributing, and also the whole business holistically now that Alere is part of it?
Miles D. White -- Chairman and Chief Executive Officer
Well, Joanne, Alere is part of the Diagnostics business, but it's not integrated with the core lab business, so what we've got here is kind of a collection of businesses by major segment. So, I think -- let me just take that last part first. I think the space that Alere expands us in -- point of care, near-patient testing, distributive testing, et cetera, which is also kind of a collection of spaces -- I think we're in a very strong position. One of the things we'd like to do, obviously, is renew or update or enhance a number of products and so forth -- in other words, put a lot more into innovation and R&D there.
But, I think we've got a very strong portfolio. Right now, I'd call it a stable portfolio that's at a low growth point, but that's not where we ultimately expect it to be. Since the time we acquired Alere, we've said for a while here, that's not going to be a high grower, but we expect it to be, and we do. I'd tell you that so far, everything that you'd have to do to integrate a business, make it part of the company, put management in place that hasn't been there before -- and so, that's all gone exceptionally well, way faster than we might have thought. So, we're really pleased with that business, we're really pleased with it in the portfolio, we're super pleased with how the management team there is doing -- all good all day, and we look forward to its contribution to our grow and innovation over the future here because I think that's exactly what it's going to do.
Back to Alinity, there's a couple of things to understand about this space or spaces. We don't always determine when the customer wants to buy or when the customer has to make a decision. So, first of all, because these are big mainframe systems, core laboratories, blood screening enterprises and so forth, they tend to be contracted or tenders that are five, seven, or even ten years. They're usually longer-term contracts. They're big installations. The change from one competitor to another or old systems to new systems and so forth -- it's not quick. It'll take a couple of months and so forth.
So, these are big mainframe sorts of enterprise decisions, and we're kind of on their schedule. So, we can do a lot to enhance that, or even speed it up, which we're doing. The receptiveness to something new if you're replacing old systems depends on the completeness of your menu so that you can do a full swap-out and not have to run two different systems at the same time, et cetera, even though a lot of labs do.
So, those are just dynamics we deal with in the market every day. I'd say our menu in Europe is full and robust. It's a big menu in the U.S. and other countries -- not as big as Europe, but coming fast, and we're talking anywhere from 150 to 200 different tests here that have to be on that box, each of which have to be individually approved and licensed, et cetera. So, we're in a really strong position that way in Europe. That menu ramp-up obviously takes a little bit of time, it takes a little bit of time in the U.S. and everywhere, so we're getting through that or past that now.
We're tracking like you would in any capital business -- prospects, which I think has more than quintupled in the last several quarters here -- and we're tracking closed rates... If we're in a competitive situation where we are already in there, I think our win rate is about 97%. We're keeping everything that we've already got and expanding beyond that. In places where we're trying to replace competitive systems, our win rate is well above 50%, and that's really good from the standpoint of those accounts have to make a decision that they're actually going to swap out everything that they've had for a number of years, and to have that kind of initial win rate here is pretty strong.
And so, we like the win rates we're seeing, both in retention, and new instruments, and new placements, and expansions, and so forth, and a lot of times, you'll get the first installation and it expands from there. So, I would say all the metrics that we would track -- including how fast it is to get up and running, test the record, and so forth -- they're all tracking exceptionally well. We're expanding our sales and service organizations in Europe as we speak. That hiring is going very well and very fast, a lot better than we did in neuromod, I can tell you that. We'll take a lesson there.
And so, the ramp-up is moving faster and faster now. We've got a very specifically detailed plan about how many, how fast, on what pace, et cetera, gosh, for years ahead here, and we've pretty well gotten every country mapped, every account mapped, et cetera, so now, it's just a matter of execution, how fast we can execution, and all that stuff. So, all that's doing really well, so I'm pretty excited about the path ahead here in the Diagnostics business on all fronts.
Joanne Wuensch -- BMO Capital Markets -- Managing Director
Thank you. And, my follow-up question is on your MitraClip franchise. We have the next-generation product, which was just FDA approved in a coop trial reading out in September. Can you just give us an update on where that business is? Thank you.
Miles D. White -- Chairman and Chief Executive Officer
I'm going to ask Scott to help me with that, Joanne.
Scott Leinenweber -- Vice President, Investor Relations
Yeah, with respect to MitraClip, you can see the performance in the numbers there, and structural heart is doing quite well. We will get a readout rate out on the U.S. coop trial data later this year, very likely at the TCT conference in September, so that'll be a big event for us. We're also doing quite a bit with respect to geographic expansion as well. We received national reimbursement in Japan here in the second quarter. That's a nice opportunity for us, too. That market is quite sizable. So, MitraClip is hitting on all cylinders with a lot of growth in front of it.
Joanne Wuensch -- BMO Capital Markets -- Managing Director
Thank you.
Miles D. White -- Chairman and Chief Executive Officer
So, during that wrap-up -- I like the way Scott wrapped that up. "It's hitting on all cylinders." Obviously, in a company of our size and diversity, everything doesn't hit on all cylinders all the time, but I'll tell you right now, I think for the markets we have -- and, let's call it the exchange and currency volatility we've all got out there and so on -- I think the company is performing exceptionally well and I feel pretty good about all the underlying performance and the strength going forward here.
Scott Leinenweber -- Vice President, Investor Relations
So, operator, we'll take one more question.
Operator
Thank you. And, our final question comes from Chris Pasquale from Guggenheim. Your line is open.
Christopher Pasquale -- Guggenheim Securities -- Director
Thanks. Miles, just a couple quick ones here from me. 1). On the EPD business and the situation in Russia, I think you had previously said you still expected that to be a headwind in 2Q. Did that come back earlier than expected? And then, just quickly on Diagnostics, the legacy Abbott point of care business has slowed a little bit over the last few quarters. Is that a function of the integration work being done there, or is there something else happening?
Miles D. White -- Chairman and Chief Executive Officer
Well, I'll take the point of care first. There's a couple things going on there, and I'd say a little bit of it integration. We had a number of management changes because we were populating the new rapid diagnostic business, so we had a lot of new over new over new there, and we may have lost touch with ourselves a little bit in the transition. There's a couple customer dynamics -- big accounts and so forth -- where we had some challenges that have since been addressed, so I expect that to improve. I don't think that's a long-term condition, but we've had a couple of slip-ups here that slowed our growth rate, and I think we'll be seeing that come back to much healthier growth rate.
With regard to Russia and EPD, I'm going to get a little bit of help here from Scott and Brian, but generally, I'd say it's as predicted. I think we're seeing the cycle pass through here in the second quarter. I don't know that it's completely done, but everything we kind of thought would play out is or has, and so, we're seeing that come back to...let's call it a better position.
Scott Leinenweber -- Vice President, Investor Relations
I would just add that our end customer demand remains in line with our expectations, we're tracking that, and I'd say this quarter, we actually returned to growth in Russia, which is a good sign based on the stabilization we're seeing and how the destocking has progressed as we had planned this far.
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
I'm actually kind of surprised we got it that close. Usually, you try to predict these things and you're never right, and it's actually turned out to be more right than we thought.
Christopher Pasquale -- Guggenheim Securities -- Director
Thanks, that's helpful, and congrats on the strong results.
Miles D. White -- Chairman and Chief Executive Officer
Thank you.
Christopher Pasquale -- Guggenheim Securities -- Director
Thank you.
Scott Leinenweber -- Vice President, Investor Relations
Well, thank you, operator, and thank you for all of your questions. This now concludes Abbott's conference call. A webcast replay of the call will be available after 11:00 a.m. Central time today at Abbott Investor Relations website at Abbottinvestor.com. Thank you for joining us today.
Operator
Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone have a wonderful day.
Duration: 61 minutes
Call participants:
Scott Leinenweber -- Vice President, Investor Relations
Miles D. White -- Chairman and Chief Executive Officer
Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer
David Lewis -- Morgan Stanley -- Managing Director
Larry Biegelsen -- Wells Fargo Securities -- Analyst
Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director
Glenn Novarro -- RBC Capital Markets -- Managing Director
Rick Wise -- Stifel Financial Corporation -- Analyst
Joanne Wuensch -- BMO Capital Markets -- Managing Director
Christopher Pasquale -- Guggenheim Securities -- Director
More ABT analysis
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) Q2 2018 Earnings Conference Call July 17, 2018, 9:00 a.m. Duration: 61 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer David Lewis -- Morgan Stanley -- Managing Director Larry Biegelsen -- Wells Fargo Securities -- Analyst Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director Glenn Novarro -- RBC Capital Markets -- Managing Director Rick Wise -- Stifel Financial Corporation -- Analyst Joanne Wuensch -- BMO Capital Markets -- Managing Director Christopher Pasquale -- Guggenheim Securities -- Director More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. This business, which is already a global leader and growing faster than its market, is well positioned for sustainable growth for years to come as we capture share and roll out the full suite of Alinity systems across additional geographies, including the U.S. | Duration: 61 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer David Lewis -- Morgan Stanley -- Managing Director Larry Biegelsen -- Wells Fargo Securities -- Analyst Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director Glenn Novarro -- RBC Capital Markets -- Managing Director Rick Wise -- Stifel Financial Corporation -- Analyst Joanne Wuensch -- BMO Capital Markets -- Managing Director Christopher Pasquale -- Guggenheim Securities -- Director More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q2 2018 Earnings Conference Call July 17, 2018, 9:00 a.m. All four of our businesses exceeded expectations for the quarter and contributed to strong growth overall, and lastly, we started the year with strong double-digit EPS guidance, and despite recent currency shifts, today we're raising our outlook even higher based on the strength of our underlying performance. | Duration: 61 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer David Lewis -- Morgan Stanley -- Managing Director Larry Biegelsen -- Wells Fargo Securities -- Analyst Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director Glenn Novarro -- RBC Capital Markets -- Managing Director Rick Wise -- Stifel Financial Corporation -- Analyst Joanne Wuensch -- BMO Capital Markets -- Managing Director Christopher Pasquale -- Guggenheim Securities -- Director More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q2 2018 Earnings Conference Call July 17, 2018, 9:00 a.m. The good news is even when it's down, the growth rate is still pretty high, so we go from a good growth rate to a great growth rate to a good growth rate, back and forth, because it's a bit volatile. | Abbott Laboratories (NYSE: ABT) Q2 2018 Earnings Conference Call July 17, 2018, 9:00 a.m. Duration: 61 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer David Lewis -- Morgan Stanley -- Managing Director Larry Biegelsen -- Wells Fargo Securities -- Analyst Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director Glenn Novarro -- RBC Capital Markets -- Managing Director Rick Wise -- Stifel Financial Corporation -- Analyst Joanne Wuensch -- BMO Capital Markets -- Managing Director Christopher Pasquale -- Guggenheim Securities -- Director More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. With that, we will now open the call for questions. |
33229.0 | 2018-07-18 00:00:00 UTC | Abbott Laboratories Stock Gets a Boost From Q2 Earnings Beat | ABT | https://www.nasdaq.com/articles/abbott-laboratories-stock-gets-boost-q2-earnings-beat-2018-07-18 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Abbott Laboratories (NYSE: ABT ) stock was up on Wednesday following the release of its earnings report for the second quarter of 2018.
Source: Open Grid Scheduler Via Flickr
Abbott Laboratories reported earnings per share of 73 cents for the second quarter of the year. This is an increase over its earnings per share of 62 cents from the same time last year. It also beat out Wall Street's earnings per share estimate of 71 cents for the quarter, making it a boon to ABT stock.
Net income reported by Abbott Laboratories for the second quarter of 2018 came in at $733 million. This is better than the company's net income of $283 million that was reported in the second quarter of the previous year.
Abbott Laboratories also saw an increase to its operating income for the second quarter of the year. The company's operating income for the period came in at $882 million. Operating income from the same period of the year prior was $386 million.
Abbott Laboratories' earnings report for the second quarter of 2018 also includes lucky revenue of $7.77 billion. This is up from the company's revenue of $6.64 billion that was reported in the second quarter of 2017. It was also good news for ABT stock by coming in above analysts' revenue estimate of $7.71 billion.
7 Alternative Internet of Things Stocks to Buy
The most recent earnings report from Abbott Laboratories also includes its guidance for the full year of 2018. The company says that it is expecting earnings per share for the year to range from $2.85 to $2.91. Wall Street is looking for earnings per share of $2.86 for the period.
ABT stock was up 2% as of Wednesday morning.
More From InvestorPlace
5 Strong Earnings Stocks to Buy Post-Netflix Plunge
4 Underappreciated Stocks to Buy Before the Analysts Weigh In
5 Stocks That Could Double In the Next 5 Years
4 Solar Stocks to Buy, 4 to Avoid
As of this writing, William White did not hold a position in any of the aforementioned securities.
Compare Brokers
The post Abbott Laboratories Stock Gets a Boost From Q2 Earnings Beat appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It also beat out Wall Street's earnings per share estimate of 71 cents for the quarter, making it a boon to ABT stock. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) stock was up on Wednesday following the release of its earnings report for the second quarter of 2018. It was also good news for ABT stock by coming in above analysts' revenue estimate of $7.71 billion. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) stock was up on Wednesday following the release of its earnings report for the second quarter of 2018. It also beat out Wall Street's earnings per share estimate of 71 cents for the quarter, making it a boon to ABT stock. It was also good news for ABT stock by coming in above analysts' revenue estimate of $7.71 billion. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) stock was up on Wednesday following the release of its earnings report for the second quarter of 2018. It also beat out Wall Street's earnings per share estimate of 71 cents for the quarter, making it a boon to ABT stock. It was also good news for ABT stock by coming in above analysts' revenue estimate of $7.71 billion. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) stock was up on Wednesday following the release of its earnings report for the second quarter of 2018. It also beat out Wall Street's earnings per share estimate of 71 cents for the quarter, making it a boon to ABT stock. It was also good news for ABT stock by coming in above analysts' revenue estimate of $7.71 billion. |
33230.0 | 2018-07-18 00:00:00 UTC | Housing Starts/Permits Disappoint; MS, USB and ABT Beat | ABT | https://www.nasdaq.com/articles/housing-startspermits-disappoint-ms-usb-and-abt-beat-2018-07-18 | nan | nan | Wednesday, July 18, 2018
Ahead of Wednesday's market open, we see new key Q2 earnings reports. Many of these are from the Financial sector, like Morgan Stanley MS and U.S. Bancorp USB , but we also hear from other industries, like Abbott Labs ABT , as well. After regular trading closes today, we'll hear from eBay EBAY , American Express AXP and IBM IBM .
But before we get into today's pre-market results, new Housing Starts and Permits numbers hit the tape, and they were far below expectations. New Housing Starts for June fell 12.3% from the -2.2% consensus, whereas Building permits - a forward indicator on future starts - tumbled 2.2% from an expected +2.2%.
Considering all the good-to-great economic reads we've been getting over the past several months, especially in Construction and related segments, these numbers bring somewhat of a negative shock. Analysts had been looking for roughly 1.3 million new starts last month - down from May's 1.35 million actual - but only brought in 1.173 million. Permits totaled 1.273 million, an improvement of 100K over the starts headline but still below the 1.3 million expected.
What do we take away from this? Not all that much, truthfully. This is but one dent in the armor of an historically robust economy, in a bull market that is almost a decade old but, if Fed Chair Jay Powell is to be taken at his word, still with room to grow bigger and stronger. Yet we will be mindful of these results when new Construction and Housing reads come in the weeks and months to come. Have these markets gotten too hot over the past couple years, and do they look to be cooling off, at least in the near term?
Morgan Stanley may have begat the crown jewel of Q2 earnings results for investment banks thus far (though Goldman Sachs' [GS] earnings report yesterday was stellar), reporting $1.30 per share on $10.6 billion in revenues - outpacing both the $1.08 per share and $10.0 billion expected. The top line also solidly beat the $9.5 billion from the year-ago quarter.
Net Income Applicable for Morgan Stanley in the quarter shot up 39% year over year, while the crucial segment of Investment Banking rose 21% from Q2 2017. Shares of MS are up 3.3% in pre-market trading , but flat year over year. For more on MS's earnings, click here.
U.S. Bancorp also outperformed expectations, but by relatively tepid margins: $1.02 per share beat the Zacks consensus by a penny, and revenues of $5.6 billion topped the $5.4 billion anticipated. Beneath the headlines, we also see positive but slight metrics - Net interest Margins grew 5 basis points year over year. For more on USB's earnings, click here.
Also, Abbott Labs reported Q2 earnings before today's open, narrowly managing earnings and sales beats as well. A bottom line of 73 cents per share took out the 71-cent consensus, and revenues of $7.77 billion outdid the expected $7.73 billion. Beneath this less-than-opulent headline, Diagnostics rose a whopping 47% year over year, and as a result helped push Abbott's full-year guidance upward on both top and bottom ends of the range, to $2.85 - 2.91 per share. The stock is up roughly 3% in early trading. For more on ABT's earnings, click here.
Mark Vickery
Senior Editor
Questions or comments about this article and/or its author? Click here>>
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
International Business Machines Corporation (IBM): Free Stock Analysis Report
U.S. Bancorp (USB): Free Stock Analysis Report
eBay Inc. (EBAY): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Morgan Stanley (MS): Free Stock Analysis Report
American Express Company (AXP): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Many of these are from the Financial sector, like Morgan Stanley MS and U.S. Bancorp USB , but we also hear from other industries, like Abbott Labs ABT , as well. For more on ABT's earnings, click here. Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report American Express Company (AXP): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report American Express Company (AXP): Free Stock Analysis Report To read this article on Zacks.com click here. Many of these are from the Financial sector, like Morgan Stanley MS and U.S. Bancorp USB , but we also hear from other industries, like Abbott Labs ABT , as well. For more on ABT's earnings, click here. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report American Express Company (AXP): Free Stock Analysis Report To read this article on Zacks.com click here. Many of these are from the Financial sector, like Morgan Stanley MS and U.S. Bancorp USB , but we also hear from other industries, like Abbott Labs ABT , as well. For more on ABT's earnings, click here. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report American Express Company (AXP): Free Stock Analysis Report To read this article on Zacks.com click here. Many of these are from the Financial sector, like Morgan Stanley MS and U.S. Bancorp USB , but we also hear from other industries, like Abbott Labs ABT , as well. For more on ABT's earnings, click here. |
33231.0 | 2018-07-18 00:00:00 UTC | Morning Movers: Clorox Slides, United Continental Flies, Morgan Stanley Jumps | ABT | https://www.nasdaq.com/articles/morning-movers-clorox-slides-united-continental-flies-morgan-stanley-jumps-2018-07-18 | nan | nan | Yawn. The Dow Jones Industrial Averag e is barely moving this morning. In today's Morning Movers, we...
Getty Images
•...fret about the lack of stocks joining the Nasdaq's rally; •...review Morgan Stanley's (MS) stellar earnings; •...and highlight a Goldman Sachs downgrade of Clorox (CLX).
For a market that has been trending higher, it sure has a tired feeling to it.
S&P 500 futures have dipped 0.1%, while Dow Jones Industrial Average futures have ticked up 3 points. Nasdaq Composite futures have declined 0.1%.
Don't get me wrong. The market has certainly been moving in the right direction. The Nasdaq, for one, closed at a record high yesterday, while the S&P 500 finally closed meaningfully above 2800 and sits at its highest level since Feb. 1. Only the Dow Jones Industrial Average isn't at a level that requires a superlative, but even it's been up 11 of the past 13 days.
Still, there's little oomph in the markets rise. Jason Goepfert of Sundial Capital Research notes that even with the Nasdaq Composite hitting new highs, as of last Friday just 57% of its constituents were trading above their 50-day moving averages, and 59% above their 200-day moving averages. That's below the average of 64% since 2002 when the Nasdaq hits a new high. And forward returns haven't been great when fewer than 60% of the stocks in the index are trading above their 200-day moving average. One month later, the index had dipped 0.1%, and it typically fell 2.2% over the next year. "The Nasdaq sported significantly below-average returns over the next 1-2 months, and again over the next year. Its one-year returns were especially terrible," Goepfert writes.
Still, there are few signs of euphoria in the market, which could be good news for stocks generally. Bernstein's Mark Diver notes that cross-border fund flows have been weak, while other measures of medium-term sentiment have also been lackluster. "Our medium-term measures of equity sentiment, which we use as contrarian indicators of 12-month forward global equity-market returns, have been growing more supportive in recent months," he writes.
But will it be enough to drive the market even higher?
Earnings & News
Abbott Laboratories (ABT) is up 2.4% to $64.30 after reporting second-quarter earnings. The drug maker earned 73 cents a share on revenue of $7.77 billion. Analysts were looking for earnings per share of 71 cents on revenue of $7.71 billion. For the full year, it sees EPS of $2.85 to $2.91, compared with the $2.86 consensus estimate.
Getty Images
Alphabet (GOOGL) is down 0.6% to $1,205.51 after the EU fined the Google parent 4.34 billion euros for illegal practices related to its Android devices.
CSX (CSX) is up 3.7% to $66.85 after reporting second-quarter earnings. The railroad earned $1.01 a share on revenue of $3.1 billion. Analysts were looking for earnings of 87 cents a share on revenue of $3 billion.
Morgan Stanley (MS) is up 3.1% to $50.70 after reporting second-quarter earnings. The bank earned $1.30 a share on revenue of $10.61 billion. Analysts were looking for earnings of $1.10 a share on revenue of $10.05 billion. Its board also raised its dividend by a nickel, to 30 cents a share, and authorized stock repurchases up to $4.7 billion.
Texas Instruments (TXN) is down 1.1% to $114.51 after announcing its chief executive, Brian Crutcher, stepped down because of conduct violations, to be replaced by Chairman Richard Templeton. The company also said it will earn $1.37 in the second quarter, compared with the $1.31 consensus EPS estimate.
United Continental Holdings (UAL) is up 4.1% to $75.61 after reporting second-quarter earnings. The airline earned $3.23 a share on revenue of $10.78 billion. Analysts were looking for earnings of $3.07 a share on revenue of $10.72 billion. For the full year, it sees EPS of $7.25 to $8.75, compared with the $7.71 per-share consensus estimate. - Teresa Rivas
Upgrades & Downgrades
Broadcom (AVGO) is down 0.6% to $207 after Goldman Sachs downgraded it to Neutral.
Broadcom Ltd. Ltd.
CF Industries (CF) is up 1% to$43.13 after RBC Capital Markets upgraded it to Sector Perform.
Comerica (CMA) has advanced 1.2% to $93 after getting upgraded to Outperform from In Line by Evercore ISI.
Clorox (CLX) has fallen 1.8% to $132.65 after getting cut to Sell from Neutral by Goldman Sachs.
Paccar (PCAR) is down 1.2% to $62.45 after BMO Capital Markets downgraded it to Market Perform.
Twitter (TWTR) is down 0.5% to $44.47 after Macquarie downgraded it to Neutral. - T.R.
Sign up to Review & Preview, a new daily email from Barron's. Every evening we'll review the news that moved markets during the day and look ahead to what it means for your portfolio in the morning.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Earnings & News Abbott Laboratories (ABT) is up 2.4% to $64.30 after reporting second-quarter earnings. In today's Morning Movers, we... Getty Images •...fret about the lack of stocks joining the Nasdaq's rally; •...review Morgan Stanley's (MS) stellar earnings; •...and highlight a Goldman Sachs downgrade of Clorox (CLX). "Our medium-term measures of equity sentiment, which we use as contrarian indicators of 12-month forward global equity-market returns, have been growing more supportive in recent months," he writes. | Earnings & News Abbott Laboratories (ABT) is up 2.4% to $64.30 after reporting second-quarter earnings. In today's Morning Movers, we... Getty Images •...fret about the lack of stocks joining the Nasdaq's rally; •...review Morgan Stanley's (MS) stellar earnings; •...and highlight a Goldman Sachs downgrade of Clorox (CLX). S&P 500 futures have dipped 0.1%, while Dow Jones Industrial Average futures have ticked up 3 points. | Earnings & News Abbott Laboratories (ABT) is up 2.4% to $64.30 after reporting second-quarter earnings. In today's Morning Movers, we... Getty Images •...fret about the lack of stocks joining the Nasdaq's rally; •...review Morgan Stanley's (MS) stellar earnings; •...and highlight a Goldman Sachs downgrade of Clorox (CLX). Jason Goepfert of Sundial Capital Research notes that even with the Nasdaq Composite hitting new highs, as of last Friday just 57% of its constituents were trading above their 50-day moving averages, and 59% above their 200-day moving averages. | Earnings & News Abbott Laboratories (ABT) is up 2.4% to $64.30 after reporting second-quarter earnings. The market has certainly been moving in the right direction. And forward returns haven't been great when fewer than 60% of the stocks in the index are trading above their 200-day moving average. |
33232.0 | 2018-07-18 00:00:00 UTC | Health Care Sector Update for 07/18/2018: ABT, MBRX, CLRB | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07182018-abt-mbrx-clrb-2018-07-18 | nan | nan | Top Health-care stocks:
JNJ: -0.2%
PFE: +0.2%
ABT: +2.7%
MRK: flat
AMGN: -0.5%
Health care shares were higher ahead of the bell on Wednesday.
Expected movers:
- Abbott Laboratories ( ABT ): Q2 adj. EPS, sales top estimates; Q3 and FY adj. EPS seen in line
- Moleculin Biotech ( MBRX ): starts preclinical toxicology testing of WP1732, plans to meet FDA submission requirements before year-end
- Cellectar Biosciences ( CLRB ): reports positive response in blood-cancer trial
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Expected movers: - Abbott Laboratories ( ABT ): Q2 adj. Health care shares were higher ahead of the bell on Wednesday. EPS seen in line - Moleculin Biotech ( MBRX ): starts preclinical toxicology testing of WP1732, plans to meet FDA submission requirements before year-end - Cellectar Biosciences ( CLRB ): reports positive response in blood-cancer trial The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Expected movers: - Abbott Laboratories ( ABT ): Q2 adj. EPS seen in line - Moleculin Biotech ( MBRX ): starts preclinical toxicology testing of WP1732, plans to meet FDA submission requirements before year-end - Cellectar Biosciences ( CLRB ): reports positive response in blood-cancer trial The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Expected movers: - Abbott Laboratories ( ABT ): Q2 adj. Health care shares were higher ahead of the bell on Wednesday. EPS, sales top estimates; Q3 and FY adj. | Expected movers: - Abbott Laboratories ( ABT ): Q2 adj. MRK: flat Health care shares were higher ahead of the bell on Wednesday. |
33233.0 | 2018-07-18 00:00:00 UTC | 3 Big Stock Charts for Wednesday: United Technologies, Abbott Laboratories and Leggett & Platt | ABT | https://www.nasdaq.com/articles/3-big-stock-charts-for-wednesday%3A-united-technologies-abbott-laboratories-and-leggett | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The market didn't start Tuesday's action on the best foot. But, some encouraging words from Federal Reserve Chairman Jerome Powell soothed investors' worries, pushing stocks collectively back into the black by an average of 0.4%. Overstock.com (NASDAQ: OSTK ) led the way with its 10%-plus gain, though beyond, noteworthy pacesetters were few and far between.
The market's dead weight certainly wasn't tough to find though. Netflix (NASDAQ: NFLX ) ended the day down to the tune of 5% after it fell short of subscriber-growth outlooks for the recently ended quarter.
Everything else was… strangely tame.
Still, a handful of stocks are setting up big moves even if they've yet to make them. Among the best of those best are Leggett & Platt (NYSE: LEG ), Abbott Laboratories (NYSE: ABT ) and United Technologies (NYSE: UTX ). Here's a closer look.
Leggett & Platt (LEG)
During the first quarter of the year, Leggett & Platt shareholders had good reason to be worried. The stock was into new 52-week low territory, and there was no end in sight.
7 Alternative Internet of Things Stocks to Buy
Investors found some relief in June, though the rebound was still tentative. It became less tentative this month, thanks to a move above a key technical line. Since then the rebound effort has stalled, but it's stalled in such a way that the bulls could be building up another thrust. That next bullish surge, however, could persist for a while because the stock's already cleared all of its most meaningful resistance levels.
Click to Enlarge • The 200-day moving average line (green) was the ceiling in June, but that line was hurdled early this month thanks to support a couple of times at the 20-day moving average line (blue). As of Tuesday, the 20-day line is above the 200-day line, confirming at least the short-term trend is a bullish one.
• Since early last week, LEG has been trapped in a narrow, horizontal range between $45.04 and $45.81. The sideways action within this range serves as a buildup phase for the next bullish leg (though a break below $45.04 still can't be ruled out).
• The monthly chart indicates a long-standing descending resistance line has been snapped, and has done so with a healthy degree of bullish volume.
Abbott Laboratories (ABT)
The one thing more affirming than an unfettered streak of bullish momentum is a quelled effort to kill a rally. That's what Abbott Laboratories shares were able to do on Tuesday, at the most opportune technical support. One more solidly bullish day could get ABT shares over a major hump.
Click to Enlarge • Monday's selloff was strong, threatening to jump-start a new wave of profit-taking. All it took was a kiss of the 20-day and 50-day moving average lines, however, to rekindle the bullish effort.
• The size/height of the Monday/Tuesday reversal is a decisive sign in and of itself, made decisively bullish by the fact that Tuesday's volume was very high … suggesting a majority opinion.
• The line that tags all the major peaks since January is at $63.44. It's been a ceiling that whole time, but a move above that technical resistance could create a technical reset of sorts and lead to a long-term move not unlike the one we saw in 2017.
United Technologies (UTX)
Though United Technologies shares have been in a respectable long-term uptrend that took shape in early 2016, the stock didn't fare too well early this year. In fact, it fell all the way back to a major rising support line.
At the proverbial 11th hour though, the stock made a pivot. That was ugly too, but since then we've seen some key bullish clues take shape.
Click to Enlarge • The biggest of those clues is the way UTX shares found clean and consistent support at the 200-day moving average line in late June and early July. That line became a pushoff point last week.
• The convergence of all the key moving average lines also sets the stage for a divergence phase. Periods of high volatility are followed by periods of low volatility, and vice versa. The convergence of the major moving averages into a near-single point this month suggests we'll start to see them move away from one another again. So far it seems that the divergence will be in a bullish direction.
• The growing degree of bullish volume underscores the notion that the divergence from here should be a bullish one. The accumulation-distribution line is not only rising, but appears to be accelerating higher.
As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter , at @jbrumley.
Legendary Investor Louis Navellier's #1 Stock to Buy NOW
Louis Navellier - the investor the New York Times called an "icon" - just helped investors make 487% in the booming Chinese stock market … 408% in the medical device sector … 150% in Netflix … all in less than 2 years! Now, Louis is urging investors to get in on what may be the opportunity of a lifetime. By using a unique investment strategy called "The Master Key," you could make hundreds of percent returns over the next few years. Click here to learn about the #1 stock recommendation from one of America's top investors.
More From InvestorPlace
5 Strong Earnings Stocks to Buy Post-Netflix Plunge
4 Underappreciated Stocks to Buy Before the Analysts Weigh In
5 Stocks That Could Double In the Next 5 Years
4 Solar Stocks to Buy, 4 to Avoid
Compare Brokers
The post 3 Big Stock Charts for Wednesday: United Technologies, Abbott Laboratories and Leggett & Platt appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) The one thing more affirming than an unfettered streak of bullish momentum is a quelled effort to kill a rally. Among the best of those best are Leggett & Platt (NYSE: LEG ), Abbott Laboratories (NYSE: ABT ) and United Technologies (NYSE: UTX ). One more solidly bullish day could get ABT shares over a major hump. | Among the best of those best are Leggett & Platt (NYSE: LEG ), Abbott Laboratories (NYSE: ABT ) and United Technologies (NYSE: UTX ). Abbott Laboratories (ABT) The one thing more affirming than an unfettered streak of bullish momentum is a quelled effort to kill a rally. One more solidly bullish day could get ABT shares over a major hump. | Among the best of those best are Leggett & Platt (NYSE: LEG ), Abbott Laboratories (NYSE: ABT ) and United Technologies (NYSE: UTX ). Abbott Laboratories (ABT) The one thing more affirming than an unfettered streak of bullish momentum is a quelled effort to kill a rally. One more solidly bullish day could get ABT shares over a major hump. | Among the best of those best are Leggett & Platt (NYSE: LEG ), Abbott Laboratories (NYSE: ABT ) and United Technologies (NYSE: UTX ). Abbott Laboratories (ABT) The one thing more affirming than an unfettered streak of bullish momentum is a quelled effort to kill a rally. One more solidly bullish day could get ABT shares over a major hump. |
33234.0 | 2018-07-18 00:00:00 UTC | Earnings Reaction History: Abbott Laboratories, 54.5% Follow-Through Indicator, 2.3% Sensitive | ABT | https://www.nasdaq.com/articles/earnings-reaction-history-abbott-laboratories-545-follow-through-indicator-23-sensitive-0 | nan | nan | Expected Earnings Release: 07/18/2018, Premarket
Avg. Extended-Hours Dollar Volume: $2,472,801
Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 57.1%
Average next regular session additional gain: 1.8%
Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.8%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 50%
Average next regular session additional loss: 2.7%
Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.8% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.8%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 50% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,472,801 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.8% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.8%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 50% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,472,801 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.8% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.8%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 50% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,472,801 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $2,472,801 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.8% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.8%. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. |
33235.0 | 2018-07-18 00:00:00 UTC | Health Care Sector Update for 07/18/2018: CLRB,ABT,MBRX,CARA | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07182018-clrbabtmbrxcara-2018-07-18 | nan | nan | Top Health Care Stocks
JNJ -1.43%
PFE -0.09%
ABT +2.99%
MRK +0.56%
AMGN -0.57%
Health care stocks were narrowly higher in late trading, including a nearly 0.3% gain for the NYSE Health Care Index. Also, shares of health care companies in the S&P 500 were up almost 0.1% as a group while the Nasdaq Biotechnology index also was climbing nearly 0.1% today.
Among health care stocks moving on news:
- Cellectar Biosciences ( CLRB ) tumbled Wednesday, at one point falling 14% lower, despite the early-stage oncology pharmaceuticals company saying it was expanding Phase II testing of its CLR131 drug candidate to include up to 30 more patients after reporting positive interim results for the medication in patients with large B-cell candidate lymphoma. Patients with certain types of the blood cancer showed a 33% overall response rate while 50% of the patients demonstrated a clinical benefit response. Tumor reductions ranged in size from 60% to more than 90%, it said.
In other sector news:
+ Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit and beating non-GAAP Street projections by $0.02 per share. Net sales rose 17% year over year to $7.77 billion, also exceeding the $7.71 billion Capital IQ analyst mean.
+ Moleculin Biotech ( MBRX ) rose more than 2% in late Wednesday trading, trying to retrace a more than 3% gain soon after the opening bell and the early-stage drugmaker saying it has begun preclinical toxicology testing of its WP1732 prospective treatment for pancreatic cancer. Moleculin also said it expects to complete work on the investigational new drug application for the fully water-soluble STAT3 inhibitor before the end of the year.
- Cara Therapeutics ( CARA ) dropped as much as 10% on Wednesday after the biotech company late Tuesday began an underwritten public offering of 4.5 million shares of its common stock. The company also granted a 30-day over-allotment option for underwriters to buy up to 675,000 additional shares. Net proceeds will fund ongoing clinical and research development activities.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news: + Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit and beating non-GAAP Street projections by $0.02 per share. Among health care stocks moving on news: - Cellectar Biosciences ( CLRB ) tumbled Wednesday, at one point falling 14% lower, despite the early-stage oncology pharmaceuticals company saying it was expanding Phase II testing of its CLR131 drug candidate to include up to 30 more patients after reporting positive interim results for the medication in patients with large B-cell candidate lymphoma. + Moleculin Biotech ( MBRX ) rose more than 2% in late Wednesday trading, trying to retrace a more than 3% gain soon after the opening bell and the early-stage drugmaker saying it has begun preclinical toxicology testing of its WP1732 prospective treatment for pancreatic cancer. | In other sector news: + Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit and beating non-GAAP Street projections by $0.02 per share. Health care stocks were narrowly higher in late trading, including a nearly 0.3% gain for the NYSE Health Care Index. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news: + Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit and beating non-GAAP Street projections by $0.02 per share. Health care stocks were narrowly higher in late trading, including a nearly 0.3% gain for the NYSE Health Care Index. Among health care stocks moving on news: - Cellectar Biosciences ( CLRB ) tumbled Wednesday, at one point falling 14% lower, despite the early-stage oncology pharmaceuticals company saying it was expanding Phase II testing of its CLR131 drug candidate to include up to 30 more patients after reporting positive interim results for the medication in patients with large B-cell candidate lymphoma. | In other sector news: + Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit and beating non-GAAP Street projections by $0.02 per share. Health care stocks were narrowly higher in late trading, including a nearly 0.3% gain for the NYSE Health Care Index. Also, shares of health care companies in the S&P 500 were up almost 0.1% as a group while the Nasdaq Biotechnology index also was climbing nearly 0.1% today. |
33236.0 | 2018-07-18 00:00:00 UTC | Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up | ABT | https://www.nasdaq.com/articles/abbott-abt-q2-earnings-revenues-top-estimates-view-up-2018-07-18 | nan | nan | Abbott LaboratoriesABT reported second-quarter 2018 adjusted earnings from continuing operations of 73 cents per share, beating the Zacks Consensus Estimate by a couple of cents. The bottom line also improved 17.7% year over year and exceeded the company's guided range of 70-72 cents. Moreover, reported earnings from continuing operation in the quarter came in at 40 cents per share compared with the year-ago figure of 15 cents.
Second-quarter worldwide sales came in at $7.77 billion, up 17% year over year on a reported basis. The top line edged past the Zacks Consensus Estimate of $7.73 billion.
On an organic basis (adjusting for the impact of foreign exchange as well as certain acquisitions and divestments) sales increased 8% year over year in the reported quarter.
Quarter in Detail
Abbott operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales rose 10.5% on a reported basis (up 12.3% on an organic basis) to $1.13 billion. This included a 1.8% adverse impact of from currency fluctuations. Sales in the key emerging markets increased 8.4% (up 12%), driven by double-digit growth across several geographies, including India and China.
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote
The Medical Devices business sales increased 11.3% on a reported basis to $2.89 billion. On an organic basis, sales grew 8.2%.
Cardiovascular and Neuromodulation sales reportedly (up 4.4% on an organic basis) rose 7.1% on double-digit growth in Electrophysiology and Neuromodulation.
Vascular product sales, however, declined 3.8% on a reported basis (down 0.3%). Within Rhythm Management, the company saw a sales decrease of 1.5% on a reported basis (a decline of 4%).
Diabetes Care sales improved 39.8% (up 33.6%), buoyed consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott.
Nutrition sales were up 7.3% year over year on a reported basis (up 6.4% on an organic basis). Foreign exchange drove sales by 0.9%. Pediatric Nutrition sales increased 5.3% on an organic basis. Adult Nutrition sales were up 7.8% organically.
Diagnostics sales soared 47.2% year over year on a reported basis (up 6.6% on a comparable operational basis). Core Laboratory grew and Point of Care Diagnostics sales grew 7.7% and 6%, respectively, on an organic basis. Molecular Diagnostics sales were up 6% as strong growth in the infectious disease testing business was partially offset by the planned scale down in other testing areas, primarily in the United States. Rapid Diagnostics recorded sales of $484 million, driven by solid contributions from infectious disease testing and cardiometabolic testing.
Full-Year Guidance Raised
Abbott has raised its 2018 adjusted earnings per share guidance. Adjusting for certain net specified items for the full year, adjusted earnings from continuing operations are now expected in the band of $2.85-$2.91 as compared to the earlier-projected range of $2.80-$2.90. The Zacks Consensus Estimate of $2.86 remains within but near to the lower end of this projected range.
The company has also provided third-quarter 2018 adjusted earnings per share outlook. It expects to report adjusted earnings from continuing operations in the range of 73-75 cents. The consensus mark of 75 cents coincides with the upper end of the predicted range.
Our Take
Abbott has steered past the Zacks Consensus Estimate for both earnings and revenues. We are optimistic about the company's strong and consistent EPD and Medical Devices performance.Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business. The company has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. Also, solid contributions from the company's other two businesses encourage us.
The company continues to benefit from a strong integration synergy of St. Jude Medical, which offers it an industry-leading pipeline across cardiovascular, neuromodulation, diabetes and vision care. We are also impressed by Abbott's Alere integration. Synergies from this consolidation in the form of revenues from Rapid Diagnostics have been driving the company's growth.
Meanwhile, the company's emerging market performance has been extremely promising on several strategic developments.
Zacks Rank & Key Picks
A few other top-ranked stocks in the broader medical space are Genomic Health GHDX , Align Technology, Inc. ALGN and Integer Holdings Corp. ITGR .
Genomic Health is expected to release second-quarter fiscal 2018 results on Aug 7. The Zacks Consensus Estimate for the quarter's adjusted EPS is pegged at 7 cents and for revenues stands at $91.9 million. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Align Technology is expected to release second-quarter 2018 results on Jul 25. The Zacks Consensus Estimate for the period's adjusted EPS is $1.09 and for revenues, $469.2 million. The stock carries a Zacks Rank #1.
Integer Holdings is slated to release second-quarter 2018 results on Apr 25. The Zacks Consensus Estimate for adjusted bottom line in the to-be-reported quarter is 90 cents and for the top line, $381.8 million. The stock carries a Zacks Rank #1.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Integer Holdings Corporation (ITGR): Free Stock Analysis Report
Genomic Health, Inc. (GHDX): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported second-quarter 2018 adjusted earnings from continuing operations of 73 cents per share, beating the Zacks Consensus Estimate by a couple of cents. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Diabetes Care sales improved 39.8% (up 33.6%), buoyed consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott. | Abbott LaboratoriesABT reported second-quarter 2018 adjusted earnings from continuing operations of 73 cents per share, beating the Zacks Consensus Estimate by a couple of cents. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote The Medical Devices business sales increased 11.3% on a reported basis to $2.89 billion. | Abbott LaboratoriesABT reported second-quarter 2018 adjusted earnings from continuing operations of 73 cents per share, beating the Zacks Consensus Estimate by a couple of cents. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote The Medical Devices business sales increased 11.3% on a reported basis to $2.89 billion. | Abbott LaboratoriesABT reported second-quarter 2018 adjusted earnings from continuing operations of 73 cents per share, beating the Zacks Consensus Estimate by a couple of cents. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. On an organic basis (adjusting for the impact of foreign exchange as well as certain acquisitions and divestments) sales increased 8% year over year in the reported quarter. |
33237.0 | 2018-07-18 00:00:00 UTC | Noteworthy Wednesday Option Activity: ABT, TRV, AMRS | ABT | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-abt-trv-amrs-2018-07-18 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 20,141 contracts has been traded thus far today, a contract volume which is representative of approximately 2.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.8% of ABT's average daily trading volume over the past month, of 4.7 million shares. Especially high volume was seen for the $65 strike call option expiring August 17, 2018 , with 2,338 contracts trading so far today, representing approximately 233,800 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $65 strike highlighted in orange:
Travelers Companies Inc (Symbol: TRV) options are showing a volume of 5,391 contracts thus far today. That number of contracts represents approximately 539,100 underlying shares, working out to a sizeable 42.6% of TRV's average daily trading volume over the past month, of 1.3 million shares. Particularly high volume was seen for the $135 strike call option expiring August 17, 2018 , with 2,522 contracts trading so far today, representing approximately 252,200 underlying shares of TRV. Below is a chart showing TRV's trailing twelve month trading history, with the $135 strike highlighted in orange:
And Amyris Inc (Symbol: AMRS) saw options trading volume of 3,219 contracts, representing approximately 321,900 underlying shares or approximately 42.3% of AMRS's average daily trading volume over the past month, of 761,585 shares. Especially high volume was seen for the $7.50 strike call option expiring December 21, 2018 , with 2,989 contracts trading so far today, representing approximately 298,900 underlying shares of AMRS. Below is a chart showing AMRS's trailing twelve month trading history, with the $7.50 strike highlighted in orange:
For the various different available expirations for ABT options , TRV options , or AMRS options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $65 strike call option expiring August 17, 2018 , with 2,338 contracts trading so far today, representing approximately 233,800 underlying shares of ABT. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 20,141 contracts has been traded thus far today, a contract volume which is representative of approximately 2.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.8% of ABT's average daily trading volume over the past month, of 4.7 million shares. | Especially high volume was seen for the $65 strike call option expiring August 17, 2018 , with 2,338 contracts trading so far today, representing approximately 233,800 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $65 strike highlighted in orange: Travelers Companies Inc (Symbol: TRV) options are showing a volume of 5,391 contracts thus far today. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 20,141 contracts has been traded thus far today, a contract volume which is representative of approximately 2.0 million underlying shares (given that every 1 contract represents 100 underlying shares). | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 20,141 contracts has been traded thus far today, a contract volume which is representative of approximately 2.0 million underlying shares (given that every 1 contract represents 100 underlying shares). Especially high volume was seen for the $65 strike call option expiring August 17, 2018 , with 2,338 contracts trading so far today, representing approximately 233,800 underlying shares of ABT. That number works out to 42.8% of ABT's average daily trading volume over the past month, of 4.7 million shares. | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 20,141 contracts has been traded thus far today, a contract volume which is representative of approximately 2.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.8% of ABT's average daily trading volume over the past month, of 4.7 million shares. Especially high volume was seen for the $65 strike call option expiring August 17, 2018 , with 2,338 contracts trading so far today, representing approximately 233,800 underlying shares of ABT. |
33238.0 | 2018-07-18 00:00:00 UTC | Health Care Sector Update for 07/18/2018: MBRX,ABT | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07182018-mbrxabt-2018-07-18 | nan | nan | Top Health Care Stocks
JNJ -1.24%
PFE -0.11%
ABT +2.62%
MRK +0.54%
AMGN -0.84%
Health care stocks were narrowly mixed in recent trading, including a slightly more than 0.2% gain for the NYSE Health Care Index. Also, shares of health care companies in the S&P 500 were down nearly 0.1% as a group while the Nasdaq Biotechnology index was falling almost 0.2% Wednesday.
Among health care stocks moving on news:
+ Moleculin Biotech ( MBRX ) was climbing over 2% higher in recent trading, trying to retrace a more than 3% gain soon after the opening bell. The early stage drugmaker Wednesday said it has begun preclinical toxicology testing of its WP1732 prospective treatment for pancreatic cancer. Moleculin also said it expects to complete work on the investigational new drug application for the fully water-soluble STAT3 inhibitor before the end of the year.
In other sector news:
+ Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit while beating Street projections for normalized EPS by $0.02 per share. Net sales rose 17% year over year to $7.77 billion, also exceeding the $7.71 billion Capital IQ analyst mean.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news: + Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit while beating Street projections for normalized EPS by $0.02 per share. Among health care stocks moving on news: + Moleculin Biotech ( MBRX ) was climbing over 2% higher in recent trading, trying to retrace a more than 3% gain soon after the opening bell. The early stage drugmaker Wednesday said it has begun preclinical toxicology testing of its WP1732 prospective treatment for pancreatic cancer. | In other sector news: + Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit while beating Street projections for normalized EPS by $0.02 per share. Among health care stocks moving on news: + Moleculin Biotech ( MBRX ) was climbing over 2% higher in recent trading, trying to retrace a more than 3% gain soon after the opening bell. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news: + Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit while beating Street projections for normalized EPS by $0.02 per share. Health care stocks were narrowly mixed in recent trading, including a slightly more than 0.2% gain for the NYSE Health Care Index. Among health care stocks moving on news: + Moleculin Biotech ( MBRX ) was climbing over 2% higher in recent trading, trying to retrace a more than 3% gain soon after the opening bell. | In other sector news: + Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit while beating Street projections for normalized EPS by $0.02 per share. Top Health Care Stocks Health care stocks were narrowly mixed in recent trading, including a slightly more than 0.2% gain for the NYSE Health Care Index. |
33239.0 | 2018-07-17 00:00:00 UTC | These Companies are Earnings All-Stars | ABT | https://www.nasdaq.com/articles/these-companies-are-earnings-all-stars-2018-07-17 | nan | nan | The second quarter earnings season is now underway in earnest.
What should you be looking out for?
These 5 companies have some of the best earnings surprise track records this week. They've either beat or met every quarter for the last 5 years or they have just one miss during that time.
That's impressive. It's not easy to beat nearly every quarter for that length of time. It means that management has a firm grip on the business and can communicate the direction the company is taking to analysts.
Can these companies continue with their hot streaks?
5 Earnings All-Stars to Watch This Week
1. Johnson & Johnson JNJ had a perfect 5-year track record heading into the report and beat again to extend its winning streak. But can the shares get back on track?
2. CSX CSX is the first of the railroads to report earnings this quarter. It has one of the best earnings surprise records in the railroad industry with just 1 miss in the last 5 years. Shares have been hot, up another 13% in 2018. Can it keep the momentum?
3. Abbott Labs ABT has a perfect 5-year earnings surprise record. In 2017, shares finally broke out of a multiyear malaise and have stormed to new 5-year highs. Will this earnings report push the shares into breakout territory again?
4. eBay EBAY is always the forgotten tech company but it hasn't missed since 2015. Shares are off their 2018 highs heading into the report. Is this a buying opportunity?
5. United Rentals URI has only missed once in the last 5 years. Shares soared to new highs in 2017 on the hot economy but have since pulled back. The largest equipment rental company in North America should still be benefitting from the hot American economy. Will this report push the shares back to new highs?
[In full disclosure, the author of this article owns shares of URI in her personal portfolio.]
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CSX Corporation (CSX): Free Stock Analysis Report
eBay Inc. (EBAY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
United Rentals, Inc. (URI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ABT has a perfect 5-year earnings surprise record. Click to get this free report CSX Corporation (CSX): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report To read this article on Zacks.com click here. It means that management has a firm grip on the business and can communicate the direction the company is taking to analysts. | Click to get this free report CSX Corporation (CSX): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT has a perfect 5-year earnings surprise record. Johnson & Johnson JNJ had a perfect 5-year track record heading into the report and beat again to extend its winning streak. | Click to get this free report CSX Corporation (CSX): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT has a perfect 5-year earnings surprise record. CSX CSX is the first of the railroads to report earnings this quarter. | Click to get this free report CSX Corporation (CSX): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT has a perfect 5-year earnings surprise record. Shares have been hot, up another 13% in 2018. |
33240.0 | 2018-07-12 00:00:00 UTC | Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings? | ABT | https://www.nasdaq.com/articles/can-established-pharmaceuticals-up-abbott-abt-q2-earnings-2018-07-12 | nan | nan | Abbott Laboratories ' ABT Established Pharmaceuticals Division (EPD) business has been recording operational sales growth in the last few quarters. We expect this strength to further get reflected in second-quarter 2018 results, scheduled for release on Jul 18.
Click here to know how the company's overall Q2 performance is likely to pan out.
Key Catalysts
The EPD business majorly focuses on the emerging markets wherein key areas include India, Russia, China and numerous regions in Latin America as well as Brazil alongside other countries. Sales in the key emerging markets increased 6.8% organically, driven by double-digit growth in India, China and Brazil in the last reported quarter.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Per the company, key emerging markets represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Management believes that these markets will continue to offer immense opportunities with favorable demographics. Accordingly, the Zacks Consensus Estimate of $903 million for EPD revenues from the key emerging markets indicates a 13.1% rise from the year-ago quarter's tally.
Favorable currency translation also left a positive impact of 3.1% on EPD revenues in the first quarter of 2018. Moreover, it is encouraging to note that management expects foreign exchange to continue acting as a tailwind in the to-be-reported quarter.
However, management seems concerned about the decelerating revenue growth rate of EPD in Russia due to a temporary disruption in distribution channel dynamics based on certain distributors' consolidations. Per the company, this should continue through the second quarter too.
Also, the ongoing tensions between the United States and China regarding the imposition of tariffs on imports, has raised concerns for major MedTech players as any adverse move might affect their sales performance in China in the near term.
Overall, we are upbeat about management's anticipation of double-digit organic growth in EPD sales during the second quarter. Furthermore, the Zacks Consensus Estimate for EPD revenues of $1.15 billion shows a 12.9% increase from the prior-year period.
In EPD, Abbott's consistent focus on enhancing local capabilities and expanding product portfolio within core therapeutic areas is aimed at specifically addressing local market needs. These efforts from the company also continue to consolidate its leadership position in the EPD markets. Abbott's sale of developed market businesses along with acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia has contributed to its EPD business.
Zacks Rank & Stocks to Consider
Abbott carries a Zacks Rank #3 (Hold).
Here are a few medical stocks worth considering from the same space as these comprise the right combination of elements to beat on earnings this time around:
ResMed Inc. RMD has an Earnings ESP of +3.97% and a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Stryker Corporation SYK has an Earnings ESP of +0.13% and a Zacks Rank #2.
McKesson Corporation MCK has an Earnings ESP of +3.95% and a Zacks Rank of 3.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
ResMed Inc. (RMD): Free Stock Analysis Report
McKesson Corporation (MCK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ' ABT Established Pharmaceuticals Division (EPD) business has been recording operational sales growth in the last few quarters. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. Sales in the key emerging markets increased 6.8% organically, driven by double-digit growth in India, China and Brazil in the last reported quarter. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ' ABT Established Pharmaceuticals Division (EPD) business has been recording operational sales growth in the last few quarters. Key Catalysts The EPD business majorly focuses on the emerging markets wherein key areas include India, Russia, China and numerous regions in Latin America as well as Brazil alongside other countries. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ' ABT Established Pharmaceuticals Division (EPD) business has been recording operational sales growth in the last few quarters. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Per the company, key emerging markets represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. | Abbott Laboratories ' ABT Established Pharmaceuticals Division (EPD) business has been recording operational sales growth in the last few quarters. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. Key Catalysts The EPD business majorly focuses on the emerging markets wherein key areas include India, Russia, China and numerous regions in Latin America as well as Brazil alongside other countries. |
33241.0 | 2018-07-12 00:00:00 UTC | Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings? | ABT | https://www.nasdaq.com/articles/can-medical-devices-strength-drive-abbott-abt-q2-earnings-2018-07-12 | nan | nan | Abbott'sABT Medical Devices business has been going strong of late on solid sub-segmental performance.
We expect this strength to get reflected in second-quarter 2018 results, which are scheduled for release on Jul 18 before the market opens.
Click here to know how the company's overall Q2 performance is expected to be.
Medical Devices in Focus
Abbott's Medical Devices segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Management expects mid-to-high single digit growth in Medical Devices second-quarter 2018 sales along with continued double-digit growth at certain sub-segments.
Consequently, the Zacks Consensus Estimate for Medical Devices revenues in the United States of $1.29 billion indicates a rise of 8.4% from the year-ago quarter. Internationally, our consensus estimate of $1.59 billion shows growth of 12.8%.
In the last quarter, sales improvement at the segment was driven by double-digit growth in Electrophysiology, Neuromodulation and Diabetes Care. Moreover, the company received approvals for a few products alongside achieving clinical trial milestones.
Let's see how things are shaping up within these sub-segments before the second-quarter results.
Electrophysiology , which accounted for 14.2% of Medical Devices revenues, has been gaining strongly from the recent launch of Confirm insertable cardiac heart monitor in the United States and Europe.
Furthermore, continued uptake of EnSite Precision Cardiac Mapping System is expected to contribute strongly to the top line in the second quarter.
Abbott strengthened its position in the business with the successive receipt of FDA and CE Mark for its new Advisor HD Grid Mapping Catheter. The company has launched the product in 20 countries since then and currently awaits the commercial launch in the United States.
The Zacks Consensus Estimate for Electrophysiology revenues of $408 million indicates an increase of 19% from a year ago. The company is expected to keep gaining strength in this business.
In the last reported quarter, the company witnessed impressive sales growth in the Heart Failure business on solid uptake of the recently launched HeartMate 3 system in the United States.
The Zacks Consensus Estimate for Heart Failure business revenues of $168 million indicates a rise of 5.7% from the year-ago quarter.
Providing an impetus to the Vascular (26.9% of total Medical Devices revenues) business in the United States, Abbott recently announced the receipt of FDA approval for XIENCE Sierra.
We encouragingly note, under the Vascular business, the company has seen a slew of developments with regard to its XIENCE Sierra coronary stent system. The company also achieved national reimbursement for XIENCE Sierra in May 2018. The company has also been getting positive responses for the XIENCE Sierra coronary stent system post its launch in Europe.
The Zacks Consensus Estimate for Vascular revenues of $740 million shows an improvement of 1.2% from the year-ago quarter.
The Structural Heart business has maintained an impressive top-line performance. In the last reported quarter, this business accounted for 10.7% of total revenues under the broader Medical Devices segment. The upside was led by continued double-digit growth of MitraClip.
In March, Abbott announced the receipt of national reimbursement in Japan for the same. Notably, in nearly 50 countries, more than 50,000 people have been treated with MitraClip.
Further, the company announced the receipt of FDA approval for the world's smallest rotatable, bileaflet mechanical heart valve - Masters HP 15mm. With the approval, the company has expanded the Masters Series portfolio under Structural Heart.
All these positive developments are expected to boost top-line contributions from this sub-segment in the to-be-reported quarter. Our estimate for Structural Heart revenues of $293 million also indicates a rise of 9.3% from the year-ago quarter.
In Diabetes Care , international sales growth of 44.2% in the prior quarter was driven by Abbott's FreeStyle Libre. The company recently initiated the launch of FreeStyleLibre in the United States as well.
Proceeding with initiatives to boost this arm, the company announced the availability of FreeStyle LibreLink app in Europe for use in smartphones (both iPhone and Android).
The Zacks Consensus Estimate for Diabetes Care revenues of $460 million indicates a surge of 36.9% from the year-ago quarter.
Meanwhile,we are upbeat about Abbott kick-starting 2018 with the receipt of FDA approval for magnetic resonance (MR)-conditional labeling for Quadra Assura MP Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Fortify Assura Implantable Cardioverter Defibrillator (ICD) - two of the company's most widely-used high voltage medical devices.
The approvals come on the heels of recent MR-conditional labeling approvals for the Assurity MRI pacemaker, Ellipse ICD and associated MRI-compatible leads. This development is expected to boost the Rhythm Management business.
Our consensus estimate for Rhythm Management revenues of $564 million shows an improvement of 2.2% from a year ago.
Zacks Rank & Stocks to Consider
Abbott carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Genomic Health GHDX , Align Technology, Inc. ALGN and Stryker Corporation SYK .
Genomic Health has an expected earnings growth rate of 187.5% for the current quarter. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Align Technology has a projected long-term earnings growth rate of 28.4% and a Zacks Rank of 2 (Buy).
Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank of 2.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
Genomic Health, Inc. (GHDX): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott'sABT Medical Devices business has been going strong of late on solid sub-segmental performance. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Electrophysiology , which accounted for 14.2% of Medical Devices revenues, has been gaining strongly from the recent launch of Confirm insertable cardiac heart monitor in the United States and Europe. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott'sABT Medical Devices business has been going strong of late on solid sub-segmental performance. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Management expects mid-to-high single digit growth in Medical Devices second-quarter 2018 sales along with continued double-digit growth at certain sub-segments. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott'sABT Medical Devices business has been going strong of late on solid sub-segmental performance. Medical Devices in Focus Abbott's Medical Devices segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business. | Abbott'sABT Medical Devices business has been going strong of late on solid sub-segmental performance. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Consequently, the Zacks Consensus Estimate for Medical Devices revenues in the United States of $1.29 billion indicates a rise of 8.4% from the year-ago quarter. |
33242.0 | 2018-07-11 00:00:00 UTC | Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings? | ABT | https://www.nasdaq.com/articles/can-abbott-abt-rise-on-robust-overall-growth-in-q2-earnings-2018-07-11 | nan | nan | AbbottABT is slated to report second-quarter 2018 results before the market opens on Jul 18. Last reported quarter, the company's earnings per share exceeded the Zacks Consensus Estimate by 1.7%. Moreover, Abbott delivered positive surprises in the trailing four quarters, the average beat being 1.99%.
Let's see how things are shaping up for this announcement.
Factors at Play
Over the past few quarters, Abbott has been riding high on a healthy growth within its Diabetes Care business. The company has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. Per a recent data, the number of Libre users now has reached over 650,000 across the globe, representing an unprecedented level of patient adoption in the industry. This has firmly boosted the company's top line numbers in the recent quarters.
This momentum should continue through the second quarter too, producing impressive results in the period. The company expects to see significant growth contributions from a line of recently launched products across the portfolio. The Zacks Consensus Estimate of $460 million for Diabetes Care revenues indicates a surge of 36.9% from the year-ago quarter.
In sync with the prior quarter, Abbott is anticipated to gain from strong performance by the Established Pharmaceuticals Division ("EPD") business, which has been recording operational sales growth over the last few quarters. Management expects sales rise in high single-digit during the second quarter of 2018. Furthermore, the Zacks Consensus Estimate of $1.15 billion for EPD revenues shows 12.9% increase from the year-earlier period.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
We are also upbeat about the consistently sturdy Diagnostics business, courtesy of solid contributions from all sub-segments, namely Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. Moreover, synergies drawn from the Alere buyout in the form of revenues from Rapid Diagnostics, have been benefiting the company.
Additionally, management estimates Rapid Diagnostics to contribute around $2 billion in 2018. The Zacks Consensus Estimate for Core Laboratory Diagnostic revenues of $1.11 billion depicts an 8.8% gain from the comparable quarter last year.
We encouragingly note that Nutrition is Abbott's fastest-growing business owing to aging population, increasing rate of chronic diseases and the rise of the middle class in the emerging markets. Furthermore, Abbott's pediatric nutrition business continues to be robust in the United States. Thus, the Zacks Consensus Estimate of $1.84 billion for Nutrition revenues translates into a 6.6% improvement from the year-ago quarter's figure.
Favorable currency translation also had a positive impact of 4.2% on the company's top line in the first-quarter 2018. We are also optimistic about management's expectation from foreign exchange, which appears to aid results in the to-be-reported quarter, driving revenues by 3.5% in turn.
Overall, second-quarter total revenues are projected at $7.26 billion, up 14.5% from the prior-year period.
What the Model Suggests
Per the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chances of beating estimates if it also has a positive Earnings ESP . You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Abbott has a Zacks Rank #3, which increases the predictive power of ESP. However, its Earnings ESP of 0.00% makes surprise prediction difficult. The Zacks Consensus Estimate for earnings of 71 cents reflects 14.5% growth year over year.
Stocks Worth a Look
Here are a few medical stocks worth considering from the same space as these comprise the right combination of elements to beat on earnings this time around.
ResMed Inc. RMD has an Earnings ESP of +3.97% and is a #1 Ranked stock. You can see the complete list of today's Zacks #1 Rank stocks here .
Stryker Corporation SYK has an Earnings ESP of +0.13% and a Zacks Rank #2.
McKesson Corporation MCK has an Earnings ESP of +3.95% and the stock is a Zacks #3 Ranked player.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
ResMed Inc. (RMD): Free Stock Analysis Report
McKesson Corporation (MCK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT is slated to report second-quarter 2018 results before the market opens on Jul 18. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. Per a recent data, the number of Libre users now has reached over 650,000 across the globe, representing an unprecedented level of patient adoption in the industry. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT is slated to report second-quarter 2018 results before the market opens on Jul 18. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote We are also upbeat about the consistently sturdy Diagnostics business, courtesy of solid contributions from all sub-segments, namely Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT is slated to report second-quarter 2018 results before the market opens on Jul 18. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote We are also upbeat about the consistently sturdy Diagnostics business, courtesy of solid contributions from all sub-segments, namely Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. | AbbottABT is slated to report second-quarter 2018 results before the market opens on Jul 18. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Consensus Estimate for Core Laboratory Diagnostic revenues of $1.11 billion depicts an 8.8% gain from the comparable quarter last year. |
33243.0 | 2018-07-11 00:00:00 UTC | iShares U.S. Medical Devices ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/ishares-us-medical-devices-etf-experiences-big-inflow-2018-07-11 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $72.1 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 11,900,000 to 12,250,000). Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.1%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $160.37 per share, with $206.90 as the 52 week high point - that compares with a last trade of $205.56. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.1%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $160.37 per share, with $206.90 as the 52 week high point - that compares with a last trade of $205.56. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.1%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $160.37 per share, with $206.90 as the 52 week high point - that compares with a last trade of $205.56. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $72.1 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 11,900,000 to 12,250,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $160.37 per share, with $206.90 as the 52 week high point - that compares with a last trade of $205.56. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $72.1 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 11,900,000 to 12,250,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $160.37 per share, with $206.90 as the 52 week high point - that compares with a last trade of $205.56. |
33244.0 | 2018-07-11 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 12, 2018 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-july-12-2018-2018-07-11 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on July 12, 2018. A cash dividend payment of $0.28 per share is scheduled to be paid on August 15, 2018. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that ABT has paid the same dividend. At the current stock price of $62.81, the dividend yield is 1.78%.
The previous trading day's last sale of ABT was $62.81, representing a -2.77% decrease from the 52 week high of $64.60 and a 31.32% increase over the 52 week low of $47.83.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABT's current earnings per share, an indicator of a company's profitability, is $.25. Zacks Investment Research reports ABT's forecasted earnings growth in 2018 as 14.5%, compared to an industry average of 11.1%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Healthcare ETF ( IYH )
Vanguard Health Care ETF ( VHT )
Vanguard Div Appreciation ETF ( VIG )
iShares Global Healthcare ETF ( IXJ )
NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ).
The top-performing ETF of this group is VHT with an increase of 5.55% over the last 100 days. IYH has the highest percent weighting of ABT at 3.05%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2018 as 14.5%, compared to an industry average of 11.1%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The following ETF(s) have ABT as a top-10 holding: iShares U.S. Healthcare ETF ( IYH ) Vanguard Health Care ETF ( VHT ) Vanguard Div Appreciation ETF ( VIG ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on July 12, 2018. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Healthcare ETF ( IYH ) Vanguard Health Care ETF ( VHT ) Vanguard Div Appreciation ETF ( VIG ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ). | ABT's current earnings per share, an indicator of a company's profitability, is $.25. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Healthcare ETF ( IYH ) Vanguard Health Care ETF ( VHT ) Vanguard Div Appreciation ETF ( VIG ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ). Abbott Laboratories ( ABT ) will begin trading ex-dividend on July 12, 2018. |
33245.0 | 2018-07-11 00:00:00 UTC | 3 Top Growth Stocks to Buy in July | ABT | https://www.nasdaq.com/articles/3-top-growth-stocks-buy-july-2018-07-11 | nan | nan | Ideally, you want to buy and hold shares of companies that will grow at a healthy pace for a long time. Paying a premium for a growth stock makes sense if that growth both materializes and leads to solid profits down the road.
There are a lot of growth stocks out there, but three of our Motley Fool contributors have identified three that would be great additions to your portfolio in July. Here's what you need to know about Texas Roadhouse (NASDAQ: TXRH) , Kulicke & Soffa Industries (NASDAQ: KLIC) , and DexCom (NASDAQ: DXCM) .
A steakhouse slowly aged to perfection
Nicholas Rossolillo(Texas Roadhouse): The restaurant industry is a challenging one. Consumers have plenty of choices, and keeping diners loyal to a brand can be a tough task. To make matters worse, the industry has had to cope with self-inflicted pain the past few years as over-expansion has caused foot traffic at the average store to decline the last few years.
Bucking the trend is casual steakhouse chain Texas Roadhouse. The restaurant has avoided the struggle most of its peers have experienced by staying true to its primary market: underserved suburban America. Providing big portions at fair prices to working-class families is still only part of the story, though. While many chains out there have put together aggressive expansion plans, Roadhouse has stayed disciplined and opened new locations at a more modest rate. Only 30 new stores will be opened this year, only about a 5% increase in total count -- which includes a new sports bar brand called Bubba's 33 that is being tested in select markets.
The stock has also been a slow-and-steady story for over a decade now, but the results have been impressive nonetheless. Shares have doubled nearly five times over at this point, but there's reason to believe they're still a good buy even close to an all-time high. When management reported on progress a couple months ago, same-store sales growth was accelerating. This metric, which measures a combination of average guest ticket and foot traffic, is one of the most important factors driving a restaurant's profit margins. A month into the second quarter of 2018, and same-store sales were up an impressive 8.5% compared to a 4.9% increase in the first quarter . With Texas Roadhouse keeping tight control over expenses and getting the most out of its existing stores, this stock is one of the best restaurant buys out there right now.
A small-cap semiconductor company
Tim Green(Kulicke & Soffa Industries): Kulicke & Soffa manufactures equipment used by the semiconductor industry to package semiconductor components. It's a small company, with annual revenue of about $800 million.
The semiconductor equipment industry is cyclical, so Kulicke & Soffa's results can swing up and down along with demand. But the long-term growth of the semiconductor industry, as well as the company's efforts to diversify into advanced packaging, should keep the numbers moving in the right direction in the long run.
Kulicke & Soffa sees its available market growing from $2.2 billion in 2017 to $2.7 billion in 2021. Its core business will drive some of this growth, but demand for advanced packaging and equipment used for automotive products like sensors and cameras will be the key drivers. Kulicke & Soffa also has plenty of cash at its disposal to make strategic acquisitions. The company's balance sheet featured over $600 million of net cash at the end of its latest quarter.
Kulicke & Soffa doesn't trade like a growth stock . Backing out the net cash, the stock trades for less than 8 times the average analyst estimate for 2018 earnings. Since earnings tend to fluctuate, this earnings multiple makes the stock look a bit cheaper than it truly is. Average earnings over the next few years could be lower if the current boom in sales dissipates. But even so, with plenty of long-term growth potential, Kulicke & Soffa is a solid growth stock pick.
This diabetes stock's revolutionizing treatment
Todd Campbell (DexCom): The diabetes market is getting bigger, and technology that helps patients better track blood sugar levels and dose their insulin is going to play a big role in the future. According to the Institute for Alternative Futures, the number of Americans with diabetes will increase from about 30 million today to nearly 55 million in 2030, and as a result, spending on diabetes is expected to soar.
A good piece of that spending could find its way to DexCom's top line. DexCom's a leading manufacturer of continuous glucose monitors (CGM) that track real-time changes in blood sugar to help patients avoid dangerous highs and lows that can accelerate diabetes progression.
CGMs use sensors, software, and hardware to record, analyze, and report blood sugar levels in real time, and they're already winning over patients who require frequent insulin injections. In 2017, DexCom's sales grew 25% to $718 million.
Last year's performance was solid, but I think sales could increase by more this year following the launch of DexCom's newest CGM, the G6. In 2017, DexCom's sales were held back by the launch of Abbott Labs ' (NYSE: ABT) Freestyle Libre, the first CGM to remove the need for diabetes patients to stick their fingers to confirm readings or to calibrate the system.
Abbott's advantage disappeared earlier this year when the FDA approved the G6. Importantly, the G6 is arguably a better system. The G6's sensors can be worn longer than those used with the Freestyle Libre, it includes alarms for blood sugar highs and lows that the Freestyle Libre doesn't, it has a shorter warm up time than the Freestyle Libre, and unlike the Freestyle Libre, it automatically sends data to a device for display.
Those advantages could spark sales growth, but the use of CGMs in new automated insulin delivery systems is what really excites me about DexCom's CGM opportunity. Recently, Tandem Diabetes won an FDA green light for a system that combines DexCom's CGM with its insulin pump to administer insulin automatically, and DexCom's CGMs are also being evaluated in a similar system that's being developed by Insulet (NASDAQ: PODD) . If these systems win widespread use, and I think they will, then it could be a boon to DexCom investors.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Nicholas Rossolillo owns shares of Texas Roadhouse. Timothy Green owns shares of Kulicke & Soffa Industries. Todd Campbell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Texas Roadhouse. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In 2017, DexCom's sales were held back by the launch of Abbott Labs ' (NYSE: ABT) Freestyle Libre, the first CGM to remove the need for diabetes patients to stick their fingers to confirm readings or to calibrate the system. DexCom's a leading manufacturer of continuous glucose monitors (CGM) that track real-time changes in blood sugar to help patients avoid dangerous highs and lows that can accelerate diabetes progression. CGMs use sensors, software, and hardware to record, analyze, and report blood sugar levels in real time, and they're already winning over patients who require frequent insulin injections. | In 2017, DexCom's sales were held back by the launch of Abbott Labs ' (NYSE: ABT) Freestyle Libre, the first CGM to remove the need for diabetes patients to stick their fingers to confirm readings or to calibrate the system. Here's what you need to know about Texas Roadhouse (NASDAQ: TXRH) , Kulicke & Soffa Industries (NASDAQ: KLIC) , and DexCom (NASDAQ: DXCM) . A small-cap semiconductor company Tim Green(Kulicke & Soffa Industries): Kulicke & Soffa manufactures equipment used by the semiconductor industry to package semiconductor components. | In 2017, DexCom's sales were held back by the launch of Abbott Labs ' (NYSE: ABT) Freestyle Libre, the first CGM to remove the need for diabetes patients to stick their fingers to confirm readings or to calibrate the system. A small-cap semiconductor company Tim Green(Kulicke & Soffa Industries): Kulicke & Soffa manufactures equipment used by the semiconductor industry to package semiconductor components. But even so, with plenty of long-term growth potential, Kulicke & Soffa is a solid growth stock pick. | In 2017, DexCom's sales were held back by the launch of Abbott Labs ' (NYSE: ABT) Freestyle Libre, the first CGM to remove the need for diabetes patients to stick their fingers to confirm readings or to calibrate the system. Here's what you need to know about Texas Roadhouse (NASDAQ: TXRH) , Kulicke & Soffa Industries (NASDAQ: KLIC) , and DexCom (NASDAQ: DXCM) . But even so, with plenty of long-term growth potential, Kulicke & Soffa is a solid growth stock pick. |
33246.0 | 2018-07-05 00:00:00 UTC | Here's Why AbbVie Stock is Good for Your Portfolio's Health | ABT | https://www.nasdaq.com/articles/heres-why-abbvie-stock-is-good-for-your-portfolios-health-2018-07-05 | nan | nan | AbbVie, Inc.ABBV shares have outperformed the large-cap pharma industry in the past three months. The stock has returned 1.5% in that timeframe against the industry 's decline of 1.1%.
It is one of the reputed names in the pharmaceutical sector. AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division
Here are six reasons to invest in the stock.
Favorable Rank & Earnings Surprise Record: AbbVie has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
It has been consistently beating earnings expectations. Earnings surpassed expectations in each of last four quarters, with an average positive surprise of 2.39%.
The company is expected to record earnings and sales growth of 39.3% and 16.8%, respectively, in 2018. Meanwhile, estimates for 2018 and 2019 increased 0.3% and 0.2%, respectively, in the past 60 days.
Valuation Looks Reasonable: Despite the outperformance, AbbVie's valuation looks fairly reasonable currently.
AbbVie currently has a forward twelve months price-to-earnings ratio (P/E F12M) of 11.25, which is near the lowest level (11.03) in the past year. When compared with the highest level of 17.99 and median level of 13.92 over the past year, there is apparently some upside left.
The space also looks inexpensive when compared with the industry, as the current as well as median F12M P/E ratio for the industry is 14.02 and 15.63, respectively.
Price-to-Earnings Forward Twelve Months (F12M) chart
Key DrugHumira Going Strong: AbbVie's flagship product Humira is approved for several inflammatory indications like rheumatoid arthritis. Humira continues to witness strong demand trends despite launch of drugs with new mechanisms of action and competition from indirect biosimilars. Currently approved for 13 indications, Humira sales have increased consistently - 11.7% in 2015, 16.1% in 2016 and 14.6% in 2017 - backed by robust demand trends. The product continues to see strong growth in the dermatology and gastroenterology markets. The company expects Humira sales to approach $21 billion in 2020.
Though two biosimilar versions of Humira are already approved by the FDA, per settlements with Amgen AMGN and Samsung Bioepis, biosimilar entry into the United States is set for 2023, thus delaying direct biosimilar competition in the country.
Strong Oncology Portfolio: AbbVie work rigorously on expanding and accelerating its presence in oncology. A key drug in its oncology portfolio is Imbruvica, which is currently approved for quite a few indications and has multi-billion dollar potential. AbbVie is exploring the potential to expand Imbruvica's label into solid tumors and autoimmune diseases. Several studies on Imbruvica are ongoing to evaluate the drug alone or in combination in different patient segments. AbbVie expects Imbruvica peak sales of more than $7 billion and revenues of about $5 billion in 2020. AbbVie has developed Imbruvica in partnership with J&J JNJ .
AbbVie is also studying another cancer drug Venclyxto/Venclexta to expand the label to address the broader relapsed/refractory chronic lymphocytic leukemia (CLL) patient population, expand into earlier lines of therapy, and broaden into other hematologic malignancies like multiple myeloma and acute myeloid leukemia. In June, regulatory applications seeking approval for the combination of Venclexta plus Roche's (RHHBY) Rituxan in relapse/refractory CLL were approved in the United States. Label expansion to include this broader patient population should boost Venclexta's commercial potential.
Meanwhile, the 2016 acquisition of drugmaker, Stemcentrx added a key late-stage candidate, rovalpituzumab tesirine or Rova-T, to AbbVie's portfolio. Rova-T is currently in registrational studies for first and second-line small cell lung cancer (SCLC). A phase I, eight-arm "basket study" on Rova-T in neuroendocrine tumors is also ongoing.
Promising Pipeline: AbbVie has a deep pipeline consisting of several interesting late-stage candidates. Promising candidates include elagolix (endometriosis), risankizumab (inflammatory diseases), Depatux-M/ABT-414 (glioblastoma multiforme), ABBV-8E12 (early Alzheimer's disease and progressive supranuclear palsy (PSP)), and upadacitinib/ABT-494 (inflammatory diseases).The company expects to move 10 tumor candidates into clinical development in 2018.
Several pivotal data readouts and regulatory milestones are expected in the second half of the year including FDA decisions on risankizumab and elagolix regulatory applications.
Mavyret Performs Beyond Expectations: AbbVie's eight-week, pan-genotypic, ribavirin-free, once-daily hepatitis C (HCV) treatment, Mavyret, gained approval in the United States, EU, Canada and Japan in 2017. Mavyret, AbbVie's next-generation HCV program, is a combination of glecaprevir, a potent protease inhibitor and pibrentasvir, a NS5A inhibitor. Mavyret has the potential to rejuvenate growth in the HCV franchise. According to AbbVie, Mavyret may be used in up to 95% of HCV patients, depending on the stage of liver disease and prior treatment history. Mavyret performed beyond expectations in the first year of launch, recording sales of almost $500 million in 2017. The positive sales trend continues in 2018 with the drug recording sales of $850 million in the first quarter of 2018. With less than a year on the market, Mavyret already commands 45% share in the United States.
Conclusion
AbbVie faces its share of challenges in the form of slower sales of HCV drugs, potential biosimilar competition to Humira, regular pipeline setbacks and rising competition. However, we believe AbbVie is well positioned to overcome these headwinds.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division Here are six reasons to invest in the stock. Promising candidates include elagolix (endometriosis), risankizumab (inflammatory diseases), Depatux-M/ABT-414 (glioblastoma multiforme), ABBV-8E12 (early Alzheimer's disease and progressive supranuclear palsy (PSP)), and upadacitinib/ABT-494 (inflammatory diseases).The company expects to move 10 tumor candidates into clinical development in 2018. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division Here are six reasons to invest in the stock. Promising candidates include elagolix (endometriosis), risankizumab (inflammatory diseases), Depatux-M/ABT-414 (glioblastoma multiforme), ABBV-8E12 (early Alzheimer's disease and progressive supranuclear palsy (PSP)), and upadacitinib/ABT-494 (inflammatory diseases).The company expects to move 10 tumor candidates into clinical development in 2018. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division Here are six reasons to invest in the stock. Promising candidates include elagolix (endometriosis), risankizumab (inflammatory diseases), Depatux-M/ABT-414 (glioblastoma multiforme), ABBV-8E12 (early Alzheimer's disease and progressive supranuclear palsy (PSP)), and upadacitinib/ABT-494 (inflammatory diseases).The company expects to move 10 tumor candidates into clinical development in 2018. | AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division Here are six reasons to invest in the stock. Promising candidates include elagolix (endometriosis), risankizumab (inflammatory diseases), Depatux-M/ABT-414 (glioblastoma multiforme), ABBV-8E12 (early Alzheimer's disease and progressive supranuclear palsy (PSP)), and upadacitinib/ABT-494 (inflammatory diseases).The company expects to move 10 tumor candidates into clinical development in 2018. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. |
33247.0 | 2018-06-27 00:00:00 UTC | The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-facebook-amgen-abbott-coca-cola-and-3m-2018-06-27 | nan | nan | For Immediate Release
Chicago, IL - June 27, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Facebook FB , Amgen AMGN , Abbott ABT , Coca-Cola KO and 3M MMM .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Tuesday's Analyst Blog:
Top Stock Reports for Facebook, Amgen and Abbott
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Facebook, Amgen and Abbott. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Buy-ranked Facebook 's shares have outperformed the S&P 500 index in the last year, gaining +27.8% vs. +11.8%. The Zacks analyst thinks Facebook is benefitting from robust growth in advertising and user base.
Facebook's user base of 2.2 billion coupled with Instagram's 1 billion users provides a huge canvas for advertisers, which, in turn, is driving the top line of the company. Rising mobile conversions on the platform is boosting mobile ad growth. Growing popularity of Stories across all major platforms, with Instagram taking center stage, is a tailwind.
Apart from mobile and video, the monetization opportunities of Messenger, WhatsApp and Oculus and a huge user base are expected to drive growth going ahead. Facebook has a strong balance sheet and generates significant cash flow, which makes it an attractive stock for investors.
(You can read the full research report on Facebook here >>> ).
Shares of Buy-ranked Amgen have gained +6.6% year to date, outperforming the Zacks Biomedical and Genetics industry, which has declined -7.2% over the same period. Amgen's newer drugs - Prolia, Xgeva, Blincyto, Vectibix, Kyprolis - are performing well.
Amgen is also progressing with its pipeline and the recent approval of migraine candidate, Aimovig was a huge boost. Amgen's restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support in 2018. However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors.
Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions.
(You can read the full research report on Amgen here >>> ).
Abbott 's shares have gained +24.9% over the last year, outperforming the Zacks Medical Products industry, which has gained +10.9% over the same period. The Zacks analyst likes the strong and consistent performance by the company's EPD and Medical Devices segments.
Also, solid contributions from Diagnostics and Nutrition business are encouraging. The company's receipt of FDA approval for XIENCE Sierra coronary stent system will help it to revive the dull Vascular business. Within Structural Heart, strong uptake of MitraClip therapy post the national reimbursement approval in Japan is a positive. Abbott's Alere buyout is another positive.
Synergies from this consolidation in the form of revenues from Rapid Diagnostics have been driving the company's growth. Meanwhile, the company's emerging market performance has been extremely promising on several strategic developments. On the flip side, sluggish Vascular business in the United States continues to dent growth.
(You can read the full research report on Abbott here >>> ).
Other noteworthy reports we are featuring today include Coca-Cola and 3M.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Facebook, Inc. (FB): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Coca-Cola Company (The) (KO): Free Stock Analysis Report
3M Company (MMM): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Facebook FB , Amgen AMGN , Abbott ABT , Coca-Cola KO and 3M MMM . Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Coca-Cola Company (The) (KO): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. | Stocks recently featured in the blog include Facebook FB , Amgen AMGN , Abbott ABT , Coca-Cola KO and 3M MMM . Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Coca-Cola Company (The) (KO): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including Facebook, Amgen and Abbott. | Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Coca-Cola Company (The) (KO): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Facebook FB , Amgen AMGN , Abbott ABT , Coca-Cola KO and 3M MMM . Here are highlights from Tuesday's Analyst Blog: Top Stock Reports for Facebook, Amgen and Abbott The Zacks Research Daily presents the best research output of our analyst team. | Stocks recently featured in the blog include Facebook FB , Amgen AMGN , Abbott ABT , Coca-Cola KO and 3M MMM . Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Coca-Cola Company (The) (KO): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including Facebook, Amgen and Abbott. |
33248.0 | 2018-06-22 00:00:00 UTC | The Implied Analyst 12-Month Target For PBUS | ABT | https://www.nasdaq.com/articles/implied-analyst-12-month-target-pbus-2018-06-22 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA ETF (Symbol: PBUS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $30.47 per unit.
With PBUS trading at a recent price near $27.76 per unit, that means that analysts see 9.76% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of PBUS's underlying holdings with notable upside to their analyst target prices are AMERCO (Symbol: UHAL), Abbott Laboratories (Symbol: ABT), and New York Community Bancorp Inc. (Symbol: NYCB). Although UHAL has traded at a recent price of $362.37/share, the average analyst target is 10.38% higher at $400.00/share. Similarly, ABT has 9.82% upside from the recent share price of $61.75 if the average analyst target price of $67.81/share is reached, and analysts on average are expecting NYCB to reach a target price of $12.61/share, which is 9.77% above the recent price of $11.49. Below is a twelve month price history chart comparing the stock performance of UHAL, ABT, and NYCB:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of UHAL, ABT, and NYCB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of PBUS's underlying holdings with notable upside to their analyst target prices are AMERCO (Symbol: UHAL), Abbott Laboratories (Symbol: ABT), and New York Community Bancorp Inc. (Symbol: NYCB). Similarly, ABT has 9.82% upside from the recent share price of $61.75 if the average analyst target price of $67.81/share is reached, and analysts on average are expecting NYCB to reach a target price of $12.61/share, which is 9.77% above the recent price of $11.49. | Three of PBUS's underlying holdings with notable upside to their analyst target prices are AMERCO (Symbol: UHAL), Abbott Laboratories (Symbol: ABT), and New York Community Bancorp Inc. (Symbol: NYCB). Similarly, ABT has 9.82% upside from the recent share price of $61.75 if the average analyst target price of $67.81/share is reached, and analysts on average are expecting NYCB to reach a target price of $12.61/share, which is 9.77% above the recent price of $11.49. Below is a twelve month price history chart comparing the stock performance of UHAL, ABT, and NYCB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, ABT has 9.82% upside from the recent share price of $61.75 if the average analyst target price of $67.81/share is reached, and analysts on average are expecting NYCB to reach a target price of $12.61/share, which is 9.77% above the recent price of $11.49. Below is a twelve month price history chart comparing the stock performance of UHAL, ABT, and NYCB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of PBUS's underlying holdings with notable upside to their analyst target prices are AMERCO (Symbol: UHAL), Abbott Laboratories (Symbol: ABT), and New York Community Bancorp Inc. (Symbol: NYCB). | Below is a twelve month price history chart comparing the stock performance of UHAL, ABT, and NYCB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of PBUS's underlying holdings with notable upside to their analyst target prices are AMERCO (Symbol: UHAL), Abbott Laboratories (Symbol: ABT), and New York Community Bancorp Inc. (Symbol: NYCB). Similarly, ABT has 9.82% upside from the recent share price of $61.75 if the average analyst target price of $67.81/share is reached, and analysts on average are expecting NYCB to reach a target price of $12.61/share, which is 9.77% above the recent price of $11.49. |
33249.0 | 2018-06-21 00:00:00 UTC | Tap Cardiovascular Devices Market Boom With These 3 Stocks | ABT | https://www.nasdaq.com/articles/tap-cardiovascular-devices-market-boom-these-3-stocks-2018-06-21 | nan | nan | With several tailwinds gradually flowing in, opportunities are growing enormously within the medical device space. The sector is currently enjoying the investment world's attention. While investors are putting their efforts in picking a subindustry that is beaming with prospects, the name which pops up first is the cardiovascular devices market.
Per World Health Organization (WHO), cardiovascular diseases are disorders of the heart and blood vessels. It includes coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions.
Going by the latest Heart Disease and Stroke Statistics 2018 report by American Heart Association, around 92.1 million U.S. adults are living with some form of cardiovascular disease or the after-effects of stroke. Further, cardiovascular diseases have been deemed to be a major cause of death of around 836,546 people in the United States. Notably, this is gradually taking the shape of a deadly epidemic.
Globally, the scenario is quite intriguing. Per a WHO report, cardiovascular diseases are the major cause behind 31% of all global deaths and took the lives of 17.7 million people in 2015.
Notably, projections related to the disease hint at the continuation of the present trend. In this regard, the number of deaths globally due to cardiovascular diseases is expected to increase to more than 23.6 million by 2030. Moreover, total direct expenditures related to cardiovascular diseases are expected to rise to $749 billion in 2035.
It goes without saying that the rising incidence of cardiovascular diseases globally has opened up opportunities for cardiovascular device makers. The market is expected to witness CAGR of 6.7% to reach $81.38 billion between 2017 and 2027 (per a report by Visiongain).
Accordingly, for investors who are keen to effectively put their money for longer-term gains, the cardiovascular devices market undoubtedly holds immense potential.
Factors Driving Cardiovascular Devices Market
Rising healthcare expenditures, unhealthy lifestyle practices along with expanded treatment options have been driving demand. Per a Centers for Medicare and Medicaid Services report published by Advisory Board, U.S. healthcare spending is projected to rise to around $5.5 trillion by 2025, representing 19.9% of GDP (based on the assumption that the Affordable Care Act will continue through 2025).
The cardiovascular devices market is largely dependent on the aging population. Per the U.S. Census Bureau report, in 2050, people aged 65 or more are likely to total 83.7 million, almost double its estimated population of 43.1 million in 2012. Data also shows that the median age is increasing in most areas of the country and the global scenario is pretty similar.
Strengthening emerging markets have been contributing largely to the rise in demand for cardiovascular devices. Per an article by a leading market intelligence firm, Life Science Intelligence, the demand for some cardiovascular devices has been growing at solid double-digit rates in many emerging countries, including the BRIC nations (Brazil, Russia, India, and China) and Turkey of late.
AI Brings a New Era
According to a research firm TechEmergence, AI is being broadly used in the following three categories for better management of cardiovascular diseases.
Artificial intelligence is being applied to automate the Atrial fibrillation process falling under the ECG monitoring category. It is also being used by companies to accurately predict the risk of cardiovascular disease and its related impacts. Finally, the companies are also involved in actively using the AI platform to improve the accuracy of patient scans for detecting cardiovascular diseases.
There are certain developments, which deserve a mention here. A leading digital health company Analytics 4 Life is actively involved in designing a machine learning algorithm to detect coronary artery disease non-invasively (without radiation or accelerating the heart).
Cardiotrack, an India-based start-up, recently introduced a technology platform that uses a hand-held device, cloud storage and artificial intelligence to capture and analyze electrocardiogram signals for specific heart conditions.
Stocks to Watch Out For
We have selected three companies, which we believe can tap the promising prospects of the cardiovascular devices market.
Boston Scientific CorporationBSX : This Zacks Rank #2 (Buy) company has Cardiovascular and Cardiac Rhythm Management (CRM) as two of its three reportable segments. Cardiovascular includes Interventional Cardiology and Peripheral Interventions businesses. The company is one of the leading players in the interventional cardiology market with its coronary stent product offerings. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
The company also markets balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters, as well as intravascular ultrasound imaging systems.
Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.
Boston Scientific's projected earnings growth rate for the current year is 10.3%. The stock delivered positive earnings surprise in two of the trailing four quarters with an average beat of 2.4%.
Over the past three months, Boston Scientific outperformed its industry . The stock has improved 19.9% compared with the industry's 7.5% gain during the period.
Medtronic plcMDT
The CRHF division develops, manufactures, and commercializes products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. The APV division offers a comprehensive portfolio of products and therapies to treat aortic disease (such as aneurysms, dissections, and transections) as well as peripheral vascular disease, and critical limb ischemia.
Further, CSH division offers therapies to treat coronary artery disease and heart valve disorders.
Medtronic has an expected earnings growth rate of 7.3% for the current year. The stock has delivered positive earnings surprise in all the trailing four quarters with an average beat of 3.9%.
Over the past three months, Medtronic outperformed its industry . The stock has improved 10.4% compared with the industry's 7.5% gain during the period.
Abbott LaboratoriesABT : This Zacks Rank #3 company has Cardiovascular and Neuromodulation business under the broader Medical Devices segment. The company offers a wide range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. These products are manufactured, marketed and distributed globally.
Heart failure related products, including the HeartMate left ventricular device family, vascular products, including the XIENCE family of drug-eluting coronary stent systems developed on the Multi-Link Vision platform, and rhythm management products, including Assurity MRI and Endurity MRI pacemaker systems are some of the prominent products offered by the company.
Abbott has an expected earnings growth rate of 14.4% for the current year. The stock has delivered positive earnings surprise in all the trailing four quarters with an average beat of 2%.
Over the past six months, Abbott outperformed its industry . The stock has improved 10.4% compared with the industry's 9.1% gain during the period.
Conclusion
As they say, strike while the iron is hot. It is the opportune time to cash in on the bountiful opportunities in the rapidly-growing cardiovascular devices market.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT : This Zacks Rank #3 company has Cardiovascular and Neuromodulation business under the broader Medical Devices segment. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Per a Centers for Medicare and Medicaid Services report published by Advisory Board, U.S. healthcare spending is projected to rise to around $5.5 trillion by 2025, representing 19.9% of GDP (based on the assumption that the Affordable Care Act will continue through 2025). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT : This Zacks Rank #3 company has Cardiovascular and Neuromodulation business under the broader Medical Devices segment. Per an article by a leading market intelligence firm, Life Science Intelligence, the demand for some cardiovascular devices has been growing at solid double-digit rates in many emerging countries, including the BRIC nations (Brazil, Russia, India, and China) and Turkey of late. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT : This Zacks Rank #3 company has Cardiovascular and Neuromodulation business under the broader Medical Devices segment. The company offers a wide range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. | Abbott LaboratoriesABT : This Zacks Rank #3 company has Cardiovascular and Neuromodulation business under the broader Medical Devices segment. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, projections related to the disease hint at the continuation of the present trend. |
33250.0 | 2018-06-19 00:00:00 UTC | IUSG, ABT, ACN, TMO: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/iusg-abt-acn-tmo-etf-inflow-alert-2018-06-19 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $67.8 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 73,300,000 to 74,450,000). Among the largest underlying components of IUSG, in trading today Abbott Laboratories (Symbol: ABT) is down about 1.4%, Accenture plc (Symbol: ACN) is off about 0.7%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 2%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average:
Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $59.23 as the 52 week high point - that compares with a last trade of $58.15. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSG, in trading today Abbott Laboratories (Symbol: ABT) is down about 1.4%, Accenture plc (Symbol: ACN) is off about 0.7%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 2%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $59.23 as the 52 week high point - that compares with a last trade of $58.15. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IUSG, in trading today Abbott Laboratories (Symbol: ABT) is down about 1.4%, Accenture plc (Symbol: ACN) is off about 0.7%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 2%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $59.23 as the 52 week high point - that compares with a last trade of $58.15. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSG, in trading today Abbott Laboratories (Symbol: ABT) is down about 1.4%, Accenture plc (Symbol: ACN) is off about 0.7%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $67.8 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 73,300,000 to 74,450,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $59.23 as the 52 week high point - that compares with a last trade of $58.15. | Among the largest underlying components of IUSG, in trading today Abbott Laboratories (Symbol: ABT) is down about 1.4%, Accenture plc (Symbol: ACN) is off about 0.7%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $67.8 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 73,300,000 to 74,450,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $59.23 as the 52 week high point - that compares with a last trade of $58.15. |
33251.0 | 2018-06-18 00:00:00 UTC | Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical | ABT | https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-boston-scientific-stryker-medtronic-abbott-and-varian | nan | nan | For Immediate Release
Chicago, IL - June 18, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Boston Scientific BSX , Stryker Corporation SYK , Medtronic MDT , Abbott ABT and Varian Medical VAR .
Industry: Medical Devices, Part 2
Link: https://www.zacks.com/commentary/167761/medtech-overcomes-policy-hurdles-long-term-prospects-bright
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry's lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.
According to an article published in Daily News, the tax before going into effect from January 2020 will save the device companies as much as $3.7 billion during the two-year suspension.
The U.S. medical device market is undergoing substantial transformation. An aging population, longer expectancy for life, growing healthcare awareness in emerging economies combined with powerful long-term tailwinds, including mergers & acquisitions (M&As) and product innovation, have been contributing to growth of the sector.
M&A Boom Continues
It is yet to be seen how far the benefits of the tax repeal have been redirected to M&As till now. Meanwhile, according to Mark Bonifacio, President of Bonifacio Consulting Services, private equity and strategic OEM (Original equipment manufacturer) buyers are competing for assets in all sectors of medical contract manufacturing and broadening their portfolios or investing in new technologies.
He strongly stated that although the start of 2018 was sluggish with respect to M&As, it was due to uncertainties over changes in the global healthcare market and the fate of Obamacare's medical device tax. Now that the doubts are gradually getting cleared, the industry is once again heading toward another year of significant M&A activity.
This year's biggest M&A deal seems to be in the cards with the Wall Street Journal's latest rumored news related to two mammoths of MedTech space, Boston Scientific and Stryker Corporation. The report says that both the rivals may consider a bid for consolidation.
The analysts seem to be optimistic about the rumored deal and believe that after the colossal mergers of Medtronic -- Covidien and Abbott-St. Jude Medical in the last couple of years, Boston Scientific also needs to make a mammoth move to maintain its foothold in the highly competitive medical-technology space.
Following the company's $25 billion consolidation with St. Jude Medical in January, Abbott recently closed the $5.3-billion acquisition of Alere. With the successful wrap up of this transaction, the combined company is anticipated to emerge as a leading player in the $7 billion point-of-care diagnostic space.
Another mega consolidation in the recent times was that of medical device major, Becton, Dickinson and Co. and medical, surgical, diagnostic, and patient care devices provider C. R. Bard, for $24 billion. After the completion of the deal in January, Becton, Dickinson is on its way to expand to new areas like vascular access segments - PICCs (peripherally inserted central catheters), midlines and drug delivery ports.
Varian Medical also inked a major M&A deal. The company recently signed an agreement to acquire Australia-based global life sciences company, Sirtex Medical Limited for a total deal value of $1.28 billion. The investment will strengthen the company's position in interventional oncology therapies. This apart, in its effort to gain foothold in the emerging economy, the company recently acquired Cooperative CL Enterprises, a leading distributor of radiotherapy equipment in Taiwan.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For Immediate Release Chicago, IL - June 18, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Boston Scientific BSX , Stryker Corporation SYK , Medtronic MDT , Abbott ABT and Varian Medical VAR . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. AdvaMed, the medical device industry's lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities. | For Immediate Release Chicago, IL - June 18, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Boston Scientific BSX , Stryker Corporation SYK , Medtronic MDT , Abbott ABT and Varian Medical VAR . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Industry: Medical Devices, Part 2 Link: https://www.zacks.com/commentary/167761/medtech-overcomes-policy-hurdles-long-term-prospects-bright With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. | For Immediate Release Chicago, IL - June 18, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Boston Scientific BSX , Stryker Corporation SYK , Medtronic MDT , Abbott ABT and Varian Medical VAR . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Industry: Medical Devices, Part 2 Link: https://www.zacks.com/commentary/167761/medtech-overcomes-policy-hurdles-long-term-prospects-bright With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. | For Immediate Release Chicago, IL - June 18, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Boston Scientific BSX , Stryker Corporation SYK , Medtronic MDT , Abbott ABT and Varian Medical VAR . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Industry: Medical Devices, Part 2 Link: https://www.zacks.com/commentary/167761/medtech-overcomes-policy-hurdles-long-term-prospects-bright With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. |
33252.0 | 2018-06-15 00:00:00 UTC | 3 High-Yield Stocks at Rock-Bottom Prices | ABT | https://www.nasdaq.com/articles/3-high-yield-stocks-rock-bottom-prices-2018-06-15 | nan | nan | Finding stocks that offer up a high yield and are trading at a bargain price isn't easy, but there are a few of them floating around. Knowing that, we asked a team of investors to each highlight a dividend stock with a big yield that is currently trading at a rock-bottom price. Here's why they called out AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and Retail Opportunity Investment Corp (NASDAQ: ROIC) .
Income, value, and growth -- this big pharma has it all
Keith Speights (AbbVie): Impeccable. That's probably the best way to describe AbbVie's credentials as a dividend stock. The big pharma company was part of Dividend AristocratAbbott Labs (NYSE: ABT) until it was spun off as a separate entity in 2013. Since then, AbbVie has kept its parent's streak of annual dividend increases going, boosting the dividend payout by a whopping 140% over the last five years.
AbbVie's dividend currently yields more than 3.7%. And there's no reason to think more dividend hikes won't be on the way. The company uses only 42% of its free cash flow to fund the dividend program, giving AbbVie ample flexibility to increase its dividends in the future.
Investors don't have to pay through the nose to enjoy that nice dividend yield. AbbVie stock trades at only 11 times expected earnings. But the drugmaker's growth prospects make its valuation look even more attractive. AbbVie could realistically achieve average annual earnings growth of 17% over the next few years.
The company's top-selling drug, Humira, faces biosimilar competition in Europe beginning later this year. However, AbbVie claims a couple of other fast-growing products -- cancer drug Imbruvica and hepatitis C drug Mavyret. More importantly, the company's pipeline could deliver several more big winners , including autoimmune disease drugs risankizumab and upadacitinib. Whether you're looking for income, value, or growth, AbbVie has it all.
Has yield, will travel
Maxx Chatsko(Brookfield Infrastructure Partners): The relationship between Mr. Market and Brookfield Infrastructure Partners has frayed in 2018, with the stock sliding 16% year to date. But the company has plenty to offer long-term investors willing to bet on a rebound , including a yield now sitting at 5%.
The near-continuous slide in market cap and unit price in 2018 is very uncharacteristic. Consider that the stock has delivered total returns (share gains plus reinvested dividends) of 405% in the last decade, which easily beats the total return of 152% from the S&P 500 in that span. In fact, that makes it one of the best investments of the last 10 years.
What's going on with Brookfield Infrastructure Partners stock? Aside from Wall Street jitters over near-term growth prospects , there's an absence of great explanations for the stock's slide. Management recently announced it was proceeding more carefully with capital deployments after it observed changes in the global economy. Since the best opportunities arise in more volatile periods, that's a good thing for the long-term growth of the business. But Wall Street is worried growth will slow in the coming quarters.
Nonetheless, management still thinks the business will deliver distribution growth of 5% to 8% in the coming years. A slew of projects including toll roads in India, utilities in South America, fiber-optic cables in France, and energy infrastructure in the United States provides confidence that healthy growth is still more than possible for Brookfield Infrastructure Partners going forward. Simply put, this is a great opportunity to buy a high-yield stock at a great price, then reap the rewards over the long haul.
A grocery-anchored REIT
Brian Feroldi(Retail Opportunity Investment Corp): Between rising interest rate and the recent troubles of the retail industry, it's not hard to figure out why Retail Opportunity Investments Corp (ROIC) has underperformed the S&P 500 over the past year. The company's business model is to buy grocery-anchored shopping centers in high-traffic areas and then lease out space to high-quality tenants. The business is structured as a real-estate investment trust , so the vast majority of profits are passed along to shareholders as a dividend (which currently yields 4.2%). Given the recent tidal wave of retail bankruptcies , it's understandable why Wall Street isn't feeling great about this business right now.
I understand that skepticism, but a look under the hood suggests that ROIC is actually in great shape. The company's lease rate has stood above 97% for 15 quarters in a row, which suggests there is plenty of demand from retailers to rent at the company's properties. That makes sense because ROIC only acquires shopping centers in densely populated areas that have a major grocery store on site. This laser-like focus on quality helps keeps traffic high even when times are tough. That's an attractive prospect for many retailers and helps to explain why ROIC has had no problem pushing through rent increases even as the overall market remains weak.
For 2018, management has decided to take its foot off the gas and see how shopping center prices react to the changing retail landscape. Long-term investors should applaud that move since buying new properties would require issuing shares at a depressed price.
Looking ahead, I think it's likely that Wall Street will eventually warm up to this business once it realizes that the company's high-quality portfolio will allow it to continue pushing through steady rent increases. If true, then income-loving investors might want to snatch up a few shares of this stock on the cheap while they still can.
10 stocks we like better than Retail Opportunity Investments
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Retail Opportunity Investments wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Brian Feroldi has no position in any of the stocks mentioned. Keith Speights owns shares of AbbVie. Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Retail Opportunity Investments. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The big pharma company was part of Dividend AristocratAbbott Labs (NYSE: ABT) until it was spun off as a separate entity in 2013. The company's business model is to buy grocery-anchored shopping centers in high-traffic areas and then lease out space to high-quality tenants. That makes sense because ROIC only acquires shopping centers in densely populated areas that have a major grocery store on site. | The big pharma company was part of Dividend AristocratAbbott Labs (NYSE: ABT) until it was spun off as a separate entity in 2013. Here's why they called out AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and Retail Opportunity Investment Corp (NASDAQ: ROIC) . Has yield, will travel Maxx Chatsko(Brookfield Infrastructure Partners): The relationship between Mr. Market and Brookfield Infrastructure Partners has frayed in 2018, with the stock sliding 16% year to date. | The big pharma company was part of Dividend AristocratAbbott Labs (NYSE: ABT) until it was spun off as a separate entity in 2013. Has yield, will travel Maxx Chatsko(Brookfield Infrastructure Partners): The relationship between Mr. Market and Brookfield Infrastructure Partners has frayed in 2018, with the stock sliding 16% year to date. A grocery-anchored REIT Brian Feroldi(Retail Opportunity Investment Corp): Between rising interest rate and the recent troubles of the retail industry, it's not hard to figure out why Retail Opportunity Investments Corp (ROIC) has underperformed the S&P 500 over the past year. | The big pharma company was part of Dividend AristocratAbbott Labs (NYSE: ABT) until it was spun off as a separate entity in 2013. AbbVie's dividend currently yields more than 3.7%. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Retail Opportunity Investments wasn't one of them! |
33253.0 | 2018-06-12 00:00:00 UTC | Boston Scientific Up on Possible Takeover Bid by Stryker | ABT | https://www.nasdaq.com/articles/boston-scientific-up-on-possible-takeover-bid-by-stryker-2018-06-12 | nan | nan | Shares of Boston Scientific Corporation BSX gained 7.4% to close at $34.32 on Jun 11, 2018, following a speculation that the company's rival Stryker Corporation SYK might consider a bid for acquiring the former. This news is per a Wall Street Journal report.
Trading in both stocks was temporarily paused during Monday's session on the NYSE. Per yesterday's close, Boston Scientific's market cap was $47.5 billion as compared to Stryker's $63 billion.
Following the above, a Reuters' report stated that it is still unclear whether Boston Scientific is open to a potential buyout proposal by Stryker. The prospective acquirer too declined to comment on the report.
Meanwhile, a Benzinga report wrote, "Any bid would have to surpass $40 per share, according to Stifel Nicolaus, and Wells Fargo predicted shares could be valued around $42, based on the Becton Dickinson-CR Bard deal, according to Bloomberg."
Previous BSX-Stryker Alliance
Significantly, this is not the first time that Stryker and Boston Scientific have come up for strategic collaborations. Back in 2010, the orthopaedic devices giant bought Boston Scientific's Neurovascular unit for $1.5 billion. That time, the rationale behind this divestment decision by Boston Scientific came as part of the company's aggressive restructuring initiatives. More specifically, the neurovascular division, one of the company's non-core businesses, was struggling with depressed sales.
Rationale Behind Latest Rumored Deal
While Boston Scientific's position on the prospects of the possible sell-off rumor is still unknown, some analysts believe that the reason behind the company's contemplation over a probable sell-off might lie in its interest to gain a further competitive edge in the medical device space.
It is important to note that post the colossal mergers of Medtronic MDT -Covidien and Abbott ABT -St. Jude Medical over the last couple of years, Boston Scientific also needed to make a mammoth move to maintain its foothold in the highly competitive medical-technology space.
If the merger gets to materialize finally, considering both Boston Scientific and Stryker's present market cap, then the consolidated entity will have a combined market cap of more than $110 billion. According to Wells Fargo Securities, this is a position only behind Medtronic and Johnson & Johnson in terms of total device revenues.
Reacting to this widely speculated buyout bid, retired Twin Cities med-tech stock analyst Thom Gunderson said that it "makes perfect sense to me. Go big or go home is the rule of the day."
The analysts seem optimistic about the alleged deal and believe that if it finally works out, Boston Scientific will score a vantage point in the fast-growing competitive heart valve replacement market where it is currently trailing behind Edwards Lifesciences EW and Medtronic.
Also, this merger is expected to reduce costs for the combined company at a time when the healthcare industry is already battling against severe pricing pressure.
Share Price Comparison
Over the past year, shares of Boston Scientific have rallied 22.9%, ahead of Stryker's 20.3% increase. While the broader sector remained much below with a 2.2% rise.
Both Boston Scientific and Stryker currently carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It is important to note that post the colossal mergers of Medtronic MDT -Covidien and Abbott ABT -St. Jude Medical over the last couple of years, Boston Scientific also needed to make a mammoth move to maintain its foothold in the highly competitive medical-technology space. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Reacting to this widely speculated buyout bid, retired Twin Cities med-tech stock analyst Thom Gunderson said that it "makes perfect sense to me. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. It is important to note that post the colossal mergers of Medtronic MDT -Covidien and Abbott ABT -St. Jude Medical over the last couple of years, Boston Scientific also needed to make a mammoth move to maintain its foothold in the highly competitive medical-technology space. Shares of Boston Scientific Corporation BSX gained 7.4% to close at $34.32 on Jun 11, 2018, following a speculation that the company's rival Stryker Corporation SYK might consider a bid for acquiring the former. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. It is important to note that post the colossal mergers of Medtronic MDT -Covidien and Abbott ABT -St. Jude Medical over the last couple of years, Boston Scientific also needed to make a mammoth move to maintain its foothold in the highly competitive medical-technology space. Shares of Boston Scientific Corporation BSX gained 7.4% to close at $34.32 on Jun 11, 2018, following a speculation that the company's rival Stryker Corporation SYK might consider a bid for acquiring the former. | It is important to note that post the colossal mergers of Medtronic MDT -Covidien and Abbott ABT -St. Jude Medical over the last couple of years, Boston Scientific also needed to make a mammoth move to maintain its foothold in the highly competitive medical-technology space. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Boston Scientific Corporation BSX gained 7.4% to close at $34.32 on Jun 11, 2018, following a speculation that the company's rival Stryker Corporation SYK might consider a bid for acquiring the former. |
33254.0 | 2018-06-08 00:00:00 UTC | Bio-Rad Banks on Solid Global Scenario, Competition Rife | ABT | https://www.nasdaq.com/articles/bio-rad-banks-on-solid-global-scenario-competition-rife-2018-06-08 | nan | nan | On Jun 7, we initiated a research report on Bio-Rad Laboratories, Inc.BIO . We are upbeat about the company delivering a robust performance overseas, while a tough competitive landscape is a concern. The stock carries a Zacks Rank #3 (Hold).
This California-based manufacturer and global supplier of clinical diagnostics and life science research products has been outperforming its industry over the past year. The stock has gained 30.7% versus the industry's 15.3% rise.
Bio-Rad kick-started 2018 on a solid note, with earnings and revenues rising year over year in the first quarter. The company has been strongly progressing with its efforts to strengthen its hold in other geographies. In first-quarter 2018, Bio-Rad derived around 62% of its net sales globally. The company delivered robust performance, primarily in North America, China and the Asia-Pacific region.
Further, constant currency sales at the Life Science segment were particularly strong in North America, China and Europe, while currency-neutral sales at the company's Clinical Diagnostics segment saw strength in China, Asia Pacific and North America.
Meanwhile, Bio-Rad operates in a highly competitive environment dominated by firms varying from large multinational corporations to start-ups. Also, the competitive and regulatory conditions in the markets where the company operates limit its ability to switch to strategies like price increases and other drivers of cost increases.
In the Life Science segment, Bio-Rad primarily competes with the likes of Becton Dickinson and Thermo Fisher Scientific TMO , among others. Again, some prominent competitors in the Clinical Diagnostics segment are Abbott Laboratories ABT and DiaSorin.
Further, Bio-Rad is exposed to risks associated with a weaker global economy and lower reimbursement rates.
Key Picks
A better-ranked stock in the broader medical sector is Intuitive Surgical ISRG , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Intuitive Surgical has a long-term expected earnings growth rate of 12.1%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Again, some prominent competitors in the Clinical Diagnostics segment are Abbott Laboratories ABT and DiaSorin. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. This California-based manufacturer and global supplier of clinical diagnostics and life science research products has been outperforming its industry over the past year. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Again, some prominent competitors in the Clinical Diagnostics segment are Abbott Laboratories ABT and DiaSorin. The company delivered robust performance, primarily in North America, China and the Asia-Pacific region. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Again, some prominent competitors in the Clinical Diagnostics segment are Abbott Laboratories ABT and DiaSorin. Further, constant currency sales at the Life Science segment were particularly strong in North America, China and Europe, while currency-neutral sales at the company's Clinical Diagnostics segment saw strength in China, Asia Pacific and North America. | Again, some prominent competitors in the Clinical Diagnostics segment are Abbott Laboratories ABT and DiaSorin. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. The stock carries a Zacks Rank #3 (Hold). |
33255.0 | 2018-06-08 00:00:00 UTC | Daily Dividend Report: PM, GE, ABT, AMAT, CDK | ABT | https://www.nasdaq.com/articles/daily-dividend-report-pm-ge-abt-amat-cdk-2018-06-08 | nan | nan | Philip Morris International ( PM ) increased the company's regular quarterly dividend by 6.5% to an annualized rate of $4.56 per share. The new quarterly dividend of $1.14 per share, up from $1.07 per share, is payable on July 11, 2018, to shareholders of record as of June 22, 2018. The ex-dividend date is June 21, 2018.
GE ( GE ) declared a $0.12 per share dividend on the outstanding common stock of the Company. The dividend is payable Wednesday, July 25, 2018 to shareowners of record at the close of business on Monday, June 18, 2018. The ex-dividend date is Friday, June 15, 2018.
Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. The cash dividend is payable Aug. 15, 2018, to shareholders of record at the close of business on July 13, 2018.
Applied Materials has approved a quarterly cash dividend of $0.20 per share payable on the company's common stock. The dividend is payable on September 13, 2018 to shareholders of record as of August 23, 2018.
CDK Global ( CDK ) has declared a regular quarterly cash dividend of $0.15 per share payable on June 29, 2018 to shareholders of record at the close of business on June 19, 2018.
VIDEO: Daily Dividend Report: PM, GE, ABT, AMAT, CDK
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. VIDEO: Daily Dividend Report: PM, GE, ABT, AMAT, CDK The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Philip Morris International ( PM ) increased the company's regular quarterly dividend by 6.5% to an annualized rate of $4.56 per share. | VIDEO: Daily Dividend Report: PM, GE, ABT, AMAT, CDK The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. Applied Materials has approved a quarterly cash dividend of $0.20 per share payable on the company's common stock. | VIDEO: Daily Dividend Report: PM, GE, ABT, AMAT, CDK The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. The new quarterly dividend of $1.14 per share, up from $1.07 per share, is payable on July 11, 2018, to shareholders of record as of June 22, 2018. | Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. VIDEO: Daily Dividend Report: PM, GE, ABT, AMAT, CDK The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The new quarterly dividend of $1.14 per share, up from $1.07 per share, is payable on July 11, 2018, to shareholders of record as of June 22, 2018. |
33256.0 | 2018-06-07 00:00:00 UTC | Noteworthy ETF Inflows: IUSG, MA, ABT, PG | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-iusg-ma-abt-pg-2018-06-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $132.2 million dollar inflow -- that's a 3.2% increase week over week in outstanding units (from 71,050,000 to 73,300,000). Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Procter & Gamble Company (Symbol: PG) is up by about 0.7%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average:
Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.92 as the 52 week high point - that compares with a last trade of $58.58. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Procter & Gamble Company (Symbol: PG) is up by about 0.7%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.92 as the 52 week high point - that compares with a last trade of $58.58. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Procter & Gamble Company (Symbol: PG) is up by about 0.7%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.92 as the 52 week high point - that compares with a last trade of $58.58. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Procter & Gamble Company (Symbol: PG) is up by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $132.2 million dollar inflow -- that's a 3.2% increase week over week in outstanding units (from 71,050,000 to 73,300,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.92 as the 52 week high point - that compares with a last trade of $58.58. | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Procter & Gamble Company (Symbol: PG) is up by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $132.2 million dollar inflow -- that's a 3.2% increase week over week in outstanding units (from 71,050,000 to 73,300,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.92 as the 52 week high point - that compares with a last trade of $58.58. |
33257.0 | 2018-06-01 00:00:00 UTC | Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S. | ABT | https://www.nasdaq.com/articles/abbott-launches-afinion-2-analyzer-rapid-test-in-the-u.s.-2018-06-01 | nan | nan | AbbottABT recently announced the launch of the latest generation of the Afinion test system - Afinion 2 analyzer - in the United States. This system delivers accurate hemoglobin A1c (HbA1c) results in 3 minutes and albumin to creatinine ratio (ACR) results in 5 minutes. Therefore, the product will enable healthcare providers to adhere to American Diabetes Association (ADA) testing guidelines efficiently and promptly.
What IsAfinion 2 Analyzer Rapid Test System?
The Afinion 2 analyzer is a rapid and compact multi-assay platform which is capable of streamlining and simplifying the delivery of actionable and accurate measurements of HbA1c and ACR results at the point of care. The Afinion 2 platform also provides all-in-one connectivity to laboratory and hospital information systems (LIS/HIS), which enables healthcare providers to use it in various out-patient settings.
Per the ADA, regular measuring of HbA1c and ACR levels are effective for long-term management of patients diagnosed with diabetes. Given the host of benefits it offers, we are upbeat about the launch of the Afinion 2 analyzer system which is expected to boost the top-line contributions from the Diagnostics division.
A Glimpse at the Diagnostics Business
Abbott's Diagnostics division manufacturesand markets diagnostic systems as well as tests in four business lines - Core Laboratory, Molecular, Point of Care and Rapid Diagnostics (reflects sales from Alere, which was acquired on Oct. 3, 2017). The division accounted for 24.9% of total sales in first-quarter 2018.
In the last reported quarter, the Diagnostics revenues grew 58.7% year over year (up 5.5% on a comparable operational basis) driven by better-than-expected performance of the company's Rapid Diagnostics business and strength in flu season across the United States.
Notably, Rapid Diagnostics recorded sales of $559 million, driven by solid contributions from infectious disease testing that include flu and strep testing. Further, management projects the uptrend in this division to continue on the back of new product launches, benefits from Alere acquisition and strength in Alinity test platform.
Market Potential
Theprevailing demographics are in favor of high incidence of diabetes among individuals. Per a report from Mordor Intelligence, theglobal marketfor diabetes care devices is expected to attain a value of $30.25 billion by 2021. Further, per Abbott, more than 30 million people (or 9.4% of the total population) in the United States are suffering from diabetes. Thus, under such circumstances, we conclude that the developmental steps undertaken by the company seem to be progressive and are strategically aligned.
Price Performance
Abbott has been gaining investors' optimism on consistently positive results. Over the past six months, the stock has outperformed the industry . Shares of the company have gained 9.9% compared with the industry's rise of 7.9%.
Zacks Rank & Stocks to Consider
Abbott currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Intuitive Surgical ISRG , Illumina, Inc. ILMN and Amedisys, Inc. AMED . While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Amedisys carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Intuitive Surgical has an expected long-term earnings growth rate of 12.1%.
Illumina expects long-term earnings growth of 20%.
Amedisys has an expected long-term earnings growth rate of 17.5%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT recently announced the launch of the latest generation of the Afinion test system - Afinion 2 analyzer - in the United States. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. The Afinion 2 analyzer is a rapid and compact multi-assay platform which is capable of streamlining and simplifying the delivery of actionable and accurate measurements of HbA1c and ACR results at the point of care. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT recently announced the launch of the latest generation of the Afinion test system - Afinion 2 analyzer - in the United States. A Glimpse at the Diagnostics Business Abbott's Diagnostics division manufacturesand markets diagnostic systems as well as tests in four business lines - Core Laboratory, Molecular, Point of Care and Rapid Diagnostics (reflects sales from Alere, which was acquired on Oct. 3, 2017). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT recently announced the launch of the latest generation of the Afinion test system - Afinion 2 analyzer - in the United States. A Glimpse at the Diagnostics Business Abbott's Diagnostics division manufacturesand markets diagnostic systems as well as tests in four business lines - Core Laboratory, Molecular, Point of Care and Rapid Diagnostics (reflects sales from Alere, which was acquired on Oct. 3, 2017). | AbbottABT recently announced the launch of the latest generation of the Afinion test system - Afinion 2 analyzer - in the United States. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Amedisys carries a Zacks Rank #2 (Buy). |
33258.0 | 2018-05-31 00:00:00 UTC | Thursday's ETF with Unusual Volume: XHE | ABT | https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-xhe-2018-05-31 | nan | nan | The SPDR S&P Health Care Equipment ETF ( XHE ) is seeing unusually high volume in afternoon trading Thursday, with over 305,000 shares traded versus three month average volume of about 41,000. Shares of XHE were trading flat on the day.
Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.1% with over 3.9 million shares changing hands so far this session, and Abbott Laboratories ( ABT ), down about 0.5% on volume of over 2.0 million shares. Livanova ( LIVN ) is the component faring the best Thursday, higher by about 13.3% on the day, while Cantel Medical Corp ( CMD ) is lagging other components of the SPDR S&P Health Care Equipment ETF, trading lower by about 9.2%.
VIDEO: Thursday's ETF with Unusual Volume: XHE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.1% with over 3.9 million shares changing hands so far this session, and Abbott Laboratories ( ABT ), down about 0.5% on volume of over 2.0 million shares. The SPDR S&P Health Care Equipment ETF ( XHE ) is seeing unusually high volume in afternoon trading Thursday, with over 305,000 shares traded versus three month average volume of about 41,000. Livanova ( LIVN ) is the component faring the best Thursday, higher by about 13.3% on the day, while Cantel Medical Corp ( CMD ) is lagging other components of the SPDR S&P Health Care Equipment ETF, trading lower by about 9.2%. | Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.1% with over 3.9 million shares changing hands so far this session, and Abbott Laboratories ( ABT ), down about 0.5% on volume of over 2.0 million shares. The SPDR S&P Health Care Equipment ETF ( XHE ) is seeing unusually high volume in afternoon trading Thursday, with over 305,000 shares traded versus three month average volume of about 41,000. Livanova ( LIVN ) is the component faring the best Thursday, higher by about 13.3% on the day, while Cantel Medical Corp ( CMD ) is lagging other components of the SPDR S&P Health Care Equipment ETF, trading lower by about 9.2%. | Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.1% with over 3.9 million shares changing hands so far this session, and Abbott Laboratories ( ABT ), down about 0.5% on volume of over 2.0 million shares. The SPDR S&P Health Care Equipment ETF ( XHE ) is seeing unusually high volume in afternoon trading Thursday, with over 305,000 shares traded versus three month average volume of about 41,000. VIDEO: Thursday's ETF with Unusual Volume: XHE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.1% with over 3.9 million shares changing hands so far this session, and Abbott Laboratories ( ABT ), down about 0.5% on volume of over 2.0 million shares. The SPDR S&P Health Care Equipment ETF ( XHE ) is seeing unusually high volume in afternoon trading Thursday, with over 305,000 shares traded versus three month average volume of about 41,000. Shares of XHE were trading flat on the day. |
33259.0 | 2018-05-29 00:00:00 UTC | The 7 Best Long-Term Stocks for Risk-Off Investors | ABT | https://www.nasdaq.com/articles/7-best-long-term-stocks-risk-investors-2018-05-29 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
A number of recent studies show that companies who focus on the big picture and long-term success tend to better stocks to buy than those that focus exclusively on the here and now.
"While the parameters of what defines a long-term-focused company are still somewhat squishy, the limited evidence so far suggests that they make better investments too," wrote Fortune's Clifton Leaf. "At least compared to short-termers: companies that are chasing quarterly earnings targets, buying back stock to pump their share prices, cutting R&D, and slashing other key investments in technology and people."
Which stocks are you interested in owning?
S&P Dow Jones Indices' October 2017 report, Long-Termism: Index Impossible?, looked at the S&P Long-Term Value Creation (LTVC) Global Index , an index created to hold mid- and large-size companies that embody long-termism , which is the idea of making decisions based on a sustainable future-oriented perspective.
S&P took a company's return on equity, balance sheet accruals ratio and financial leverage, averaged the score of the three metrics to quantify the financial quality of a particular company. Those that scored higher got included in the index.
20 2018 Losers That Will Be Big Winners
Here are seven long-term stocks to buy, some of which are held by the index.
Long-Term Stocks to Buy: Xylem (XYL)
If it's got anything to do with water there's a good chance that Xylem Inc (NYSE: XYL ) is involved in some capacity.
Recently named the 2018 Water Technology Company of the Year by Global Water Intelligence, a provider of water industry information, it's participating in what is arguably the most important industry in the world - without water, we die a quick death.
" Xylem has established itself as a leading provider of intelligent solutions that address the water industry's most persistent challenges," stated the company's press release on winning the award. "Xylem was identified as the company that "moved the needle in the water technology sector in 2017…to become an outright leader in the rapidly growing market for smart water solutions."
There's money to be made by doing good in the world.
Xylem's first quarter adjusted net income grew 31% to $93 million on the back of a 14% increase in revenue. Orders were up 10% in the quarter with its water infrastructure segment - it provides the equipment necessary to turn dirty water into clean water - it expects 2018 full-year revenue of at least $5.1 billion with adjusted earnings per share of at least $2.82 a share.
With water shortages happening around the world, it's incumbent on companies like Xylem to think bigger in order to help conserve clean drinking water. If you care about the environment, XYL is a stock to consider.
Long-Term Stocks to Buy: S&P Global (SPGI)
It is only appropriate that the company that created the S&P LTVC Global Index is one of the top ten holdings .
Last October I namedS&P Global Inc (NYSE: SPGI ) one of the best non-bank financial stocks to buy. Not only do I like it because it operates a business that's growing but also because it's a Dividend Aristocrat, those stocks that have increased their annual dividend payment for at least 25 consecutive years.
SPGI announced its first-quarter earnings April 26 beating on both the top- and bottom-line. Revenues in the quarter were $1.6 billion , 8% higher than a year ago, while its adjusted earnings per share rose 24% in the quarter to $2.00 a share.
All four of its operating segments had good growth in the quarter led by a 25% increase from its S&P Dow Jones Indices business, its 72%-owned subsidiary.
20 Stocks Millennial Investors Can't Get Enough Of
Free cash flow positive, SPGI has done a good job diversifying its business. Up 19% year to date through May 23, SPGI hasn't had a losing year since 2008.
Long-Term Stocks to Buy: Abbott Labs (ABT)
Right there in the first sentence of its Q1 2018 press release are the words "long-term sustainable and organic growth."
Companies like Abbott Laboratories (NYSE: ABT ) that are focused on the long-term don't care much about short-term gyrations in revenues and earnings. As a result, it's able to produce results superior to many of its industry peers.
Organic revenues in the first quarter grew by 6.9% to $7.4 billion with particularly strong performances from its medical devices and established pharmaceutical segments.
Companies thinking big picture are all about delivering new and better products to its customers.
In the first quarter, it launched Confirm Rx, the world's first insertable cardiac monitor. Abbott reported that its FreeStyle Libre glucose monitoring system now has 650,000 users around the world, an excellent adoption rate for a product that only was launched in the U.S. in 2018 and Europe in 2014.
Yielding 1.8% and expected to generate adjusted earnings per share of $2.85 in fiscal 2018, ABT stock is currently trading at a reasonable valuation.
It's time to buy.
Long-Term Stocks to Buy: Unilever (UN)
After turning down the $143 billion buyout offer from Kraft Heinz Co (NASDAQ: KHC ) in 2017 as woefully inadequate, Unilever NV (ADR) (NYSE: UN ) has been focused on simplifying its business including moving its headquarters to Amsterdam and eliminating its separate class of shares traded on the London Stock Exchange.
The vote to do so happens in August. If the recent vote by shareholders on executive compensation is any indication - 36% of shareholders voted against the plan to boost compensation to CEO Paul Polman - the move to Amsterdam might not be a sure thing.
"it's a simpler corporate arrangement at the end of the day," said Laith Khalaf, senior analyst at Hargreaves Landson. "There is a slimming down of the corporate costs. In the grand scale of Unilever, it's probably not hugely significant, but I think that is their rationale for doing it."
Unilever's got a strong group of brands that it continues to narrow down to a manageable number which should make it even more attractive to investors in the future.
30 Marijuana Stocks to Buy as the Future Turns Green
At the end of the day, despite the protests of U.K. investors, the move makes sense in the long term.
Long-Term Stocks to Buy: Praxair (PX)
You know a company is pursuing a significant acquisition when there is a heading at the top of its investor relations home page entitled "merger update."
Praxair, Inc. (NYSE: PX ), a leading provider of specialty gases, began its merger dance with Linde AG almost a year ago to the day. Valued at $78 billion, the "merger of equals" as they're calling it, would have combined annual revenue of $29 billion with a market cap in excess of $70 billion.
Together, the new Praxair will become the second-largest provider of industrial gases with operations on every continent except Antarctica.
Praxair expects the merger to be completed in the second half of 2018.
As for Praxair's business, it had good Q1 2018 results with revenues up 10% to $3 billion with an adjusted operating profit of $672 million, 17% higher than a year earlier.
I'm not usually a fan of big M&A deals because the synergies and cost savings advertised never seem to materialize. In the case of the Praxair/Linde tie-up, I'm inclined to believe the estimate of $1.2 billion in cost savings found over the next three years.
It's a boring business but one in which economies of scale matter.
Long-Term Stocks to Buy: Netflix (NFLX)
If there's a company that thinks more long-term than Netflix, Inc. (NASDAQ: NFLX ), I can't think of it.
Just imagine you're Reed Hastings in 2006.
You've got a DVD rental business that you operate through the mail, but it's cumbersome, not to mention expensive. You try to come up with a business that will completely disrupt the traditional television and movie industry.
Your idea?
"Why don't we save on postage and physical inventory by giving our monthly subscribers the same content (and more) over the internet?"
A simple idea, but hellishly difficult to execute properly, which in hindsight we know it's done flawlessly.
Back in November 2016, I recommended NFLX stock despite its lofty valuation because I felt it was becoming the world's first global TV network with a growing international subscriber base worthy of a nosebleed valuation.
It's up 207% in the 18 months since.
I'm not saying this to toot my own horn; I'm saying it because if you think Netflix is overvalued today, I'm here to tell you there's a good chance I'll be repeating the 207% line after another 18 months.
7 Triple-A Stocks to Buy for the Summer
Of all the companies on this list, Netflix is the biggest long-termer. It's not even close.
Long-Term Stocks to Buy: Intuitive Surgical (ISRG)
I've followed Intuitive Surgical, Inc. (NASDAQ: ISRG ) for a long time primarily because I'm fascinated by its robotic surgical systems despite the fact I'm not particularly enamored by medical-related stocks.
Back in 2013, I included ISRG as a bonus pick as part of an article I wrote about several stocks to buy and sell.
The stock was tanking due to it losing analyst support on fears Obamacare would reduce hospital spending for frivolous products such as expensive surgical systems. I wasn't buying any of that thinking.
"Perhaps business won't come as easily in the future, but with no debt and $1.3 billion in cash, it can buy back shares until some of the systemic issues are successfully dealt with," I wrote July 12, 2013. "Until then, I'd take advantage of every double-digit drop in its stock price if you're patient enough to stomach it for the long-term rewards."
In 2014, as the analysts had suggested, revenues fell 6% to $2.1 billion. In the three years since they've grown by 47%, which has put a fire under ISRG stock, up 41% annually over the same period.
Louis Navellier recently had this to say about Intuitive Surgical:
"ISRG's timing is spectacular. First, we're entering a new tech wave of artificial intelligence, driverless cars, personal assistants, etc. People are comfortable letting technology take over," Navellier wrote May 11. "Second, as baby boomers start hitting retirement age, minimally invasive surgery becomes a rite of passage."
Intuitive Surgical couldn't have known either of these points would come into play when it first started selling the da Vinci Surgical Systems but, in my opinion, it is a byproduct of long-term thinking.
As of this writing, Will Ashworth did not hold a position in any of the aforementioned securities.
Compare Brokers
The post The 7 Best Long-Term Stocks for Risk-Off Investors appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Long-Term Stocks to Buy: Abbott Labs (ABT) Right there in the first sentence of its Q1 2018 press release are the words "long-term sustainable and organic growth." Companies like Abbott Laboratories (NYSE: ABT ) that are focused on the long-term don't care much about short-term gyrations in revenues and earnings. Yielding 1.8% and expected to generate adjusted earnings per share of $2.85 in fiscal 2018, ABT stock is currently trading at a reasonable valuation. | Long-Term Stocks to Buy: Abbott Labs (ABT) Right there in the first sentence of its Q1 2018 press release are the words "long-term sustainable and organic growth." Companies like Abbott Laboratories (NYSE: ABT ) that are focused on the long-term don't care much about short-term gyrations in revenues and earnings. Yielding 1.8% and expected to generate adjusted earnings per share of $2.85 in fiscal 2018, ABT stock is currently trading at a reasonable valuation. | Long-Term Stocks to Buy: Abbott Labs (ABT) Right there in the first sentence of its Q1 2018 press release are the words "long-term sustainable and organic growth." Companies like Abbott Laboratories (NYSE: ABT ) that are focused on the long-term don't care much about short-term gyrations in revenues and earnings. Yielding 1.8% and expected to generate adjusted earnings per share of $2.85 in fiscal 2018, ABT stock is currently trading at a reasonable valuation. | Long-Term Stocks to Buy: Abbott Labs (ABT) Right there in the first sentence of its Q1 2018 press release are the words "long-term sustainable and organic growth." Companies like Abbott Laboratories (NYSE: ABT ) that are focused on the long-term don't care much about short-term gyrations in revenues and earnings. Yielding 1.8% and expected to generate adjusted earnings per share of $2.85 in fiscal 2018, ABT stock is currently trading at a reasonable valuation. |
33260.0 | 2018-05-28 00:00:00 UTC | 2 Giant Medical Device Companies Transforming Diabetes | ABT | https://www.nasdaq.com/articles/2-giant-medical-device-companies-transforming-diabetes-2018-05-28 | nan | nan | Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) are massive companies with their corporate fingers in many different markets. However, each has recently launched revolutionary diabetes devices that are changing how doctors care for their patients. Are these two stocks buys?
In this clip from The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to explain how continuous glucose monitors and insulin pumps are improving patient lives.
A full transcript follows the video.
10 stocks we like better than Walmart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 8, 2018
The author(s) may have a position in any stocks mentioned.
This video was recorded on May 23, 2018.
Kristine Harjes: Let's start with the goliath of today's discussion, which is Medtronic. The ticker is MDT. They're a huge company, a $115 billion market cap. To be clear, they are not a pure-play in diabetes. They're also working in cardiovascular and pain and surgery and a bunch of other areas. But, they do have a diabetes segment.
Todd Campbell: Right, and that diabetes segment doesn't represent a huge amount of the company's revenue, but there is some pretty exciting stuff going on at Medtronic in diabetes that's making that segment a bigger driver of the company's quarter-to-quarter performance.
Medtronic has long participated in what's called the continuous glucose monitor market, the CGM market. You mentioned there were two ways, two medical devices, that were getting more increasingly used by patients to evaluate and control their disease. One of those two is the continuous glucose monitors. They've always been a participant within that marketplace.
But, what happened in 2017 is that they won FDA approval for something called the MiniMed 670G. The 670G is the first "closed-loop" artificial pancreas system that the FDA has signed off on. Essentially, what we're talking about there is a system that will automatically evaluate your blood sugar levels by testing every five minutes, and then, as necessary, automatically administer insulin to help to keep that blood sugar in check.
Harjes: Which is really a pretty cool development. You think about going from the single point-in-time finger pricks, and then evolving the care to a CGM. Picture a sine curve, for my math nerds out there, where you can actually see that your levels are rising and falling, and watch that trend over time. That's even more complete information. Then, with this what they're calling artificial pancreas, that's a step even beyond the information of the CGM. Now, it's actually taking action on it, too, and adjusting insulin in response to that information. That is a huge step forward for convenience and timeliness of reacting to the data.
Right now, there are about 20,000 patients that are using this device, which was approved back in September 2016. And it should probably begin to gather even more use.
Campbell: Yeah. I've polled some of my friends who are diabetics -- this is a type 1 diabetes solution, primarily, because those are the people who are going to need to be managing the disease most intensely -- and they tend to prefer some of the other options we're going to talk about right now over this. But I think, over time, as the technology evolves and these systems get easier on the patient to use, etc, I think you'll see more and more patients using this.
You have 1.5 million Americans alone with type 1 diabetes. So, 20,000 patients worldwide using it, you don't have a huge amount of penetration. Nevertheless, it was still responsible for Medtronic's diabetes revenue growing by double digits year over year in Q1. Now, they didn't break out the exact sales of the MiniMed 670G. But what they did say is that diabetes segment sales in Q1 were $584 million. Which is pretty good. But, remember, Medtronic's sales in Q1 were $7.4 billion. So, if you're looking for a pure-play in diabetes, this isn't going to be it.
Harjes: Right. Another stock that's also not going to be your pure-play but is interesting to talk about in this space is Abbott. Their ticker is ABT. It's another huge company. They're over $100 billion. Again, they have a diabetes segment that's just one part of the larger company. Abbott, I believe, doesn't even break out their diabetes revenue, it just falls into the Other bucket for them. That Other bucket, for context, was a total of $430 million in revenue out of a total of $7.4 billion in the last quarter. So, again, they're only dealing with this market a little bit relative to the entire business, but they're still doing some interesting things.
They have their FreeStyle Libre, which was the first CGM that was approved that didn't require additional finger pricks for calibration of the system. When this came out, it was pretty revolutionary. We're going a little bit out of order here, because the next stock that we want to talk about is the stock that created the first CGM. But, I will leave you in suspense for which company that was, if you don't already know. When Abbott came out with its system, the stock that made the original CGM took a beating.
Campbell: Yeah. One of the big knocks against CGMs, these continuous glucose monitors, has been that they still require the finger sticks for calibrating them regularly. That's why, when the FDA approved the FreeStyle Libre from Abbott last year, it was such a big and intense and wonderful development for patients. As a result, that's turned into quite a commercial opportunity for Abbott.
Most of our listeners would probably be familiar with Abbott if they're income investors, because Abbott has a very long track record of -- as a matter of fact, it's a dividend aristocrat -- increasing its dividend every year. They don't necessarily think about Abbott for the diabetes business. But maybe that will change, because since they launched the FreeStyle Libre, in Q1 alone, their diabetes revenue grew 30% year over year. That's remarkable growth for a medical device segment of this size. Now, granted, again, like Medtronic, a very small proportion of the overall pie here at Abbott. But still an intriguing stock to keep an eye on.
Kristine Harjes has no position in any of the stocks mentioned. Todd Campbell has no position in any of the stocks mentioned. The Motley Fool owns shares of Medtronic. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) are massive companies with their corporate fingers in many different markets. Their ticker is ABT. They have their FreeStyle Libre, which was the first CGM that was approved that didn't require additional finger pricks for calibration of the system. | Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) are massive companies with their corporate fingers in many different markets. Their ticker is ABT. In this clip from The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to explain how continuous glucose monitors and insulin pumps are improving patient lives. | Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) are massive companies with their corporate fingers in many different markets. Their ticker is ABT. In this clip from The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to explain how continuous glucose monitors and insulin pumps are improving patient lives. | Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) are massive companies with their corporate fingers in many different markets. Their ticker is ABT. They're a huge company, a $115 billion market cap. |
33261.0 | 2018-05-28 00:00:00 UTC | Abbott Presents Positive Data for AMPLATZER Amulet Device | ABT | https://www.nasdaq.com/articles/abbott-presents-positive-data-for-amplatzer-amulet-device-2018-05-28 | nan | nan | AbbottABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Data was presented at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in Paris. Further, these results were published in EuroIntervention.
What is AMPLATZER Amulet Occlusion Device?
The AMPLATZER Amulet occluder is an advanced, minimally-invasive LAA occlusion device designed to seal off the LAA in people suffering from non-valvular atrial fibrillation in a time-efficient manner. This device blocks the LAA at its opening and reduces the chance of blood clots reaching the bloodstream and causing strokes.
The AMPLATZER Amulet device comes in several sizes to cater to several types of complex patient anatomies. Moreover, it is claimed to be used on patients for whom blood-thinner medication is not a very safe option or is contraindicated.
Notably, the AMPLATZER Amulet device is currently an investigational device in the United States.
Study in Details
The AMPLATZER Amulet Observational Post-Market Study had 1,088 non-valvular AF patients enrolled worldwide. The Amulet device was effectively implanted in 99% of the enrolled patients with a follow-up period through 24 months post-device implant for assessment.
Notably, the results through one-year follow-up demonstrate that treatment through AMPLATZER Amulet had lowered the risk for ischemic stroke by 57% and also reduced the chance of ischemic stroke, transient ischemic attack or systemic embolism by 60%.
A Glimpse of the Structural Heart Business
The Structural Heart business has maintained an impressive top-line performance. In the last reported quarter, sales at the segment rose 14.5% on a reported basis.
Notably, the Structural Heart business accounted for 10.7% of total revenues under the broader Medical Device segment. The upside was led by continued double-digit growth of MitraClip - the company's market-leading device for the repair of MR. The company recently announced encouraging results from a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system. In March, the company announced the receipt of national reimbursement in Japan for the same. Notably, in nearly 50 countries, more than 50,000 people have been treated with MitraClip. Ministry of Health Labour and Welfare (MHLW) approved the MitraClip System in Japan last November.
Further, the company announced the receipt of FDA approval for the world's smallest rotatable, bileaflet mechanical heart valve - Masters HP 15mm. With the approval, the company has expanded the Masters Series portfolio under Structural Heart.
Market Prospects
Abbott's strategy to gain traction in the Structural Heart segment seems to be aligned with data provided by Allied Market Research and the company . Per the report, the global atrial fibrillation market is estimated to reach a worth of $8,319 million by 2022, at a CAGR of 13% from 2014 to 2022. Per the company, almost 33.5 million people suffer from atrial fibrillation globally.
Share Price Performance
Abbott has been gaining investor confidence on consistently positive results. Over the past six months, the stock has outperformed the industry . The stock has gained 11.3%, in comparison with the industry's 7%.
Zacks Rank & Stocks to Consider
Abbott currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Intuitive Surgical ISRG , Illumina, Inc ILMN and Amedisys, Inc. AMED . While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Amedisys carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Intuitive Surgical has an expected long-term earnings growth rate of 12.1%.
Illumina expects long-term earnings growth of 20%.
Amedisys has an expected long-term earnings growth rate of 17.5%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently announced encouraging results from a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. A few better-ranked stocks in the broader medical sector are Intuitive Surgical ISRG , Illumina, Inc ILMN and Amedisys, Inc. AMED . | AbbottABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the results through one-year follow-up demonstrate that treatment through AMPLATZER Amulet had lowered the risk for ischemic stroke by 57% and also reduced the chance of ischemic stroke, transient ischemic attack or systemic embolism by 60%. | AbbottABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. The AMPLATZER Amulet occluder is an advanced, minimally-invasive LAA occlusion device designed to seal off the LAA in people suffering from non-valvular atrial fibrillation in a time-efficient manner. |
33262.0 | 2018-05-25 00:00:00 UTC | Five Top MedTech Stocks in Diabetes | ABT | https://www.nasdaq.com/articles/five-top-medtech-stocks-diabetes-2018-05-25 | nan | nan | It's not just drugmakers that are disrupting the massive diabetes market. Medical device makers are also developing new approaches that can help diabetics better control their disease. From medtech Goliaths Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) to small pure plays Dexcom (NASDAQ: DXCM) , Insulet Corp. (NASDAQ: PODD) , and Tandem Diabetes Care (NASDAQ: TNDM) , we've got you covered.
On this episode of The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes and Motley Fool contributor Todd Campbell explain how artificial pancreases, continuous glucose monitors, and insulin pumps are reshaping diabetes treatment and what could be at stake for investors.
A full transcript follows the video.
10 stocks we like better than Walmart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 8, 2018
The author(s) may have a position in any stocks mentioned.
This video was recorded on May 23, 2018.
Kristine Harjes: Welcome to Industry Focus , the podcast that dives into a different sector of the stock market every day. We're talking Healthcare today, May 23rd. I'm your host, Kristine Harjes. Calling in to Fool HQ in Alexandria, Virginia is fool.com healthcare contributor Todd Campbell. Todd, what's the latest?
Todd Campbell: I'm excited! I'm excited to talk today about what I think could be one of the most important investing themes in healthcare over the course of the next ten to 20 years.
Harjes: Absolutely. Today, just to dive right in, we're talking about the diabetes space, specifically some medical device makers within the diabetes space. We got a listener email from Brian B, thanks for writing in, who noticed that we tend to cover a lot of pharma companies and drug makers. It's true, we do. They have a lot of growth potential, I think they're very exciting. They have clinical updates all the time.
But, Brian suggested that we spend a little bit more time of our coverage talking about medical devices and their makers. So, today, we thought we would do just that, specifically regarding the diabetes market. The impact of this disease, as you already alluded to, Todd, is staggering, and the number of patients is growing very quickly. Can you kick us off with some more background?
Campbell: Sure. I think it might be helpful to begin with, what is diabetes? I think we've all heard of diabetes, but we may not fully understand what the disease is. In healthy people, when we consume food and we get glucose into our bloodstream, the pancreas releases insulin, and that insulin allows our body to store the glucose for energy later on. In fact, glucose is the primary source of energy for the brain.
In type 1 diabetes, because of either genetic or environmental factors, patients don't produce insulin, so they can't store the glucose. As a result, they end up with too much glucose in their bloodstream. That's called high blood sugar. In type 2 patients, basically, what happens is, they develop a resistance to the insulin that they produce, so they're not able to store the glucose.
In both of those situations, Kristine, we're talking about a potentially life-threatening situation. You have consequences associated with diabetes that include everything from nerve loss to an increased risk of cardiovascular death. There are 30 million Americans alone with diabetes. Kristine, any guess as to how many people with prediabetes in the United States?
Harjes: Probably at least double the number of diabetics.
Campbell: 84 million! 84 million with elevated blood sugar levels that put them at the risk of diabetes. It's no wonder that there are 1.5 million new diabetes diagnoses in the U.S. alone every year.
Harjes: Yeah. And treatment on diabetes is going to continue to eat up more and more of our overall healthcare costs. From $408 billion to $622 billion, the levels of spending will rise between the years of 2015 and 2030, according to one study. It's a disease where it really does need to be managed for life. It's a chronic condition, and it is, as you mentioned, a life-threatening one, particularly if it's inadequately controlled.
Traditionally, diabetics have had to prick their fingers for blood to measure their glucose levels throughout the day, and take action when necessary. So, while there are companies that are focused on making insulin or other non-insulin drugs to help regulate levels of insulin and glucose in the blood, there are also companies who are focused on the monitoring and trying to get the most practical information about the action that diabetics should then take. So, that's where you have your medical device makers come in.
Campbell: We oftentimes talk about, Kristine, the different drugs that are being brought to market by biopharma to try and help our bodies deal with these elevated levels of blood sugar. We don't oftentimes talk about the medical device companies, the med tech companies, that are out there trying to improve upon our understanding of our disease -- so, if we are a diabetic, helping us be able to have greater insight into our blood sugar levels so that we can treat ourselves better than we have in the past.
If you were a diabetic in the 70s or 80s or 90s, I don't want to say it was a guessing game on insulin, but you were really depending on these finger sticks that you would do four to ten times a day to try to figure out, should I be taking insulin or not; or, you were relying on, basically, how your body was feeling. Like, am I starting to get a little woozy, or whatever. And unfortunately, if you wait for those symptoms to arrive, you're already having a problem. The idea would be to control the disease better so that you don't run the risk of either hypoglycemia or hyperglycemia, which are two very dangerous conditions that can occur in diabetics.
Harjes: Yep, absolutely. There have been a couple of advances that are really exciting for diabetics to get more information more continuously and be better able to react in real-time when the levels are getting a little bit out of whack, as opposed to having to wait for the symptoms to show -- which, of course, at that point, that's later than necessary. At that point, ideally, you already would have adjusted.
I think our best approach here is to go company by company that's working in the space, talking a little bit about what they've done. Let's start with the goliath of today's discussion, which is Medtronic. The ticker is MDT. They're a huge company, a $115 billion market cap. To be clear, they are not a pure-play in diabetes. They're also working in cardiovascular and pain and surgery and a bunch of other areas. But, they do have a diabetes segment.
Campbell: Right, and that diabetes segment doesn't represent a huge amount of the company's revenue, but there is some pretty exciting stuff going on at Medtronic in diabetes that's making that segment a bigger driver of the company's quarter-to-quarter performance.
Medtronic has long participated in what's called the continuous glucose monitor market, the CGM market. You mentioned there were two ways, two medical devices, that were getting more increasingly used by patients to evaluate and control their disease. One of those two is the continuous glucose monitors. They've always been a participant within that marketplace.
But, what happened in 2017 is that they won FDA approval for something called the MiniMed 670G. The 670G is the first "closed-loop" artificial pancreas system that the FDA has signed off on. Essentially, what we're talking about there is a system that will automatically evaluate your blood sugar levels by testing every five minutes, and then, as necessary, automatically administer insulin to help to keep that blood sugar in check.
Harjes: Which is really a pretty cool development. You think about going from the single point-in-time finger pricks, and then evolving the care to a CGM. Picture a sine curve, for my math nerds out there, where you can actually see that your levels are rising and falling, and watch that trend over time. That's even more complete information. Then, with this what they're calling artificial pancreas, that's a step even beyond the information of the CGM. Now, it's actually taking action on it, too, and adjusting insulin in response to that information. That is a huge step forward for convenience and timeliness of reacting to the data.
Right now, there are about 20,000 patients that are using this device, which was approved back in September 2016. And it should probably begin to gather even more use.
Campbell: Yeah. I've polled some of my friends who are diabetics -- this is a type 1 diabetes solution, primarily, because those are the people who are going to need to be managing the disease most intensely -- and they tend to prefer some of the other options we're going to talk about right now over this. But I think, over time, as the technology evolves and these systems get easier on the patient to use, etc, I think you'll see more and more patients using this.
You have 1.5 million Americans alone with type 1 diabetes. So, 20,000 patients worldwide using it, you don't have a huge amount of penetration. Nevertheless, it was still responsible for Medtronic's diabetes revenue growing by double digits year over year in Q1. Now, they didn't break out the exact sales of the MiniMed 670G. But what they did say is that diabetes segment sales in Q1 were $584 million. Which is pretty good. But, remember, Medtronic's sales in Q1 were $7.4 billion. So, if you're looking for a pure-play in diabetes, this isn't going to be it.
Harjes: Right. Another stock that's also not going to be your pure-play but is interesting to talk about in this space is Abbott. Their ticker is ABT. It's another huge company. They're over $100 billion. Again, they have a diabetes segment that's just one part of the larger company. Abbott, I believe, doesn't even break out their diabetes revenue, it just falls into the Other bucket for them. That Other bucket, for context, was a total of $430 million in revenue out of a total of $7.4 billion in the last quarter. So, again, they're only dealing with this market a little bit relative to the entire business, but they're still doing some interesting things.
They have their FreeStyle Libre, which was the first CGM that was approved that didn't require additional finger pricks for calibration of the system. When this came out, it was pretty revolutionary. We're going a little bit out of order here, because the next stock that we want to talk about is the stock that created the first CGM. But, I will leave you in suspense for which company that was, if you don't already know. When Abbott came out with its system, the stock that made the original CGM took a beating.
Campbell: Yeah. One of the big knocks against CGMs, these continuous glucose monitors, has been that they still require the finger sticks for calibrating them regularly. That's why, when the FDA approved the FreeStyle Libre from Abbott last year, it was such a big and intense and wonderful development for patients. As a result, that's turned into quite a commercial opportunity for Abbott.
Most of our listeners would probably be familiar with Abbott if they're income investors, because Abbott has a very long track record of -- as a matter of fact, it's a dividend aristocrat -- increasing its dividend every year. They don't necessarily think about Abbott for the diabetes business. But maybe that will change, because since they launched the FreeStyle Libre, in Q1 alone, their diabetes revenue grew 30% year over year. That's remarkable growth for a medical device segment of this size. Now, granted, again, like Medtronic, a very small proportion of the overall pie here at Abbott. But still an intriguing stock to keep an eye on.
Harjes: For sure. I already started to intro our next company as the first company to get a CGM approved. This one is Dexcom, their ticker is DXCM. They're a much smaller company, around a $7.5 billion market cap. About a decade ago, they were able to achieve this distinction of being the first FDA-approved maker of a continuous glucose monitor, which was pretty revolutionary. We mentioned Abbott's system, and how that was very disruptive. Where does that leave Dexcom? Are they old news now, or are they still able to compete?
Campbell: A lot of people were very concerned about what this would mean for Dexcom. Now, Dexcom is 100% exposed to the diabetes marketplace, so this would be a pure-play within the area. They were pioneers and remain, I think, pioneers in CGM technology. They have taken an agnostic approach to developing CGMs, meaning that they want their CGM to be able to be used with whatever insulin pump or insulin delivery device a patient chooses. That could be an advantage for Dexcom longer-term.
They closed the gap to the FreeStyle Libre earlier this year when the FDA approved their latest generation CGM, that's the G6. The G6 also doesn't require finger sticks for calibration. It does have one advantage in that the FDA approved it to be interoperable with other devices. That's the first time the FDA has given that kind of a nod in its language to one of these CGMs. That means that this CGM can be used, again, agnostically, with other insulin pumps made by other companies we're going to talk about in a second, or even with apps that are developed for smartphones, etc.
Harjes: Right. I'll add one other distinction that Dexcom has going for it. In a head-to-head study of the G5, which was its previous system, vs. the FreeStyle, which was Abbott's system, it showed that the G5 actually outperformed in terms of time required to detect hypoglycemia. That study just came out earlier this year and should be a little bit of a tailwind for them in trying to compete with Abbott. But, I also truly don't think that the winner that comes out on top is necessarily going to be the only winner. This is an enormous market, as we led off with at the very beginning of the episode, so I can see room for multiple winners.
Campbell: That's an awesome point. On the FreeStyle Libre, Abbott is saying that they're adding, I think, 50,000 patients a month. This is a huge market. And two-thirds of those patients, I think, are type 1, and one-third is type 2. We're barely scratching the surface in type 2 diabetes for CGMs.
I think, as these machines get more savvy, smaller, more efficient, more easily used, and potentially cheaper, payers are going to begin to reimburse them more widely. Just to put it in context, too, with the FreeStyle Libre being on the market, Dexcom still delivered year over year growth in the first quarter of 30%. That was $184 million in revenue. This year, they're guiding for sales of $850-860 million. So, despite the threat from Abbott, it's not like this company is seeing a deceleration in its sales.
Harjes: Those are your CGM makers. Let's move on and talk a little bit about the insulin pump makers themselves. One of them that we want to highlight is called Insulet, ticker PODD. They're a $5 billion market cap company, and they make something that's called the Omnipod Insulin Management System.
Campbell: These are really cool devices. They look a little bit like the old AirPort that was made by Apple , they're kind of a saucer-like device. They're relatively small, though, and you can stick them on your skin to deliver insulin directly into your body. You can wear them for up to three days. It's a very freeing device. I happen to know someone, a neighbor who's a young 15-year-old, very active, and he wears one and absolutely loves it. It's paired up, typically, with a CGM. Oftentimes, it's being paired up with CGMs that are made by Dexcom. Its sales last year, in 2017, grew 26% to $460 million. And, thanks to some new Medicare reimbursement coverage, sales should grow to between $565-580 million this year. That's up 22-25%.
So, again, a pure-play insulin pump maker that also, intriguingly, wants to challenge Medtronic. They're developing their own closed-loop system. We talked a little bit about Medtronic and their 670G, which is their artificial pancreas system. Well, Insulet is developing its own. That system will be pairing up its pods with Dexcom's CGM. And according to management, they plan on incorporating, over time, the latest Dexcom that just got approved, the G6.
Harjes: There are several different intriguing partnerships and overlaps between some of these businesses. It's actually difficult to pick apart who's going to head-to-head as a competitor and who's playing nice with interoperability and working together to develop things, because all of these companies are fairly closely tied together.
You mentioned reimbursement. I do want to stress that that's actually a really important point to look into for each of these companies. When a new device is approved, that doesn't necessarily mean that it's going to be covered, particularly by Medicare and Medicaid, which cover an enormous amount of patients. So, you'll see in some of the earnings reports and press releases for these companies that they will highlight, "Our newest device just got approved for coverage by Medicare Part D prescription drug benefit program." That's always really good news to see. So, another key development to look out for with all of these companies.
Campbell: Right, because otherwise you're paying for this stuff out of pocket and it can get pretty costly. It's been one of the things that's held back the penetration of the CGMs, especially, is showing and convincing payers that better control of your blood sugar levels over time will reduce their costs, it's a long-term money-saving thing. We've talked on the show about this in the past, Kristine, how difficult it is, because most people change their insurance within a few years. So, the company may be paying for something now that has a long-term benefit may actually not benefit from that long-term benefit, and maybe it's Medicare or someone else who actually gets the benefit from it.
Harjes: And these are largely razor-and-blade model businesses, which, from the business perspective, is really great. You have the initial sale of the device and then you have disposable consumable elements of it that produce recurring revenue. But, if you look at that from the payer side, maybe that's not quite as good, because that means that you're going to be on the hook for paying for not just the device, but also all of the consumables that go along with it.
The last company that we want to talk about today is somewhat similar to Insulet in that they are an insulin pump maker. They're called Tandem Diabetes Care, ticker TNDM. Pretty small company here. Actually, I think they're the smallest we've talked about today. They're only a $660 million market cap company. They've been extremely volatile, they have been extremely dilutive of their shareholders. But, they have some partnerships with Dexcom, and they're doing some interesting things.
Campbell: They make the touchscreen t:slim X2 insulin pump. It's the only pump, they claim, that can allow for remote feature updates from a computer. That could be advantageous to people who want to be able to buy it once and be able to get some updates on it. It is, like Dexcom and Insulate, 100% exposed to the diabetes market, so theoretically its demand and sales are going to grow right alongside diabetes growth.
It is also working, like Insulate is, on its own closed-loop artificial pancreas system that could theoretically someday challenge Medtronic. But, we're still probably at least a year away from starting to see that product come on the market, maybe two years, depending on how these trials play out. On that artificial pancreas system, it's also working with Dexcom. It's pairing up Dexcom's CGM with its pump.
You mentioned that it's the smallest of the bunch that we're talking about today, absolutely. Its revenue in the first quarter was much smaller than these other companies. It was about $27 million in the first quarter. In 2017, they only did $108 million in sales. First quarter sales, though, were up 44%. That's good. We'll have to see whether or not they continue to win market share away from these other pump makers.
I think one of the things, though, that we have to remember, Kristine, to tell all of our investors is that these pure-plays that we're talking about? They're all losing money.
Harjes: That's true. It makes them kind of hard to value on traditional metrics. And even when you use stuff like price-to-sales, they actually still look very expensive. I think that's a question worth exploring a little bit. Most of these companies do look like they're extremely expensive. Are there any bargains to be found in this space?
Campbell: Well, bargains are always relative. Right, Kristine? We talk about this when we talk about investing all the time. I think, yeah, it's great if you can buy a stock on sale. But what's more important over a ten or 20 or 30-year long-term time horizon is, how big is the market opportunity, and is there a competitive advantage that could allow one of these companies to win vs. another company.
So, yes, the price-to-sales ratios are elevated on these stocks. You're running anywhere between 5-10X for the pure-plays. But you can justify that if you say to yourself, "Yeah, but, we're only scratching the surface on the tens of millions of patients, theoretically, that could begin to use CGMs and pumps over the course of the next ten to 20 years."
My advice to investors would be, yeah, recognize that if you're a value investor, you're not going to be buying these three pure-plays. You might want to look at Medtronic and Abbott instead. But, if you're a growth investor, stay focused on the big picture, which is that the patient population, the addressable market, is going to climb significantly over the course of the next decade.
Harjes: And if, by chance, you're looking at Tandem specifically because it's so small, and saying, "Why shouldn't they be just as large as Insulet? Let me buy them now," I do want to make sure that I mention, this is a company that, as you mentioned, Todd, is losing money. But, that alone is not a terribly bad thing. That's OK for the place that they are right now in their business cycle.
But, they have a large amount of debt. They have $72 million in cash. Most of that came from an equity offering in February. They have been extremely dilutive. Shares outstanding have risen 900% over the last one year, 400% since just January. This is a company that is fairly early stage relative to a company like Insulet, so they need financing, and they need to take these sorts of actions in order to keep their business running.
So, when you're comparing your stocks, I wouldn't necessarily say, "Hey, these two have the same addressable market, but Tandem is so much cheaper on a market cap basis, let me immediately go for that." I mean, I think it's an interesting company, but it's a lot riskier than the more developed, more mature Insulet, which is, by its own accord, also not going to be as mature and as developed as something like Medtronic.
Campbell: Yeah. Maybe, of the three pure-plays, Dexcom is the more mature. I don't want to say it's less risky, because it's a plenty risky stock, Kristine. [laughs] Just look at its stock price chart over the course of the last three years, right? But, the fact that it's agnostic and it has exposure to both Tandem and to Insulet, maybe that makes it a little bit less risky, because it doesn't matter which one of Insulet or Tandem gets to market first with a competitor to Medtronic's closed-loop system.
Harjes: Yep, I agree. Thank you so much, Todd! That'll do it for today's show. I hope everyone enjoyed the break from our normal drug maker coverage. As always, people on the program may have interests in the stocks that they talk about, and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. This show is produced by Austin Morgan. For Todd Campbell, I'm Kristine Harjes. Thanks for listening and Fool on!
Kristine Harjes owns shares of Apple. Todd Campbell owns shares of Apple. The Motley Fool owns shares of and recommends Apple. The Motley Fool owns shares of Medtronic and has the following options: long January 2020 $150 calls on Apple and short January 2020 $155 calls on Apple. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | From medtech Goliaths Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) to small pure plays Dexcom (NASDAQ: DXCM) , Insulet Corp. (NASDAQ: PODD) , and Tandem Diabetes Care (NASDAQ: TNDM) , we've got you covered. Their ticker is ABT. Campbell: We oftentimes talk about, Kristine, the different drugs that are being brought to market by biopharma to try and help our bodies deal with these elevated levels of blood sugar. | From medtech Goliaths Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) to small pure plays Dexcom (NASDAQ: DXCM) , Insulet Corp. (NASDAQ: PODD) , and Tandem Diabetes Care (NASDAQ: TNDM) , we've got you covered. Their ticker is ABT. On this episode of The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes and Motley Fool contributor Todd Campbell explain how artificial pancreases, continuous glucose monitors, and insulin pumps are reshaping diabetes treatment and what could be at stake for investors. | From medtech Goliaths Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) to small pure plays Dexcom (NASDAQ: DXCM) , Insulet Corp. (NASDAQ: PODD) , and Tandem Diabetes Care (NASDAQ: TNDM) , we've got you covered. Their ticker is ABT. On this episode of The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes and Motley Fool contributor Todd Campbell explain how artificial pancreases, continuous glucose monitors, and insulin pumps are reshaping diabetes treatment and what could be at stake for investors. | From medtech Goliaths Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) to small pure plays Dexcom (NASDAQ: DXCM) , Insulet Corp. (NASDAQ: PODD) , and Tandem Diabetes Care (NASDAQ: TNDM) , we've got you covered. Their ticker is ABT. They don't necessarily think about Abbott for the diabetes business. |
33263.0 | 2018-05-25 00:00:00 UTC | A Focus on Eye Care Is Setting Up Johnson & Johnson Stock for the Future | ABT | https://www.nasdaq.com/articles/focus-eye-care-setting-johnson-johnson-stock-future-2018-05-25 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When you're one of the largest firms on the planet, it takes some serious growth to get the needle moving. Small jumps aren't going to do it. And that's just the problem facing healthcare giant Johnson & Johnson ( NYSE: JNJ ).
Thanks to its massive size, JNJ has only been experiencing about 2% growth to its EPS per quarter over the last few years. While steady growth is appreciated by some investors, that's not that great overall and doesn't necessarily support its constant valuation premium.
To that end, Johnson & Johnson needs to find some serious growth to keep investors coming back to its shares. And it may have just done so in its last earnings report.
Vision care is quickly becoming a major growth engine for JNJ. All in all, Johnson & Johnson's newfound eye-care focus could be the healthcare stock's saving grace and a major growth engine.
A Big Jump for Johnson & Johnson
By all measures, Johnson & Johnson had a pretty good quarter . The healthcare giant's overall portfolio did well, with new drugs, medical devices and even consumer products showing steady increases in sales/profits. But some segments of JNJ's portfolio did much better - try 34% better.
The 3 Best Stocks to Invest in Right Now
That would be Johnson and Johnson's vision-care segment. For the quarter, eye-care products at JNJ brought in $1.12 billion last quarter. Last year at the same time, vision only made around $798 million. While that's still small when compared to its overall portfolio and sales of new blockbuster drugs, the growth at vision is still staggering. By far, it was the biggest grower in its portfolio.
Moreover, vision care represents one of the largest untapped and ignored segments of the healthcare industry.
By Johnson & Johnson's own data, roughly 285 million people around the world face impaired vision. Treating these people and causes of poor vision is a lucrative endeavor. The global ocular drug market is expected to grow by a CAGR of 8.4% to reach $48 billion by 2025.
And this doesn't take into account the medical device market for contacts or eyeglasses. According to JNJ, less than 10% of the global population who could wear contacts do, with key emerging markets like China having penetration at just 7%. So, there is a lot of potential and growth ahead.
More Eye Care for JNJ Coming
To that end, Johnson & Johnson has made some great moves into the eye-health sector.
Back in 2016 , it made a big $4.33-billion purchase of the Abbott Laboratories (NYSE: ABT ) Medical Optics unit. That gave it access to the eye surgery space for cataracts and laser refractive procedures, as well as consumer eye products.
It then followed up that big buy with dry-eye device maker TearScience and contact subscription startup Sightbox . Just last month, JNJ paid $15 million to be a part of NeuroVision Imaging 's latest round of fundraising. The firm makes a 3D eye-imaging system.
Given the growth JNJ has experienced so far, this was the right decision. Continuing to tap the estimated $80 billion total market makes a ton of sense and will provide a much-needed shot in the arm for Johnson & Johnson's decent - albeit slow - EPS growth. So, there's good reason to believe that JNJ will continue to pursue eye-care initiatives and buyouts.
Even more so when you consider that the eye-care segment continues to be a fragmented industry. Most drugmakers and device makers, such as Nightstar Therapeutics PLC (NASDAQ: NITE ) or Clearside Biomedical Inc (NASDAQ: CLSD ), are very small.
JNJ's size gives it a huge advantage and allows it to exploit potential synergies. When you're already the leading producer of contacts, it makes it very easy to offer therapies/drugs for those lenses. Likewise, adding additional surgical equipment to your umbrella makes an easy bolt-on that has instant results to sales/earnings.
And given the growth potential and already-realized earnings jumps its seen, eye care becomes very exciting for Johnson & Johnson.
Seeing the Clear Vision at Johnson & Johnson
Eye care remains one of the brightest spots in the healthcare firm's overall product portfolio. There's plenty of growth to be had, and JNJ's current standing makes it very easy to keep that growth going. Bolt-ons, M&A and drug development in the space should help overcome the firm's slow pace of earnings growth.
Johnson & Johnson Stock Looks Attractive on the Big Dip
For investors, buying Johnson & Johnson stock today makes a ton of sense. All in all, eye care should help keep its valuation growing and make the drugmaker even better.
20 Gambling Stocks to Play the Booming Economy
Buy the Post-Earnings Lull from Johnson & Johnson
3 Big Pharma Stocks with Huge Future Growth Potential
Disclosure: None.
Compare Brokers
The post A Focus on Eye Care Is Setting Up Johnson & Johnson Stock for the Future appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Back in 2016 , it made a big $4.33-billion purchase of the Abbott Laboratories (NYSE: ABT ) Medical Optics unit. While steady growth is appreciated by some investors, that's not that great overall and doesn't necessarily support its constant valuation premium. The healthcare giant's overall portfolio did well, with new drugs, medical devices and even consumer products showing steady increases in sales/profits. | Back in 2016 , it made a big $4.33-billion purchase of the Abbott Laboratories (NYSE: ABT ) Medical Optics unit. And that's just the problem facing healthcare giant Johnson & Johnson ( NYSE: JNJ ). More Eye Care for JNJ Coming To that end, Johnson & Johnson has made some great moves into the eye-health sector. | Back in 2016 , it made a big $4.33-billion purchase of the Abbott Laboratories (NYSE: ABT ) Medical Optics unit. A Big Jump for Johnson & Johnson By all measures, Johnson & Johnson had a pretty good quarter . And given the growth potential and already-realized earnings jumps its seen, eye care becomes very exciting for Johnson & Johnson. | Back in 2016 , it made a big $4.33-billion purchase of the Abbott Laboratories (NYSE: ABT ) Medical Optics unit. A Big Jump for Johnson & Johnson By all measures, Johnson & Johnson had a pretty good quarter . And given the growth potential and already-realized earnings jumps its seen, eye care becomes very exciting for Johnson & Johnson. |
33264.0 | 2018-05-25 00:00:00 UTC | S&P 500 Analyst Moves: ABT | ABT | https://www.nasdaq.com/articles/sp-500-analyst-moves-abt-2018-05-25 | nan | nan | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #38 analyst pick, moving up by 1 spot.
This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values.
Looking at the stock price movement year to date, Abbott Laboratories is showing a gain of 9.1%.
VIDEO: S&P 500 Analyst Moves: ABT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #38 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. | VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #38 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. | VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #38 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. |
33265.0 | 2018-05-25 00:00:00 UTC | Abbott Presents Positive Study Results for Tendyne Device | ABT | https://www.nasdaq.com/articles/abbott-presents-positive-study-results-for-tendyne-device-2018-05-25 | nan | nan | AbbottABT has been in the spotlight of late on favorable developments in its Medical Device business including its core Structural Heart division. The company recently announced encouraging results from a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system. Data was presented at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in Paris.
Although this global study of Tendyne device expects to register up to 350 adult patients, the early results were based on successful implantation of Tendyne device in 97 of the first 100 patients. The patients enrolled under the study suffered from symptomatic mitral regurgitation (MR) and were not eligible for open heart surgery to repair or replace the mitral valve.
Notably, the results at the end of 30 days demonstrated that patients treated with Tendyne witnessed a major reduction of mitral regurgitation symptoms and low mortality rates. Further, the improvement in symptoms was assessed based on New York Heart Association (NYHA) grade severity and the Kansas City Cardiomyopathy Questionnaire (KCCQ).
Tendyne Device in Details
Repositionable, completely retrievable and minimally invasive replacement option - Tendyne Device - is used to treat functional, degenerative and mixed causes of MR that cannot be treated through minimally invasive valve repair or open-heart surgery.
Notably, the Tendyne device is currently under clinical investigation for approval in Europe. Further, the company plans to enroll the first patient under the U.S. pivotal trial for the same in the near term.
A Glimpse of the Structural Heart Business
Abbott's Structural Heart business maintained an impressive top-line performance. In the last reported quarter, the segment's sales rose 14.5% on a reported basis.
Notably, the Structural Heart business accounted for 10.7% of total revenues in the broader Medical Device segment. The upside was led by continued double-digit growth of MitraClip - the company's market-leading device for the repair of MR. In March, the company announced the receipt of national reimbursement in Japan for the same. Notably, in nearly 50 countries, more than 50,000 people have been treated with MitraClip. Ministry of Health Labour and Welfare (MHLW) approved the MitraClip System in Japan last November.
Further, the company announced the receipt of FDA approval for the world's smallest rotatable, bileaflet mechanical heart valve - Masters HP 15mm. With the approval, the company has expanded the Masters Series portfolio under the Structural Heart business.
Market Prospects
Abbott's strategy to gain traction in the Structural Heart segment seems to be aligned with data provided by Allied Market Research and data provided by the company . Per the report, the Tanscatheter Mitral Valve Repair & Replacement market is estimated to reach a worth of $1,878 million (both repair and replacement valves) by 2023, at a CAGR of 30% from 2017 to 2023. Per the company, almost one in 10 people over the age of 75 suffer moderate to severe MR.
Share Price Performance
Abbott has been gaining investor confidence on consistently positive results. Over the past six months, the stock has outperformed the industry . The stock has gained 11.3%, in comparison with the industry's 6.7% gain.
Zacks Rank & Stocks to Consider
Abbott currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Intuitive Surgical ISRG , Illumina, Inc ILMN and Amedisys, Inc. AMED . While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Amedisys carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Intuitive Surgical has an expected long-term earnings growth rate of 12.1%.
Illumina has an expected long-term earnings growth rate of 20%.
Amedisys has an expected long-term earnings growth rate of 17.5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT has been in the spotlight of late on favorable developments in its Medical Device business including its core Structural Heart division. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the results at the end of 30 days demonstrated that patients treated with Tendyne witnessed a major reduction of mitral regurgitation symptoms and low mortality rates. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT has been in the spotlight of late on favorable developments in its Medical Device business including its core Structural Heart division. A Glimpse of the Structural Heart Business Abbott's Structural Heart business maintained an impressive top-line performance. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT has been in the spotlight of late on favorable developments in its Medical Device business including its core Structural Heart division. Although this global study of Tendyne device expects to register up to 350 adult patients, the early results were based on successful implantation of Tendyne device in 97 of the first 100 patients. | AbbottABT has been in the spotlight of late on favorable developments in its Medical Device business including its core Structural Heart division. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently announced encouraging results from a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system. |
33266.0 | 2018-05-25 00:00:00 UTC | How to Invest in Diabetes Stocks | ABT | https://www.nasdaq.com/articles/how-invest-diabetes-stocks-2018-05-25 | nan | nan | Where there's a problem, there's an opportunity.
Diabetes certainly presents a huge problem. It's the seventh-highest cause of death in the United States. It's also one of the fastest-growing diseases: At 29 million, the number of people in the U.S. with diabetes is nearly triple the number 20 years ago. And the problem isn't limited to the U.S.; diabetes is also the fastest-growing chronic disease in the world.
Many publicly traded companies, both large and small, are developing new drugs and medical devices for diabetes care. The opportunities for investors lie in buying the stocks of the companies most likely to succeed in the growing diabetes market. Here's what you need to know about how to invest in diabetes stocks.
What is diabetes?
Before investing in diabetes stocks, it's important to understand exactly what diabetes is: a common disease that occurs when individuals' blood glucose ("blood sugar") levels become too high.
Glucose enters the bloodstream from food. Normally, insulin, a hormone produced by the pancreas, helps make sure the glucose moves from the blood to cells, to provide energy for those cells. But when the body doesn't make enough insulin -- or doesn't use it properly -- glucose stays in the blood rather than reaching the cells. If not managed, diabetes can lead to several serious health problems; these include eye problems, dental disease, foot problems, heart disease, kidney disease, nerve damage, and stroke.
The A1C test is the most frequently used method of testing for diabetes. It's a blood test that measures the amount of hemoglobin -- a protein in blood that carries oxygen -- with attached glucose. The measurement reflects the patient's average blood glucose levels over the previous three months. A1C levels are reported as a percentage, with a higher percentage representing higher blood glucose levels. Individuals with diabetes have A1C levels of 6.5% or higher.
How big is the diabetic population?
More than 30 million Americans have diabetes, according to the Centers for Disease Control and Prevention (CDC). Another 84 million have prediabetes -- where blood glucose levels are high (between 5.7% and 6.4%) but not high enough to be considered diabetes. Prediabetes is a risk factor for diabetes, and the higher the patient's A1C level is, the greater the risk.
Types of diabetes
There are three common types of diabetes, along with other less common types of the disease.
Type 1 diabetes
With type 1 diabetes, the body doesn't make insulin at all. Most frequently this is because the immune system attacks cells in the pancreas that produce insulin. Patients with this type of diabetes must take insulin every day to live. Around 1.25 million Americans have type 1 diabetes, with the disease typically diagnosed in children and young adults.
Type 2 diabetes
The most common form of diabetes is type 2 diabetes. With this type, the body either doesn't produce enough insulin, or doesn't use it very well. Type 2 diabetes can be caused by several factors, including lack of physical activity, being overweight, insulin resistance, and genetics. Around 28 million Americans have this form of the disease.
Gestational diabetes
Gestational diabetes occurs in 2% to 10% of pregnant women in the U.S. Changes during pregnancy, such as increased production of hormones and weight gain, cause the body to use insulin less effectively; as a result, the body can't make enough insulin. Around 50% of women with gestational diabetes go on to develop type 2 diabetes.
Other types of diabetes
Two other less common types of the disease are monogenic diabetes and cystic-fibrosis-related diabetes. "Monogenic" diabetes results from changes in a single gene (the more common forms are "polygenic"); this type accounts for 1% to 4% of all cases of diabetes.
Cystic-fibrosis-related diabetes (CFRD) occurs when the thick, sticky mucus associated with cystic fibrosis (a genetic disease) causes scarring of the pancreas. This scarring results in the pancreas being unable to make enough insulin. More than 30,000 Americans have cystic fibrosis, with 20% of adolescents with the disease also suffering from CFRD and between 40% and 50% of the adults having CFRD.
How is diabetes treated?
Some cases of Type 2 diabetes can be managed through diet and exercise. However, type 1 diabetes and many cases of type 2 diabetes require more involved treatment. There are several components that can be part of managing and treating diabetes.
Glucose monitoring
Monitoring glucose levels is critical for both type 1 and type 2 diabetic patients.
Individuals with type 1 diabetes typically must check their glucose levels four to 10 times per day, including prior to eating, before and after exercise, and before going to sleep. Some type 1 patients must also check their glucose levels during the night. Also, some people with type 1 diabetes use continuous glucose monitors (CGMs), devices with sensors beneath the skin that check blood glucose levels every few minutes.
Type 2 diabetic patients usually must monitor their glucose levels at least twice each day -- before breakfast and dinner. Some individuals with type 2 diabetes must check their glucose levels before each meal and at bedtime.
Insulin
All type 1 diabetic patients and many type 2 diabetic patients must take insulin. There are four key types of insulin:
Data source: American Diabetes Association.
Insulin can be administered using a variety of devices:
Needle and syringe
Insulin pen (an easy-to-use penlike device for self-injection)
Insulin pump (a small device that delivers regular small doses, and higher doses when needed)
Inhaler
Injection port (a short tube inserted beneath the skin)
Jet injector (a high-pressure insulin spray)
Other medications
Some type 2 diabetic patients also are prescribed non-insulin medications. Common types of diabetes medications include:
Data source: American Diabetes Association.
Factors driving the diabetes market
By 2030, diabetes is projected to affect nearly 55 million Americans and 552 million people worldwide. In the U.S., total annual medical and societal costs related to diabetes are projected to increase by 53% to more than $622 billion. And the global total direct and indirect cost of diabetes is estimated to almost double by 2030 to $2.5 trillion.
Several factors are driving growth in the diabetic patient population and increased spending on diabetes.
1. Aging populations
One key trend that will likely increase the number of cases of diabetes is the growth in senior populations across the world. As people age, they're less likely to get enough exercise, which can result in added weight -- both of which are key factors that can contribute to type 2 diabetes.
2. Lower levels of physical activity in youth
Not just the older part of the population is a cause for concern. Children and adolescents are also getting less physical activity, which has already led to a higher prevalence of type 2 diabetes in youth. Only one in three U.S. children is physically active every day, according to the U.S. Department of Health and Human Services. Children spend more than seven and a half hours a day, on average, in front of a computer, smartphone, TV, or video game screen.
3. Developing nations adopting Western lifestyles
Another driver of greater diabetes prevalence comes from developing countries. As the middle classes expand in these nations, their citizens are more likely to adopt lifestyles associated with the Western world, including unhealthy diets and less exercise.
4. New drugs and devices for managing diabetes
Obviously, the increased numbers of patients diagnosed with diabetes will play a key role in higher costs. Ironically, better treatments for diabetes are also anticipated to contribute by prolonging the lives of patients with diabetes, which increases the costs over the long run of managing their related health problems. In addition, new drugs and devices for managing diabetes are more expensive than older products, driving costs up even more.
Diabetes stocks
Diabetes stocks fall into three broad categories: Drugmakers, medical-device makers, and companies that market medical supplies for diabetes. Below is a list of diabetes stocks with market caps of at least $200 million.
Data source: Yahoo! Finance. P/E = price-to-earnings ratio; N/A = not applicable. Data as of May 25, 2018.
Factors to consider in evaluating diabetes stocks
What should you look for in a diabetes stock? Well, for starters, you'll want to evaluate the company just as you'd research any potential investment . Key factors to consider include:
1. Diabetes products' contribution to total revenue
How significant is the diabetes market to the company? A company that makes most of its revenue in other ways won't benefit as much from the growth in the diabetes market.
Pfizer, for example, co-markets new diabetes drugs Steglatro, Steglujan, and Segluromet with Merck. But those are the only diabetes drugs in Pfizer's lineup; although they're expected to become a blockbuster franchise for the two companies, diabetes will still represent only a small portion of Pfizer's overall revenue.
If you are looking to put money behind the diabetes market specifically, investing in a stock like Pfizer might not be your best bet. Buying a pure-play stock like Senseonics gives you greater exposure to the diabetes market, but it's also riskier than a diversified company like Pfizer. If this market doesn't grow as quickly as projected, it would have a much greater negative impact on Senseonics than it would Pfizer.
2. Competitive advantages and risks
Although the diabetes market is huge, it's still very competitive. Companies that enjoy competitive advantages stand a better chance of long-term success.
However, even successful products face the risk of losing market share to a rival. When brand-name drugs lose patent exclusivity, other companies can launch cheaper generic versions of the drug. With a biologic drug -- one made from a living organism or its products -- rivals can launch knockoff biosimilars after it loses patent exclusivity.
Of course, a drug doesn't have to have its patents expire to lose market share. New drugs can come on the scene that are more effective, safer, and/or less costly.
3. Development risks
The drug development process is risky. This process begins with preclinical testing in animals. If that testing goes well, approval must be obtained from regulators to advance to testing in humans.
There are usually three phases of clinical testing of a new drug in humans. Phase 1 typically involves only a few patients and focuses on assessing the safety of the drug. Phase 2 includes more patients and evaluates the efficacy of the drug in addition to safety. Phase 3 clinical studies are usually much larger and take more time -- often between one and four years. These phase 3 studies focus on efficacy and potential adverse reactions. If drugs are shown to be successful in clinical testing, drugmakers submit for regulatory approval by the U.S. Food and Drug Administration (FDA) and similar agencies in other countries.
Each step in this process holds the potential for failure. For every 10 drug candidates that start in phase 1 clinical studies, on average only one will make it all the way to approval.
The process for winning approval for new medical devices targeting diabetes care also requires several hurdles to be jumped. Companies must first test prototypes of the new medical devices in controlled settings that don't involve humans. The pathway to approval then depends on the risk that the device presents. Devices that hold significant risks for patients must go through clinical trials and FDA review similar to that for new drugs. There's no guarantee that a new medical device will be cleared for marketing by the FDA.
So what should investors do about these development risks? Choosing stocks with pipeline candidates in late-stage development is less risky than picking stocks with early-stage drugs. Also, companies with more pipeline candidates have more "shots on goal," which improves the overall chances of success.
4. Reimbursement risks
Once a drug or medical device wins regulatory approval, there's another challenge: securing reimbursement. In the U.S., pharmaceutical and medical-device companies must negotiate with health insurers to get their products covered for reimbursement. Drugmakers also have to negotiate with pharmacy benefits managers (PBMs) -- third-party administrators of programs that attempt to control prescription drug costs for their customers. In Europe, where universal healthcare plans are paid for by national governments, companies must negotiate pricing on a country-by-country basis.
It's possible that a new product can get a green light from regulatory agencies but not win favor with payers. Even if a product does secure reimbursement coverage, there's no guarantee that the desired price will be negotiated. Payers can also put additional obstacles in the way, such as mandating that patients obtain prior authorization before using a new product. All of this is to say that just because a new product is approved, that doesn't mean you can count on it succeeding commercially.
Top diabetes stocks to consider
So in light of these key factors and risks, what are the best diabetes stocks to consider? I think three especially stand out.
Abbott Labs
Although Abbott Labs doesn't currently detail how much of its revenue is generated from diabetes-care products, diabetes is becoming an increasingly important growth driver for the company. This new dynamic is primarily the result of FDA approval in September 2017 for Abbott's new flash glucose monitoring system FreeStyle Libre .
It's important for many diabetic patients to continuously monitor their blood glucose levels. The drawback to most continuous glucose monitoring (CGM) systems is that they require patients to calibrate the systems by sticking their fingers several times per day to test blood glucose levels.
FreeStyle Libre eliminates the need for those pesky finger sticks, and has a much lower cost than most CGM systems. As you might imagine, those are significant competitive advantages for Abbott. Dexcom recently launched its G6 CGM system that doesn't require finger sticks, but it's more expensive than the FreeStyle Libre.
Abbott Labs is highly unlikely to need to raise any cash by issuing more stock: The company reported more than $4 billion in cash, cash equivalents, and marketable securities at the end of the first quarter. Abbott also has one of the most stable dividends around, with the company paying a dividend every quarter since 1924 and increasing its dividend payout for 46 consecutive years -- making it a longtime member of the elite Dividend Aristocrats .
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is considerably more risky than Abbott Labs. The company only has one FDA-approved product right now -- Xermelo, for carcinoid syndrome diarrhea; the drug launched in the first quarter of 2017. Lexicon awaits regulatory approval for its first diabetes drug, sotagliflozin.
So why consider buying Lexicon stock? Wall Street analysts think it could be one of the fastest-growing diabetes stocks on the market this year. That's for good reason: If approved, sotagliflozin will be the first combination SGLT1/SGLT2 inhibitor.
SGLT2 (SGLT stands for "sodium-glucose linked transporter," and the numbers denote the type of cotransporter) is responsible for most of the glucose reabsorption performed by the kidneys. SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and, to a lesser extent than SGLT2, glucose reabsorption in the kidneys. Sotagliflozin could be a huge winner because it's potentially more effective than SGLT2 inhibitors such as Invokana and Jardiance. As an added bonus, it treats both type 1 and type 2 diabetes.
Novo Nordisk
Novo Nordisk ranks as one of the leaders in the diabetes drug market. The Danish drugmaker's insulin products Levemir, Tresiba, NovoMix, and NovoRapid are huge moneymakers. But the main reason I like Novo Nordisk is the company's newer products.
The FDA granted approval to type 2 diabetes drug Ozempic in December. Market research firm EvaluatePharma thinks that Ozempic will be the second-biggest new drug launched in 2018 , with more than $2.7 billion in annual sales by 2022. I also like the prospects for Novo's obesity drug Saxenda, which I see as a great fit with the company's diabetes lineup.
Don't forget Novo Nordisk's dividend, either. Over the last 10 years, investors received an additional 78% in total returns thanks to the drugmaker's dividend. And with a payout ratio of less than 50%, Novo has plenty of flexibility for dividend hikes in the future.
Unmet opportunities
There are also two unmet opportunities in diabetes that investors should be aware of.
One is in new products that help prevent the disease. Type 2 diabetes is largely preventable through diet and exercise. New superfoods created by gene editing could be game-changers down the road, helping people avoid gaining extra weight that could make them more likely to develop diabetes.
Another is in more convenient ways to monitor glucose levels. Abbott's FreeStyle Libre is a fantastic innovation on this front, but more advances could be on the way. For example, Alphabet 's Verily Life Sciences unit is working with Novartis to develop a smart contact lens that senses glucose levels in tears. These contact lenses would change color if diabetic patients' glucose levels aren't where they need to be.
Such developments are likely years down the road, at best. But diabetes is such a huge problem that making these technologies become reality should be worth the effort.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 8, 2018
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Keith Speights owns shares of Alphabet (A shares) and Pfizer. The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool owns shares of Johnson & Johnson and Medtronic. The Motley Fool recommends Becton Dickinson, Insulet, and Novo Nordisk. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Drugmakers also have to negotiate with pharmacy benefits managers (PBMs) -- third-party administrators of programs that attempt to control prescription drug costs for their customers. New superfoods created by gene editing could be game-changers down the road, helping people avoid gaining extra weight that could make them more likely to develop diabetes. For example, Alphabet 's Verily Life Sciences unit is working with Novartis to develop a smart contact lens that senses glucose levels in tears. | Also, some people with type 1 diabetes use continuous glucose monitors (CGMs), devices with sensors beneath the skin that check blood glucose levels every few minutes. Common types of diabetes medications include: Data source: American Diabetes Association. The drawback to most continuous glucose monitoring (CGM) systems is that they require patients to calibrate the systems by sticking their fingers several times per day to test blood glucose levels. | Type 2 diabetes The most common form of diabetes is type 2 diabetes. Other types of diabetes Two other less common types of the disease are monogenic diabetes and cystic-fibrosis-related diabetes. Diabetes stocks Diabetes stocks fall into three broad categories: Drugmakers, medical-device makers, and companies that market medical supplies for diabetes. | Type 1 diabetes With type 1 diabetes, the body doesn't make insulin at all. Glucose monitoring Monitoring glucose levels is critical for both type 1 and type 2 diabetic patients. Insulin All type 1 diabetic patients and many type 2 diabetic patients must take insulin. |
33267.0 | 2018-05-24 00:00:00 UTC | Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing | ABT | https://www.nasdaq.com/articles/abbott-gets-fda-nod-for-xience-sierra-to-boost-vascular-wing-2018-05-24 | nan | nan | AbbottABT , providing an impetus to the Vascular business in the United States, recently announced the receipt of FDA approval for XIENCE Sierra. Notably, XIENCE Sierra is the latest in the family of XIENCE everolimus-eluting coronary stent system.
XIENCE Sierra in Details
XIENCE Sierra is equipped with a thinner profile, enhanced flexibility, longer length and small diameter. Further, this advanced stent and delivery system effectively aids in treating complex cases, involving multiple or totally-blocked vessels, by providing increased flexibility and precision to the doctors.
Per management, about 70% of the reported cases involve patients suffering from complex blockages. We believe, this FDA approval will aid in driving top-line contributions from Abbott's Vascular business.
Vascular Business at a Glance
Recently, Abbott's Vascular business has continued to deliver stable top-line performance. In the last reported quarter, this segment's sales improved 5.2% on a reported basis.
Notably, the Vascular business accounted for 27% of total revenues in the broader Medical Device segment. We encouragingly note, under Vascular business, Abbott has been on a slew of developments in regards with its XIENCE Sierra coronary stent system. The company was awarded national reimbursement for XIENCE Sierra from Japan's Ministry of Health Labour and Welfare in May, following the receipt of regulatory approval in April.
Abbott has also been getting positive responses for the XIENCE Sierra coronary stent system post its launch in Europe in late last year.
Market Potential
Per Grand View Research, we can safely conclude that this development will help Abbott cash in on the opportunities in the coronary stents market. According to the report, the global coronary stents market is expected to witness a CAGR of roughly 6.2% between 2013 and 2024.
Share Price Movement
Over the past six months, Abbott has been outperforming its industry . The stock has gained 10.1% compared with the industry's increase of 6%.
Zacks Rank & Stocks to Consider
Abbott currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Intuitive Surgical ISRG , Illumina, Inc ILMN and Amedisys, Inc. AMED . While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Amedisys carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Intuitive Surgical has an expected long-term earnings growth rate of 12.1%.
Illumina has an expected long-term earnings growth rate of 20%.
Amedisys has an expected long-term earnings growth rate of 17.5%.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT , providing an impetus to the Vascular business in the United States, recently announced the receipt of FDA approval for XIENCE Sierra. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Further, this advanced stent and delivery system effectively aids in treating complex cases, involving multiple or totally-blocked vessels, by providing increased flexibility and precision to the doctors. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT , providing an impetus to the Vascular business in the United States, recently announced the receipt of FDA approval for XIENCE Sierra. A few better-ranked stocks in the broader medical sector are Intuitive Surgical ISRG , Illumina, Inc ILMN and Amedisys, Inc. AMED . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT , providing an impetus to the Vascular business in the United States, recently announced the receipt of FDA approval for XIENCE Sierra. We encouragingly note, under Vascular business, Abbott has been on a slew of developments in regards with its XIENCE Sierra coronary stent system. | AbbottABT , providing an impetus to the Vascular business in the United States, recently announced the receipt of FDA approval for XIENCE Sierra. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. We encouragingly note, under Vascular business, Abbott has been on a slew of developments in regards with its XIENCE Sierra coronary stent system. |
33268.0 | 2018-05-22 00:00:00 UTC | Cardiovascular Systems Rides on New Products Amid Tight Race | ABT | https://www.nasdaq.com/articles/cardiovascular-systems-rides-on-new-products-amid-tight-race-2018-05-22 | nan | nan | On May 21, we issued an updated research report on Cardiovascular Systems, Inc.CSII . Notably, a number of factors continue to drive optimism for the stock. For instance, the company's firm position in the coronary arterial disease (CAD) and peripheral arterial disease (PAD) market spaces, positive study results highlighting its effective technologies, an impressive portfolio expansion as well as a strong gross margin scenario. The player carries a Zacks Rank #3 (Hold).
This medical device manufacturer, developer and marketer of innovative solutions, which treat patients with peripheral and coronary arterial diseases including those with arterial calcium, saw a solid third quarter of fiscal 2018. The company witnessed a year-over-year rise in revenues at both CAD and PAD businesses. Also, the gross margin expansion was impressive.
Over the past three months, shares of Cardiovascular Systems have outperformed its industry . The stock has surged 32.2% compared with the 5.1% increase of the industry.
The company is putting efforts to innovate products through R&D investments. The market is also looking forward to its recently-launched coronary device in Japan, reflecting the company's focus on widening international footprint.
Cardiovascular Systems, Inc. Price
Cardiovascular Systems, Inc. Price | Cardiovascular Systems, Inc. Quote
Cardiovascular Systems has been broadening its product portfolio to enhance the market reach. It is currently pursuing product improvement and evaluating new technologies to strengthen and develop its portfolio of powerful micro invasive tools.
We are also upbeat about Cardiovascular Systems' new partnership, which has helped extending its portfolio. The company is now the U.S. distributor of OrbusNeich balloon products. OrbusNeich PCI balloons include the Sapphire II Pro, which has recently received an FDA approval for the 1.0 mm coronary balloon. Moreover, the company has signed an original equipment manufacturer agreement with Integer Holdings Corporation for CSI-branded ZILIENT guidewires.
Additionally, we are optimistic about the favorable trends in the PAD and CAD spaces. Per American Heart Association, as many as 8-12 million Americans suffer the PAD syndrome. Moreover, an aging population coupled with rising incidence of diabetes and obesity is likely to aggravate the frequency of PAD complaints. Thus, the company's growth in these areas offers a huge scope for the unique PAD Orbital Atherectomy System (OAS) of Cardiovascular Systems to address the hitherto unmet needs in the market.
On the flip side, the company faces cutthroat competition in the niche space. Its OAS products contend with a variety of other products or devices for the treatment of vascular disease including stents, balloon angioplasty catheters and atherectomy catheters as well as products used in vascular surgery. Larger players contesting in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . Moreover, on the profitability front, Cardiovascular Systems struggles with a long history of net loss since its inception in 1989 with no immediate recovery in sight.
Key Picks
Some better-ranked stocks in the broader medical sector are Intuitive Surgical ISRG and Amedisys, Inc. AMED . While Intuitive Surgical sports a Zacks Rank #1 (Strong Buy), Amedisys carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Intuitive Surgical has a long-term expected earnings growth rate of 12.1%.
Amedisys has a long-term expected earnings growth rate of 17.5%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Larger players contesting in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. It is currently pursuing product improvement and evaluating new technologies to strengthen and develop its portfolio of powerful micro invasive tools. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Larger players contesting in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . For instance, the company's firm position in the coronary arterial disease (CAD) and peripheral arterial disease (PAD) market spaces, positive study results highlighting its effective technologies, an impressive portfolio expansion as well as a strong gross margin scenario. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Larger players contesting in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . For instance, the company's firm position in the coronary arterial disease (CAD) and peripheral arterial disease (PAD) market spaces, positive study results highlighting its effective technologies, an impressive portfolio expansion as well as a strong gross margin scenario. | Larger players contesting in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. On May 21, we issued an updated research report on Cardiovascular Systems, Inc.CSII . |
33269.0 | 2018-05-18 00:00:00 UTC | Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report? | ABT | https://www.nasdaq.com/articles/why-is-abbott-abt-up-2-since-its-last-earnings-report-2018-05-18 | nan | nan | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Shares have added about 2% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is ABT due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Recent Earnings
Abbott reported first-quarter 2018 adjusted earnings from continuing operations of 59 cents per share, beating the Zacks Consensus Estimate by a cent. The bottom line also improved 22.9% year over year and met the high end of the company's guided range of 57-59 cents. Moreover, reported earnings in the quarter came in at 23 cents per share compared with the year-ago figure of 22 cents.
First-quarter worldwide sales came in at $7.39 billion, up 16.6% year over year on a reported basis. The top line also exceeded the Zacks Consensus Estimate of $7.26 billion by 1.8%.
On an organic basis (adjusting for the impact of foreign exchange and certain divestments) sales increased 6.9% year over year in the reported quarter.
Quarter in Detail
Abbott operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales rose 9.9% on a reported basis (up 6.8% on an organic basis) to $1.04 billion. This included a positive impact of 3.1% from currency fluctuations. Sales in the key emerging markets increased 8.7% (up 6.8%), driven by double-digit growth in India, China and Brazil.
The Medical Devices business sales increased 14.6% on a reported basis to $2.74 billion. On an organic basis, sales grew 9.4%.
Cardiovascular and Neuromodulation sales reportedly (up 6.2% on an organic basis) rose 10.5% on double-digit growth in Electrophysiology and Neuromodulation.
Vascular product sales, however, declined 6% on a reported basis (up 1.6%). Within Rhythm Management, the company saw a sales increase of 4.7% on a reported basis (a decline of 1.2%).
Diabetes Care sales improved 44.2% (up 32.9%), buoyed by double-digit international sales growth, led by a consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott.
Nutrition sales were up 7% year over year on a reported basis (up 4.7% on an organic basis). Foreign exchange drove sales by 2.2%. Pediatric Nutrition sales increased 7.3% on an organic basis. Adult Nutrition sales were up 4.3% organically.
Diagnostics sales soared 58.7% year over year on a reported basis (up 5.5% on a comparable operational basis). Core Laboratory and Point of Care Diagnostics sales grew 6.3% and 4%, respectively, on an organic basis. Molecular Diagnostics sales were up a nominal 1.3% as strong growth in the infectious disease testing business was partially offset by the planned scale down in other testing areas, primarily in the United States. Rapid Diagnostics recorded sales of $559 million, driven by solid contributions from infectious disease testing including flu and strep testing.
Full-Year Guidance
Abbott has reiterated its 2018 earnings per share guidance. Adjusting for certain net specified items for the full year, adjusted earnings from continuing operations are still expected in the band of $2.80-$2.90. The Zacks Consensus Estimate of $2.86 remains within this projected range.
The company has also provided second-quarter 2018 adjusted earnings per share outlook. It expects to report adjusted earnings from continuing operations in the range of 70-72 cents. The consensus mark of 71 cents falls within but near the lower end of the predicted range.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. There has been one revision higher for the current quarter compared to three lower.
Abbott Laboratories Price and Consensus
Abbott Laboratories Price and Consensus | Abbott Laboratories Quote
VGM Scores
At this time, ABT has a great Growth Score of A, though it is lagging a lot on the momentum front with a C. The stock was also allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Based on our scores, the stock is more suitable for growth investors than those looking for value and momentum.
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift. Notably, ABT has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Will the recent positive trend continue leading up to its next earnings release, or is ABT due for a pullback? Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote VGM Scores At this time, ABT has a great Growth Score of A, though it is lagging a lot on the momentum front with a C. The stock was also allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy. | Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote VGM Scores At this time, ABT has a great Growth Score of A, though it is lagging a lot on the momentum front with a C. The stock was also allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy. It has been about a month since the last earnings report for Abbott LaboratoriesABT . Will the recent positive trend continue leading up to its next earnings release, or is ABT due for a pullback? | Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote VGM Scores At this time, ABT has a great Growth Score of A, though it is lagging a lot on the momentum front with a C. The stock was also allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy. It has been about a month since the last earnings report for Abbott LaboratoriesABT . Will the recent positive trend continue leading up to its next earnings release, or is ABT due for a pullback? | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Will the recent positive trend continue leading up to its next earnings release, or is ABT due for a pullback? Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote VGM Scores At this time, ABT has a great Growth Score of A, though it is lagging a lot on the momentum front with a C. The stock was also allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy. |
33270.0 | 2018-05-15 00:00:00 UTC | 3 Top Healthcare Stocks to Buy in May | ABT | https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-may-2018-05-15 | nan | nan | Healthcare products tend to remain in demand no matter what is going on in the global economy. That's why the sector is a great place to hunt for high-quality investments.
So which stocks do our healthcare experts have their eye on right now? We asked these three Motley Fool investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Cardinal Health (NYSE: CAH) , and Masimo (NASDAQ: MASI) .
A big pharma stock that has it all
Keith Speights (AbbVie): AbbVie was rocking along, with the stock soaring more than 50% in 2017 and up over 20% year to date in 2018. But the good times came to a screeching halt in late March when the company announced disappointing results for experimental lung cancer drug Rova-T. AbbVie lost all its gains made so far this year and then some.
But AbbVie continues to be the best big-pharma stock on the market, in my opinion. While the Rova-T setback certainly stung, the company still has a pipeline loaded with potential winners, including endometriosis and uterine fibroid drug elagolix, and autoimmune disease drugs risankizumab and upadacitinib.
AbbVie's Q1 results reminded investors just how much the company has going for it even without its strong pipeline candidates. The company blew past Wall Street estimates on soaring sales for immunology drug Humira, cancer drug Imbruvica, and a surprisingly strong launch for new hepatitis-C drug Mavyret.
Investors looking for growth should still like AbbVie despite its Rova-T challenges. Income-seeking investors have just as much to like. AbbVie's dividend yield currently stands just a notch below 4%. The company has increased its dividend payout by a whopping 140% since it was spun off from parent Abbott Labs (NYSE: ABT) in 2013.
Thanks to the sell-off following the Rova-T update in March, AbbVie stock now trades at 11.4 times expected earnings. With its great growth prospects, that's a bargain price. AbbVie is a big-pharma stock that has it all: growth, income, and a great value.
Betting on a long-term rebound
Sean Williams(Cardinal Health): Sometimes I find that the most intriguing stocks are those being avoided like the plague by Wall Street. If you're looking for a solid turnaround candidate and income play in the healthcare sector, I'd suggest taking a closer look at the beaten-down Cardinal Health.
There's no sugarcoating that Cardinal Health -- which supplies medical devices, generic drugs, and other supply-chain needs for hospitals, medical offices, and ambulatory surgical centers -- bombed in its recently reported third-quarter results. Shares of the company had their worst day in 14 years (a 19% decline) after Cardinal Health announced that a higher effective tax rate, along with weaker generic drug pricing, caused its profit to miss the mark -- a 33% decline in adjusted earnings per share (EPS) from the prior-year quarter to $0.81. Cardinal Health's full-year adjusted EPS guidance was also reduced to a new range of $4.85 to $4.95, down from $5.25 to $5.50.
That probably sounds bad on the surface, but the issues impacting Cardinal Health are generally cosmetic and should be resolved within the next 12 to 18 months, in my opinion.
The first issue -- the higher-than-expected tax rate -- was derived from inventory write-offs at medical device producer Cordis, which Cardinal Health acquired from Johnson & Johnson (NYSE: JNJ) three years ago. Here's the thing about Cordis: It's growing. Top-line sales of the cardiovascular device maker have steadily pushed higher as the division has given Cardinal Health a broader geographic presence. The issue lies in working out the kinks in Cordis' supply chain. Though this won't happen overnight, management has implemented measures that should yield positive results in 2019.
As for weaker generic-drug pricing, this isn't anything new. Generic drugmakers like Teva Pharmaceutical Industries (NYSE: TEVA) have been pressured by weaker generic drug prices since the third quarter of last year. However, weakness in pricing has recently shown signs of stabilizing. Generic drug manufacturers and Wall Street analysts both seem to believe that 2019 will offer much-needed price stabilization for generic therapies. Considering that generics make up the bulk of total written prescription -- about nine out of 10 -- it seems only logical that pricing power will return to generic drugmakers and distributors sooner rather than later.
What we're left with is a healthcare company valued at less than 10 times Wall Street's 2019 EPS consensus that also happened to increase its quarterly dividend by 3% this past week. For you income seekers at home, this value stock is now yielding 3.6%! Though it could take some time to find its legs again, Cardinal Health looks to be an intriguing turnaround play for value- and income-oriented investors.
Slow and steady wins the race
Brian Feroldi (Masimo): Medical device stocks might not grab as many headlines as biotechnology stocks, but they sure can make wonderful long-term investments.
Consider Masimo, a medical device company that sells noninvasive devices that monitor oxygen levels in the blood . This company has been steadily winning market share for years, which has helped drive consistent gains on its top and bottom lines. The stock has followed suit, and investors who bought in during the company's IPO in 2007 are sitting on total gains of more than 370%.
The company's most recent quarter proved yet again that its competitive position is as strong as ever. Revenue grew more than 8% to $213 million thanks to healthy reorders from existing customers and new business wins. Adjusted EPS grew 15% thanks to margin improvements and stock buybacks . Wall Street expects that the prosperity can continue for years as current estimates call for double-digit gains on the bottom line over the next five years.
The only knock against investing in Masimo that I see is that the stock isn't particularly cheap right now. Shares trade for more than 32 times forward earnings, which is certainly pricing in a lot of prosperity. However, Masimo boasts a debt-free balance sheet, is run by its founder, is highly profitable, and has a strong history of outperforming expectations. Those are highly attractive qualities that make me believe this is a company that deserves its premium price tag.
10 stocks we like better than Masimo
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Masimo wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 8, 2018
Brian Feroldi has no position in any of the stocks mentioned. Keith Speights owns shares of AbbVie. Sean Williams owns shares of Teva Pharmaceutical Industries. The Motley Fool owns shares of and recommends Johnson & Johnson and Masimo. The Motley Fool has the following options: short May 2018 $140 calls on Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company has increased its dividend payout by a whopping 140% since it was spun off from parent Abbott Labs (NYSE: ABT) in 2013. But the good times came to a screeching halt in late March when the company announced disappointing results for experimental lung cancer drug Rova-T. AbbVie lost all its gains made so far this year and then some. Top-line sales of the cardiovascular device maker have steadily pushed higher as the division has given Cardinal Health a broader geographic presence. | The company has increased its dividend payout by a whopping 140% since it was spun off from parent Abbott Labs (NYSE: ABT) in 2013. The company blew past Wall Street estimates on soaring sales for immunology drug Humira, cancer drug Imbruvica, and a surprisingly strong launch for new hepatitis-C drug Mavyret. There's no sugarcoating that Cardinal Health -- which supplies medical devices, generic drugs, and other supply-chain needs for hospitals, medical offices, and ambulatory surgical centers -- bombed in its recently reported third-quarter results. | The company has increased its dividend payout by a whopping 140% since it was spun off from parent Abbott Labs (NYSE: ABT) in 2013. We asked these three Motley Fool investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Cardinal Health (NYSE: CAH) , and Masimo (NASDAQ: MASI) . A big pharma stock that has it all Keith Speights (AbbVie): AbbVie was rocking along, with the stock soaring more than 50% in 2017 and up over 20% year to date in 2018. | The company has increased its dividend payout by a whopping 140% since it was spun off from parent Abbott Labs (NYSE: ABT) in 2013. We asked these three Motley Fool investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Cardinal Health (NYSE: CAH) , and Masimo (NASDAQ: MASI) . AbbVie's Q1 results reminded investors just how much the company has going for it even without its strong pipeline candidates. |
33271.0 | 2018-05-14 00:00:00 UTC | Notable ETF Outflow Detected - VIG, ABT, UTX, LMT | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-vig-abt-utx-lmt-2018-05-14 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $43.3 million dollar outflow -- that's a 0.2% decrease week over week (from 270,530,982 to 270,105,982). Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.4%, United Technologies Corp (Symbol: UTX) is up about 0.6%, and Lockheed Martin Corp (Symbol: LMT) is lower by about 1.5%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $89.90 per share, with $108.99 as the 52 week high point - that compares with a last trade of $102.05. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.4%, United Technologies Corp (Symbol: UTX) is up about 0.6%, and Lockheed Martin Corp (Symbol: LMT) is lower by about 1.5%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $89.90 per share, with $108.99 as the 52 week high point - that compares with a last trade of $102.05. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.4%, United Technologies Corp (Symbol: UTX) is up about 0.6%, and Lockheed Martin Corp (Symbol: LMT) is lower by about 1.5%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $89.90 per share, with $108.99 as the 52 week high point - that compares with a last trade of $102.05. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.4%, United Technologies Corp (Symbol: UTX) is up about 0.6%, and Lockheed Martin Corp (Symbol: LMT) is lower by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $43.3 million dollar outflow -- that's a 0.2% decrease week over week (from 270,530,982 to 270,105,982). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $89.90 per share, with $108.99 as the 52 week high point - that compares with a last trade of $102.05. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.4%, United Technologies Corp (Symbol: UTX) is up about 0.6%, and Lockheed Martin Corp (Symbol: LMT) is lower by about 1.5%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $89.90 per share, with $108.99 as the 52 week high point - that compares with a last trade of $102.05. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33272.0 | 2018-05-11 00:00:00 UTC | Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings? | ABT | https://www.nasdaq.com/articles/merck-vs.-pfizer%3A-which-stock-looks-better-post-q1-earnings-2018-05-11 | nan | nan | Both Merck & Co., Inc. MRK and Pfizer, Inc. PFE reported upbeat first-quarter results on May 1. In fact, both pharma giants managed to outpace their earnings estimate but missed on the revenue front. However, the companies' top and bottom lines rose year over year.
Merckhas a Zacks Rank #2 (Buy), while Pfizer possesses a Zacks Rank #3 (Hold). Now, but let's see which stock is better positioned in terms of fundamentals, post earnings. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Other major earnings came from other pharma giants like Abbott ABT and Johnson & Johnson JNJ .
Q1 Earnings Performance
In the first quarter, Merck reported adjusted earnings per share of $1.05, surpassing the Zacks Consensus Estimate by six cents. The bottom line increased 19.3% from the year-ago period. Meanwhile, the company's revenues of $10.04 billion fell short of the Zacks Consensus Estimate of $10.12, but increased 6% year over year. (Read More: Merck Beats on Q1 Earnings, Lags Sales, Raises Outlook )
Pfizer posted first-quarter earnings of 77 cents per share, beating the Zacks Consensus Estimate by only 3 cents. Earnings advanced 12% from the year-ago period, due to lower tax rates and share count. Moreover, revenues increased 1% year over year to $12.91 billion but missed the Zacks Consensus Estimate of $13.09 billion. (Read More: Pfizer Stock Falls on Q1 Sales Miss, Earnings Beat )
Price Performance
Merck has witnessed a rise of 5.8% in the past three months, while Pfizer has advanced only 2.6%. So Merck is a clear winner in this respect with better returns than both rival Merck and the broader industry , which declined 2% during the same period.
Valuation
The most appropriate ratio to evaluate these two drug makers is perhaps EV/EBITDA. This metric is usually used to compare two stocks in the same industry. It is superior to other metrics such as P/E because it is not affected by the different capital structures of the two companies.
Net Margin
The pharmaceutical industry enjoys higher profit margins than several other sectors. This is possibly one of the reasons why critics of the sector continually draw attention to exorbitant drug pricing, which helps the sector maintain its steep margins.
Debt-to-Equity Ratio
The debt-to-equity (D/E) ratio is a good indicator of the financial health of a company and a good proxy for its debt-servicing capacity. In the context of a capital-intensive industry like pharma, this is an indicator of a company's long-term sustainability.
Earnings History and Estimate Revisions
Merck delivered positive surprises in all the last four quarters, with an average earnings surprise of 8.55%. In comparison, Pfizer delivered an earnings beat in all the trailing four quarters and posted an average positive earnings surprise of around 5.23%.
When considering estimate revisions, Merck's earnings estimate for the current year has improved 1.2% over the past 30 days. Meanwhile, Pfizer's earnings estimate has declined by 0.3% over the same period.
Conclusion
In our comparative analysis, we found that both the two pharma giants have certain positives. Pfizer holds a better leverage position and has a higher net margin. However, in terms of valuation, Merck is more underpriced than Pfizer. Further, Merck has comparatively higher price performance than Pfizer.
Moreover, Merck also holds an edge over Pfizer when considering its average positive earnings surprise and estimate revisions. What clinches the case in favor of Merck at this point of time is that it has a better Zacks Rank than Pfizer. In this respect, our analysis clearly indicated that Merck is better positioned than Pfizer and thus calls for investors' attention post earnings.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other major earnings came from other pharma giants like Abbott ABT and Johnson & Johnson JNJ . Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings advanced 12% from the year-ago period, due to lower tax rates and share count. | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Other major earnings came from other pharma giants like Abbott ABT and Johnson & Johnson JNJ . (Read More: Merck Beats on Q1 Earnings, Lags Sales, Raises Outlook ) Pfizer posted first-quarter earnings of 77 cents per share, beating the Zacks Consensus Estimate by only 3 cents. | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Other major earnings came from other pharma giants like Abbott ABT and Johnson & Johnson JNJ . Q1 Earnings Performance In the first quarter, Merck reported adjusted earnings per share of $1.05, surpassing the Zacks Consensus Estimate by six cents. | Other major earnings came from other pharma giants like Abbott ABT and Johnson & Johnson JNJ . Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Q1 Earnings Performance In the first quarter, Merck reported adjusted earnings per share of $1.05, surpassing the Zacks Consensus Estimate by six cents. |
33273.0 | 2018-04-30 00:00:00 UTC | June 2019 Options Now Available For Abbott Laboratories (ABT) | ABT | https://www.nasdaq.com/articles/june-2019-options-now-available-abbott-laboratories-abt-2018-04-30 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the June 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 417 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new June 2019 contracts and identified one put and one call contract of particular interest.
The put contract at the $57.50 strike price has a current bid of $2.86. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $57.50, but will also collect the premium, putting the cost basis of the shares at $54.64 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $59.38/share today.
Because the $57.50 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 62%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 4.97% return on the cash commitment, or 4.35% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $57.50 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $60.00 strike price has a current bid of $4.05. If an investor was to purchase shares of ABT stock at the current price level of $59.38/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $60.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 7.86% if the stock gets called away at the June 2019 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $60.00 strike highlighted in red:
Considering the fact that the $60.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 48%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 6.82% boost of extra return to the investor, or 5.97% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 28%, while the implied volatility in the call contract example is 24%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $59.38) to be 18%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $60.00 strike highlighted in red: Considering the fact that the $60.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the June 2019 expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $60.00 strike highlighted in red: Considering the fact that the $60.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the June 2019 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new June 2019 contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $60.00 strike highlighted in red: Considering the fact that the $60.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the June 2019 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new June 2019 contracts and identified one put and one call contract of particular interest. | At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new June 2019 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABT's trailing twelve month trading history, with the $60.00 strike highlighted in red: Considering the fact that the $60.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the June 2019 expiration. |
33274.0 | 2018-04-27 00:00:00 UTC | 9 Highest-Yielding Dividend Aristocrats to Buy Today | ABT | https://www.nasdaq.com/articles/9-highest-yielding-dividend-aristocrats-buy-today-2018-04-27 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividend aristocrats have a cult-like following among income investors, and for good reason. To be a dividend aristocrat, a company must be a member of the S&P 500 Index and have paid higher dividends for 25 consecutive years.
Businesses that have rewarded shareholders with rising dividends over the course of several decades tend to generate dependable cash flow, operate in large and growing markets, and be managed very conservatively.
As a result, dividend aristocrats have outperformed the S&P 500 by about 3% annually over the past decade, while also recording less volatility. Even during the worst of times, when the S&P lost 37% in 2008, the dividend aristocrats only lost 22%.
Investors can view data on the complete list of dividend aristocrats here .
In this article, we identified nine of the highest-yielding dividend aristocrats that investors may want to consider for income.
These companies have largely withstood the test of time and also have strong Dividend Safety Scores, a metric created by Simply Safe Dividends to assess how secure a company's current payout is.
7 Stocks Goldman Sachs Thinks Are Set to Rip Higher
Since inception, Dividend Safety Scores have flagged over 98% of dividend cuts before they occurred, providing predictive value. Investors can learn more about Dividend Safety Scores here . Let's review nine of the highest-yielding dividend aristocrats that have passed the test.
Dividend Aristocrats to Buy Today: AT&T (T)
Source: Mike Mozart via Flickr
Ticker: T
Sector: Telecom Services
Dividend Yield:
AT&T (NYSE: T ) is the largest communications company by revenue in the world. The company offers consumers, businesses, and governments an extensive array of services, ranging from wireless voice and data, to satellite TV, to broadband internet, managed networking and wireline services.
In total, AT&T serves 157 million wireless subscribers in North America, 3 million business customers, 16 million internet connections and 47 million pay-TV connections. Since most of AT&T's customers are monthly subscribers, providing recurring revenue, the business enjoys solid cash flow visibility.
The company can use this cash flow to improve the performance of its wireless network and invest in offering additional services and capabilities to grow its business. To better meet the internet's needs to accommodate rapid growth in video and data usage, for example, AT&T has been investing in 5G wireless technology, which it expects to launch in 12 U.S. markets by late 2018.
Of course, AT&T has been busy expanding its portfolio of offerings as well. The company acquired DirecTV in 2015 to become the country's largest pay-TV provider, and the firm is in the middle of a legal battle to gain regulator's blessing for its planned acquisition of Time Warner.
While these deals significantly increased AT&T's debt load and added operational risk, the company appears to be on solid ground to continue its dividend growth streak, which stands at 34 years.
Research firm Simply Safe Dividends conducted an in-depth review of AT&T's dividend profile, planned acquisition of Time Warner, and more that income investors can read here .
Dividend Aristocrats to Buy Today: AbbVie (ABBV)
Source: Black Stripe via Wikimedia (Modified)
Ticker: ABBV
Sector: Healthcare
Dividend Yield: 3.9%
AbbVie (NYSE: ABBV ) is one of the largest global biopharmaceutical companies in the world. The company was formed as a spin-off from Abbott Laboratories (ABT) in 2013 and produces drugs for treating chronic autoimmune diseases in different therapeutic areas such as rheumatology, oncology, and virology.
AbbVie has a strong global presence with 28 million patients in more than 170 countries using AbbVie products each year. However, the U.S. accounts for more than 60% of the company's revenue.
A huge portfolio of successful products, a strong late-stage pipeline of promising medicines, a well-known brand, extensive R&D capabilities, and a large patent portfolio are the company's strengths.
AbbVie stands in a good position to benefit from growing drug demand to treat complex and serious diseases, especially as the population ages. While AbbVie's blockbuster arthritis drug Humira accounts for over 60% of sales and an even greater share of its profit, the firm is also targeting to launch 20 new products by 2020 which should fuel future growth and provide some diversification.
AbbVie has grown its dividend at an impressive 15% compound annual growth rate over the last three years. The company has a reasonable payout ratio near 50% and generates plenty of free cash flow. Management expressed further confidence in the business when they recently increased AbbVie's dividend by 35% and also authorized a new $10 billion stock repurchase program.
5 Stocks That Could Be the Next Amazon
Given the growing worldwide demand for quality drugs and the company's capabilities, AbbVie should be able to continue its healthy dividend growth in the future as well.
Dividend Aristocrats to Buy Today: Exxon Mobil (XOM)
Source: Shutterstock
Ticker: XOM
Sector: Energy
Dividend Yield: 4.2%
Exxon Mobil (NYSE: XOM ) is one of the largest oil and gas integrated companies in the world. The firm mainly operates in the business of exploration, production and transportation of crude oil, natural gas, and petroleum products, but it also has sizable downstream and chemicals businesses.
With over 125 years of operating history, Exxon Mobil has developed a leading position in the petroleum and petrochemical industries. Economies of scale, strategic pipeline networks, extensive global distribution channels, and an integrated business model are Exxon's biggest competitive advantages.
Oil & gas is a highly capital-intensive industry, which acts as a strong entry barrier for newcomers. For example, Exxon Mobil plans to invest more than $50 billion in the U.S. over the next five years, but its scale and efficient operations have helped the company generate positive free cash flow in each of the last 10 years.
While the price of oil remains well off its five-year high, Exxon's dividend remains on solid ground. Management estimates that earnings will triple in its upstream segment and double in the downstream and chemicals businesses by 2025, and such confidence was reflected in the company's recent announcement to raise its payout by 6.5%.
Exxon has paid uninterrupted dividends since 1882 and raised its payout each year since 1983. That trend is likely to continue for the foreseeable future, and investors can read an in-depth analysis of Exxon's dividend, competitive strengths and key risks here .
Dividend Aristocrats to Buy Today: Kimberly-Clark (KMB)
Source: Shutterstock
Ticker: KMB
Sector: Consumer Staples
Dividend Yield: 3.8%
Kimberly Clark (NYSE: KMB ) is one of the largest consumer products companies in the world and owns popular brands such as Kleenex, Scott, Huggies, and Kotex. The company's operating segments can be segregated into personal care (50% of revenue), consumer tissue (32%) and K-C Professional (18%). Sales in North America constitute nearly 50% of total revenues with foreign markets accounting for the rest.
Kimberly-Clark serves nearly one-fourth of the world's population in more than 175 countries. This is enabled by its extensive sales and marketing network consisting of a large number of channel partners.
The company has leveraged its 145 years of experience to design innovative consumer essential products. Over the years, Kimberly-Clark has developed a strong reputation for quality, with most of its brands commanding the No. 1 or No. 2 market position in many countries.
Input cost inflation, private label competition, and e-commerce have all created challenges more recently. The company is responding by investing more in product innovation and implementing an aggressive cost savings target which is expected to result in savings of over $1.5 billion by the end of 2021.
Meanwhile, the company's significant presence in developing countries should lead to higher demand over time as rising living standards increase demand for personal care and hygiene products.
Kimberly-Clark recently increased its dividend by 3.1%, which marks its 46th consecutive annual dividend growth. Given new product launches, its aggressive cost reduction target and shareholder-friendly cash deployment program, the company should continue its single-digit pace of dividend growth in the future.
With its dividend yield sitting near 4%, representing close to an all-time high, Kimberly-Clark is one of the best high dividend stocks to review here .
Dividend Aristocrats to Buy Today: Procter & Gamble (PG)
Source: Mike Mozart via Flickr (Modified)
Ticker: PG
Sector: Consumer Staples
Dividend Yield: 3.9%
Procter & Gamble (NYSE: PG ) is a leading consumer goods company selling products in more than 180 countries. The business has become a leading household name and is a global leader in ten product categories.
The company's reportable segments are Fabric & Home Care (32% of sales); Baby, Feminine & Family Care (28%); Beauty (18%); Healthcare (12%), Grooming (10%). P&G's umbrella of well-known brands consists of famous brands like Ariel, Bounty, Head & Shoulders, Olay, Pampers, Gillette, Tide and many more.
Developed markets account for 65% of sales while developing markets constitute the rest. North America is P&G's largest market with 45% of sales.
With 180 years of experience, the company has successfully carved out a leading position in the global consumer goods industry. P&G's well-known brand name and its strong reputation for quality have allowed it to develop a customer base consisting of millions of loyal consumers around the world.
While developed markets are experiencing several growth challenges today, fast-growing emerging markets hold a lot of promise for many of the company's consumer products. P&G's extensive product portfolio, excellent retail distribution network, and quality reputation are its key competitive advantages.
Procter & Gamble is currently implementing a $10 billion savings program to increase its profit margins. Management has set a target to return more than $70 billion in cash to its shareholders through fiscal 2019, which means moderate dividend growth should continue.
3 Energy Stocks to Play a Breakout in Oil
Procter & Gamble is a member of the dividend kings group here with 62 years of consecutive dividend increases. Perhaps more impressively, the firm has paid uninterrupted dividends for 128 years, last raising its payout by 4%.
Dividend Aristocrats to Buy Today: Consolidated Edison (ED)
Source: Wikimedia
Ticker: ED
Sector: Utilities
Dividend Yield: 3.5%
Consolidated Edison (NYSE: ED ) is a leading American utility selling energy-related services to 10 million customers in New York City and Westchester County.
More than 90% of the company's revenues are derived from regulated activities, making the company's cash flows safe and predictable in nature. The Electricity business accounted for 72% of 2017 revenues, followed by gas (18%), steam (4%) and non-utility businesses (6%).
Nearing almost a century of existence, Consolidated Edison has developed an extensive distribution network, a diverse customer base, and a reputation for providing safe and reliable services.
While increased energy efficiency and new technologies like battery storage, smart meters, and electric vehicles are changing the way customers consume energy, Consolidated Edison's core New York market should remain a major power consumer for many years to come.
As a result, Consolidated Edison was able to recently raise its dividend by 3.6%, which was its 44th consecutive annual increase. The utility has been growing its dividend at about 3% per year over the last three years and appears to be in a good position to continue rewarding shareholders with low single-digit increases.
With some investors worrying about the impact of higher interest rates on this sector, an in-depth review of the effect of rising rates on utilities can be found here .
Dividend Aristocrats to Buy Today: Chevron Corporation (CVX)
Source: swong95765 via Flickr (Modified)
Ticker: CVX
Sector: Energy
Dividend Yield:
Chevron (NYSE: CVX ) is one of the world's leading integrated oil and gas companies. The firm owns an extensive network of energy, chemicals, and petroleum businesses worldwide.
Chevron operates through two segments - upstream, accounting for 60% of earnings, and downstream, which constitutes the remaining 40%.
The company has a very global presence, with operations spread across North America, South America, Europe, Africa, Asia and Australia. The U.S. and international markets each accounted for approximately 50% of the company's 2017 earnings.
Chevron's key advantages are its vertically integrated operations, economies of scale, and relatively low-cost production. The company's presence across the entire energy supply chain also makes it relatively less vulnerable to commodity price fluctuations compared to its pure-play exploration and production peers.
The company increased its dividend payout for the 31st year in a row in 2018. While Chevron's recent dividend raise was 3.7%, lower than its 5-year CAGR of 4.2%, it was still decent given today's low oil prices.
7 'Strong Buy' Stocks Bloggers Are Raving About
With the business continuing to expect mid-single-digit worldwide production growth in 2018, plus oil prices climbing and cost cuts continuing, Chevron's dividend appears to remain on solid ground.
Dividend Aristocrats to Buy Today: Coca-Cola (KO)
Source: Coca-Cola
Ticker: KO
Sector: Consumer Staples
Dividend Yield: 3.6%
Coca-Cola ( KO ) is one of the largest holdings in Warren Buffett's dividend stock portfolio and also the largest beverage company in the world, with a portfolio of more than 500 non-alcoholic beverage brands. Out of the 60 billion servings of beverages consumed worldwide every day, Coca-Cola accounts for more than 1.9 billion.
The company owns four of the world's top sparkling soft drink brands: Coca-Cola, Diet Coke, Fanta and Sprite. Its products can be categorized into sparkling soft drinks; water, enhanced water and sports drinks; juice, dairy and plant-based beverages; tea and coffee; and energy drinks.
Coca-Cola's reach is truly global, with its massive distribution network covering 27 million customer outlets in 200 countries. Strong brands, financial strength, an extensive distribution network, and global reach are some of Coca Cola's key competitive advantages.
Coca-Cola has increased its dividend in each of the last 56 years and last raised its payout by 5.4%. The company has set targets of a 75% payout ratio and 7-9% annual earnings growth over the long term, which means its dividend will likely continue increasing at a mid-single-digit pace.
Dividend growth could remain somewhat lower than earnings growth the next few years as the business continues investing in healthier drinks, which will help ensure that Coca-Cola remains a force for many years to come.
Dividend Aristocrats to Buy Today: Federal Realty Investment Trust (FRT)
Source: Aude via Wikimedia (Modified)
Ticker: FRT
Sector: Real Estate
Dividend Yield: 3.4%
Federal Realty Investment Trust (NYSE: FRT ) is the only dividend aristocrat in the real estate sector. Investors can learn everything they need to know about investing in real estate investment trusts in this in-depth guide here .
Federal Realty is one of the oldest, fully integrated retail REITs in the U.S. The REIT's portfolio consists of 104 properties with a combined area of 24 million square feet. These are mostly high-quality retail properties such as shopping centers, offices, residential units, and hotel complexes. The properties had 94% occupancy with approximately 3,000 tenants as of December 2017.
Federal Realty focuses on owning properties located in densely populated, affluent communities in Washington, D.C., Boston, San Francisco and Los Angeles. This is one of the company's major strengths as a good location is of primary importance in this business.
High occupancy levels and a diverse base of tenants provide strong cash flow visibility. Federal Realty is also in a good position to maintain steady rent increases with its landlord-friendly leases and high rollover growth.
Federal Realty has paid quarterly dividends to its shareholders continuously since it was founded in 1962. It has also increased dividends for 50 consecutive years, which is a record in the REIT industry.
The Only 10 ETFs You Will Need
The company last raised its dividend by 2% and has recorded a dividend CAGR of 6.3% over the last three years. Single-digit dividend growth is likely to continue.
Brian Bollinger is long AT&T, Exxon Mobil, Kimberly-Clark, Procter & Gamble, and Consolidated Edison.
Compare Brokers
The post 9 Highest-Yielding Dividend Aristocrats to Buy Today appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company was formed as a spin-off from Abbott Laboratories (ABT) in 2013 and produces drugs for treating chronic autoimmune diseases in different therapeutic areas such as rheumatology, oncology, and virology. The company acquired DirecTV in 2015 to become the country's largest pay-TV provider, and the firm is in the middle of a legal battle to gain regulator's blessing for its planned acquisition of Time Warner. While these deals significantly increased AT&T's debt load and added operational risk, the company appears to be on solid ground to continue its dividend growth streak, which stands at 34 years. | The company was formed as a spin-off from Abbott Laboratories (ABT) in 2013 and produces drugs for treating chronic autoimmune diseases in different therapeutic areas such as rheumatology, oncology, and virology. Dividend Aristocrats to Buy Today: Procter & Gamble (PG) Source: Mike Mozart via Flickr (Modified) Ticker: PG Sector: Consumer Staples Dividend Yield: 3.9% Procter & Gamble (NYSE: PG ) is a leading consumer goods company selling products in more than 180 countries. Dividend Aristocrats to Buy Today: Consolidated Edison (ED) Source: Wikimedia Ticker: ED Sector: Utilities Dividend Yield: 3.5% Consolidated Edison (NYSE: ED ) is a leading American utility selling energy-related services to 10 million customers in New York City and Westchester County. | The company was formed as a spin-off from Abbott Laboratories (ABT) in 2013 and produces drugs for treating chronic autoimmune diseases in different therapeutic areas such as rheumatology, oncology, and virology. Dividend Aristocrats to Buy Today: Procter & Gamble (PG) Source: Mike Mozart via Flickr (Modified) Ticker: PG Sector: Consumer Staples Dividend Yield: 3.9% Procter & Gamble (NYSE: PG ) is a leading consumer goods company selling products in more than 180 countries. Dividend Aristocrats to Buy Today: Coca-Cola (KO) Source: Coca-Cola Ticker: KO Sector: Consumer Staples Dividend Yield: 3.6% Coca-Cola ( KO ) is one of the largest holdings in Warren Buffett's dividend stock portfolio and also the largest beverage company in the world, with a portfolio of more than 500 non-alcoholic beverage brands. | The company was formed as a spin-off from Abbott Laboratories (ABT) in 2013 and produces drugs for treating chronic autoimmune diseases in different therapeutic areas such as rheumatology, oncology, and virology. AbbVie has a strong global presence with 28 million patients in more than 170 countries using AbbVie products each year. 2 market position in many countries. |
33275.0 | 2018-04-26 00:00:00 UTC | Universal Health (UHS) Q1 Earnings & Revenues Lag Estimates | ABT | https://www.nasdaq.com/articles/universal-health-uhs-q1-earnings-revenues-lag-estimates-2018-04-26 | nan | nan | Universal Health Services Inc.UHS reported first-quarter 2018 adjusted earnings of $2.45 per share, missing the Zacks Consensus Estimate by 5.4%. However, the bottom line grew 17% year over year.
Net revenues increased 2.9% year over year to $2.7 billion. However, the top line lagged the Zacks Consensus Estimate by 2%.
Total operating expenses of $2.4 billion at the end of the first quarter also increased 4.2% year over year.
Segment Update
Acute Care Hospitals:
Adjusted admissions and adjusted patient days increased 2.3% and 5.4%, respectively, from the prior-year quarter. Net revenues (on a same facility basis) climbed 3.7% in the first quarter.
Behavioral hospitals :
On a same facility basis, adjusted admissions increased 1.6% while adjusted patient days declined 0.4%, both on a year-over-year basis. Net revenues increased 3% during the quarter under review on a same facility basis.
Universal Health Services, Inc. Price, Consensus and EPS Surprise
Universal Health Services, Inc. Price, Consensus and EPS Surprise | Universal Health Services, Inc. Quote
Financial Update
As of Mar 31, 2018, the company had cash and cash equivalents of nearly $73 million, down 1.3% from year-end 2017.
Total assets were $11 billion as of Mar 31, 2018, up 2.4% from year-end 2017.
The company managed to lower its debt burden, evident from its long-term debt of $3.4 billion as of Mar 31, 2018, which declined 4% from year-end 2017.
For the first three months of2018, net cash provided by operating activities totaled $364 million, down 24.7% year over year.
Buyback Program
In November 2017, the board of directors authorized a $400-million increase in Universal Health's stock repurchase program, raising the aggregate authorization to $1.2 billion from the previous $800 million approved in 2016 and 2014.
Concurrently, during the first quarter, the company repurchased 42,000 shares at an aggregate cost of $4.6 million.
Zacks Rank & Performance of Peers
Universal Health currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Universal Health Services, Inc. (UHS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Universal Health Services, Inc. (UHS): Free Stock Analysis Report To read this article on Zacks.com click here. Universal Health Services Inc.UHS reported first-quarter 2018 adjusted earnings of $2.45 per share, missing the Zacks Consensus Estimate by 5.4%. | Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Universal Health Services, Inc. (UHS): Free Stock Analysis Report To read this article on Zacks.com click here. Universal Health Services, Inc. Price, Consensus and EPS Surprise Universal Health Services, Inc. Price, Consensus and EPS Surprise | Universal Health Services, Inc. Quote Financial Update As of Mar 31, 2018, the company had cash and cash equivalents of nearly $73 million, down 1.3% from year-end 2017. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Universal Health Services, Inc. (UHS): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Universal Health Services, Inc. Price, Consensus and EPS Surprise Universal Health Services, Inc. Price, Consensus and EPS Surprise | Universal Health Services, Inc. Quote Financial Update As of Mar 31, 2018, the company had cash and cash equivalents of nearly $73 million, down 1.3% from year-end 2017. | Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Universal Health Services, Inc. (UHS): Free Stock Analysis Report To read this article on Zacks.com click here. Universal Health Services Inc.UHS reported first-quarter 2018 adjusted earnings of $2.45 per share, missing the Zacks Consensus Estimate by 5.4%. |
33276.0 | 2018-04-25 00:00:00 UTC | SPYG, ABT, CRM, CHTR: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/spyg-abt-crm-chtr-etf-inflow-alert-2018-04-25 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $96.3 million dollar inflow -- that's a 5.0% increase week over week in outstanding units (from 58,400,108 to 61,300,108). Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Salesforce.com Inc (Symbol: CRM) is off about 1.6%, and Charter Communications Inc (Symbol: CHTR) is lower by about 1.3%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average:
Looking at the chart above, SPYG's low point in its 52 week range is $7.2019 per share, with $35.959 as the 52 week high point - that compares with a last trade of $33.03. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Salesforce.com Inc (Symbol: CRM) is off about 1.6%, and Charter Communications Inc (Symbol: CHTR) is lower by about 1.3%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.2019 per share, with $35.959 as the 52 week high point - that compares with a last trade of $33.03. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Salesforce.com Inc (Symbol: CRM) is off about 1.6%, and Charter Communications Inc (Symbol: CHTR) is lower by about 1.3%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.2019 per share, with $35.959 as the 52 week high point - that compares with a last trade of $33.03. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Salesforce.com Inc (Symbol: CRM) is off about 1.6%, and Charter Communications Inc (Symbol: CHTR) is lower by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $96.3 million dollar inflow -- that's a 5.0% increase week over week in outstanding units (from 58,400,108 to 61,300,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.2019 per share, with $35.959 as the 52 week high point - that compares with a last trade of $33.03. | Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Salesforce.com Inc (Symbol: CRM) is off about 1.6%, and Charter Communications Inc (Symbol: CHTR) is lower by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $96.3 million dollar inflow -- that's a 5.0% increase week over week in outstanding units (from 58,400,108 to 61,300,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.2019 per share, with $35.959 as the 52 week high point - that compares with a last trade of $33.03. |
33277.0 | 2018-04-25 00:00:00 UTC | Anthem (ANTM) Beats on Q1 Earnings, Raises '18 Guidance | ABT | https://www.nasdaq.com/articles/anthem-antm-beats-on-q1-earnings-raises-18-guidance-2018-04-25 | nan | nan | Anthem Inc.'sANTM first-quarter 2018 adjusted net income per share of $5.41 surpassed the Zacks Consensus Estimate by 12%. The bottom line also rose 15.6% year over year.
Operating revenues of $22.3 billion missed the Zacks Consensus Estimate of $22.5 billion. The top line, however, remained flat year over year.
Quarterly Operational Update
Medical enrollment declined 2.5% year over year to 39.6 million members. This downside was primarily caused by a reduced footprint in the Individual ACA (Affordable Care Act)-compliant marketplace.
Anthem's benefit expense ratio of 81.5% improved 220 basis points (bps) from the prior-year quarter, driven by the return of the health insurance tax in 2018 and an improved medical cost performance across all its business segments.
SG&A expense ratio of 15.3% deteriorated 100 bps from the year-ago quarter due to return of the health insurance tax in 2018 and the impact of an increased investment spend this year to support growth initiatives.
Segment Update
Commercial & Specialty Business
Operating revenues were $9 billion in the first quarter, down 12% year over year.
Operating gain totaled $1.4 billion, up 8.1% year over year owing to Penn Treaty assessments recorded in the first quarter of 2017 and an improved medical cost performance.
Operating margin was 15.5%, down 280 bps year over year.
Government Business
Operating revenues were $13.3 billion in the first quarter, up 10.3% from the prior-year quarter.
Operating gain was $490.9 million, up 54.1% year over year. The upside reflects the impact of the HealthSun and America's 1st Choice acquisitions as well as organic membership growth in the Medicare business plus retroactive revenue adjustments in the Medicaid business.
Operating margin was 3.7%, contracting 110 bps year over year.
Other
Operating revenues were $13.5 million in the first quarter, up 221.4% from the prior-year period.
The segment reported an operating loss of $31.4 million, narrower than the same of $35.6 million in the prior-year quarter.
Anthem, Inc. Price, Consensus and EPS Surprise
Anthem, Inc. Price, Consensus and EPS Surprise | Anthem, Inc. Quote
Financial Update
As of Mar 31, 2018, Anthem had cash and cash equivalents of $4.6 billion, up 28% from year-end 2017.
As of Mar 31, 2018, its long-term debt increased 4.2% to $18.1 billion from year-end 2017.
Operating cash outflow was $2.2 billion in the quarter under review, down 18% year over year.
Share Repurchase and Dividend Update
During the reported quarter, Anthem repurchased 1.7 million shares of its common stock for $395 million.
As of Mar 31, 2018, it had approximately $6.8 billion of share repurchase authorization remaining.
During the first quarter, Anthem paid a quarterly dividend of 75 cents per share.
On Apr 24, 2018, the board approved a dividend of 75 cents per share payable Jun 25 to shareholders of record on Jun 8.
Guidance for 2018
Anthem expects adjusted net income to be greater than $15.30 per share, up from the previous projection of more than $15.
Medical membership is now expected in the range of 40.1-40.3 million, up from the previous projection of 40-40.2 million.
Operating revenues are anticipated in the range of $91-$92 billion, more than the earlier forecast of $90.5-$91.5 billion.
Anthem estimates operating cash flow to be more than $4 billion.
Zacks Rank and Performance of Peers
Anthem carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 (Strong Buy) Rank stocks here .
Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Anthem, Inc. (ANTM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. This downside was primarily caused by a reduced footprint in the Individual ACA (Affordable Care Act)-compliant marketplace. | Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Anthem, Inc. Price, Consensus and EPS Surprise Anthem, Inc. Price, Consensus and EPS Surprise | Anthem, Inc. Quote Financial Update As of Mar 31, 2018, Anthem had cash and cash equivalents of $4.6 billion, up 28% from year-end 2017. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Segment Update Commercial & Specialty Business Operating revenues were $9 billion in the first quarter, down 12% year over year. | Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Operating revenues of $22.3 billion missed the Zacks Consensus Estimate of $22.5 billion. |
33278.0 | 2018-04-24 00:00:00 UTC | Centene (CNC) Q1 Earnings & Revenues Top, '18 View Lowered | ABT | https://www.nasdaq.com/articles/centene-cnc-q1-earnings-revenues-top-18-view-lowered-2018-04-24 | nan | nan | Centene Inc.CNC reported first-quarter 2018 adjusted net income per share of $2.17, which beat the Zacks Consensus Estimate by 13%. Also, the bottom line improved 93% year over year.
For the first quarter, total revenues rose 13% to $13.2 billion from the year-ago period, primarily driven by growth in the Health Insurance Marketplace business in 2018 as well as expansions and new programs across many states in both 2017 and this year. Moreover, the top line slightly surpassed the Zacks Consensus Estimate by 0.01%.
Quarterly Operational Update
As of Mar 31, 2018, managed care membership came in at 12.8 million, a 6% increase over March 31, 2017.
Health Benefit Ratio (HBR) for the first quarter was 84.3% compared with 87.6% in the prior-year quarter. This reflects a year-over-year deterioration of 330 basis points (bps), stemming from membership growth in the Health Insurance Marketplace business, lower medical costs in Medicaid business and the reinstatement of the health insurer fee in 2018.
Adjusted Selling, General & Administrative (SG&A) expense ratio of 10.3% for the first quarter of 2018 compared with 9.3% for the first quarter of 2017. This represents a deterioration of 100 basis points year over year, arising from growth in the Health Insurance Marketplace business, operating at a higher SG&A expense ratio.
Centene Corporation Price, Consensus and EPS Surprise
Centene Corporation Price, Consensus and EPS Surprise | Centene Corporation Quote
Financial Update (As of Mar 31, 2018)
Centene had cash and cash equivalents of $5.7 billion, up 39% from 2017 end.
Total assets of $25.2 billion grew 15%.
Centene's long-term debt totaled $5.2 billion, up 10%.
At the end of the first quarter of 2018, cash inflow from operations was $1.8 billion, up 48% year over year.
2018 Guidance Updated
Centene expects adjusted earnings per share in the range of $6.75-$7.15, down from the previous projection of $6.95-$7.35.
Total revenues are anticipated in the band of $58.2-$59.0 billion, down from the earlier forecast of $60.6-$61.4 billion.
HBR is estimated at 85.9-86.4% compared with the past view of 86.2-86.7%
Adjusted SG&A expense ratio is predicted at 9.4-9.8%, up from the former outlook of 9.2-9.7%.
Zacks Rank and Performance of Peers
Centene carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Centene Corporation (CNC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. For the first quarter, total revenues rose 13% to $13.2 billion from the year-ago period, primarily driven by growth in the Health Insurance Marketplace business in 2018 as well as expansions and new programs across many states in both 2017 and this year. | Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Centene Corporation Price, Consensus and EPS Surprise Centene Corporation Price, Consensus and EPS Surprise | Centene Corporation Quote Financial Update (As of Mar 31, 2018) Centene had cash and cash equivalents of $5.7 billion, up 39% from 2017 end. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. This represents a deterioration of 100 basis points year over year, arising from growth in the Health Insurance Marketplace business, operating at a higher SG&A expense ratio. | Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Centene Inc.CNC reported first-quarter 2018 adjusted net income per share of $2.17, which beat the Zacks Consensus Estimate by 13%. |
33279.0 | 2018-04-23 00:00:00 UTC | The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-goldman-abbott-altria-paypal-and-progressive-2018-04-23 | nan | nan | For Immediate Release
Chicago, IL - April 23, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Goldman SachsGS , Abbott LabsABT , AltriaMO , PayPalPYPL and Progressive CorpPGR .
Here are highlights from Friday's Analyst Blog:
Top Analyst Reports for Goldman Sachs, Abbott Labs and Altria
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Goldman Sachs, Abbott Labs and Altria. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Strong Buy-ranked Goldman Sachs ' shares have gained +5% in the past six months, underperforming the +13.1% gain of the Zacks Investment Banking industry. However, the company boasts an impressive earnings surprise history. It surpassed the Zacks Consensus Estimate for earnings in all the trailing four quarters.
The company's first-quarter 2018 results witnessed top-line strength. Strong trading activities on high volatility supported the bottom-line numbers. Though regulatory issues are concerns, the Zacks analyst thinks the company's well-diversified business and focus to capitalize on growth opportunities through strategic moves will continue to strengthen the overall business.
Its cost-control measures are commendable. Additionally, the company's steady capital-deployment activities have boosted investors' confidence.
Shares of Buy-ranked Abbott Labs have gained +6.8% over the last six months, outperforming the Zacks Medical Products industry, which has gained +2.8% over the same period. Post a better-than-expected result by Abbott in the first quarter 2018; the Zacks analyst is upbeat about the strong and consistent EPD and Medical Devices performance by the company. Also, solid contributions from Diagnostics and Nutrition business are encouraging.
Within Structural Heart, strong uptake of MitraClip therapy post the national reimbursement approval in Japan also buoys optimism. Abbott continues to benefit from a strong integration synergy of St. Jude Medical. Abbott's Alere buyout is another positive. Synergies from this consolidation in the form of revenues from Rapid Diagnostics have been driving the company's growth.
Meanwhile, the company's emerging market performance has been extremely promising on several strategic developments. On the flip side, sluggish pediatric vascular business in the United States continues to dent growth.
Altria 's shares have outperformed the Zacks Tobacco industry in the last three months (-18.9% vs. -21.8%), aided by expansion in the smokeless products category. Rising health consciousness and stern government regulations to curb tobacco consumption has been hurting cigarette volumes and denting Altria's top line for quite some time. Also, the likelihood of these concerns lingering is evident from investors' bearish stance on the stock. Moreover, Altria's Wine category remains sluggish due to stiff competition.
Nevertheless, Altria has been progressing well with expansion in the smokeless products category. This fueled its smokeless product revenue in fourth-quarter 2017, wherein earnings kept its stellar year-over-year growth trend intact. Results were backed by solid pricing, higher OCI and lower tax rates.
Investments in key growth areas, efforts to lift Marlboro's share and expected gains from tax reforms led to a robust earnings view. However, estimates have dropped lately ahead of Altria's earnings release.
Other noteworthy reports we are featuring today include PayPal and Progressive Corp.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report
The Progressive Corporation (PGR): Free Stock Analysis Report
Altria Group, Inc. (MO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Goldman SachsGS , Abbott LabsABT , AltriaMO , PayPalPYPL and Progressive CorpPGR . Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report The Progressive Corporation (PGR): Free Stock Analysis Report Altria Group, Inc. (MO): Free Stock Analysis Report To read this article on Zacks.com click here. Rising health consciousness and stern government regulations to curb tobacco consumption has been hurting cigarette volumes and denting Altria's top line for quite some time. | Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report The Progressive Corporation (PGR): Free Stock Analysis Report Altria Group, Inc. (MO): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Goldman SachsGS , Abbott LabsABT , AltriaMO , PayPalPYPL and Progressive CorpPGR . Here are highlights from Friday's Analyst Blog: Top Analyst Reports for Goldman Sachs, Abbott Labs and Altria The Zacks Research Daily presents the best research output of our analyst team. | Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report The Progressive Corporation (PGR): Free Stock Analysis Report Altria Group, Inc. (MO): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Goldman SachsGS , Abbott LabsABT , AltriaMO , PayPalPYPL and Progressive CorpPGR . Here are highlights from Friday's Analyst Blog: Top Analyst Reports for Goldman Sachs, Abbott Labs and Altria The Zacks Research Daily presents the best research output of our analyst team. | Stocks recently featured in the blog include Goldman SachsGS , Abbott LabsABT , AltriaMO , PayPalPYPL and Progressive CorpPGR . Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report The Progressive Corporation (PGR): Free Stock Analysis Report Altria Group, Inc. (MO): Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including Goldman Sachs, Abbott Labs and Altria. |
33280.0 | 2018-04-20 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABT | https://www.nasdaq.com/articles/5-dividend-growth-stocks-upside-analyst-targets-2018-04-20 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
Another consideration with dividend growth stocks is just how much the dividend is growing . We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
These five stocks are part of our full Dividend Aristocrats List . The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com .
Get the latest Zacks research report on BMS - FREE
Get the latest Zacks research report on ATO - FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . Get the latest Zacks research report on BMS - FREE Get the latest Zacks research report on ATO - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Get the latest Zacks research report on BMS - FREE Get the latest Zacks research report on ATO - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. Get the latest Zacks research report on BMS - FREE Get the latest Zacks research report on ATO - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33281.0 | 2018-04-18 00:00:00 UTC | Earnings Reaction History: Abbott Laboratories, 63.6% Follow-Through Indicator, 2.4% Sensitive | ABT | https://www.nasdaq.com/articles/earnings-reaction-history-abbott-laboratories-636-follow-through-indicator-24-sensitive | nan | nan | Expected Earnings Release: 04/18/2018, Premarket
Avg. Extended-Hours Dollar Volume: $2,032,183
Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 62.5%
Average next regular session additional gain: 1.7%
Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 1.7%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 66.7%
Average next regular session additional loss: 2.7%
Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 62.5% Average next regular session additional gain: 1.7% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 1.7%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,032,183 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 62.5% Average next regular session additional gain: 1.7% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 1.7%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,032,183 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 62.5% Average next regular session additional gain: 1.7% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 1.7%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,032,183 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $2,032,183 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 62.5% Average next regular session additional gain: 1.7% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 1.7%. Historical earnings event related premarket and after-hours trading activity in ABT indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. |
33282.0 | 2018-04-18 00:00:00 UTC | Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained | ABT | https://www.nasdaq.com/articles/abbott-abt-q1-earnings-revenues-top-18-view-retained-2018-04-18 | nan | nan | Abbott ABT reported first-quarter 2018 adjusted earnings from continuing operations of 59 cents per share, beating the Zacks Consensus Estimate by a penny. The bottom line also improved 22.9% year over year and met the high end of the company's guided range of 57-59 cents. Moreover, reported earnings in the quarter came in at 23 cents per share compared with the year-ago figure of 22 cents.
First-quarter worldwide sales came in at $7.39 billion, up 16.6% year over year on a reported basis. The top line also exceeded the Zacks Consensus Estimate of $7.26 billion by 1.8%.
On an organic basis (adjusting for the impact of foreign exchange and certain divestments) sales increased 6.9% year over year in the reported quarter.
Quarter in Detail
Abbott operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales rose 9.9% on a reported basis (up 6.8% on an organic basis) to $1.04 billion. This included a positive impact of 3.1% from currency fluctuations. Sales in the key emerging markets increased 8.7% (up 6.8%), driven by double-digit growth in India, China and Brazil.
The Medical Devices business sales increased 14.6% on a reported basis to $2.74 billion. On an organic basis, sales grew 9.4%.
Cardiovascular and Neuromodulation sales reportedly (up 6.2% on an organic basis) rose 10.5% on double-digit growth in Electrophysiology and Neuromodulation.
Vascular product sales, however, declined 6% on a reported basis (up 1.6%). Within Rhythm Management, the company saw a sales increase of 4.7% on a reported basis (a decline of 1.2%).
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote
Diabetes Care sales improved 44.2% (up 32.9%), buoyed by double-digit international sales growth, led by a consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott.
Nutrition sales were up 7% year over year on a reported basis (up 4.7% on an organic basis). Foreign exchange drove sales by 2.2%. Pediatric Nutrition sales increased 7.3% on an organic basis. Adult Nutrition sales were up 4.3% organically.
Diagnostics sales soared 58.7% year over year on a reported basis (up 5.5% on a comparable operational basis). Core Laboratory and Point of Care Diagnostics sales grew 6.3% and 4%, respectively, on an organic basis. Molecular Diagnostics sales were up a nominal 1.3% as strong growth in the infectious disease testing business was partially offset by the planned scale down in other testing areas, primarily in the United States. Rapid Diagnostics recorded sales of $559 million, driven by solid contributions from infectious disease testing including flu and strep testing.
Full-Year Guidance
Abbott has reiterated its 2018 earnings per share guidance. Adjusting for certain net specified items for the full year, adjusted earnings from continuing operations are still expected in the band of $2.80-$2.90. The Zacks Consensus Estimate of $2.86 remains within this projected range.
The company has also provided second-quarter 2018 adjusted earnings per share outlook. It expects to report adjusted earnings from continuing operations in the range of 70-72 cents. The consensus mark of 71 cents falls within but near the lower end of the predicted range.
Our Take
Abbott has steered past the Zacks Consensus Estimate for both earnings and revenues. We are optimistic about the company's strong and consistent EPD and Medical Devices performance. Also, solid contributions from the company's other two businesses encourage us.
The company continues to benefit from a strong integration synergy of St. Jude Medical, which offers it an industry-leading pipeline across cardiovascular, neuromodulation, diabetes and vision care. We are also impressed by Abbott's Alere buyout. Synergies from this consolidation in the form of revenues from Rapid Diagnostics have been driving the company's growth.
Meanwhile, the company's emerging market performance has been extremely promising on several strategic developments.
Zacks Rank & Key Picks
Abbott carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical sector are Abaxis, Inc. ABAX , Bio-Rad Laboratories, Inc. BIO and Align Technology, Inc. ALGN . While Abaxis and Bio-Rad sport a Zacks Rank #1 (Strong Buy), Align carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Abaxis is expected to release fourth-quarter fiscal 2018 results on Apr 26. The Zacks Consensus Estimate for the quarter's adjusted EPS is pegged at 32 cents and for revenues stands at $67.2 million.
Bio-Rad is expected to release first-quarter 2018 results on May 3. The Zacks Consensus Estimate for the period's adjusted EPS is 90 cents and for revenues, $530.4 million.
Align Technologies is slated to release first-quarter 2018 results on Apr 25. The Zacks Consensus Estimate for adjusted bottom line in the to-be-reported quarter is 98 cents and for the top line, $408.3 million.
Can Hackers Put Money INTO Your Portfolio?
Earlier this year, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor's Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Abaxis,Inc. (ABAX): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT reported first-quarter 2018 adjusted earnings from continuing operations of 59 cents per share, beating the Zacks Consensus Estimate by a penny. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Abaxis,Inc. The company continues to benefit from a strong integration synergy of St. Jude Medical, which offers it an industry-leading pipeline across cardiovascular, neuromodulation, diabetes and vision care. | Abbott ABT reported first-quarter 2018 adjusted earnings from continuing operations of 59 cents per share, beating the Zacks Consensus Estimate by a penny. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Abaxis,Inc. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote Diabetes Care sales improved 44.2% (up 32.9%), buoyed by double-digit international sales growth, led by a consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott. | Abbott ABT reported first-quarter 2018 adjusted earnings from continuing operations of 59 cents per share, beating the Zacks Consensus Estimate by a penny. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Abaxis,Inc. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote Diabetes Care sales improved 44.2% (up 32.9%), buoyed by double-digit international sales growth, led by a consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott. | Abbott ABT reported first-quarter 2018 adjusted earnings from continuing operations of 59 cents per share, beating the Zacks Consensus Estimate by a penny. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Abaxis,Inc. On an organic basis (adjusting for the impact of foreign exchange and certain divestments) sales increased 6.9% year over year in the reported quarter. |
33283.0 | 2018-04-18 00:00:00 UTC | MS, USB, ABT & TXT Leads Q1 Earnings | ABT | https://www.nasdaq.com/articles/ms-usb-abt-txt-leads-q1-earnings-2018-04-18 | nan | nan | Triple-digit gains in regular-day Tuesday trading in both the Dow and Nasdaq were bolstered by a number of different things - strong housing starts and a lack of relative geopolitical tension early this week among them - but nothing so influential as a very strong Q1 earnings season. We are still in the early stages so far (only a week has passed since Delta Air Lines beat estimates on both top and bottom lines), but overall results have been notably better than expected.
While after-the-bell earnings reports yesterday were better than expected across the board, some companies performed more impressively than others. While Intuitive SurgicalISRG posted a robust earnings beat, IBMIBM eked out a positive surprise on new corporate tax benefits alone. (IBM's Watson enterprise has thus far failed to inspire fresh investment in Big Blue.) As a result, IBM has shed more than 5% in today's pre-market, while ISRG shares are up 5% this morning.
New Q1 earnings reports are following suit, starting with Morgan StanleyMS , which left estimates in the dust this morning. This investment banking major posted $1.45 per share on $11.1 billion in quarterly revenues, outpacing the $1.28 and $10.5 billion in the Zacks consensus estimates, respectively. Net income grew 38% in Q1, whereas Sales & Trading rose 26%. For more on MS's earnings, click here.
Fellow financial institution U.S. BankUSB beat earnings estimates by a penny to 95 cents per share, but missed on revenue expectations, bringing in $5.47 billion as opposed to the $5.53 billion our analysts were looking for. This still represents good year-over-year growth from $5.29 billion in Q1 2017, but pre-market trading shows USB shares slipping half a percentage point at this hour. For more on USB's earnings, click here.
Based on Chicago's North Shore, Abbott LabsABT also topped earnings consensus by a penny to 59 cents per share. Revenues also slightly surpassed expectations in Q1, reporting $7.39 billion in sales. Guidance for full-year 2018 has been posted at between $2.80 and $2.90 per share, and the Zacks consensus is roughly at the midpoint. Shares are off 1.3% ahead of today's opening bell. For more on ABT's earnings, click here.
Defense components major TextronTXT , however, performed much better this morning - 76 cents per share blew away expectations of 46 cents, and more than double the 37 cents per share a year ago. Sales of $3,296 million also impressed, both above the estimated $3,114 million and the year-ago figure of $3,093 million. Industrial sales perked up 14%, and the company saw gains from its Arctic Cat acquisition. Shares are up 6.7% in today's pre-market. For more on TXT's earnings, click here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
International Business Machines Corporation (IBM): Free Stock Analysis Report
U.S. Bancorp (USB): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Textron Inc. (TXT): Free Stock Analysis Report
Morgan Stanley (MS): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Based on Chicago's North Shore, Abbott LabsABT also topped earnings consensus by a penny to 59 cents per share. For more on ABT's earnings, click here. Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Textron Inc. (TXT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Textron Inc. (TXT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Based on Chicago's North Shore, Abbott LabsABT also topped earnings consensus by a penny to 59 cents per share. For more on ABT's earnings, click here. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Textron Inc. (TXT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Based on Chicago's North Shore, Abbott LabsABT also topped earnings consensus by a penny to 59 cents per share. For more on ABT's earnings, click here. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Textron Inc. (TXT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Based on Chicago's North Shore, Abbott LabsABT also topped earnings consensus by a penny to 59 cents per share. For more on ABT's earnings, click here. |
33284.0 | 2018-04-18 00:00:00 UTC | Abbott (ABT) Beats on Earnings and Revenues in Q1 | ABT | https://www.nasdaq.com/articles/abbott-abt-beats-on-earnings-and-revenues-in-q1-2018-04-18 | nan | nan | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. The company has reshaped its portfolio through strategic acquisitions/divestitures in recent times.
In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
The company rides on its strong EPD business and strategic buyouts. In 2017, Abbott completed the acquisition of Alere, which is expected to enhance the company's stance in healthcare. However, foreign currency headwinds raise major concerns for the company, since a considerable percentage of Abbott's revenues come from outside the United States.
Abbott has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4.5%.
Currently, Abbott has a Zacks Rank #3 (Hold), but that could definitely change following the company's first quarter 2018 earnings report which was just released. (You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here ) We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Abbott' first quarter 2018 adjusted earnings per share from continuing operations of 59 cents outpaced the Zacks Consensus Estimate by a penny.
Revenues: Abbott posted first quarter worldwide revenues of $7.39 billion beating the Zacks Consensus Estimate for revenues by 1.8%.
Key Stats: Worldwide revenues increased by 6.9% on organic basis and by 16.7% on year-over-year basis. The revenues for Nutrition segment came in at $1.76 billion, up 7% year over year. Diagnostics segment reported sales worth $1.84 billion, up 58.7% on year-over-year basis. Established Pharmaceuticals revenues were $1.04 billion, up, 9.9% from the year-ago quarter. Medical Devices revenues came in at $2.74 billion, up 14.6% from the year-ago quarter.
Major Factors: The company expects full year earnings per share to be in the range of $2.80 to $2.90, reflecting 14% growth at midpoint. Several new products launched by the company have contributed to a strong growth. Furthermore, in January, Abbott announced U.S. FDA approval of for magnetic resonance (MR)-conditional labeling for its Quadra Assura and Quadra Assura MP devices.
Stock Price: Following the earnings release, share prices decreased by 1.4% during the pre-market trading session.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote The company rides on its strong EPD business and strategic buyouts. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. (You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here ) We have highlighted some of the key stats from this just-revealed announcement below: Earnings: Abbott' first quarter 2018 adjusted earnings per share from continuing operations of 59 cents outpaced the Zacks Consensus Estimate by a penny. |
33285.0 | 2018-04-18 00:00:00 UTC | Q1 Earnings Keep Markets in the Green: MS, USB, ABT & TXT | ABT | https://www.nasdaq.com/articles/q1-earnings-keep-markets-green-ms-usb-abt-txt-2018-04-18 | nan | nan | Wednesday, April 18, 2018
Triple-digit gains in regular-day Tuesday trading in both the Dow and Nasdaq were bolstered by a number of different things - strong housing starts and a lack of relative geopolitical tension early this week among them - but nothing so influential as a very strong Q1 earnings season. We are still in the early stages so far (only a week has passed since Delta Air Lines beat estimates on both top and bottom lines), but overall results have been notably better than expected.
While after-the-bell earnings reports yesterday were better than expected across the board, some companies performed more impressively than others. While Intuitive Surgical ISRG posted a robust earnings beat, IBM IBM eked out a positive surprise on new corporate tax benefits alone. (IBM's Watson enterprise has thus far failed to inspire fresh investment in Big Blue.) As a result, IBM has shed more than 5% in today's pre-market, while ISRG shares are up 5% this morning.
New Q1 earnings reports are following suit, starting with Morgan Stanley MS , which left estimates in the dust this morning. This investment banking major posted $1.45 per share on $11.1 billion in quarterly revenues, outpacing the $1.28 and $10.5 billion in the Zacks consensus estimates, respectively. Net income grew 38% in Q1, whereas Sales & Trading rose 26%. For more on MS's earnings, click here.
Fellow financial institution U.S. Bank USB beat earnings estimates by a penny to 95 cents per share, but missed on revenue expectations, bringing in $5.47 billion as opposed to the $5.53 billion our analysts were looking for. This still represents good year-over-year growth from $5.29 billion in Q1 2017, but pre-market trading shows USB shares slipping half a percentage point at this hour. For more on USB's earnings, click here.
Based on Chicago's North Shore, Abbott Labs ABT also topped earnings consensus by a penny to 59 cents per share. Revenues also slightly surpassed expectations in Q1, reporting $7.39 billion in sales. Guidance for full-year 2018 has been posted at between $2.80 and $2.90 per share, and the Zacks consensus is roughly at the midpoint. Shares are off 1.3% ahead of today's opening bell. For more on ABT's earnings, click here.
Defense components major Textron TXT , however, performed much better this morning - 76 cents per share blew away expectations of 46 cents, and more than double the 37 cents per share a year ago. Sales of $3,296 million also impressed, both above the estimated $3,114 million and the year-ago figure of $3,093 million. Industrial sales perked up 14%, and the company saw gains from its Arctic Cat acquisition. Shares are up 6.7% in today's pre-market. For more on TXT's earnings, click here.
Mark Vickery
Senior Editor
Questions or comments about this article and/or its author? Click here>>
https://www.zacks.com/bio/mark-vickery
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
International Business Machines Corporation (IBM): Free Stock Analysis Report
U.S. Bancorp (USB): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Textron Inc. (TXT): Free Stock Analysis Report
Morgan Stanley (MS): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Based on Chicago's North Shore, Abbott Labs ABT also topped earnings consensus by a penny to 59 cents per share. For more on ABT's earnings, click here. Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Textron Inc. (TXT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Textron Inc. (TXT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Based on Chicago's North Shore, Abbott Labs ABT also topped earnings consensus by a penny to 59 cents per share. For more on ABT's earnings, click here. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Textron Inc. (TXT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Based on Chicago's North Shore, Abbott Labs ABT also topped earnings consensus by a penny to 59 cents per share. For more on ABT's earnings, click here. | Based on Chicago's North Shore, Abbott Labs ABT also topped earnings consensus by a penny to 59 cents per share. For more on ABT's earnings, click here. Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Textron Inc. (TXT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. |
33286.0 | 2018-04-18 00:00:00 UTC | Health Care Sector Update for 04/18/2018: ABT, FCSC, ENDP, SLDB | ABT | https://www.nasdaq.com/articles/health-care-sector-update-04182018-abt-fcsc-endp-sldb-2018-04-18 | nan | nan | Top Health care stocks:
JNJ: +0.1%
PFE: flat
ABT: -1.3%
MRK: -0.1%
AMGN: flat
Health care shares were mixed ahead of the bell on Wednesday.
Expected movers:
- Abbott Laboratories ( ABT ): posts Q1 beat
- Fibrocell ( FCSC ): launches review of strategic alternatives; shares halted
- Endo ( ENDP ): gets notice that Eagle Pharmaceuticals ( EGRX ) seeks US regulatory nod for generic Vasostrict
- Solid Biosciences ( SLDB ): plans response to US FDA letter relating to SGT-001 trial halt
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Expected movers: - Abbott Laboratories ( ABT ): posts Q1 beat - Fibrocell ( FCSC ): launches review of strategic alternatives; shares halted - Endo ( ENDP ): gets notice that Eagle Pharmaceuticals ( EGRX ) seeks US regulatory nod for generic Vasostrict - Solid Biosciences ( SLDB ): plans response to US FDA letter relating to SGT-001 trial halt The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AMGN: flat Health care shares were mixed ahead of the bell on Wednesday. Unauthorized reproduction is strictly prohibited. | Expected movers: - Abbott Laboratories ( ABT ): posts Q1 beat - Fibrocell ( FCSC ): launches review of strategic alternatives; shares halted - Endo ( ENDP ): gets notice that Eagle Pharmaceuticals ( EGRX ) seeks US regulatory nod for generic Vasostrict - Solid Biosciences ( SLDB ): plans response to US FDA letter relating to SGT-001 trial halt The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AMGN: flat Health care shares were mixed ahead of the bell on Wednesday. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Expected movers: - Abbott Laboratories ( ABT ): posts Q1 beat - Fibrocell ( FCSC ): launches review of strategic alternatives; shares halted - Endo ( ENDP ): gets notice that Eagle Pharmaceuticals ( EGRX ) seeks US regulatory nod for generic Vasostrict - Solid Biosciences ( SLDB ): plans response to US FDA letter relating to SGT-001 trial halt The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AMGN: flat Health care shares were mixed ahead of the bell on Wednesday. All rights reserved. | Expected movers: - Abbott Laboratories ( ABT ): posts Q1 beat - Fibrocell ( FCSC ): launches review of strategic alternatives; shares halted - Endo ( ENDP ): gets notice that Eagle Pharmaceuticals ( EGRX ) seeks US regulatory nod for generic Vasostrict - Solid Biosciences ( SLDB ): plans response to US FDA letter relating to SGT-001 trial halt The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AMGN: flat Health care shares were mixed ahead of the bell on Wednesday. Copyright (C) 2016 MTNewswires.com. |
33287.0 | 2018-04-18 00:00:00 UTC | Health Care Sector Update for 04/18/2018: SLDB,FCSC,ABT,ENDP,EGRX | ABT | https://www.nasdaq.com/articles/health-care-sector-update-04182018-sldbfcscabtendpegrx-2018-04-18 | nan | nan | Top Health Care Stocks
JNJ -2.05%
PFE +0.52%
ABT -0.61%
MRK -0.78%
AMGN +0.26%
Health care stocks were little changed just before Wednesday close, including a 0.1% decline for the NYSE Health Care Index in late trade. Also today, shares of health care companies in the S&P 500 were up more than 0.1% as a group while the Nasdaq Biotechnology index also was posting a 0.1% gain.
Among health care stocks moving on news:
+ Solid Biosciences ( SLDB ) has returned to positive ground Wednesday afternoon, bouncing back from a nearly 2% decline, after saying the U.S. Food and Drug Administration has delivered a letter to the specialty drugmaker explaining the factors that led to the agency's March 14 clinical hold on Phase I/II testing of its SGT-001 investigational gene therapy for the treatment of Duchenne muscular dystrophy in response to a serious adverse event involving the first patient dosed in the trial. the patient was hospitalized several days after being dosed with SGT-001 when laboratory tests showed a drop in his platelet count followed by a reduction in red blood cell count and evidence of complement activation. Following medical treatment, all of his laboratory parameters have either improved or returned to normal. The company plans to submit a response to the FDA letter in the coming weeks, it said Wednesday.
In other sector news:
+ Fibrocell Science Inc ( FCSC ) jumped more than 5% higher on Wednesday after the genetic therapy company said it was launching a review of strategic alternatives, including a possible sale or other business combination. Fibrocell also said it has hired Canaccord Genuity to be its financial advisor during the review process.
- Abbott Laboratories ( ABT ) was less than 2% lower in late trade, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. Excluding one-time items, the company earned $0.59 per share, topping the Capital IQ consensus by a penny. Total sales grew to $7.39 billion, also exceeding the $7.28 billion analyst mean.
- Endo International ( ENDP ) declined Wednesday after saying Eagle Pharmaceuticals ( EGRX ) has submitted an abbreviated new drug application seeking permission to produce a generic version of Endo's Vasostrict synthetic anti-diuretic hormone used to raise blood pressure in patients experiencing shock.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | - Abbott Laboratories ( ABT ) was less than 2% lower in late trade, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. Among health care stocks moving on news: + Solid Biosciences ( SLDB ) has returned to positive ground Wednesday afternoon, bouncing back from a nearly 2% decline, after saying the U.S. Food and Drug Administration has delivered a letter to the specialty drugmaker explaining the factors that led to the agency's March 14 clinical hold on Phase I/II testing of its SGT-001 investigational gene therapy for the treatment of Duchenne muscular dystrophy in response to a serious adverse event involving the first patient dosed in the trial. In other sector news: + Fibrocell Science Inc ( FCSC ) jumped more than 5% higher on Wednesday after the genetic therapy company said it was launching a review of strategic alternatives, including a possible sale or other business combination. | - Abbott Laboratories ( ABT ) was less than 2% lower in late trade, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. Top Health Care Stocks Health care stocks were little changed just before Wednesday close, including a 0.1% decline for the NYSE Health Care Index in late trade. | - Abbott Laboratories ( ABT ) was less than 2% lower in late trade, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. Health care stocks were little changed just before Wednesday close, including a 0.1% decline for the NYSE Health Care Index in late trade. Among health care stocks moving on news: + Solid Biosciences ( SLDB ) has returned to positive ground Wednesday afternoon, bouncing back from a nearly 2% decline, after saying the U.S. Food and Drug Administration has delivered a letter to the specialty drugmaker explaining the factors that led to the agency's March 14 clinical hold on Phase I/II testing of its SGT-001 investigational gene therapy for the treatment of Duchenne muscular dystrophy in response to a serious adverse event involving the first patient dosed in the trial. | - Abbott Laboratories ( ABT ) was less than 2% lower in late trade, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. Top Health Care Stocks Health care stocks were little changed just before Wednesday close, including a 0.1% decline for the NYSE Health Care Index in late trade. |
33288.0 | 2018-04-18 00:00:00 UTC | Health Care Sector Update for 04/18/2018: FCSC,ABT,ENDP,EGRX | ABT | https://www.nasdaq.com/articles/health-care-sector-update-04182018-fcscabtendpegrx-2018-04-18 | nan | nan | Top Health Care Stocks
JNJ -1.93%
PFE +0.58%
ABT -1.29%
MRK -0.52%
AMGN +0.47%
Health care stocks were mixed Wednesday, including a less than 0.1% decline for the NYSE Health Care Index in recent trading. Shares of health care companies in the S&P 500 were up almost 0.3% as a group while the Nasdaq Biotechnology index was posting a 0.6% gain.
Among health care stocks moving on news:
+ Fibrocell Science Inc ( FCSC ) jumped more than 5% on Wednesday after the genetic therapy company said it was launching a review of strategic alternatives, which may include the sale of the company or a business combination. Fibrocell said it has hired Canaccord Genuity to be its strategic financial adviser and assist with the review process. The company also said it does not have a specific timetable for completing the strategic examination, adding it will not make additional updates unless it has a material event to announce. It finished the quarter ended March 31 with $12.2 million in cash and equivalents, which the company said will be sufficient to fund its operations for another year.
In other sector news:
- Abbott Laboratories ( ABT ) was less than 2% lower, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. Excluding one-time items, the company earned $0.59 per share, topping the Capital IQ consensus by a penny. Total sales grew to $7.39 billion, also exceeding the $7.28 billion analyst mean.
- Endo International ( ENDP ) declined Wedensday after saying Eagle Pharmaceuticals ( EGRX ) has submitted an abbreviated new drug application seeking permission to produce a generic version of Endo's Vasostrict synthetic anti-diuretic hormone used to raise blood pressure in patients experiencing shock.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news: - Abbott Laboratories ( ABT ) was less than 2% lower, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. The company also said it does not have a specific timetable for completing the strategic examination, adding it will not make additional updates unless it has a material event to announce. It finished the quarter ended March 31 with $12.2 million in cash and equivalents, which the company said will be sufficient to fund its operations for another year. | In other sector news: - Abbott Laboratories ( ABT ) was less than 2% lower, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. Top Health Care Stocks Health care stocks were mixed Wednesday, including a less than 0.1% decline for the NYSE Health Care Index in recent trading. | In other sector news: - Abbott Laboratories ( ABT ) was less than 2% lower, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. Health care stocks were mixed Wednesday, including a less than 0.1% decline for the NYSE Health Care Index in recent trading. Shares of health care companies in the S&P 500 were up almost 0.3% as a group while the Nasdaq Biotechnology index was posting a 0.6% gain. | In other sector news: - Abbott Laboratories ( ABT ) was less than 2% lower, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. Top Health Care Stocks Shares of health care companies in the S&P 500 were up almost 0.3% as a group while the Nasdaq Biotechnology index was posting a 0.6% gain. |
33289.0 | 2018-04-18 00:00:00 UTC | Morning Movers: Morgan Stanley Gains, Intuitive Surgical Climbs, First Solar Shines | ABT | https://www.nasdaq.com/articles/morning-movers-morgan-stanley-gains-intuitive-surgical-climbs-first-solar-shines-2018-04 | nan | nan | Earnings and reports of a meeting between the U.S. and North Korea are helping lift the Dow Jones Industrial Average today. Can the blue-chip benchmark make it three days in a row?
Bloomberg News
S&P 500 futures have gained 0.4%, while Dow Jones Industrial Average futures have risen 84 points, or 0.3%. Nasdaq Composite futures have risen 0.3%.
The change in sentiment really is notable. While the usual suspects are still touting slowing global growth (and they are right about that) others are talking about a return to Goldilocks. Evercore ISI's Dennis DeBusschere, for one, compares the environment to 2016. "The volatility narrative is shifting and seems more like 2016 this week with Tech leading the market, CPI in Europe weaker than expected, China cutting the RRR rate, global bond yields declining and U.S. financial conditions are easing," he wrote in a note to clients this morning.
Tigress Financial's Ivan Geinseth offered similar thoughts. "So it seems all lights green again as expectations for strong global growth and good corporate results so far are starting to drive the market higher once again and as history is shown near-term corrections tend to be a buying opportunity for long-term investors in the market," Feinseth says.
And away we go. - Ben Levisohn
Earnings & News
Abbot Laboratories (ABT) is down 1.4% to $58.96 after reporting first-quarter earnings. The health care firm earned 59 cents a share on revenue of $7.39 billion, while analysts were looking for earnings of 58 cents a share on revenue of $7.28 billion. For the full year, it reaffirmed guidance for earnings between $2.80 and $2.9 a share, compared to the $2.86 per share consensus estimate.
Getty Images
CSX (CSX) is up 4.7% to $59.25 after reporting first-quarter earnings. The rail operator said it earned 78 cents a share on revenue of $2.88 billion. Analysts were looking for earnings of 66 cents a share on revenue of $2.8 billion.
Interactive Brokers Group (IBRK) is up 0.1% to $74.50 after reporting first-quarter earnings. The online broker earned 63 cents a share on revenue of $527 million, while analysts expected earnings of 59 cents on revenue of $502.56 million.
International Business Machines (IBM) is down 5.5% to $152.10 after reporting first-quarter earnings. The tech giant said that it earned $2.45 a share, on revenue of $19.1 billion, while analysts were looking for earnings of $2.42 a share on revenue of $18.81 billion. For the full year, it reiterated guidance for earnings per share of $13.80 a share, compared to the $13.84 consensus estimate.
Intuitive Surgical (ISRG) is up 5.3% to $458.50 after reporting first-quarter earnings. The medical robot maker earned $2.44 a share on revenue of $848 million, while analysts expected earnings of $2.06 a share on revenue of $773.2 million.
Lam Research (LRCX) is down 3.7% to $204.43 after reporting fiscal third-quarter earnings. The chip equipment maker said it earned $4.79 a share on revenue of $2.89 billion, compared to the $4.38 a share and revenue of $2.85 billion analysts were looking for. For the current quarter, it sees earnings coming in between $4.80 and $5.20 a share, on revenue of $2.95 billion to $3.25 billion. Consensus estimates call for $4.65 a share in earnings on revenue of $2.94 billion.
Morgan Stanley (MS) is up 2.4% to $54.50 after reporting first-quarter earnings. The bank earned $1.45 a share on revenue of $11.08 billion, while analysts were looking for earnings of $1.25 a share on revenue of $10.37 billion.
Och-Ziff Management (OZM) is up 6.6% to $2.40 after naming a new chief financial officer.
Paycom (PAYC) is up 2.2% to $118.55 after naming a new chief operating officer and chief information officer.
Scotts Miracle-Gro (SMG) is down 2% to $83.40 after announcing it will acquire the assets of Sunlight Supply, the nation's largest distributor of hydroponic products, in a $450 million deal.
Tesla (TSLA) is up 1.8% to $293 after an internal memo from Elon Musk circulated, showing he wants to target a Model 3 weekly production rate of 3,000 to 4,000 by next month and 6,000 by June.
United Continental (UAL) is up 3.2% to $69.51 after reporting first-quarter earnings. The airline earned 50 cents a share on revenue of $9.03 billion, compared to the 41 cents a share and $9.01 billion in revenue that analysts predicted. For the full year, it expects earnings between $7 and $8.50 a share, up from a previous forecast of $6.50 to $8.50 a share, with a midpoint above the $7.57 per share consensus estimate.
U.S. Bancorp (USB) is up 08% to $51.40 after reporting first-quarter earnings. The bank earned 95 cents a share, matching analysts' expectations, on revenue of $5.47 billion, compared to the $5.53 billion consensus estimate.
VMWare (VMW) is up 4.1% to $137.22 on news that Carl Icahn has taken a stake in the firm. - Teresa Rivas
Upgrades & Downgrades
Altria (MO) is down 2% to $62.70 after Citigroup downgraded it to Neutral.
Dollar Tree (DLTR) is up 1.6% to $100.41 after Loop Capital upgraded it to Buy.
eBay (EBAY) is up 6.1% to $43.10 after Morgan Stanley double upgraded it to Overweight from Underweight.
First Solar (FSLR) is up 2.9% to $74.80 after Bank of America Merrill Lynch upgraded it to Buy.
GrubHub (GRUB) is down 2% to $101.56 after Morgan Stanley downgraded it to Equal Weight.
Juniper Networks (JNPR) is down 4% to $24.40 after Goldman Sachs downgraded it to Sell. - T.R.
Sign up to Review & Preview, a new daily email from Barron's. Every evening we'll review the news that moved markets during the day and look ahead to what it means for your portfolio in the morning.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | - Ben Levisohn Earnings & News Abbot Laboratories (ABT) is down 1.4% to $58.96 after reporting first-quarter earnings. "The volatility narrative is shifting and seems more like 2016 this week with Tech leading the market, CPI in Europe weaker than expected, China cutting the RRR rate, global bond yields declining and U.S. financial conditions are easing," he wrote in a note to clients this morning. Scotts Miracle-Gro (SMG) is down 2% to $83.40 after announcing it will acquire the assets of Sunlight Supply, the nation's largest distributor of hydroponic products, in a $450 million deal. | - Ben Levisohn Earnings & News Abbot Laboratories (ABT) is down 1.4% to $58.96 after reporting first-quarter earnings. The online broker earned 63 cents a share on revenue of $527 million, while analysts expected earnings of 59 cents on revenue of $502.56 million. The medical robot maker earned $2.44 a share on revenue of $848 million, while analysts expected earnings of $2.06 a share on revenue of $773.2 million. | - Ben Levisohn Earnings & News Abbot Laboratories (ABT) is down 1.4% to $58.96 after reporting first-quarter earnings. The health care firm earned 59 cents a share on revenue of $7.39 billion, while analysts were looking for earnings of 58 cents a share on revenue of $7.28 billion. The tech giant said that it earned $2.45 a share, on revenue of $19.1 billion, while analysts were looking for earnings of $2.42 a share on revenue of $18.81 billion. | - Ben Levisohn Earnings & News Abbot Laboratories (ABT) is down 1.4% to $58.96 after reporting first-quarter earnings. The health care firm earned 59 cents a share on revenue of $7.39 billion, while analysts were looking for earnings of 58 cents a share on revenue of $7.28 billion. The medical robot maker earned $2.44 a share on revenue of $848 million, while analysts expected earnings of $2.06 a share on revenue of $773.2 million. |
33290.0 | 2018-04-17 00:00:00 UTC | IWD, ABT, MDT, CVS: ETF Outflow Alert | ABT | https://www.nasdaq.com/articles/iwd-abt-mdt-cvs-etf-outflow-alert-2018-04-17 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $66.9 million dollar outflow -- that's a 0.2% decrease week over week (from 303,150,000 to 302,600,000). Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.6%, and CVS Health Corporation (Symbol: CVS) is lower by about 0.3%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average:
Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $122.19. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.6%, and CVS Health Corporation (Symbol: CVS) is lower by about 0.3%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $122.19. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.6%, and CVS Health Corporation (Symbol: CVS) is lower by about 0.3%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $122.19. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.6%, and CVS Health Corporation (Symbol: CVS) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $66.9 million dollar outflow -- that's a 0.2% decrease week over week (from 303,150,000 to 302,600,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $122.19. | Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.6%, and CVS Health Corporation (Symbol: CVS) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $66.9 million dollar outflow -- that's a 0.2% decrease week over week (from 303,150,000 to 302,600,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $122.19. |
33291.0 | 2018-04-17 00:00:00 UTC | Varian Medical (VAR) Q2 Earnings: Is a Surprise in Store? | ABT | https://www.nasdaq.com/articles/varian-medical-var-q2-earnings%3A-is-a-surprise-in-store-2018-04-17 | nan | nan | Varian Medical Systems Inc.VAR is scheduled to report second-quarter fiscal 2018 earnings on Apr 26, after the market closes . Favorable revenue opportunity from its various Oncology and Imaging Component products, growing adoption of Proton Therapy and strong overseas presence are likely to drive the company's second-quarter fiscal 2018 earnings.
Last quarter, the company delivered adjusted earnings of $1.06 per share, which beat the Zacks Consensus Estimate of 98 cents. Adjusted earnings also improved 112% on a year-over-year basis. Revenues totaled $678.5 million, which beat the Zacks Consensus Estimate of $639.47 million.
In the second quarter of 2018, the Zacks Consensus Estimate for revenues is pegged at $693.9 million, reflecting a rise of 5.9% year over year. The Zacks Consensus Estimate for adjusted earnings is pegged at $1.03 per share, indicating an increase of 15.7% year over year.
Varian Medical Systems, Inc. Price and EPS Surprise
Varian Medical Systems, Inc. Price and EPS Surprise | Varian Medical Systems, Inc. Quote
Let's delve into factors which are likely to impact Varian Medical's upcoming quarterly results.
Factors at Play
Oncology to Drive Growth: We are upbeat about Varian Medical's oncology business that accounted for around 95% of the company's total revenues in the last quarter. Notably, the company has been addressing the tier 1 and mid-tier markets through its Edge, Truebeam and VitalBeam products and has been winning international contracts in the oncology space.
In a bid to overhaul its Oncology Systems segment, Varian Medical recently acquired Montreal-based privately-held Evinance Innovation, Inc. - a clinical decision support (CDS) software company. The deal was initiated in September 2017. The company had stated that it will utilize Evinance's patented technology to offer better services to clients.
On Mar 20, Varian Medical announced that St. Petersburg Center of Nuclear Medicine successfully completed its first pediatric patient treatment with the Varian ProBeam proton therapy system.
Product Launch: The successful launch of Halcyon Therapy System deserves a mention in this regard. Varian Medical has been undertaking initiatives to attract customers to its broad spectrum of products. Recently, the company unveiled the Halcyon radiotherapy treatment system recently.
In the first quarter of fiscal 2018, the Halcyon platform witnessed 62 orders since its inception in 2017. This reflects solid demand for the platform in the quarters ahead.
On Jan 8, Varian Medical announced that its Halcyon system has received Taiwan FDA approval, which will allow the company to market this new cancer treatment system in the country.
On Feb 6, Varian Medical announced the Halcyon cancer treatment platform received Atomic Energy Regulatory Board (AERB) Certificate for Import and Supply in India.
For 2018, the company expects revenues in the range of 4-7%. Adjusted earnings per share are expected in the band of $4.24-$ 4.36, while cash flow from operations are projected in the range of $475-$550 million.
Cut-throat Competition: Varian Medical competes with large electronic companies such as Siemens and Philips as well as with smaller and more specialized radiation therapy equipment manufacturers like Elekta and Accuray.
In the emerging proton therapy market, the company faces competition from Hitachi, Ion Beam Applications, Mevion Medical Systems and Sumitomo. Intense competition is anticipated to increase R&D expenditures in the nascent proton therapy market, which will dent margins. Moreover, pricing pressure in traditional radiotherapy is a major concern.
Earnings Whispers
Our proven model does not show earnings beat for Varian Medical this quarter. This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Varian Medical currently has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Varian Medical carries a Zacks Rank #3 which increases the predictive power of ESP. However, the company's 0.00% ESP makes surprise prediction difficult.
Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Bio-Rad Laboratories BIO has an Earnings ESP of +20.43% and a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here .
Cardinal Heath CAH has an Earnings ESP of +0.33% and a Zacks Rank #2.
Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3.
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion - more than a 3,800% increase in the previous 12 months. They're now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Click here to access these stocks>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Favorable revenue opportunity from its various Oncology and Imaging Component products, growing adoption of Proton Therapy and strong overseas presence are likely to drive the company's second-quarter fiscal 2018 earnings. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Varian Medical Systems, Inc. Price and EPS Surprise Varian Medical Systems, Inc. Price and EPS Surprise | Varian Medical Systems, Inc. Quote Let's delve into factors which are likely to impact Varian Medical's upcoming quarterly results. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Varian Medical Systems, Inc. Price and EPS Surprise Varian Medical Systems, Inc. Price and EPS Surprise | Varian Medical Systems, Inc. Quote Let's delve into factors which are likely to impact Varian Medical's upcoming quarterly results. | Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, the company delivered adjusted earnings of $1.06 per share, which beat the Zacks Consensus Estimate of 98 cents. |
33292.0 | 2018-04-17 00:00:00 UTC | Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings? | ABT | https://www.nasdaq.com/articles/can-hospital-products-unit-aid-baxter-bax-in-q1-earnings-2018-04-17 | nan | nan | Baxter International Inc. BAX is scheduled to report first-quarter 2018 earnings on Apr 26, before the market opens. Positive tidings on the regulatory front, expanding product portfolio, strategic collaborations and strong presence in the international markets are key positives at the moment.
We expect the company to witness steady growth in Hospital Products sales - one of the major revenue components. While this is projected to drive first-quarter 2018 earnings, an expected improvement in revenues in other sub-segments will generate impressive results.
Last quarter, Baxter posted adjusted earnings per share of 64 cents, which beat the Zacks Consensus Estimate by 5 cents and improved from the year-ago quarter's figure of 57 cents.
For the current quarter, the Zacks Consensus Estimate for revenues is pegged at $2.62 billion, reflecting a rise of 5.9% year over year. The Zacks Consensus Estimate for adjusted earnings per share is pegged at 62 cents, indicating an increase of 6.9% year over year.
Baxter International Inc. Price and EPS Surprise
Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote
Let's delve into other factors which are likely to impact Baxter's first-quarter 2018 results.
Hospital Products to Drive Q1 Results
Baxter has an impressive product portfolio with improved existing products and new product development. Recently, the company announced a distribution agreement for the U.S. launch of the Arisure Closed System Transfer device.
In the last quarter, Hospital Sales were driven by solid demand for injectable pharmaceuticals and hospital pharmacy compounding services. Sales in the segment benefited from solid demand for the company's advanced surgery products and cytotoxic contract manufacturing services.
Overall, the Zacks Consensus Estimate for Hospital Products revenues is pegged at $1.67 billion. This reflects an increase of 5.6% from the year-ago quarter.
Here we take a sneak peek at the major sub-segments within the Hospital Products and how are they poised to gain in the to-be-reported quarter:
Surgical Care: Surgical Care (includes anesthesia and BioSurgery) sales recorded year-over-year sales growth in the last quarter, on low double-digit growth for anesthesia and critical care products, driven by growing demand for inhaled anesthetics internationally as well as increased U.S. sales of BREVIBLOC - a fast-acting IV beta blocker.
On Mar 19, Baxter completed the acquisition of two hemostat and sealant products from Mallinckrodt plc to expand the existing surgical portfolio of hemostats and sealants, especially for intraoperative bleeding. Notably, the company bought RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant product lines from Mallinckrodt.
Baxter's surgical portfolio includes products like FLOSEAL Hemostatic Matrix, TISSEEL Fibrin Sealant, COSEAL Surgical Sealant and VASCU-GUARD Patch among others. The portfolio is composed of hemostasis (addressing bleeding), tissue sealing and hard tissue regeneration as well as soft tissue repair and microsurgery with products available in nearly 60 countries.
The company consistently strives to improve its Advanced Surgery business. For 2018, the company expects advanced surgery business to increase 3-4% on a constant-currency (cc) basis.
Baxter announced plans to focus on launching advanced surgery products in Japan in the coming days.
The Zacks Consensus Estimate for the segment's sales is pegged at $576 million, reflecting a rise of 1.1% from the year-ago quarter.
Fluid Systems: Within Hospital Products, sales in Fluid Systems is expected to be solid on robust IV solution sales in the United States. We expect Fluid Systems to maintain the trend in the first quarter.
This is evident from the Zacks Consensus Estimate for Fluid Systems of $621 million for the first quarter, reflecting 6.2% rise from the year-ago quarter.
Integrated Pharmacy Solutions (IPS): Global sales of IPS, another sub segment within Hospital Products, increased by a formidable margin in the last quarter, partly on the back of increased sales for premixed injectable drugs.
However, Baxter's cyclophosphamide performance over the last five years has lacked luster, majorly. Lower cyclophosphamide sales pose threats to the Integrated Pharmacy Solutions franchise business. For 2018, Baxter expects U.S. cyclophosphamide sales to be approximately $95 million, reflecting a decline from $185 million in 2017. For the upcoming quarterly result, lower cyclophosphamide sales are expected to impact the top line by low single digits.
For the first quarter of 2018, the Zacks Consensus Estimate for IPS is pegged at $598 million, showing an increase of 8.3% from the year-ago number.
Other Factors at Play
Guidance: Baxter expects first-quarter adjusted earnings in the range of 60-62 cents. However, net sales in the first quarter is expected to be affected by approximately $25 million due to disruptions in the Puerto Rico facility. For 2018, Baxter estimates sales growth of approximately 6-7% at cc. Adjusted earnings for 2018 are expected in the band of $2.72-$2.80.
Regulatory Approvals: Baxter has been witnessing positive tidings on the regulatory front. Recently, Baxter announced the approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin).
Management confirmed that the FDA has granted two new approvals for temporary importation of certain drugs from the facilities in Canada and Mexico. With this development, Baxter now has four operational sites approved to address demand in the U.S. markets.
Dull Projection for Pharmaceutical Unit: For 2018, the pharmaceutical business, which includes Baxter's broad generic injectables portfolio, anesthesia and critical care products as well as hospital pharmacy compounding services conducted outside the United States is expected to be flat on a year-over-year basis. The lackluster performance is primarily driven by increased competition for select products in the segment.
Further, in the Other business segment, which primarily includes Baxter's contract manufacturing services, management expects low single-digit decline in 2018. Per management, sales in the segment benefited from a customer stockpile order in 2017. Baxter expects lower manufacturing revenues from Shire, which it acquired two years ago.
What Our Model Predicts
Our quantitative model does not predict an earnings beat for Baxter this quarter.
This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates.
Zacks ESP: Earnings ESP for Baxter is 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Baxter carries a Zacks Rank #2.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Bio-Rad Laboratories BIO has an Earnings ESP of +20.43% and a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here.
Cardinal Heath CAH has an Earnings ESP of +0.33% and a Zacks Rank #2.
Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3.
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion - more than a 3,800% increase in the previous 12 months. They're now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Click here to access these stocks>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Baxter International Inc. (BAX): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Sales in the segment benefited from solid demand for the company's advanced surgery products and cytotoxic contract manufacturing services. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Here we take a sneak peek at the major sub-segments within the Hospital Products and how are they poised to gain in the to-be-reported quarter: Surgical Care: Surgical Care (includes anesthesia and BioSurgery) sales recorded year-over-year sales growth in the last quarter, on low double-digit growth for anesthesia and critical care products, driven by growing demand for inhaled anesthetics internationally as well as increased U.S. sales of BREVIBLOC - a fast-acting IV beta blocker. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Last quarter, Baxter posted adjusted earnings per share of 64 cents, which beat the Zacks Consensus Estimate by 5 cents and improved from the year-ago quarter's figure of 57 cents. | Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. We expect the company to witness steady growth in Hospital Products sales - one of the major revenue components. |
33293.0 | 2018-04-17 00:00:00 UTC | 5 Amazing Earnings Charts This Week | ABT | https://www.nasdaq.com/articles/5-amazing-earnings-charts-week-2018-04-17 | nan | nan | This is the first big week of earnings season and that means we'll get a lot of big cap companies reporting, including several Dow components.
We're also hearing from some companies that you might not pay much attention to, but you should. They run the gamut of industries from drug manufacturers, to equipment plays, paint and coatings, high end tool providers and pool products.
But these companies all have something else in common: great earnings surprise track records.
It's not easy to beat every quarter for years. There is just a couple dozen companies that have perfect records. Even one miss, however, is an impressive track record and hard to maintain.
These are some of the best earnings charts of those companies reporting this week.
5 Amazing Earnings Charts This Week
Abbott Labs ABT has a perfect record and the shares have finally broken out to new highs. 2018 has been a little dicey though. Will another earnings beat help the shares regain momentum?
United Rentals URI has missed just once in the last 5 years. Shares have rallied on hopes that the Congress would pass a big infrastructure plan which would boost this big equipment lender.
PPG Industries PPG hasn't missed in 5 years but shares have been stuck in a narrow trading range the last 3 years. What will take them to new heights?
Snap-On SNA hasn't missed in 5 years either but the shares are also stalled in a narrow trading range. It looked like they might break out to start the year but, instead, they have sunk to the low end of the range. Will the corporate tax cuts help the stock regain momentum?
Pool Corporation POOL specializes in pools and pool products. It has missed only once in the last 5 years and shares are near 5-year highs. With the consumer feeling good, and looking for leisure and experiences, Pool could be perfectly positioned to benefit.
[The author of this article owns shares of URI in her personal portfolio.]
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
United Rentals, Inc. (URI): Free Stock Analysis Report
PPG Industries, Inc. (PPG): Free Stock Analysis Report
Pool Corporation (POOL): Free Stock Analysis Report
Snap-On Incorporated (SNA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 5 Amazing Earnings Charts This Week Abbott Labs ABT has a perfect record and the shares have finally broken out to new highs. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report PPG Industries, Inc. (PPG): Free Stock Analysis Report Pool Corporation (POOL): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. They run the gamut of industries from drug manufacturers, to equipment plays, paint and coatings, high end tool providers and pool products. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report PPG Industries, Inc. (PPG): Free Stock Analysis Report Pool Corporation (POOL): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. 5 Amazing Earnings Charts This Week Abbott Labs ABT has a perfect record and the shares have finally broken out to new highs. PPG Industries PPG hasn't missed in 5 years but shares have been stuck in a narrow trading range the last 3 years. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report PPG Industries, Inc. (PPG): Free Stock Analysis Report Pool Corporation (POOL): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. 5 Amazing Earnings Charts This Week Abbott Labs ABT has a perfect record and the shares have finally broken out to new highs. PPG Industries PPG hasn't missed in 5 years but shares have been stuck in a narrow trading range the last 3 years. | 5 Amazing Earnings Charts This Week Abbott Labs ABT has a perfect record and the shares have finally broken out to new highs. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report PPG Industries, Inc. (PPG): Free Stock Analysis Report Pool Corporation (POOL): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. There is just a couple dozen companies that have perfect records. |
33294.0 | 2018-04-17 00:00:00 UTC | Pre-Market Earnings Report for April 18, 2018 : ABT, MS, ASML, USB, TXT, MTG, QCRH | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-april-18-2018-abt-ms-asml-usb-txt-mtg-qcrh-2018-04-17 | nan | nan | The following companies are expected to report earnings prior to market open on 04/18/2018. Visit our Earnings Calendar for a full list of expected earnings releases.
Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2018. The medical products company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.58. This value represents a 20.83% increase compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 1.37%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 20.72 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Morgan Stanley ( MS ) is reporting for the quarter ending March 31, 2018. The investment bankers company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.28. This value represents a 28.00% increase compared to the same quarter last year. In the past year MS has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 9.09%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for MS is 11.79 vs. an industry ratio of 12.50.
ASML Holding N.V. ( ASML ) is reporting for the quarter ending March 31, 2018. The capital goods company's consensus earnings per share forecast from the 2 analysts that follow the stock is $1.38. This value represents a 23.21% increase compared to the same quarter last year. In the past year ASML has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 41.6%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ASML is 28.28 vs. an industry ratio of 16.30, implying that they will have a higher earnings growth than their competitors in the same industry.
U.S. Bancorp ( USB ) is reporting for the quarter ending March 31, 2018. The bank company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.94. This value represents a 14.63% increase compared to the same quarter last year. In the past year USB has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2018 Price to Earnings ratio for USB is 12.69 vs. an industry ratio of 13.10.
Textron Inc. ( TXT ) is reporting for the quarter ending March 31, 2018. The aerospace and defense company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.46. This value represents a no change for the same quarter last year. TXT missed the consensus earnings per share in the 4th calendar quarter of 2017 by -3.9%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for TXT is 19.49 vs. an industry ratio of 17.60, implying that they will have a higher earnings growth than their competitors in the same industry.
MGIC Investment Corporation ( MTG ) is reporting for the quarter ending March 31, 2018. The insurance company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.35. This value represents a 12.90% increase compared to the same quarter last year. In the past year MTG has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 59.26%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for MTG is 7.69 vs. an industry ratio of 11.50.
QCR Holdings, Inc. ( QCRH ) is reporting for the quarter ending March 31, 2018. The bank (midwest) company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.71. This value represents a 4.41% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for QCRH is 13.91 vs. an industry ratio of 14.40.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2018. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 20.72 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 20.72 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2018. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 20.72 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2018. In the past year ABT has beat the expectations every quarter. | In the past year ABT has beat the expectations every quarter. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2018. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 20.72 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry. |
33295.0 | 2018-04-16 00:00:00 UTC | Can Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings? | ABT | https://www.nasdaq.com/articles/can-instruments-drive-intuitive-surgical-isrg-q1-earnings-2018-04-16 | nan | nan | Intuitive Surgical Inc .'s ISRG first-quarter 2018 results, expected to release on Apr 17 after market close, are expected to show steady growth in the instruments and accessories segment.
Revenues in all other segments are also expected to help the company generate solid results.
Last quarter, the company posted adjusted earnings of $2.54 per share, beating the Zacks Consensus Estimate of $2.27. Revenues totaled $892.4 million, which also outpaced the Zacks Consensus Estimate of $864 million.
For the first quarter, the Zacks Consensus Estimate for revenues is pinned at $766.61 million, indicating a year-over-year increase of 13.7%. The consensus estimate for earnings is $1.99, reflecting a year-over-year rise of 17.1%. Intuitive Surgical delivered positive earnings surprises in the past four quarters, the average being 15.01%.
Let's delve deeper:
Instruments & Accessories in Focus
The instruments and accessories segment delivered solid results last quarter, accounting for 52.3% of total revenues. The company's flagship da Vinci surgical system continues to be a revenue driver for the segment.
For the first quarter, 2018 the Zacks Consensus Estimate for revenues is pegged at $435 million, showing a rise of 14.2% year over year.
Intuitive Surgical, Inc. Price and Consensus
Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote
In 2017, the company had introduced da Vinci X and Xi surgical systems in response to customer needs. In the fourth quarter, the da Vinci install base grew 13% year over year to 4,409 units. In fact, the company shipped 216 da Vinci systems in the fourth quarter, compared with 163 in the prior-year period.
The company also submitted 510(k) for the da Vinci X, Xi and Sp platforms in the same quarter.
Other Factors at Play
Guidance
For 2018, Intuitive Surgical anticipates full-year procedure growth of 11% to 15%. The solid forecast indicates that the company will release encouraging numbers for the first quarter as well.
Procedure growth is expected to be driven by U.S. general surgery and procedures outside the United States.
Management expects operating expenses to rise 16-18% in 2018 as the company continues to invest in emerging markets and new technology, including computer-assisted surgery.
Gross margin is expected within 70-71.5% of net revenues in 2018.
Global Exposure
Intuitive Surgical gained significantly on the CE Mark approval for da Vinci X in Europe. Increased use of da Vinci in general surgery in the United States, continued growth in neurology in Europe and Japan and multispecialty growth in Korea and China also contributed to the rally.
Additionally, in the fourth quarter, the Ministry of Health in Japan listed for reimbursement in 12 procedures. In the quarter, revenues from outside the United States increased 17%, both sequentially and on year-over-year basis.
Competition
Intuitive Surgical is currently facing stiff competition in the niche space. After the regulatory approval of Transenterix's surgical robot for abdominal surgery last October, competition for Intuitive Surgical has intensified. Moreover, the MedTech giant Medtronic poses threat as it is possibly working on the launch of surgical robots this year.
Here is what our quantitative model predicts:
Although Intuitive Surgical carries a Zacks Rank #3 (Hold), it does not have a positive Earnings ESP needed for increasing the odds of an earnings beat.
Zacks ESP : The Earnings ESP for Intuitive Surgical is 0.00. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Intuitive Surgical carries a Zacks Rank #3, which increases the predictive power of ESP. However, we also need a positive ESP to be confident of an earnings beat.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post earnings beat this quarter.
Bio-Rad Laboratories BIO has an Earnings ESP of +20.4% and a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Cardinal Heath CAH has an Earnings ESP of +0.33% and a Zacks Rank #2 (Buy).
Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Management expects operating expenses to rise 16-18% in 2018 as the company continues to invest in emerging markets and new technology, including computer-assisted surgery. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Intuitive Surgical, Inc. Price and Consensus Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote In 2017, the company had introduced da Vinci X and Xi surgical systems in response to customer needs. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Intuitive Surgical, Inc. Price and Consensus Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote In 2017, the company had introduced da Vinci X and Xi surgical systems in response to customer needs. | Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues in all other segments are also expected to help the company generate solid results. |
33296.0 | 2018-04-16 00:00:00 UTC | 3 Stocks to Buy Ahead of Earnings | ABT | https://www.nasdaq.com/articles/3-stocks-buy-ahead-earnings-2018-04-16 | nan | nan | Stocks opened higher on Monday as investors seem to think the U.S.-led air strikes on Syria won't lead to a much larger conflict. The strikes also coincided with the real start of first quarter earnings season, which investors should use as a way to fight off the volatility that has plagued markets recently.
Earnings season kicked into gear last Friday when banking giants, JPMorgan Chase JMP , Citigroup C , and PNC Financial PNC , reported their Q1 financial results. Going forward, investors should use this highly anticipated period to try to recoup any losses they might have suffered during the extended bearish run.
With that said, investors still need to be selective during earnings season and hunt for stocks that look poised to top quarterly earnings estimates. Conversely, investors should stay away from any companies that might disappoint by reporting lower-than-expected earnings results.
Luckily, Zacks Premium customers can utilize the Earnings ESP Screener in order to search for stocks that are expected to surprise, in one way or the other.
This is done because, generally speaking, when an analyst posts an estimate right before an earnings release, it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago.
A positive Earnings ESP paired with a Zacks Rank #3 (Hold) or better ranking helps us feel confident about the potential for an earnings beat. In fact, our 10-year backtest has revealed that this methodology has accurately produced a positive surprise 70% of the time.
Today, we are giving our readers a free look at three stocks that look ready to post an earnings beat this week.
Check them out now:
1. Honeywell International HON
Shares of Honeywell climbed on Monday, which might signal that investors have reason to be excited about the company famous for its thermostats and other control technologies for buildings, homes, and industries. Honeywell is indeed expected to see its revenues climb by 4.7% to reach $9.94 billion, based on our current Zacks Consensus Estimates. Meanwhile, the company's earnings are projected to climb by 13.9% to $1.89 per share.
Honeywell is also currently a Zacks Rank #3 (Hold) and sports an Earnings ESP of 0.46%. Diving a little deeper, HON's Most Accurate Estimate-the representation of the most recent analyst sentiment-calls for earnings of $1.90 per share, which comes in 1 cent above our current consensus estimate. This means that Honeywell could be ready to top Q1 earnings estimates when it reports its financial results before the market opens on Friday, April 20.
2. E-Trade Financial ETFC
Volatility might not be great for investors, but online broker age firms such as E-Trade can benefit hugely. This has been reflected in E-Trade's stock price, which is up 71% over the last year, and also managed to come out of the recent market downturn nearly unscathed. E-Trade is expected to see its first quarter revenues climb by 23.3% to reach $681.74 million. The company's bottom line is projected to hit $0.78 per share, which would mark stellar 62.5% expansion from the year-ago period.
Better still, E-Trade is currently a Zacks Rank #2 (Buy) and rocks an Earnings ESP of 1.14%, with its Most Accurate Estimate coming in 1 cent above our current consensus estimate. Therefore, investors should consider E-Trade a stock that looks poised to beat earnings estimates when it reports its Q1 financial results after market close on Thursday, April 19.
3. Abbott Laboratories ABT
Shares of Abbott popped on Monday morning just a couple of days before the diversified healthcare company is set to report its first quarter earnings results. And it looks like Abbott investors have reason to be excited, with the company's quarterly revenues projected to surge by more than 14% to hit $7.26 billion.
Meanwhile, Abbott's earnings are expected to expand by 20.8% to reach $0.58 per share. The company is also currently a Zacks Rank #3 (Hold) and boasts an Earnings ESP of 0.75%. This means that investors might see Abbott top Q1 earnings estimates when the company reports its financial results before the opening bell on Wednesday, April 18.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report
Citigroup Inc. (C): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Honeywell International Inc. (HON): Free Stock Analysis Report
E*TRADE Financial Corporation (ETFC): Free Stock Analysis Report
JMP Group LLC (JMP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT Shares of Abbott popped on Monday morning just a couple of days before the diversified healthcare company is set to report its first quarter earnings results. Click to get this free report The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report E*TRADE Financial Corporation (ETFC): Free Stock Analysis Report JMP Group LLC (JMP): Free Stock Analysis Report To read this article on Zacks.com click here. Diving a little deeper, HON's Most Accurate Estimate-the representation of the most recent analyst sentiment-calls for earnings of $1.90 per share, which comes in 1 cent above our current consensus estimate. | Click to get this free report The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report E*TRADE Financial Corporation (ETFC): Free Stock Analysis Report JMP Group LLC (JMP): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT Shares of Abbott popped on Monday morning just a couple of days before the diversified healthcare company is set to report its first quarter earnings results. This means that Honeywell could be ready to top Q1 earnings estimates when it reports its financial results before the market opens on Friday, April 20. | Click to get this free report The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report E*TRADE Financial Corporation (ETFC): Free Stock Analysis Report JMP Group LLC (JMP): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT Shares of Abbott popped on Monday morning just a couple of days before the diversified healthcare company is set to report its first quarter earnings results. With that said, investors still need to be selective during earnings season and hunt for stocks that look poised to top quarterly earnings estimates. | Abbott Laboratories ABT Shares of Abbott popped on Monday morning just a couple of days before the diversified healthcare company is set to report its first quarter earnings results. Click to get this free report The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report E*TRADE Financial Corporation (ETFC): Free Stock Analysis Report JMP Group LLC (JMP): Free Stock Analysis Report To read this article on Zacks.com click here. Better still, E-Trade is currently a Zacks Rank #2 (Buy) and rocks an Earnings ESP of 1.14%, with its Most Accurate Estimate coming in 1 cent above our current consensus estimate. |
33297.0 | 2018-04-13 00:00:00 UTC | Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings? | ABT | https://www.nasdaq.com/articles/can-solid-medical-devices-drive-abbotts-abt-q1-earnings-2018-04-13 | nan | nan | Abbott 's ABT Medical Devices business has been on a strong growth trajectory of late on solid contributions from all sub-segments.
We expect this strength to get reflected in first-quarter 2018 results, which are scheduled for release on Apr18 before the market opens.
Click here to know how the company's overall Q1 performance is expected to be.
Medical Device in Focus
Abbott's Medical Device segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business. We note that, management expects mid-to-high single digit growth in Medical Devices sales in the first quarter of 2018.
Consequently, the Zacks Consensus Estimate for Medical Devices revenues of $2.68 billion indicates a rise of 11.7% from the year-ago quarter.
In the last quarter, sales improvement at the segment was driven by double-digit growth in Heart Failure, Electrophysiology, Structural Heart, Neuromodulation and Diabetes Care. Moreover, the company also received approvals for a few products alongside achieving clinical trial milestones.
Let's see how things are shaping up within these sub-segments before the first-quarter results.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Electrophysiology: In Electrophysiology, which accounted for 13.9% of Medical Devices revenues, Abbott strengthened its position with the launch of Confirm insertable cardiac heart monitor in the United States and Europe.
The Zacks Consensus Estimate for Electrophysiology revenues of $359 million indicates an increase of 13.6% from the year-ago quarter. The company is expected to keep gaining strength in this business.
Heart Failure: In the last quarter, the company witnessed impressive sales growth in Heart Failure business on solid uptake of the recently launched HeartMate 3 system in the United States. Management informed that it is working on expanding the indications for the product to include destination therapy for patients who are barred from opting for transplants.
The Zacks Consensus Estimate for Heart Failure business revenues of $160 million indicates a rise of 12.7% from the year-ago quarter.
Vascular: In Vascular (26.8% of total Medical devices revenues) Abbott launched XIENCE Sierra drug-eluting coronary stent system in Europe during the last quarter, following the receipt of CE Mark in October 2017. Following encouraging response toward the product, the company now plans to make itcommercially available in the United States in 2018.
The Zacks Consensus Estimate for Vascular revenues of $719 million shows an improvement of 2.3% from the year-ago quarter.
Structural Heart: Abbott has also been gaining on strength in the Structural Heart business. Improvementin structural heart business was led by continued double-digit growth of MitraClip, the company's market-leading device for the repair of mitral regurgitation in the last quarter. Notably, in nearly 50 countries, more than 50,000 people have been treated with the MitraClip.
In March, the company announced the receipt of Japan's Ministry of Health, Labour and Welfare ("MHLW") approval for its MitraClip therapy. The move is likely to improve the company's Structural Heart business in near term. Further, MHLW approved the MitraClip System in Japan in November 2017.
The Zacks Consensus Estimate for Structural Heart revenues of $293 million indicates a rise of 14.5% from the year-ago quarter.
Diabetes Care: In Diabetes Care, international sales growth of 33.2% in the prior quarter was driven by Abbott's FreeStyleLibre, an innovative sensor-based glucose monitoring system that eliminates the need for routine finger sticks. The company recently initiated the launch of FreeStyleLibre in the United States too. Notably, the FreeStyleLibre system is partially or fully covered in 21 countries including the United States, France, Germany and Japan.
Forging ahead with initiatives to boost this arm, the company announced the availability of FreeStyleLibreLink app in Europe for use in smartphones (both iPhone and Android).
The Zacks Consensus Estimate for Diabetes Care revenues of $409 million indicates a surge of 40.1% from the year-ago quarter.
Rhythm Management: We are upbeat about Abbott kick-starting 2018 by receiving FDA approval for magnetic resonance (MR)-conditional labeling for Quadra Assura MP Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Fortify Assura Implantable Cardioverter Defibrillator (ICD) - two of the company's most widely-used high voltage medical devices.
The approvals come on the heels of recent MR-conditional labeling approvals for the Assurity MRI pacemaker, Ellipse ICD and associated MRI-compatible leads. Further, it expands Abbott's portfolio of MRI-ready devices for patients indicated for ICDs and/or CRT-D devices who may need an MRI in the future. This latest development is expected to further boost the Rhythm Management business.
Our estimate of Rhythm Management revenues of $519 million also shows an improvement from the year-ago period.
Zacks Rank & Stocks to Consider
Abbott carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories BIO , Myriad Genetics, Inc. MYGN and Abiomed, Inc. ABMD .
Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. It has a long-term expected earnings growth rate of 15%.
Myriad Genetics has a long-term expected earnings growth rate of 10%. The stock carries a Zacks Rank of 2 (Buy).
Abiomed has a long-term expected earnings growth rate of 31.5%. The stock carries a Zacks Rank of 2.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott 's ABT Medical Devices business has been on a strong growth trajectory of late on solid contributions from all sub-segments. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Improvementin structural heart business was led by continued double-digit growth of MitraClip, the company's market-leading device for the repair of mitral regurgitation in the last quarter. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Medical Devices business has been on a strong growth trajectory of late on solid contributions from all sub-segments. In the last quarter, sales improvement at the segment was driven by double-digit growth in Heart Failure, Electrophysiology, Structural Heart, Neuromodulation and Diabetes Care. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Medical Devices business has been on a strong growth trajectory of late on solid contributions from all sub-segments. Medical Device in Focus Abbott's Medical Device segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business. | Abbott 's ABT Medical Devices business has been on a strong growth trajectory of late on solid contributions from all sub-segments. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Medical Device in Focus Abbott's Medical Device segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business. |
33298.0 | 2018-04-12 00:00:00 UTC | Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings? | ABT | https://www.nasdaq.com/articles/can-solid-epd-business-drive-abbotts-abt-q1-earnings-2018-04-12 | nan | nan | Abbott 's ABT Established Pharmaceuticals Division ("EPD") business has been recording operational sales growth in the last few quarters. We expect this strength to get reflected in first-quarter 2018 results as well, which are scheduled for release on Apr 18.
Click here to know how the company's overall Q1 performance is expected to be.
Key Catalysts
This business majorly focuses on emerging markets. Notably, the key emerging markets include India, Russia, China and numerous others in Latin America as well as Brazil along with other countries. Sales in key emerging markets increased 15% (up 12.5%on comparable operational basis) driven by double-digit growth in India, China and Latin America in the last reported quarter.
Moreover, management believes that these emerging markets will continue to offer immense opportunities with favorable demographics. Accordingly, the Zacks Consensus Estimate for EPD revenues from key emerging markets of $844 million indicates a rise of 15.6% from the year-ago quarter.
Although immaterial for the to-be-reported quarter, the ongoing tensions between the United States and China regarding the imposition of tariffs on imports, has raised concerns for major MedTech players as any adverse move may affect their sales performance in China in near term.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
We encouragingly note that, management expects high single-digit growth in EPD sales in the first quarter of 2018. Furthermore, the Zacks Consensus Estimate for EPD revenues of $1.09 billion shows a rise of 14.7% from the year-ago quarter.
Favorable currency translation also had a positive impact of 1.4% on EPD revenues in the last reported quarter. We encouragingly note that, management expects foreign exchange to continue to act as a tailwind in the to-be-reported quarter.
In EPD, Abbott's consistent focus on enhancing local capabilities and expanding product portfolio within core therapeutic areas is targeted specifically to address local market needs. These efforts from the company also continue to strengthen its leadership position in the EPD markets. Abbott's sale of developed market businesses along with acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia has contributed to the EPD business.
Zacks Rank & Stocks to Consider
Abbott carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories BIO , Myriad Genetics, Inc. MYGN and Abiomed, Inc ABMD .
Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. It has long-term expected earnings growth rate of 15%.
Myriad Genetics has long-term expected earnings growth rate of 10%. The stock carries a Zacks Rank of 2 (Buy).
Abiomed has long-term expected earnings growth rate of 31.5%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report
Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott 's ABT Established Pharmaceuticals Division ("EPD") business has been recording operational sales growth in the last few quarters. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the key emerging markets include India, Russia, China and numerous others in Latin America as well as Brazil along with other countries. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Established Pharmaceuticals Division ("EPD") business has been recording operational sales growth in the last few quarters. Accordingly, the Zacks Consensus Estimate for EPD revenues from key emerging markets of $844 million indicates a rise of 15.6% from the year-ago quarter. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Established Pharmaceuticals Division ("EPD") business has been recording operational sales growth in the last few quarters. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote We encouragingly note that, management expects high single-digit growth in EPD sales in the first quarter of 2018. | Abbott 's ABT Established Pharmaceuticals Division ("EPD") business has been recording operational sales growth in the last few quarters. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Key Catalysts This business majorly focuses on emerging markets. |
33299.0 | 2018-04-11 00:00:00 UTC | Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings? | ABT | https://www.nasdaq.com/articles/can-steady-overall-growth-drive-abbotts-abt-q1-earnings-2018-04-11 | nan | nan | AbbottABT is slated to report first-quarter 2018 results, before the market opens on Apr 18. Last quarter, the company's earnings per share exceeded the Zacks Consensus Estimate by 1.4%. Moreover, Abbott has delivered positive earnings surprises in the trailing four quarters, the average beat being 4.5%. Let's see how things are shaping up for this announcement.
Factors at Play
Over the past few quarters, Abbott has been on a healthy growth trajectory inthe Medical Devices business. The company has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. Notably, the FreeStyle Libre system is partially or fully covered in 21 countries, including France, Germany and Japan.
Historically, the company has been witnessing solid growth in the global Diabetes Care business, primarily on the back of contributions from FreeStyle Libre. This apart, investors are confident about Abbott's developments in other businesses which form part of the Medical Devices segment. The Zacks Consensus Estimate for Medical Devices revenues of $2.68 billion indicates a rise of 11.7% from the year-ago quarter.
Similar to the prior quarter, Abbott is expected to gain from strong performance by the Established Pharmaceuticals Division ("EPD") business, which has been recording operational sales growth in the last few quarters. Management expects high single-digit sales growth in the first quarter of 2018. Furthermore, the Zacks Consensus Estimate for EPD revenues of $1.09 billion shows a rise of 14.7% from the year-ago quarter.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
We are also upbeat about the Diagnostics business which has been going strong on solid contributions from all sub-segments - Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. Moreover, synergies from the Alere buyout, in the form of revenues from Rapid Diagnostics, have been benefiting the company.
Moreover, management expects Rapid Diagnostics to contribute around $5 million in the first quarter. The Zacks Consensus Estimate for Diagnostic revenues of $1.76 billion shows a rise of 51.7% from the year-ago quarter.
We encouragingly note that Nutrition is Abbott's fastest-growing business, courtesy of an aging population, increasing rate of chronic diseases and the rise of the middle class in the emerging markets. Furthermore, Abbott's pediatric nutrition business continues to be strong in the United States. Thus, the Zacks Consensus Estimate for Nutrition revenues of $1.73 billion indicates a rise of 5.5% from the year-ago quarter.
Favorable currency translation also had a positive impact of 2% on total revenues in the last reported quarter. We encouragingly note that management expects foreign exchange to boost results in the to-be-reported quarter, driving the top line by 3.5%.
Overall, first-quarter total revenues are projected at $7.26 billion, up 14.5% from the prior-year quarter.
What Our Model Suggests
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP . You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Abbott has a Zacks Rank #3 and an Earnings ESP of +0.89%, a combination that suggests that the company is likely to beat estimates.
The Zacks Consensus Estimate for earnings of 58 cents reflects a 20.8% rise on a year-over-year basis.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter.
Myriad Genetics, Inc. MYGN has an Earnings ESP of +0.61% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Henry Schein, Inc. HSIC has an Earnings ESP of +3.34% and a Zacks Rank #3.
Quest Diagnostics Incorporated DGX has an Earnings ESP of +3.19% and a Zacks Rank #3.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report
Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottABT is slated to report first-quarter 2018 results, before the market opens on Apr 18. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Historically, the company has been witnessing solid growth in the global Diabetes Care business, primarily on the back of contributions from FreeStyle Libre. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT is slated to report first-quarter 2018 results, before the market opens on Apr 18. Furthermore, the Zacks Consensus Estimate for EPD revenues of $1.09 billion shows a rise of 14.7% from the year-ago quarter. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT is slated to report first-quarter 2018 results, before the market opens on Apr 18. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote We are also upbeat about the Diagnostics business which has been going strong on solid contributions from all sub-segments - Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT is slated to report first-quarter 2018 results, before the market opens on Apr 18. The Zacks Consensus Estimate for Medical Devices revenues of $2.68 billion indicates a rise of 11.7% from the year-ago quarter. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.